tegafur has been researched along with oxonic acid in 3138 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (1.15) | 18.2507 |
| 2000's | 1071 (34.13) | 29.6817 |
| 2010's | 1862 (59.34) | 24.3611 |
| 2020's | 169 (5.39) | 2.80 |
| Authors | Studies |
|---|---|
| Taguchi, T | 3 |
| Baba, H; Maehara, Y; Mimori, K; Mori, M; Sugimachi, K | 1 |
| Fujioka, A; Fukushima, M; Nakano, K; Okabe, H; Oyama, K; Saito, H; Satake, H; Shirasaka, T; Takechi, T; Takeda, S; Uchida, J; Unemi, N | 1 |
| Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G | 1 |
| Hasegawa, H; Hayashi, T; Ohmae, S; Tanaka, G | 1 |
| Hayashi, T; Hirota, T; Kito, S; Kurokawa, K; Tanaka, G; Yamaguchi, S | 1 |
| Besshi, K; Hakoi, K; Hayashi, T; Ohmae, S | 1 |
| Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S | 1 |
| Imamura, K; Izumi, K; Shinomiya, M | 1 |
| Ikebuchi, K; Sato, T; Shinomiya, M; Yukiyama, S | 1 |
| Ikebuchi, K; Shinomiya, M; Yukiyama, S | 1 |
| Fujimura, T; Furuhashi, T; Kato, M; Koida, M | 1 |
| Ikebuchi, K; Izumi, K; Kouchi, Y; Maeda, Y; Morinaga, H | 1 |
| Kouchi, Y; Maeda, Y; Ohuchida, A; Sato, S | 1 |
| Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A | 1 |
| Kitamura, R; Matsushima, E; Yoshida, K | 1 |
| Akazawa, S; Ariyoshi, Y; Fujita, H; Furue, H; Hara, Y; Hasegawa, K; Inuyama, Y; Kanamaru, R; Kimura, K; Kurihara, M; Nakao, I; Niitani, H; Ota, K; Saito, T; Shimoyama, T; Suga, S; Sugimachi, K; Taguchi, T; Takai, S; Takashima, S; Toge, T; Tsukagoshi, S | 1 |
| Fukushima, M; Kato, T; Shimamoto, Y; Shirasaka, T | 1 |
| Aoyama, H; Horikoshi, N; Kimura, M; Morimoto, K; Noguchi, S; Ota, J; Sano, M; Taguchi, T; Takashima, S; Toge, T | 1 |
| Inuyama, Y; Kida, A; Kohno, N; Satake, B; Tsukuda, M | 2 |
| Fujioka, A; Fukushima, M; Kato, T; Nakano, K; Ohshimo, H; Okabe, H; Satake, H; Shimamoto, Y; Shirasaka, T; Takechi, T; Takeda, S; Uchida, J | 1 |
| Ajani, JA | 2 |
| Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 2 |
| Fukushima, M; Kato, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T; Uchida, J; Yonekura, R | 1 |
| Horikoshi, N; Mitachi, Y; Ohtsu, A; Sakata, Y; Sugimachi, K; Taguchi, T | 1 |
| Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K | 1 |
| Aiba, K; Araki, H; Mikami, Y; Shirasaka, T; Suzuki, M; Terashima, M | 1 |
| Kurihara, M; Maehara, Y; Sugimachi, K; Taguchi, T | 1 |
| Baba, M; Kamiya, K; Kanai, T; Konno, H; Matsumoto, K; Nakamura, S; Tanaka, T | 1 |
| Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
| Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y | 1 |
| Horikoshi, N; Maehara, Y; Mitachi, Y; Sakata, Y; Shimada, Y; Sugimachi, K; Taguchi, T | 1 |
| Chollet, P; de Vries, MJ; Ganser, A; Hanauske, A; Rambusch, E; Schöffski, P; Wiese, KH | 1 |
| Fukushima, M; Kawaguchi, Y; Matsushima, E; Nagayama, S; Yamamoto, Y | 1 |
| Hasegawa, K; Koizumi, W; Kurihara, M; Nakano, S | 1 |
| Arai, K; Fujii, T; Iwasaki, Y; Kitamura, M; Saitoh, K; Shirasaka, T; Takahashi, T | 1 |
| de Vries, MJ; Gall, H; Giaccone, G; Hanauske, AR; Noordhuis, P; Peters, GJ; Pinedo, HM; Schornagel, JH; Swart, MS; Turner, SL; van Groeningen, CJ | 1 |
| Hirata, K; Shirasaka, T; Terashima, M; Tsuji, A; Yamamitsu, S | 1 |
| Baba, H; Horikoshi, N; Mitachi, Y; Ohtsu, A; Sakata, Y; Sugimachi, K; Taguchi, T | 1 |
| Hironaga, K; Kawaguchi, Y; Nagayama, S; Yamaguchi, S; Yamamoto, A; Yoshisue, K | 1 |
| Ikeda, Y; Mizuno, H; Nishimura, G; Satake, K; Taguchi, T; Tsukuda, M; Yanoma, S | 1 |
| Boku, N; Fukushima, M; Miyamoto, S; Ochiai, A; Ohtsu, A; Okabe, H; Yoshida, S | 1 |
| Ikeda, K; Kawaguchi, Y; Masuda, H; Matsushima, E; Nagayama, S; Yoshisue, K | 1 |
| Saeki, T; Takashima, S | 1 |
| Peeters, M; Van Cutsem, E | 1 |
| Araki, H; Fukushima, M; Kamiyama, Y; Shirasaka, T | 1 |
| Shirasaka, T; Taguchi, T; Tsuji, A; Yamamitsu, S | 1 |
| Hoff, PM | 2 |
| Hirose, F; Ikeda, Y; Nakamura, Y; Nishimura, G; Satake, K; Taguchi, T; Tsukuda, M; Yanoma, S | 1 |
| Diasio, RB | 1 |
| Ohtsu, A; Tahara, M | 1 |
| Asanuma, F; Kaneo, K; Miyagawa, T; Ohsaku, M; Toyoda, H; Uesato, K; Yamada, Y | 1 |
| Furuichi, N; Kawai, M; Misawa, K; Ohashi, H; Takahashi, Y; Tomita, H; Yamamori, T; Yasuda, K | 1 |
| Wada, H | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Chon, Y; Hara, H; Morita, S; Niki, M; Nishiguchi, K; Nomura, E; Okuzawa, M; Shinohara, H; Tanigawa, N | 1 |
| Hoff, PM; Saad, ED | 1 |
| Kubota, T | 2 |
| Higaki, K; Ikeda, T; Kobayashi, N; Ninomiya, M; Ohno, S; Okamura, S; Onoda, T; Shiozaki, S; Takakura, N | 1 |
| Kawaguchi, Y; Nagayama, S; Shindo, T; Yoshisue, K | 1 |
| Fukuda, S; Inoue, K; Okamura, K; Osako, T; Taneda, T; Tsuruzoe, S | 1 |
| Elasmar, SA; Hoff, PM; Saad, ED | 1 |
| White, RM | 1 |
| Hasegawa, K; Koizumi, W; Kurihara, M; Ohtsu, A; Sakata, Y; Taguchi, T | 1 |
| Inuyama, Y; Shirasaka, T; Taguchi, T; Tsukuda, M | 1 |
| Ishizuka, S; Kasuga, I; Kunisawa, A; Kurakawa, E; Minemura, K; Ohyashiki, K; Utsumi, K; Yoshida, T | 1 |
| Ichiro, M; Iwahashi, M; Nakamori, M; Nakamura, M; Nishino, E; Sakaguchi, S; Tani, M; Tanimura, H; Ueda, K; Yamaue, H | 1 |
| Kobayashi, A; Yamaguchi, M | 1 |
| Akamo, Y; Hayakawa, T; Manabe, T; Mohri, N; Takeyama, H | 1 |
| Iwatani, Y; Kusunoki, N; Miyazaki, N; Ohshima, T; Shimada, Y; Yamazaki, T | 1 |
| Doi, S; Makari, Y; Maruyama, H; Naoi, M; Tanaka, N; Yanagisawa, T | 1 |
| Furuse, K; Hasegawa, K; Kawahara, M; Kudoh, S; Matsui, K; Niitani, H; Segawa, Y; Yoshimori, K | 1 |
| Hihara, J; Hirai, T; Inoue, H; Kagawa, Y; Kim, R; Nishimoto, N; Nishiyama, M; Toge, T; Yoshida, K | 1 |
| Hayashi, Y; Kamata, T; Kanno, M; Koyasaki, N; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, T | 1 |
| Hiraiwa, A; Indo, T; Iwase, H; Iyo, T; Kaida, S; Mizuno, T; Nakamura, M; Nakarai, K | 3 |
| Fukuda, H; Sugihara, Z; Tasaka, K; Tomofuzi, Y | 1 |
| Deguchi, Y; Nashimoto, A; Sasaki, J; Tanaka, O; Yabusaki, H | 1 |
| Fujimura, T; Fushida, S; Kayahara, M; Kitagawa, H; Miwa, K; Ninomiya, I; Nishimura, G; Ohta, T; Shimizu, K | 1 |
| Goto, M; Hamaguchi, T; Matsumura, Y; Muro, K; Shirao, K; Tsukioka, Y; Yamada, Y | 1 |
| Giaccone, G; Peters, GJ; van Groeningen, CJ | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Ichinose, Y; Kawahara, M; Kudoh, S; Niitani, H; Ohashi, Y; Sugiura, T; Takada, M | 1 |
| Harada, T; Kinoshita, S; Kitagawa, S; Morishita, M; Morita, K; Nakagawa, M; Nakamura, M; Yagi, S; Yamada, T; Yokoi, K; Yoshida, K | 1 |
| Hongo, S; Kusumoto, Y; Nakagawa, M; Sado, S; Tamaki, H; Watanabe, A; Yamada, T; Yoriki, R | 1 |
| Aikawa, M; Itoh, S; Kawaguchi, A; Kihara, K; Kitte, T; Koyanagi, N; Morita, M; Nagaie, T; Nakagawa, M; Nakanishi, K; Shimotakahara, A; Wada, H; Wakiyama, S; Yagi, S | 1 |
| Hayashi, Y; Kawasaki, Y; Kobayakawa, K; Ohtsuru, M; Oka, H; Okazaki, M; Yamamura, J; Yamamura, M; Yasuda, S | 1 |
| Ako, E; Kubo, N; Sawai, Y; Yamada, Y | 1 |
| Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S | 1 |
| Funakoshi, A; Iguchi, H; Matsuo, S; Miyagi, Y; Ouchi, J; Sumii, T; Uchimura, K; Yokota, M | 1 |
| Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y | 1 |
| Ajisaka, H; Fujita, H; Inokuchi, M; Iwata, K; Kaji, M; Konishi, K; Maeda, K; Miwa, A; Yabushita, K; Yamamoto, S; Yoshioka, I | 1 |
| Fujiwara, Y; Fukuhara, K; Hashimoto, Y; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Takada, N; Takemura, M; Tanaka, Y; Ueno, M | 1 |
| Cho, H; Kanari, M; Kobayashi, O; Konishi, K; Motohashi, H; Sairenji, M; Tsuburaya, A; Yoshikawa, T | 1 |
| Araki, S; Asakura, R; Itou, A; Kobayashi, K; Naganuma, J; Teruya, M; Yanagida, O | 1 |
| Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A | 1 |
| Emoto, T; Fujii, M; Fujikawa, M; Hamada, E; Komaki, T; Naka, Y; Yoshikawa, K; Yoshioka, Y | 1 |
| Ariyoshi, N; Daigo, S; Fujieda, M; Ikeda, K; Kamataki, T; Koizumi, W; Nagayama, S; Nishioka, Y; Saigenji, K; Takahashi, Y; Tanabe, S; Yamazaki, H | 1 |
| Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T | 3 |
| Isomoto, H; Kohno, S; Mizuta, Y; Morikawa, S; Murase, K; Murata, I; Nakamura, T; Ohnita, K; Taura, K; Yamasaki, K | 1 |
| Ohta, Y; Shuto, T; Takemura, M; Takemura, S | 1 |
| Inoue, S; Kitamura, M; Umekita, N | 1 |
| Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Iwazawa, T; Kanoh, T; Kinuta, M; Matsui, S; Monden, T; Nakano, Y; Okada, K; Okamoto, S; Tamagaki, S; Tono, T; Yano, H; Yasue, A | 1 |
| Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G | 1 |
| Chinen, T; Harada, N; Ihara, Y; Kubo, S; Misawa, T; Nasu, T; Nawada, H; Yoshida, K | 1 |
| Kanai, T; Kawano, Y; Kitajima, M; Kubota, T; Otani, Y; Saikawa, Y | 1 |
| Iizuka, R; Kakihara, N; Matsumura, H; Takahashi, S; Takenaka, A | 1 |
| Sugimura, T | 1 |
| Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H | 2 |
| Abe, S; Kitago, M; Kojima, M; Kurihara, H; Ogihara, T; Sasanuma, H; Tamura, H; Wada, M | 1 |
| Hara, A; Harada, T; Hashimoto, K; Iwamoto, S; Izumi, N; Miyazaki, H; Satake, K; Shiomi, T; Tsunematu, I | 1 |
| Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Nakaguchi, K; Nakamura, M; Sue, F; Tanaka, J; Yokouchi, H; Yoshihara, W | 2 |
| Fujiya, M; Kasai, S; Kino, Y; Kohgo, Y; Matsuda, M; Saitoh, Y; Satoh, T; Shibata, N; Tanabe, H; Watari, J; Yasuda, A; Yokota, K | 1 |
| Ono, H; Sato, M; Watanabe, Y; Yano, T | 1 |
| Fukuda, S; Furuta, Y; Homma, A; Inuyama, Y; Oridate, N; Suzuki, F | 1 |
| Ina, K; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kusugami, K; Mizuno, T; Nakamura, M; Nakarai, K; Okeya, M; Shimada, M | 2 |
| Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y | 1 |
| Ishihara, A; Ishiodori, H; Koga, Y; Kudo, S; Nakamura, T; Ochiai, T; Ogata, K; Ohchi, T | 1 |
| Aoki, T; Arai, W; Hosoya, Y; Hyodo, M; Kurasina, K; Nagai, H; Saito, S; Tamada, K; Yasuda, Y; Yokoyama, T | 1 |
| Hirayama, Y; Takabayashi, H; Takeuchi, T; Tanaka, T; Watanabe, S | 1 |
| Asano, H; Goto, N; Kametani, M; Nakai, M; Oonishi, T; Shiroko, J; Tanabashi, S; Ukita, M; Yoshimura, K | 1 |
| Eng, C; Kindler, HL; Schilsky, RL | 1 |
| Denno, R; Kanai, M; Kinoshita, K; Obama, K; Takabayashi, A; Uchida, Y | 1 |
| Ichimura, K; Ishikawa, K; Nishino, H; Shinozaki, T; Tanaka, H | 1 |
| Hara, A; Hashimoto, K; Mizuno, C; Nakajo, S; Shima, T; Shiomi, T; Tanino, M | 1 |
| Bando, E; Dohba, S; Ii, T; Itoh, H; Kawamura, T; Kiriyama, M; Kojima, Y; Takegawa, S; Watanabe, K | 1 |
| Fujiwara, Y; Monden, M; Okada, Y; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T; Yoshioka, S | 1 |
| Gotoh, M; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H | 1 |
| Ajani, JA; Dwivedy, S; Hoff, PM; Lassere, Y; Medgyesy, D; Pazdur, R; Russo, M; Saad, ED; Wenske, C | 1 |
| Ito, T; Kitagawa, T; Kurihara, Y; Morimoto, Y; Nakai, S; Nishimura, J; Tanaka, Y; Yamamoto, S | 1 |
| Ikeda, S; Ikegami, N; Kaetsu, T; Kusano, M; Murayama, J; Sakamaki, H; Suzuki, S; Tanaka, K; Yajima, S | 1 |
| Hashimoto, K; Iguchi, H; Nakamura, A; Sunami, K; Takayama, M; Yamane, H | 1 |
| Hamano, K; Hirohata, S; Inoue, H; Kawaguchi, K; Maeda, T; Matsumoto, I; Nakashima, T; Niki, T; Nishisaki, H; Okutani, T; Sashikata, T; Yasutake, K | 1 |
| Hasegawa, S; Imazu, H; Masui, T; Matsubara, T; Nozoe, Y; Ochiai, M; Sakurai, Y | 1 |
| Kokai, H; Nikkuni, K; Saito, M; Tsukahara, A | 1 |
| Chida, N; Imai, G; Ishibashi, J; Iwabuchi, M; Matsuda, Y; Mochida, A; Shiina, M; Suzuki, S; Suzuki, T; Tadokoro, K; Takahashi, H; Yamada, K; Yokoyama, H | 1 |
| Akiba, Y; Aoki, D; Hibi, T; Ishii, H; Kato, S; Mukai, M; Naito, K; Takada, Y; Watanabe, C | 1 |
| Araki, Y; Inaba, S; Koyama, H; Matsushita, Y; Matsuyama, T; Nakata, M; Ogino, A; Shimizu, T; Yamada, E | 1 |
| Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y | 1 |
| Hayashi, H; Hayashi, Y; Kamata, T; Kanno, M; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, T; Ueda, Y | 1 |
| de Boer, RF; Duffaud, F; Fumoleau, P; Reinke, F; Roth, AD; Schellens, JH; Schöffski, P; Van den Brande, J; Vermorken, JB; Wanders, J; Weigang-Köhler, K | 1 |
| Hyodo, M; Kumano, H; Ohdaira, T; Ohtuka, S; Omoto, Y; Sekiguchi, C | 1 |
| Fujitani, K; Hirao, M; Kida, H; Tsujinaka, T; Yoshioka, S | 1 |
| Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y | 2 |
| Akiyama, S; Ito, K; Ito, S; Kodera, Y; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yamamura, Y | 1 |
| Endo, H; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Kubo, Y; Kurita, A; Masumoto, T; Moriwaki, T; Nakauchi, M; Nasu, J; Nishina, T; Tanimizu, M; Tsuzuki, T | 1 |
| Takeda, M; Tanaka, N; Yoshioka, H | 1 |
| Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Tamura, M; Tsuge, T; Watabe, S | 1 |
| Fumoleau, P; Gall, H; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schornagel, JH; Smid, K; Swart, MS; Turner, SL; Van Gennip, AH; Van Groeningen, CJ; Van Kuilenburg, AB; Voorn, D; Wanders, J | 1 |
| Chollet, P; Cure, H; De Boer, R; Fumoleau, P; Grünwald, V; Pavlidis, N; Schellens, JH; Schöffski, P; Wanders, J; Weigang-Köhler, K | 1 |
| Maehara, Y | 1 |
| Sasaki, T | 2 |
| Boku, N; Doi, T; Hamamoto, Y; Kawai, H; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Yano, T; Yoshida, S | 1 |
| Cho, H; Imada, T; Kobayashi, O; Konishi, K; Motohashi, H; Sairenji, M; Tsuburaya, A | 1 |
| Emi, Y; Kakeji, Y; Kimura, Y; Maehara, Y; Sakurai, M; Takahashi, I; Yonemura, Y | 1 |
| Boku, N; Inoue, K; Kinoshita, T; Konishi, M; Nakagohri, T; Oda, T; Ohtsu, A; Takahashi, S; Yoshida, S | 1 |
| Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M | 1 |
| Fukuda, K; Kaibara, N; Tsujitani, S | 1 |
| Furushima, K; Harihara, Y; Ito, K; Konishi, T; Nara, S; Noie, T | 1 |
| Goda, F; Hagiike, M; Ishimura, K; Izuishi, K; Karasawa, Y; Maeta, H; Okano, K; Usuki, H; Yachida, S | 1 |
| Abe, K; Fujiwara, H; Gotoh, M; Hoshino, Y; Irinoda, T; Kanzaki, N; Kogure, M; Nakaya, T; Nemoto, T; Ohtani, S; Oyama, K; Saito, K; Takagane, A; Terashima, M; Yonezawa, H | 1 |
| Hihara, J; Nishiyama, M; Ohta, K; Tanabe, K; Toge, T; Ueno, H; Yoshida, K | 1 |
| Ikeda, H; Inokuchi, T; Irie, A; Mizoguchi, Y; Shibahara, K; Takebe, Y; Yamada, K | 1 |
| Masuda, T; Mitachi, Y; Miyagawa, K; Oogoshi, T; Takahashi, K | 1 |
| Hasegawa, S; Imazu, H; Matsubara, T; Nakamura, Y; Nozoe, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I | 1 |
| Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T | 2 |
| Aratake, Y; Funakoshi, A; Hatanaka, F; Iguchi, H; Matsuo, S; Sumii, T; Uchimura, K; Yokota, M | 1 |
| Kanehiro, T; Morifuji, M; Murakami, Y; Sasaki, M; Sueda, T; Uemura, K; Yokoyama, T; Yokoyama, Y | 1 |
| Sawabu, N | 1 |
| Kawabata, H; Murata, A; Nakajima, H; Takase, I; Watanabe, T | 1 |
| Adachi, I; Emoto, T; Fujii, M; Fujikawa, M; Kamei, A; Komaki, T; Naka, Y; Nezu, R; Yokota, T; Yoshikawa, K; Yoshioka, Y | 1 |
| Hayakawa, Y; Inaba, T; Irinoda, T; Kaizuka, H; Meguro, E; Okada, S; Wakabayashi, J; Yamaguchi, S | 1 |
| Ashihara, E; Ichikawa, H; Kadoya, M; Kawahito, Y; Naito, Y; Omatsu, T; Sugino, S; Takanashi, Y; Takegami, T; Yamamoto, A; Yoshida, N; Yoshikawa, T | 1 |
| Ishibiki, Y; Kamano, T; Kawai, K; Matsuda, M; Sasaki, M; Shirasaka, T; Suzuki, Y; Watanabe, T | 1 |
| Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H | 1 |
| Fujisaki, M; Hino, T; Hirahata, S; Hunabashi, M; Inuzuka, K; Ishida, O; Kamei, S; Maeda, D; Takahashi, T; Tokura, H | 1 |
| Fujimoto, Y; Kawami, H; Shigematsu, H | 1 |
| Kuramochi, H; Ohashi, M; Tenma, N | 1 |
| Goto, M; Hamaguchi, T; Matsumura, Y; Muro, K; Nagayama, S; Shimada, Y; Shirao, K; Yamada, Y | 1 |
| Azuma, M; Higuchi, K; Kitamura, T; Koizumi, W; Nagaba, S; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Sato, A; Shimada, K; Taguchi, S | 1 |
| Atomi, Y; Kusano, M; Mitsumori, N; Nakajima, M; Nimura, H; Suzuki, S; Tokunaga, A; Tsukagoshi, S; Yoshiyuki, T | 1 |
| Hamakawa, H; Nakashiro, K; Shinohara, Y; Shintani, S; Terakado, N; Yano, J | 1 |
| Aoki, H; Fujii, M; Hayashi, S; Karube, H; Masuda, H; Ookame, H; Sakamoto, N; Takayama, T; Wakabayashi, K | 1 |
| Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H | 1 |
| Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T | 1 |
| Hara, A; Hashimoto, K; Koizumi, Y; Nakajo, S; Obata, H; Sakamoto, K; Shiomi, T; Tomita, M | 1 |
| Akiba, Y; Hibi, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Saikawa, Y; Yoshida, M; Yoshimizu, N | 1 |
| Fukuizumi, K; Fukumori, K; Miyahara, T; Muranaka, T; Nishi, H; Saitsu, H; Sakai, H; Sata, M; Shakado, S; Takami, Y; Takemoto, R; Watanabe, J; Yamashita, N; Yasumori, K | 1 |
| Endo, H; Endo, S; Hirao, K; Hirasaki, S; Hyodo, I; Kurita, A; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tajiri, H; Terao, T | 1 |
| Abe, K; Fujiwara, H; Fukushima, M; Irinoda, T; Nakaya, T; Oyama, K; Saito, K; Shirasaka, T; Takagane, A; Takahashi, M; Takechi, T; Terashima, M; Yonezawa, H | 1 |
| Hosokawa, A | 1 |
| Doi, T; Ohtsu, A | 1 |
| Hirabayashi, N; Hisamatu, K; Kirihara, Y; Mukaida, H; Nagamine, I; Oeda, M; Ohara, M; Oshita, A; Saeki, S; Satou, Y; Takiyama, W | 1 |
| Horiuchi, C; Kagesato, Y; Kawai, S; Mikami, Y; Mochimatsu, I; Tanigaki, Y; Tsukuda, M | 1 |
| Kameyama, H; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H | 1 |
| Akaiwa, J; Kondo, Y; Makuuchi, H; Morita, M; Nabeshima, K; Nakamura, K; Nishi, T; Ogoshi, K; Okamoto, Y; Soeda, J; Tajima, T | 1 |
| Ichiki, M; Nakagawa, A; Sai, K; Sugawara, H | 1 |
| Fujiwara, Y; Koishi, K; Nakagawa, K; Nakao, K; Nishizaki, K; Ooiwa, N; Yamamura, T | 1 |
| Aihara, T; Fukunaga, M; Kim, T; Kittaka, N; Kozuma, Y; Miki, H; Ozato, H; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N; Wada, H | 1 |
| Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H | 2 |
| Furukawa, J; Katsumoto, Y; Kinuta, M; Maruyama, K; Maruyama, N; Nagai, K; Nakaguchi, K; Sue, F; Tanaka, J; Yokouchi, H | 1 |
| Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Matsuura, N; Naoi, Y; Tanigawa, T; Tsujie, M; Yamamoto, H | 1 |
| Esumi, K; Furukawa, H; Imamura, H; Ishida, H; Kato, H; Kawasaki, T; Masuda, N; Masutani, S; Shimizu, J; Tatsuta, M; Yamamoto, K | 1 |
| Comets, E; Fumoleau, P; Hoff, P; Ikeda, K; Tanigawara, Y; Wanders, J | 1 |
| Baba, H; Kakeji, Y; Maehara, Y; Oki, E; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Nashimoto, A; Tanaka, O; Yabusaki, H | 1 |
| Suzuki, S; Yoshihara, T | 1 |
| Fujita, T; Fukuda, K; Komatsubara, S; Mano, M; Nishi, H; Ohmura, Y; Takao, T; Yano, T | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H | 1 |
| Boku, N; Gotoh, M; Koizumi, W; Matsumura, Y; Nagashima, F; Ohtsu, A; Saigenji, K; Shirao, K; Tanabe, S | 1 |
| Hayashi, K; Kitamura, Y; Oguma, H; Sasagawa, T; Takasaki, K | 1 |
| Akiba, Y; Hibi, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Saikawa, Y; Shigematsu, N; Takahashi, T; Yoshida, M | 1 |
| Hachino, Y; Kawato, N; Makihara, K; Mishima, H; Morimoto, S; Shono, Y; Tabuse, K; Tsuji, T; Tsujinaka, T | 1 |
| Akagi, Y; Hashimoto, Y; Ito, K; Murakami, Y | 1 |
| Hamada, M; Horimi, T; Ishikawa, T; Iwata, J; Morita, S; Nishie, M; Nishioka, Y; Okabayashi, T; Sakurama, K; Shibuya, Y; Shima, Y; Tsuji, A | 1 |
| Simada, K; Tamaki, T; Tubakihara, H; Tujimura, H | 1 |
| Matsuura, T; Mitsugi, K; Nagano, C; Seo, M; Tokumitsu, Y | 1 |
| Chin, K; Hatsuno, T; Horisawa, M; Kajikawa, M; Kataoka, M; Kei, F; Kinoshita, M; Kondo, K; Miura, K; Ohshima, Y; Shimoyama, S; Yamamura, K | 1 |
| Danenberg, KD; Danenberg, PV; Hayashi, K; Kawakami, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yochim, JM | 1 |
| Hamakawa, H; Hara, S; Hino, S; Nonaka, T; Shintani, S | 1 |
| Doi, R; Indou, T; Iwase, H; Iyo, T; Kaida, S; Nakarai, K; Okeya, M; Shimada, M | 1 |
| Akesaka, K; Furuya, K; Katsuta, T; Kitajima, T; Moritaka, T; Nakanishi, N; Ueda, N | 1 |
| Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Saito, S; Shirasaka, T; Yasuda, Y; Yokoyama, T | 1 |
| Fukunaga, S; Hirakawa, K; Inoue, T; Ishikawa, T; Kato, Y; Nakata, B; Nishiguchi, Y; Ohira, M; Takashima, T; Yamagata, S; Yashiro, M | 1 |
| Fujiwara, Y; Fukuhara, K; Harada, S; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y | 1 |
| Fujiwara, Y; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y | 1 |
| Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Tsuzuki, T | 1 |
| Fujimura, T; Kodera, Y; Miyashita, K; Oshita, H; Tanemura, H; Yamamura, Y | 1 |
| Aoki, H; Fujii, M; Hayashi, S; Karube, H; Masuda, H; Ookame, H; Sakamoto, N; Takayama, T; Tanaka, T; Wakabayashi, K | 1 |
| Aotake, T; Fujii, H; Hirose, Y; Matsushita, T; Tanaka, F; Yamamoto, H | 1 |
| Inazawa, K; Ishiyama, T; Nakamura, T; Suzuki, T | 1 |
| Akiba, Y; Hibi, T; Hosoe, N; Ishii, H; Izumiya, M; Mori, S; Nagata, H; Suzuki, J; Takaishi, H; Ueda, T; Yamagishi, Y | 1 |
| Schöffski, P | 1 |
| Hirakawa, K; Morita, S; Nakata, B; Ohashi, Y; Saji, S; Sakamoto, J | 1 |
| Horikoshi, N; Kimura, M; Miura, S; Morimoto, K; Saeki, T; Sano, M; Shimizu, S; Taguchi, T; Takashima, S | 1 |
| Hasegawa, S; Hattori, H; Imazu, H; Komori, Y; Masui, T; Matsubara, T; Nagai, K; Nakamura, Y; Ochiai, M; Sakurai, Y; Syoji, M; Tonomura, S; Uyama, I; Yoshida, I | 1 |
| Asai, K; Kasai, S; Kino, Y; Kobayashi, T; Kono, T; Ohara, K; Onuma, S; Yamamoto, Y | 1 |
| Goto, T; Kitada, K; Morita, N; Noda, H; Okita, K; Shiraishi, K; Takenaka, H | 1 |
| Doi, R; Goto, H; Indo, T; Iwase, H; Iyo, T; Kaida, S; Nakarai, K; Okeya, M; Shimada, M | 1 |
| Hara, A; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T | 2 |
| Fujiwara, Y; Kimura, Y; Makari, Y; Monden, M; Takiguchi, S; Yano, M; Yasuda, T | 1 |
| Kajikawa, H; Miyahara, H; Nario, K | 1 |
| Mishima, K; Nakamura, H; Obara, S; Yamamoto, K; Yoshimura, Y | 1 |
| Hirakawa, K; Hirata, K; Horikoshi, N; Isomoto, H; Mitachi, Y; Ohtsu, A; Okamura, T; Saitoh, S; Satoh, A; Shirao, K; Takada, H | 1 |
| Doi, R; Iwase, H; Kaida, S; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T | 1 |
| Baba, M; Hiramatsu, Y; Kamiya, K; Kondo, K; Konno, H; Nakamura, S; Ohta, M; Tanaka, T; Terada, H | 1 |
| Aizawa, S; Endo, M; Hashizume, T; Mitsui, T; Morohashi, H; Murata, K; Nishizawa, R; Shibazaki, I | 1 |
| Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K | 1 |
| Harada, K; Kawaguchi, S; Onoue, T; Sato, M; Yoshida, H | 2 |
| Beijnen, JH; Fumoleau, P; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schellens, JH; Schornagel, JH; Schrijvers, A; Van Groeningen, CJ; Voorn, D | 1 |
| Arai, W; Hirashima, Y; Hosoya, Y; Hyodo, M; Nagai, H; Shirasaka, T; Yasuda, Y; Yokoyama, T | 1 |
| Amano, S; Kaneda, H; Kanou, H; Kawasaki, A; Kuboi, Y; Mimatsu, K; Oida, T | 1 |
| Hara, A; Harada, T; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T | 1 |
| Hibuse, Y; Michigami, S; Morita, M; Ogawa, Y; Yada, K | 1 |
| Hirata, K; Inoue, D; Kashiwagi, K; Maeda, H; Sasaki, K; Shibuya, H; Takashima, T | 1 |
| Arai, K; Fukushima, N; Hiratsuka, M; Kimura, H; Kinoshita, T; Kojima, H; Nakajima, T; Nashimoto, A; Okamura, T; Sairenji, M; Sakamoto, J; Sasako, M; Yamamura, Y | 1 |
| Akatsu, Y; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Saikawa, Y; Yoshida, M | 1 |
| Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Furukawa, H; Ishii, K; Kamata, T; Kanno, M; Senda, K; Tajima, H; Takeda, T; Yoshimoto, K | 1 |
| Doi, R; Indo, T; Iwase, H; Kaida, S; Kato, E; Nakarai, K; Okeya, M; Shimada, M; Tuzuki, T | 1 |
| Hagiuda, J; Hoshimoto, S; Igarashi, N; Koyama, Y; Matsui, H; Miyakita, M; Takanosu, S | 1 |
| Joujima, T; Kaneko, H; Katsumata, D; Miyachi, K; Odaka, N; Ohkawa, T; Onodera, S; Sasaki, K; Shimoda, W; Sunagawa, M; Tsumuraya, M; Yoda, N | 1 |
| Kawabata, Y; Kusumoto, C; Miyamoto, K | 1 |
| Hiraga, S; Kishimoto, S; Miyoshi, Y | 1 |
| Chu, QS; Damle, B; DeCillis, AP; Denis, L; Hammond, LA; Letrent, SP; Molpus, K; Ochoa, L; Rha, SY; Roedig, B; Rowinsky, EK; Schwartz, G | 1 |
| Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T | 1 |
| Higaki, J; Ide, H; Inayama, M; Iwase, K; Kamiike, W; Kim, H; Mikata, S; Miyazaki, M; Oimatsu, N; Yoshikawa, S | 1 |
| Hirano, Y; Kawaura, Y; Kinoshita, S; Shimizu, J; Tatsuzawa, Y | 1 |
| Ishiguro, S; Isobe, N; Iwabuchi, H; Kawabe, A; Yamamoto, T; Yamasaki, S | 1 |
| Kitajima, M; Komatsu, Y; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Tanigawara, Y; Toge, T | 1 |
| Rustum, YM | 1 |
| Hirayama, R; Ichikawa, W; Nihei, Z; Sasaki, Y; Shimizu, M; Shirota, Y; Suto, K; Takahashi, T; Yamashita, T | 1 |
| Hirakawa, K; Nakata, B; Yamagata, S | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 2 |
| Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
| Kawabata, M; Yasutomo, N | 1 |
| Fujita, S; Inoue, Y; Katsura, H; Nomura, M; Sakao, J; Souda, S; Yokotani, H | 1 |
| Anazawa, S; Fujita, T; Kusuyama, A; Nagayama, A; Yajima, H; Yanaga, K | 1 |
| Ishimura, K; Karasawa, Y; Maeta, H; Ushiyama, T; Wakabayashi, H | 1 |
| Iguchi, H; Kanazawa, A; Kusuki, M; Nakamura, A; Nishiura, H; Yamane, H | 1 |
| Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J | 1 |
| Doi, R; Indo, T; Iwase, H; Kaida, S; Kato, E; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T | 1 |
| Aoyama, H; Horikoshi, N; Kimura, M; Miura, S; Morimoto, K; Noguchi, S; Ota, J; Saek, T; Sano, M; Shimizu, S; Taguchi, T; Takashima, S | 1 |
| Ahmed, SU; Okamoto, M; Oshikawa, T; Sato, M; Tano, T | 1 |
| Kotobuki, T; Niinobu, T; Otsuka, A; Taniguchi, M; Yamamoto, M | 1 |
| Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Shirouzu, K; Takeda, J; Yano, S | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H | 1 |
| Fukunaga, K; Kawai, M; Kotobuki, T; Niinobu, T; Taniguchi, H; Yamamoto, M | 1 |
| Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kato, H; Kawasaki, T; Kishi, K; Kishimoto, T; Masutani, S; Nakayama, T; Shimizu, J; Takemoto, H; Tatsuta, M; Yamamoto, K | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T | 1 |
| Fujiwara, Y; Miyata, H; Monden, M; Takiguchi, S; Yano, M; Yasuda, T | 1 |
| Damdinsuren, B; Dono, K; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, T; Yang, Y | 1 |
| Azuma, M; Higuchi, K; Koizumi, W; Nagaba, S; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S | 1 |
| Hirakawa, K; Nakata, B | 1 |
| Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T | 1 |
| Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
| Baba, H; Emi, Y; Ishida, T; Kakeji, Y; Maehara, Y | 1 |
| Toge, T; Yoshida, K | 1 |
| Andou, K; Hibi, T; Kurosawa, Y; Nagahashi, S; Nishiwaki, M; Okuda, K; Sugihara, T; Suzuki, H; Terada, S | 1 |
| Aiba, M; Hamaguchi, K; Katsube, T; Konno, S; Murayama, M; Naritaka, Y; Obu, M; Ogawa, K; Shimakawa, T; Yagawa, Y | 1 |
| Kaneko, K; Tanaka, S; Tsukahara, A | 1 |
| Ichinose, Y; Kawahara, M; Nakai, Y; Niitani, H; Sakai, H; Sugiura, T; Yoshimori, K | 1 |
| Fukushima, M; Mushiake, H; Nukatsuka, M; Shimao, K; Tahara, H; Tsunoda, T | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yonemori, K | 1 |
| Kabashima, A; Matsusaka, T; Nishizaki, T; Ojima, Y; Sakaguchi, Y; Shimabukuro, R; Tashiro, H; Yamamoto, H; Yamamura, S | 1 |
| Adachi, E; Arima, T; Atsuchi, Y; Ijuin, H; Imamura, K; Imamura, S; Kotobuki, S; Nakano, K; Tokitou, D | 1 |
| Asahina, Y; Hamano, K; Inoue, K; Itakura, J; Izumi, N; Miyake, S; Nishimura, M; Noguchi, O; Tsuchiya, K; Uchihara, M; Ueda, K | 1 |
| Ishikawa, H; Niimi, Y; Ohyama, T; Watanabe, A; Yamada, T; Yamamoto, K | 1 |
| Fujiwara, Y; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Ohkawa, S; Tarao, K; Ueno, M | 1 |
| Hirohashi, Y; Matsuyama, S; Sumi, K | 1 |
| Akita, H; Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Ohizumi, H; Sakata, Y; Takei, M; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S | 1 |
| Honda, K; Kondo, H; Niitsu, Y; Sato, Y; Sumiyoshi, T; Takahari, D; Tsuji, Y; Yoshizaki, N | 1 |
| Ito, K; Nagashima, F; Ohtsu, A; Yoshida, S | 1 |
| Hamada, M; Horimi, T; Iwata, J; Nishioka, Y; Ozaki, K; Shima, Y; Tsuji, A | 1 |
| Fukuizumi, K; Fukumori, K; Miyahara, T; Muranaka, T; Nishi, H; Saitsu, H; Sakai, H; Shakado, S; Takami, Y; Takemoto, R; Watanabe, J; Yamashita, N; Yasumori, K | 1 |
| Hachisuka, Y; Hatano, H; Johira, H; Kawata, N; Kimura, M; Miyata, N; Ohmori, K; Sanada, E; Uomoto, M; Watanabe, N; Watanabe, R; Yunoki, S | 1 |
| Abiko, R; Akasaka, H; Fujita, K; Hoshikawa, Y; Inaba, H; Itoh, F; Katoh, N; Kimura, M; Kitajima, S; Kobayashi, M; Koro, T; Miyazaki, A; Nakaya, S; Ogihara, K; Okamoto, M; Tsuda, T; Watanabe, Y; Yamauchi, S | 1 |
| Hiraki, M; Ishimitsu, T; Noguchi, R; Sakai, M; Shinozaki, Y; Tabuchi, M; Tani, H; Yunotani, S | 1 |
| Kawasaki, H; Kobori, H; Maruyama, M; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Yamada, K | 1 |
| Koizumi, H; Nakamura, K; Nakane, Y; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Tanabe, S; Tsuchiya, K | 1 |
| Kegoya, Y; Kodoi, A; Nagamine, I; Nakayama, H; Seto, Y; Takashima, I | 1 |
| Hamai, Y; Hihara, J; Ohta, K; Suzuki, T; Tanabe, K; Taomoto, J; Toge, T; Yoshida, K | 1 |
| Fukuhara, K; Iwasaki, H; Lee, S; Nishikawa, T; Osugi, H; Takemura, M | 1 |
| Deguchi, Y; Doi, H; Higuchi, A; Komai, Y; Sakai, M; Shioya, M; Takenaka, K | 1 |
| Kabashima, A; Matsusaka, T; Nishizaki, T; Ojima, Y; Okita, K; Sakaguchi, Y; Tashiro, H; Yamamura, S | 1 |
| Danenberg, KD; Danenberg, PV; Hayashi, K; Kuramochi, H; Schneider, S; Takasaki, K; Uchida, K; Yang, D; Yochim, JM | 1 |
| Abe, N; Atomi, Y; Sugiyama, M | 1 |
| Chisoku, H; Doi, T; Fukuda, Y; Katagiri, W; Kishino, M; Miwa, Y; Nakazawa, M; Ohnishi, T; Takase, T; Yui, S; Yura, Y | 1 |
| Chin, K; Furuta, K; Hatsuno, T; Horisawa, M; Kajikawa, M; Kataoka, M; Kinoshita, M; Kondo, K; Miura, K; Ohshima, Y; Shimoyama, S; Yamamura, K | 1 |
| Akanuma, M; Hata, Y; Kuriyama, H; Nonaka, T; Sawatari, T; Tsuboi, H | 1 |
| Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T | 1 |
| Fujioka, A; Fukushima, M; Ikeda, K; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Takechi, T | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Hirakawa, N; Komune, S; Kuratomi, Y; Masuda, M; Nakamura, K; Nakashima, T; Shioyama, Y; Umezaki, T; Yamamoto, T | 1 |
| Harada, N; Ihara, Y; Kubo, S; Misawa, T; Nakamura, K; Nasu, T; Ogino, H; Sadamoto, Y | 1 |
| Fukaya, S; Manabe, T; Matsumoto, K; Mizuno, I; Mohri, N; Shinagawa, N; Yasuda, A | 1 |
| Fujita, S; Okajima, S; Ooka, M; Tanaka, N; Tanaka, T | 1 |
| Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M | 1 |
| Aizawa, H; Asano, Y; Endo, Y; Fujita, H; Hatta, W; Imamura, J; Kaneko, K; Kayaba, S; Kimizuka, G; Kitamura, M; Kumagai, S; Kusuda, K; Oikawa, T; Sawada, M; Suzuki, Y; Takehana, K | 1 |
| Hasegawa, M; Hirano, K; Nakamura, K | 1 |
| Kabeshima, Y; Kageyama, T; Kameyama, N; Takahashi, Y; Tamura, Y; Toizumi, A | 1 |
| Emi, Y; Fukushima, M; Kakeji, Y; Maehara, Y; Takahashi, I; Uchida, J | 1 |
| Akamoto, S; Goda, F; Hagiike, M; Izuishi, K; Karasawa, Y; Maeta, H; Okada, S; Tsuboi, Y; Usuki, H; Yachida, S | 1 |
| Hamai, Y; Hihara, J; Tanabe, K; Toge, T; Ukon, K; Yoshida, K | 1 |
| Hirakawa, K; Ishikawa, T; Komoto, M; Nakata, B; Nomura, S; Ohira, M; Sawada, T; Takashima, T | 1 |
| Harada, S; Hashiguchi, K; Hiraki, M; Yakushiji, H | 1 |
| Ajani, J; Esmaeli, B; Golio, D; Lubecki, L | 1 |
| Hamai, Y; Hihara, J; Ohta, K; Tanabe, K; Toge, T; Ukon, K; Yoshida, K | 1 |
| Chijiiwa, K; Eto, TA; Hotokezaka, M; Iwamura, T; Shibata, N | 1 |
| Hiramatsu, K; Mizukami, Y; Momiyama, M; Nagashima, T; Niimi, K; Suzuki, M | 1 |
| Akiba, Y; Hibi, T; Higuchi, H; Iizuka, H; Izumiya, M; Nagata, H; Takaishi, H; Yamagishi, Y | 1 |
| Higashiyama, H; Ino, K; Kitai, T; Miki, A; Seo, S; Ukikusa, M | 1 |
| Kamata, S; Kotanagi, H; Kumagai, Y; Ohuchi, S; Sakusabe, M; Sawata, T; Seki, H | 1 |
| Imai, T; Kawaura, Y; Ohtake, Y; Tatsuzawa, Y; Waseda, R | 1 |
| Hamuro, J | 1 |
| Harada, K; Kawaguchi, S; Kawashima, Y; Sato, M; Yoshida, H | 1 |
| Hiki, N; Imamura, K; Kaminishi, M; Mafune, K; Shimoyama, S; Yamaguchi, H | 1 |
| Ichikawa, D; Kakihara, N; Koizumi, K; Kurioka, H; Morii, J; Morita, S; Nakamura, K; Nishiyama, M; Sakamoto, J; Shimotsuma, M; Takenaka, A; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Fujitani, K; Furukawa, H; Gotoh, M; Iishi, H; Katsu, K; Kawabe, S; Narahara, H; Taguchi, T; Takiuchi, H; Tatsuta, M; Tsujinaka, T | 1 |
| Ilson, D | 1 |
| Ajani, JA; Anbe, H; Carr, KL; Faust, J; Houghton, M; Ikeda, K; Urrea, P; Yao, JC | 1 |
| Aikou, T; Aridome, K; Arima, H; Hokita, S; Ishigami, S; Maeda, S; Maenohara, S; Miyazono, F; Natsugoe, S; Nomura, H; Saihara, T; Suenaga, K; Takao, S; Takatori, H; Uchikado, Y | 1 |
| Fujimori, M; Fukuyama, Y; Hayasaka, A; Inkyo, T; Koma, Y; Nagashima, F; Ohbu, M; Saisho, H; Sakai, Y; Saotome, T; Sato, T; Shimizu, S; Tsuchiya, S; Tsuyuguchi, T; Yugeta, H | 1 |
| Akatsu, Y; Kitajima, M; Kubota, T; Kumai, K; Nakamura, R; Nakamura, T; Otani, Y; Saikawa, Y; Takahashi, T; Yoshida, M | 1 |
| Inoue, S; Kawahara, Y; Kitamura, M; Kusano, T; Shioiri, T; Umekita, N; Warabi, M | 1 |
| Ishii, Y; Suzuki, K; Takahashi, M; Yoshida, S | 1 |
| Fujii, M; Hasegawa, Y; Kida, A; Kono, N; Sugita, M; Tsukuda, M; Yoshihara, T | 2 |
| Hosoda, S; Kamano, T; Miyakawa, A; Okuzawa, A; Sakamoto, K; Sakamoto, S; Yurimoto, S | 1 |
| Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S | 1 |
| Aratake, K; Itabashi, M; Kameoka, S; Mitsuhashi, M; Ogawa, S; Seshimo, A; Shirotani, N | 1 |
| Kobayashi, O; Tsuburaya, A; Yoshikawa, T | 1 |
| Endo, M; Hasegawa, I; Hirashima, N; Kato, A; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y | 1 |
| Jin, Y; Kasahara, A; Rino, Y; Sugano, N; Takanashi, Y; Tamagawa, H; Yamamoto, Y; Yoneyama, K | 1 |
| Ebina, T; Kawasaki, H; Kobori, H; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Tanaka, M; Yamada, K | 1 |
| Kanemoto, H; Takagi, T; Ueda, N | 1 |
| Fukasawa, T; Goto, H; Kikuchi, Y; Morita, Y; Nakajima, T; Shoji, T | 1 |
| Ando, K; Ishihara, C; Ishiwa, N; Morinaga, S; Noguchi, Y; Ogoshi, T; Shotsu, M; Takeda, A; Yamamoto, Y; Yoshida, S; Yoshikawa, T | 1 |
| Ishiguro, A; Mizuno, Y; Munakata, M; Sakata, Y; Shitara, K; Wada, R | 1 |
| Fujii, M; Goubaru, M; Makino, Y; Ogata, M; Ohta, T; Tanaka, S | 1 |
| Kubota, K; Yamamoto, S | 1 |
| Kobayashi, M; Kodera, Y; Macdonald, JS; Miyashita, Y; Morita, S; Sakamoto, J; Tsuburaya, A | 1 |
| Goto, T; Hayashi, T; Irimura, K; Kouchi, Y; Morinaga, H; Moriyama, K; Ohuchida, A; Yoshizawa, Y | 1 |
| Bandou, H; Ishiguro, K; Kinoshita, S; Koizumi, H; Kotake, M; Morita, K; Murakami, N; Tawaraya, K; Yamada, T; Yoshino, H | 1 |
| Bando, E; Endou, Y; Kawamura, T; Miyamoto, K; Sasaki, T; Shimada, T; Tanaka, M; Tochiori, S; Yonemura, Y | 1 |
| Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K | 1 |
| Furukawa, H; Imamura, H; Kishimoto, T; Tatsuta, M; Yamamoto, K | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Oshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K | 1 |
| Baba, H; Beppu, T; Okabe, K; Sano, O; Yamanaka, T | 1 |
| Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 2 |
| Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Ooshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K | 1 |
| Damdinsuren, B; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T; Yoshioka, S | 1 |
| Fuji, N; Itoh, T; Kurioka, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Fujitani, K; Furukawa, H; Gotoh, M; Hirao, M; Narahara, H; Satomi, E; Taguchi, T; Takiuchi, H; Tsujinaka, T | 1 |
| Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Fujii, M | 3 |
| Asano, R; Iida, M; Kadokura, Y; Katsuno, M; Kobayashi, S; Kubota, H; Morimoto, M; Sanbe, T; Tachibana, S; Takemura, H | 1 |
| Adachi, T; Hatoh, T; Kanno, A; Kusakabe, M; Nishio, K; Oshita, H; Saito, S; Sugiyama, A; Tanemura, H; Tomita, E; Yamada, M; Yamada, T | 1 |
| Aikou, T; Aridome, K; Hokita, S; Ishigami, S; Matsumoto, M; Nakajo, A; Natsugoe, S; Okumura, H | 1 |
| Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K | 1 |
| Aoki, T; Hamaya, M; Kouno, T; Nishida, J; Ogata, T; Sato, S; Seo, K; Tsuchida, A; Yoshida, K | 1 |
| Jingu, K; Kagaya, A; Ochiai, T; Sasagawa, K | 1 |
| I, S; Ikawa, S; Katsuragi, K; Kubota, D; Matsuyama, M; Ohba, K; Terakura, M | 1 |
| Itoh, K; Minami, H | 1 |
| Chisoku, H; Fukuda, Y; Iwai, S; Kishino, M; Nakazawa, M; Ohmae, M; Ohnishi, T; Sumi, T; Yui, S; Yura, Y | 1 |
| Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N | 1 |
| Hirata, D; Imagawa, H; Kuga, Y; Maruhashi, A; Moriya, T; Nishida, T; Ohya, T; Okanobu, H; Takahashi, M; Takemura, Y; Tanaka, T | 1 |
| Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T | 1 |
| Ito, K | 1 |
| Kiriyama, K; Koshikawa, K; Shikano, T; Suenaga, H; Taniguchi, K; Wada, M | 1 |
| Goto, H; Ina, K; Inagaki, J; Ito, A; Ito, N; Kataoka, T; Matsui, W; Nagao, S | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Sakao, J; Souda, S | 1 |
| Amagasa, H; Kusano, M; Nakao, K; Suzuki, N; Tsunoda, A; Yamazaki, K | 1 |
| Honda, R; Kanazawa, S; Kase, H; Seo, A; Teramoto, T; Tokura, N | 1 |
| Mitsuyama, S; Nishihara, K | 1 |
| Sato, Y | 1 |
| Sano, M; Sato, N | 1 |
| Ajani, JA; Benson, AB; Haller, DG; Lee, FC; Lenz, HJ; Phan, AT; Singh, DA; Strumberg, D; Yanagihara, R; Yao, JC | 1 |
| Hirakawa, K; Nakazawa, K; Ohira, M; Sawada, T; Tendo, M; Yamada, N; Yashiro, M | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 3 |
| Abe, T; Hosokawa, M; Kusumi, T; Sasaki, S; Taniguchi, M; Ueda, M; Watanabe, A; Yamashita, T | 1 |
| Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y | 1 |
| Aihara, T; Kim, C; Kittaka, N; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N | 1 |
| Kimura, H; Koyama, F | 1 |
| Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N | 1 |
| Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Oki, E; Takahashi, I; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
| Kanie, S; Kawabata, R; Koida, M; Ohuchida, A; Tanaka, G; Yoshida, T | 1 |
| Kobayashi, T; Nakanome, A; Ogawa, T; Sagai, S; Shiga, K | 1 |
| Hamakawa, H; Hino, S; Nakashiro, K; Shintani, S | 1 |
| Aita, K; Goto, T; Matsubara, T; Nemoto, H; Sanada, Y; Sasaya, S; Shirahata, A; Yoshizawa, Y | 1 |
| Von Hoff, DD | 1 |
| Kamano, T; Kawai, K; Kitajima, M; Ochiai, T; Sakamoto, K; Shirasaka, T; Tsuruoka, Y; Watabe, S | 1 |
| Fukushima, M; Konishi, K; Mizuiri, H; Sakata, Y; Suzuki, T; Tanabe, K; Ukon, K; Wada, Y; Yoshida, K | 1 |
| Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T | 1 |
| Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H | 1 |
| Asanuma, F; Atsuda, K; Etou, T; Hiraku, O; Masuda, A; Miyagawa, T; Morinaga, S; Osaku, M; Sasaki, K; Suzuki, T; Suzuki, Y; Tongu, M; Yamada, T; Yamada, Y | 1 |
| Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H | 1 |
| Ishimine, T; Kameyama, S; Kohakura, F; Kugai, Y; Kurashita, K; Miyazato, K; Murayama, R; Nagamine, Y; Shinzato, S; Tomimori, K; Uchima, H | 1 |
| Goto, M; Katsu, K; Kawabe, S; Kii, T; Kuwakado, S; Nishitani, H; Ohta, S; Takiuchi, H; Tanaka, T | 1 |
| Fujioka, T; Hirashima, Y; Kagawa, K; Kitajima, K; Kumamoto, T; Murakami, K; Noguchi, T; Sugi, S | 1 |
| Abe, T; Ise, H; Kamiyama, Y; Moriya, T; Nakagawa, K; Ohnuma, M; Uchiyama, T; Watanabe, M | 1 |
| Endo, S; Hashimoto, K; Higami, T; Itagaki, T; Itakura, M; Kataoka, Y; Koike, M; Nio, Y; Nishi, T; Yano, S | 1 |
| Kandabashi, K; Maeda, Y; Mikoshiba, M; Okamoto, R; Omuro, Y; Sasaki, E; Sasaki, T | 1 |
| Ishimasa, H; Itoi, A; Murata, H; Takashima, M; Tomoda, K | 1 |
| Hasuo, T; Ikeshima, S; Ishihara, K; Iwatsuki, M; Kuramoto, M | 1 |
| Moriyama, H; Oda, M; Tsunezuka, Y | 1 |
| Fujishiro, R; Ichinose, T; Naruse, Y; Sakamoto, R; Yamazaki, A | 1 |
| Aita, K; Moon, Y; Oshiro, Y; Yamamoto, Y | 1 |
| Harada, K; Kawashima, Y; Sato, M; Yoshida, H | 2 |
| Fukushima, M; Ikeda, T; Kitajima, M; Kubota, T; Ohmiya, H; Suto, A; Takeshita, T | 1 |
| Higuchi, K; Koizumi, W; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Hirayama, R; Ichikawa, W; Nihei, Z; Sasaki, Y; Shimizu, M; Shirota, Y; Suto, K; Takahashi, T | 1 |
| Gotoh, M; Hirabayashi, N; Ninomiya, M; Nishiyama, M; Sakamoto, J; Sato, Y; Takakura, N; Takiyama, W; Terashima, M; Todo, S; Yoshida, K | 1 |
| Kodera, Y | 1 |
| Kobayashi, M; Miyashita, Y; Nagata, N; Oba, K; Sakamoto, J; Tsuburaya, A | 1 |
| Fukushima, M; Hasegawa, S; Nagayama, S; Okabe, H; Ozaki, N; Sakai, Y; Satoh, S; Takabayashi, A; Watanabe, G | 1 |
| Higuchi, K; Kishimoto, H; Mori, S; Tauchi, K | 1 |
| Ajani, JA; Faust, J; Tetzlaff, ED | 1 |
| Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K | 1 |
| Nakagawa, S; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H | 1 |
| Horiba, K; Ishikawa, N; Kanazawa, Y; Oaki, Y; Okawa, K; Seya, T; Shirakawa, T; Tajiri, T; Tanaka, N; Tokunaga, A; Yamada, T; Yokoi, K; Yoshioka, M | 1 |
| Bando, K; Ishizuka, T; Tajiri, T; Yanagi, K; Yoshimura, K; Yoshiyasu, M | 1 |
| Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
| Akiya, T; Doi, T; Esaki, T; Hyodo, I; Kato, T; Kinjo, F; Koizumi, W; Komatsu, Y; Maeda, Y; Miyata, Y; Munakata, M; Nakano, S; Narahara, H; Saitoh, S; Sakata, Y; Shimamura, T; Takiuchi, H; Yamaguchi, K | 1 |
| Anbe, H; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Houghton, M; Kulke, MH; Meyerhardt, JA; Regan, E; Ryan, DP; Urrea, P; Zhang, J; Zhu, AX | 1 |
| Fujimura, T; Hirono, Y; Kaji, M; Kinami, S; Miwa, K; Naitoh, H; Tani, T; Ueda, Y; Yamagishi, H; Yamaguchi, A | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kobayashi, M; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R | 1 |
| Goto, A | 2 |
| Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
| Ishida, T; Munakata, K; Munakata, M; Ohtsuka, Y; Saito, J; Sato, S; Sugawara, A; Watanabe, K; Yoshikawa, M | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M | 1 |
| Kanamaru, T; Tanaka, K; Yamamoto, M | 1 |
| Fukushima, M; Milas, L; Nakamura, Y; Nakata, E; Nemoto, K; Nomiya, T; Ogawa, Y; Takai, Y; Yamada, S | 1 |
| Shirasaka, T; Taguchi, T | 1 |
| Fukushima, M | 1 |
| Furuhata, T; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Sohma, K; Taguchi, T; Tominaga, K; Uno, S; Yamada, Y; Yamaguchi, K; Yamamitsu, S | 1 |
| Yamada, Y | 1 |
| Kudou, T; Munakata, M; Sakata, Y; Shitara, K | 1 |
| Ohtsu, A | 1 |
| Azuma, M; Hanaoka, N; Higuchi, K; Ishido, K; Katada, C; Mihara, S; Nakatani, K; Nakayama, N; Naruke, A; Nishimura, K; Ryu, T; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S; Wasaburo, K | 1 |
| Hyodo, I | 1 |
| Hirakawa, K; Nakata, B; Tsuji, A | 1 |
| Asaka, M; Komatsu, Y; Miyagishima, T; Yuki, S | 1 |
| Narahara, H; Sugimoto, N | 1 |
| Hihara, J; Tanabe, K; Ukon, K; Wada, Y; Yoshida, K | 1 |
| Egashira, A; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Takahashi, I | 1 |
| Gotoh, M; Kawabe, S; Takiuchi, H | 1 |
| Aikou, T; Aridome, K; Hamanoue, M; Hokita, S; Ishigami, S; Miyazono, F; Nakajo, A; Natsugoe, S; Uenosono, Y | 1 |
| Kitajima, M; Kiyota, T; Kubo, A; Kubota, T; Kumai, K; Nakamura, R; Saikawa, Y; Shigematsu, N; Wada, N; Yoshida, M | 1 |
| Kashimura, H; Kashiwagi, H; Mitsumori, N; Nimura, H; Takahashi, N; Takayama, S; Yanaga, K | 1 |
| Fukagawa, T; Katai, H; Saka, M; Sano, T; Sasako, M | 1 |
| Eguchi, T; Shirao, K | 1 |
| Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S | 1 |
| Kamiyama, G; Kusano, M; Nakao, K; Narita, K; Oonaka, T; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K | 1 |
| Baba, H; Egashira, A; Ikeda, K; Kakeji, Y; Koga, T; Maehara, Y; Morita, M; Nishida, K; Oki, E; Tokunaga, E; Yoshida, R | 1 |
| Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T | 2 |
| Taniguchi, M; Tsujie, H; Watanabe, A | 1 |
| Funato, N; Hiramatsu, H; Ito, H; Shimizu, A; Tokashiki, R; Tsukahara, K; Yoshida, T | 1 |
| Inoue, T; Iwai, H; Minami, T; Nagata, K; Nagata, M; Ogura, M; Ohnishi, S; Tsuji, H; Yamashita, T; Yukawa, H | 1 |
| Tahara, M | 1 |
| Harada, K; Sato, M | 1 |
| Nakazawa, M | 1 |
| Kawahara, M; Yumine, K | 1 |
| Ichinose, Y; Wataya, H | 1 |
| Atagi, S | 1 |
| Saeki, T | 1 |
| Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S | 1 |
| Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Iwase, H | 1 |
| Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Takeda, Y; Umeshita, K | 1 |
| Akaza, H | 1 |
| Hayashi, Y; Kamisawa, H; Kohri, K; Kojima, Y; Sasaki, S; Yamada, Y | 1 |
| Kawasaki, M; Watanabe, J; Watanabe, K | 1 |
| Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y | 1 |
| Furukawa, M; Inoue, M; Kawase, I; Kijima, T; Kumagai, T; Niju, T; Okumura, M; Osaki, T; Tachibana, I; Takimoto, T; Yoshida, M | 1 |
| Kamigaki, T; Kawasaki, K; Kuroda, D; Kuroda, Y; Maki, K; Nakamura, T; Shinoda, H; Shirasaka, D; Takase, S; Tamura, T | 1 |
| Hanada, N; Inoue, K; Kuriwaki, K; Mochinaga, M; Osako, T; Shimajiri, S | 1 |
| Ishizuka, D; Kobayashi, K; Tada, T; Ueki, K; Wakakuwa, R | 1 |
| Hayashi, N; Ishida, H; Kodama, T; Mori, K; Noguchi, M; Okamoto, R; Okino, T; Takahashi, H | 1 |
| Anazawa, S; Eto, K; Kosuge, M; Mitsuyama, Y; Mouri, T; Ogawa, M; Ushigome, T; Watanabe, M; Yamagata, T; Yanaga, K | 1 |
| Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T | 1 |
| Arai, Y; Aramaki, T; Inaba, Y; Matsueda, K; Sato, Y; Seki, H; Takeuchi, Y; Yamaura, H | 1 |
| Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R | 1 |
| Fujiwara, I; Hachimine, Y; Kobayashi, A; Mizuta, M; Mizuta, N; Nakajima, H; Nakatsukasa, K; Sakaguchi, K; Sawai, K | 1 |
| Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D | 1 |
| Fujiwara, T; Gouchi, A; Kagawa, S; Matsuoka, J; Nishizaki, M; Tanaka, N; Teraishi, F; Tokunaga, N; Uno, F | 1 |
| Hara, S; Hashizume, S; Ishikawa, H; Iwasaki, K; Kamohara, R; Kondou, M; Minami, H; Sumida, Y; Tokunaga, T; Yoshida, K | 1 |
| Matoba, K; Ozasa, H; Shimizu, R; Toshimitsu, H | 1 |
| Egami, K; Maruyama, H; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yokoyama, T | 1 |
| Abeshima, S; Hasegawa, N; Ichimura, T; Kaneko, H; Kawabata, M; Konishi, K; Yoshida, Y | 1 |
| Hayashida, K; Iijima, N; Ishii, K; Kitazawa, K; Miura, M; Ohara, S | 1 |
| Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Saito, H; Sugiyama, A | 1 |
| Hamada, A; Masa, K; Saito, H; Sasaki, Y; Terazaki, H; Watanabe, H; Yokoo, K | 1 |
| Ishiguro, A; Kasai, M; Munakata, M; Sakata, Y; Shitara, K | 1 |
| Kagawa, I; Matsumoto, Y; Nishiwaki, K; Ohi, A | 1 |
| Funakoshi, A; Senju, T; Sumii, T | 1 |
| Mizuno, N; Sawaki, A; Yamao, K | 1 |
| Ikeda, M; Ueno, H | 2 |
| Boku, N; Fukutomi, A; Yoshino, T | 1 |
| Asada, M; Chiba, T; Fukui, T; Nishio, A; Ohashi, S; Yazumi, S | 1 |
| Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R | 1 |
| Hirakawa, K; Hirata, K; Mitachi, Y; Nakata, B; Shirasaka, T; Takeuchi, T; Tsuji, A; Yamamitsu, S | 1 |
| Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC | 1 |
| Hayashi, H; Kato, H; Matsushima, Y | 1 |
| Nakagawa, K | 1 |
| Hatakeyama, G; Hosoi, Y; Koeda, K; Obuchi, T; Sugimura, Y | 1 |
| Hagiwara, C; Hirama, K; Matsumoto, R; Ohguro, H; Sakamoto, Y | 1 |
| Aikou, T; Kitazono, M; Kubo, F; Maemura, K; Noma, H; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Ishii, E; Kondo, M; Munakata, M; Sakata, Y; Shitara, K; Wada, R | 1 |
| Iitaka, D; Kobayashi, S; Koh, T; Miyamoto, Y; Nanri, M; Oguro, A; Suzuki, T; Ujiie, K; Yamazaki, J | 1 |
| Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K | 1 |
| Ajani, JA; Benson, AB; Haller, DG; Lee, FC; Lenz, HJ; Phan, AT; Singh, D; Strumberg, D; Yanagihara, R; Yao, JC | 1 |
| Ito, S; Tanaka, A | 1 |
| Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H | 1 |
| Ishihara, T; Ito, H; Kawakami, H; Nakagawa, A; Nakamura, K; Saisho, H; Shirai, Y; Sudo, K; Uno, T; Yamaguchi, T | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Higuchi, M; Nishinaka, H; Yamano, Y | 1 |
| Asagoe, K; Azechi, H; Inoue, F; Ishii, K; Katsurada, A; Kondo, M; Nishikawa, K; Nishiura, H; Nonami, M; Otani, Y; Saiga, T; Shigemori, M; Suwa, H; Tojo, M | 1 |
| Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M | 2 |
| Kaji, S; Maruyama, T; Ozawa, T; Yagawa, A; Yasumura, T | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Kusakari, C; Matsubara, Y; Nagasaki, T; Nagayasu, T; Nakamura, Y; Nakano, H; Soda, H; Yamaguchi, H | 1 |
| Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S | 1 |
| Akamaru, Y; Ito, A; Kasugai, T; Momiyama, T; Nakamura, Y; Ohse, N; Yamamoto, S; Yamasaki, Y; Yumiba, T | 1 |
| Hiraoka, K; Mizutani, S; Nakahara, M; Oyama, T; Takahashi, H; Tori, M; Tsujimoto, M; Uchikoshi, F; Ueshima, S; Yamagami, Y; Yoshidome, K | 1 |
| Aoki, T; Hisada, M; Ishizaki, T; Katsumata, K; Mori, Y; Suzuki, S; Tsuchida, A; Wada, T | 1 |
| Itoh, F; Katakura, Y; Kobayashi, M; Matsumoto, N; Nakahara, K; Suzuki, M | 1 |
| Matsukawa, M; Sato, A | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Aoki, H; Iijima, H; Imai, H; Ishihara, S; Iwasaki, Y; Kaira, K; Mori, M; Saito, R; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Asechi, H; Hatano, E; Ikai, I; Nagata, H; Narita, M; Uemoto, S; Yanagida, A; Yasuchika, K | 1 |
| Ichinari, H; Kawano, F; Matsuda, S; Mine, K; Taneda, Y; Yonei, A | 1 |
| Hayakawa, Y; Hioki, J; Irinoda, T; Kimura, T; Kobayashi, M; Matsumoto, Y; Meguro, E; Noda, Y; Takagane, A | 1 |
| Aoyagi, K; Imaizumi, T; Koufuji, K; Matono, K; Miyagi, M; Ogata, Y; Shirouzu, K; Takeda, J; Yano, S | 1 |
| Aikou, T; Aridome, K; Arigami, T; Hokita, S; Ishigami, S; Nakajo, A; Natsugoe, S; Takatori, H; Uenosono, Y | 1 |
| Fukushima, M; Koizumi, K; Nakagawa, F; Oka, T; Sugimoto, Y; Tsujimoto, H; Tsukioka, S; Uchida, J; Watanabe, T | 1 |
| Chinen, T; Fujita, J; Hirata, T; Hokama, A; Kinjo, F; Kinjo, N; Nakachi, N; Nakamoto, M; Uchima, N; Watanabe, T | 1 |
| Banba, M; Hidaka, K; Ikeda, E; Katayama, M; Kawahara, T; Nishikawa, A; Okajima, T; Shigematsu, T; Tanaka, M | 1 |
| Fujiwara, S; Harada, K; Kawahara, K; Kitano, S; Moriyama, H; Noguchi, T | 1 |
| Akagawa, T; Fujioka, S; Hara, T; Hiramatsu, K; Hirata, A; Ito, T; Kato, K; Kutsuna, Y; Machiki, Y; Matsuba, H; Miyata, T | 1 |
| Fukushima, M; Hasegawa, S; Kawashima, K; Matsumoto, S; Nagayama, S; Nomura, A; Okabe, H; Sakai, Y; Satoh, S; Watanabe, G; Yoshibayashi, H | 1 |
| López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
| Homma, S; Kohashi, S; Kondo, M; Maeda, Y; Nakano, S; Oshima, T; Sato, Y; Shoumura, H; Takahashi, M; Todo, S; Une, Y | 1 |
| Aikou, T; Arigami, T; Hokita, S; Ishigami, S; Matsumoto, M; Nakajo, A; Natsugoe, S; Okumura, H; Setoyama, T; Uchikado, Y; Uenosono, Y | 1 |
| Funada, R; Harada, K; Hasegawa, K; Homma, N; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T | 1 |
| Hamano, R; Hirao, T; Kobayashi, T; Masuzawa, T; Shibata, K; Tokuoka, M | 1 |
| Hasegawa, Y; Kataoka, Y; Kawamura, S; Kimura, H; Okumura, S; Shimada, E; Tei, M | 1 |
| Koizumi, W; Munakata, M; Sakata, Y; Shitara, K | 1 |
| Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Tono, T; Yano, K | 1 |
| Doi, K; Kudo, K; Matsuo, A; Ogata, K; Ohchi, T; Ootao, R | 2 |
| Aikou, T; Maemura, K; Mataki, Y; Noma, H; Shinchi, H; Takao, S | 1 |
| Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S | 1 |
| Hayashi, K; Inoue, Y; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M | 1 |
| Kim, R; Saif, MW | 1 |
| Ando, T; Maruoka, Y; Ogiuchi, H; Ogiuchi, Y | 1 |
| Anegawa, E; Aoki, M; Iwamoto, O; Koga, C; Koga, M; Kusukawa, J; Tezuka, M | 1 |
| Harada, K; Kawashima, Y; Uchida, D; Yoshida, H | 1 |
| Kaneta, H; Kato, T; Kitagawa, Y; Notani, K; Satoh, A; Satoh, T | 1 |
| Katayama, T; Watari, M | 1 |
| Gabe, A; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ohta, M; Teruya, T; Yonamine, T | 1 |
| Aoki, T; Mino, A; Murahashi, K; Nishino, K; Sowa, M; Tachimori, A; Takagaki, K | 1 |
| Nagai, T; Ohgaki, K; Sugie, T | 1 |
| Arima, S; Futami, K; Kamitani, T; Koga, M | 1 |
| Komatsu, Y | 1 |
| Motoo, Y | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Ohkawa, S; Okusaka, T; Saito, H; Yamao, K | 1 |
| Ahn, JB; Chung, HC; Gong, SJ; Jeung, HC; Kim, HK; Kim, S; Kim, SY; Lim, HY; Noh, SH; Park, CH; Rha, SY | 1 |
| Furuse, J; Ikeda, H; Ikeda, M; Ishii, H; Ito, Y; Kagami, Y; Kawashima, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T | 4 |
| Fuchimoto, M; Fujikura, H; Hato, S; Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Inokuchi, M; Kawano, T; Kojima, K; Sekita, Y; Sugihara, K; Yamada, H; Yamashita, T | 1 |
| Miyagi, H; Nakamura, K; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Takahashi, S; Tsuchiya, K | 1 |
| Hidaka, K; Murakami, S; Samejima, R; Sumi, K | 1 |
| Akamatsu, M; Karimata, H; Nagahama, M; Nishimaki, T; Takaesu, H; Teruya, J | 1 |
| Ishikawa, H; Migita, K; Nakamura, T; Ohyama, T; Sakamoto, C; Watanabe, A; Yamamoto, K | 1 |
| Aoki, M; Ishiguro, A; Itoh, J; Munakata, A; Munakata, M; Sakata, Y; Shitara, K; Suzuki, K; Takahata, T | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, H; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Sohn, HJ | 1 |
| Baba, H; Maehara, Y; Matsui, T; Morita, S; Sakamoto, J; Takiuchi, H; Tsuburaya, A | 1 |
| Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Akaike, M; Imada, T; Rino, Y; Saeki, H; Sugimasa, Y; Takemiya, S; Yanoma, S; Yukawa, N | 1 |
| Kashiwagi, H; Toyama, Y; Usuba, T; Watanabe, K; Yanaga, K | 1 |
| Hampton, T | 1 |
| Ae, T; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Hayashi, K; Inaba, Y; Isobe, H; Miura, T; Moriya, T; Takiguchi, M; Watabe, S | 1 |
| Kohno, H; Ogawa, A; Okajima, A; Taguchi, T; Takenouchi, Y; Tsugane, K | 1 |
| Hirata, K; Ito, T; Sato, T; Takashima, T | 1 |
| Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H | 1 |
| Aoki, Y; Kobayashi, J; Kuroiwa, N; Miyazaki, M; Mori, M; Morishima, Y; Nakano, M; Satomi, D; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yoshida, Y | 1 |
| Cho, H; Hasegawa, S; Kobayashi, O; Osaragi, T; Sairenji, M; Tsuburaya, A; Yoshida, T; Yoshikawa, T | 1 |
| Ishiguro, A; Itoh, J; Munakata, A; Munakata, M; Sakata, Y; Shitara, K; Suzuki, K; Takahata, T | 1 |
| Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ooyama, R; Toeda, H; Toriumi, F; Yamada, A; Yoneyama, K | 1 |
| Murakami, S; Yamamoto, Y | 1 |
| Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ | 2 |
| Doi, T; Hattori, S; Hosokawa, A; Kojima, T; Minashi, K; Muto, M; Ohtsu, A; Sugiyama, T; Yano, T; Yoshida, S | 1 |
| Boku, N; Koizumi, W; Nagashima, F; Ohtsu, A; Shirao, K | 1 |
| Kurata, T; Negoro, S; Satouchi, M; Shimada, T; Takada, Y; Urata, Y; Yoshimura, S | 1 |
| Fujikawa, A; Hiroshima, K; Kasahara, Y; Kitamura, A; Kuriyama, T; Kurosu, K; Sakao, S; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K | 1 |
| Hirakawa, K; Kim, WY; Nakata, B | 1 |
| Amano, S; Aramaki, O; Kano, H; Kawasaki, A; Kuboi, Y; Mimatsu, K; Ogura, M; Oida, T | 1 |
| Hatakeyama, K; Kobayashi, T; Kurosaki, I; Kurosaki, R; Matsuo, H; Ohashi, M; Yajima, K | 1 |
| Hanada, N; Hori, K; Kusano, S; Momi, H | 1 |
| Amano, A; Ohkawa, S; Ueno, M | 1 |
| Aizaki, K; Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Ito, H; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Sawada, S; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Kitajima, M; Kiyota, T; Kubota, T; Kumagai, K; Kumai, K; Nakamura, R; Ohashi, M; Saikawa, Y; Yoshida, M | 1 |
| Aiba, K; Aoki, H; Kashiwagi, H; Koyama, T; Mitsumori, N; Nimura, H; Takahashi, N; Yanaga, K | 1 |
| Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB | 1 |
| Hirata, K; Kato, J; Kuroiwa, G; Matsunaga, T; Miyanishi, K; Nagashima, H; Niitsu, Y; Ohnuma, H; Okamoto, T; Sagawa, T; Sato, Y; Takahashi, Y; Takayama, T; Takimoto, R; Yamaguchi, K | 1 |
| Inoue, T; Kiba, T; Murata, H; Nagata, K; Nagata, M; Shimode, Y; Tomoda, K; Tsuji, H; Yamashita, T; Yukawa, H | 1 |
| Hayakawa, K; Koizumi, W; Kokuba, Y; Okayasu, I; Sato, T; Watanabe, M | 1 |
| Bando, T; Harada, K; Tamatani, T; Yoshida, H | 1 |
| Fujii, M; Kanamori, N; Kochi, M; Sou, K; Takahashi, T; Takayama, T; Wakabayashi, K | 1 |
| Akamaru, Y; Beppu, N; Ito, A; Kasugai, T; Momiyama, T; Nakamura, Y; Ohno, K; Sugimoto, Y; Tamaoka, N; Watanabe, Y; Yamasaki, Y; Yumiba, T | 1 |
| Gotoh, M; Hashimoto, Y; Hoshino, Y; Kashimura, S; Kogure, M; Odashima, Y; Osuka, F; Otani, S; Saito, T; Saze, Z; Soeta, N; Terashima, M; Watanabe, K | 1 |
| Ishida, M; Kimura, T; Mimura, T; Niguma, T; Tsutsui, N | 1 |
| Aoki, T; Kato, F; Katsumata, K; Mori, Y; Tokita, H; Tsuchida, A; Yamamoto, J | 1 |
| Doi, T; Fujimi, A; Izumi, K; Kanisawa, Y; Kikuchi, S; Kitahara, T; Ohta, H; Okuda, T; Sato, Y | 1 |
| Ajani, JA; Cen, P | 1 |
| Ferdous, T; Harada, K; Yoshida, H | 1 |
| Itoh, J; Kawasaki, H; Kijima, H; Matsuya, H; Miyamoto, K; Sasaki, M; Shibata, S | 1 |
| Morita, R; Nishikawa, M; Okuda, T; Sakata, C; Tokuhara, T | 1 |
| Fujii, M; Hirota, M; Matsuda, C; Mikata, S; Morimoto, Y; Nishikawa, K; Tanaka, Y | 1 |
| Ichikawa, K; Katou, T; Kodera, Y; Okuda, N; Takahashi, K; Yagi, Y; Yamaoka, T | 1 |
| Han, I; Hatori, S; Iwasaki, H; Murakami, H; Suzuki, M; Takanashi, Y; Yamakawa, M | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E; Yoshino, M | 1 |
| Hoshi, Y; Kameda, K; Munakata, M; Muto, O; Sakata, Y; Shitara, K | 1 |
| Arakawa, T; Fujiwara, Y; Higuchi, K; Kuwamura, H; Oshitani, N; Sasaki, E; Tominaga, K; Watanabe, T | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Saisho, H; Sato, T; Tanaka, K; Yamao, K; Yonemoto, N | 1 |
| Koide, N; Miyagawa, S; Murakami, M; Ota, H; Saito, H; Sato, T; Suzuki, A | 1 |
| Arai, K; Fujii, M; Furukawa, H; Higashino, M; Imamura, H; Kinoshita, T; Kurita, A; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T; Yamamura, Y | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Kitagawa, Y; Kitajima, M; Kubo, A; Kubota, T; Kumagai, K; Kumai, K; Nakamura, R; Saikawa, Y; Shigematsu, N | 1 |
| Kusano, M; Nakao, K; Narita, K; Suzuki, N; Tsunoda, A; Watanabe, M; Yamazaki, K; Yasuda, N | 1 |
| Fujiyama, J; Hori, S; Miki, A; Ohtani, H; Sawada, Y; Tsuda, A | 1 |
| Hirano, S; Kikuchi, Y; Kouzuma, T; Saito, T; Sato, T | 1 |
| Kitagawa, Y; Kitajima, M; Kubota, T; Kumai, K; Nakamura, R; Saikawa, Y; Wada, N; Yoshida, M | 1 |
| Ishibashi, M; Kogo, M; Masuda, N; Moridera, K; Nishimura, N; Nishioji, K; Noguchi, K; Takayama, T; Urade, M | 1 |
| Hiraoka, K; Mizutani, S; Nakahara, M; Oyama, T; Takahashi, H; Tori, M; Uchikoshi, F; Ueshima, S; Yamagami, Y; Yoshidome, K | 1 |
| Chikuba, A; Chikuba, H; Nakamoto, M; Nezu, M; Shimamura, H; Suzuki, T; Takiue, T; Teraishi, F | 1 |
| Ako, E; Kanemura, M; Kubo, N; Nishimura, S; Nobuhara, Y; Sunami, T; Yo, T | 1 |
| Matsui, K; Morita, S; Shinbo, M; Tazawa, K; Tsukada, K; Yamada, A; Yamagishi, F; Yoshida, T | 1 |
| Hamakawa, H; Harada, K; Nagahata, S; Nagayama, M; Osaki, T; Ryoke, K; Sato, M; Ueyama, Y; Yoshimura, Y | 1 |
| Cho, BM; Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Lee, BJ; Shin, HJ; Sohn, CH; Wang, SG | 1 |
| Horiba, K; Ishikawa, N; Ishiwata, T; Kanazawa, Y; Koizumi, M; Naito, Z; Ohaki, Y; Okazaki, H; Seya, T; Shinji, S; Tajiri, T; Tanaka, N; Yamada, T; Yokoi, K | 1 |
| Fukuda, M; Ito, H; Iwanami, Y; Miyamoto, Y; Nagai, H; Nakata, A; Nanjo, H; Takano, H | 1 |
| Hayashi, K; Maruyama, K; Mori, K; Motoyama, S; Ogawa, J; Sato, Y; Suzuki, H; Usami, S | 1 |
| Nakano, T; Tomimatsu, H | 1 |
| Fujisawa, T; Hirano, H; Koyanagi, M; Mori, T; Ouchi, S; Sano, W; Tachibana, S; Tsuchihashi, D; Uchikoga, O; Ueyama, S; Yoshimura, H | 1 |
| Hoki, N; Ishikawa, H; Mizuno, N; Sawaki, A; Takagi, T; Yamao, K | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N | 1 |
| Doki, Y; Fujita, J; Fujiwara, Y; Kawabata, R; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, Y; Yamasaki, M | 1 |
| Arai, M; Fujita, Y; Fujitani, S; Fukuda, K; Hashimoto, A; Horiki, N; Ishii, N; Izuka, Y; Suzuki, S; Tsukamoto, M | 1 |
| Iga, N; Kanaya, Y; Maruyama, S; Masuda, H; Shimo, T; Shoga, K; Tomii, K; Yokoyama, N | 1 |
| Arita, A; Fujimoto, M; Mochizuki, K; Sakai, Y | 1 |
| Hirakawa, K; Mitachi, Y; Morita, S; Nakata, B; Ohashi, Y; Saji, S; Sakamoto, J; Shirasaka, T; Tsuji, A | 1 |
| Morizane, C | 1 |
| Chida, K; Inui, N; Kaida, Y; Nakamura, H; Suda, T; Watanabe, H | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Masumoto, T; Ohkawa, S; Okusaka, T; Sawaki, A | 1 |
| Fujimoto, T; Kuhara, K; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Shimakawa, T; Umehara, A; Yokomizo, H; Yoshimatsu, K | 1 |
| Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M | 1 |
| Fujimura, T; Fukushima, N; Fushida, S; Goda, F; Hirono, Y; Imano, M; Kaji, M; Kurita, A; Kurita, N; Nashimoto, A; Ohta, T; Tanemura, H; Tsujitani, S; Watanabe, Y; Yamaguchi, K | 1 |
| Aoki, T; Hamada, H; Kenno, S; Nagaoka, Y; Oguro, S; Okuda, K; Shimokuni, T; Takada, J; Tani, C; Uno, Y | 1 |
| Iwagami, S; Iwasaki, Y; Matsumoto, H; Nunobe, S; Ohashi, M; Takahashi, K; Watanabe, F; Yamaguchi, T; Yasutome, M | 1 |
| Ami, K; Ando, M; Ganno, H; Ito, T; Kato, H; Nagahama, T; Ohbu, M; Taira, M; Tei, S | 1 |
| Doi, M; Egawa, T; Hayashi, S; Ito, Y; Kitano, M; Nagashima, A; Sekine, K; Shimizu, M; Yoshii, H | 1 |
| Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Tani, M | 1 |
| Doi, T; Handa, R; Hoshi, M; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Oshima, K; Oshima, S | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohshiro, R; Ohta, K; Ohzato, H; Takemoto, H; Tatsuta, M | 1 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M | 1 |
| Baba, H; Nagahama, T; Sawada, Y; Shimoda, M; Shimoda, S; Suzuki, K | 1 |
| Iwagami, S; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nishigori, T; Nunobe, S; Ohashi, M; Takahashi, K; Yamaguchi, T; Yasutome, M | 1 |
| Aoki, T; Hatano, H; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Uemura, Y | 1 |
| Egawa, C; Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Hamaguchi, T; Kajiwara, T; Kato, K; Matsubara, J; Moriwaki, T; Nakajima, TE; Nishina, T; Oka, T; Okayama, Y; Shimada, Y; Shimoda, T; Shirao, K; Yamada, Y | 1 |
| Hizawa, N; Ohara, G; Satoh, H | 1 |
| Fujita, J; Hoshimoto, S; Ikeda, M; Kato, T; Morise, Z; Sugioka, A | 1 |
| Aikou, T; Aridome, K; Hokita, S; Ishigami, S; Natsugoe, S; Sasaki, K | 1 |
| Boku, N; Fukutomi, A; Kinoshita, T; Kondo, S; Maeda, A; Nagino, M; Uesaka, K | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Imamoto, H; Imamura, H; Imano, M; Ishida, H; Kimura, Y; Narahara, H; Shimokawa, T; Takiuchi, H | 1 |
| Kitagawa, Y; Kitajima, M; Kubota, T; Kumagai, K; Kumai, K; Nakamura, R; Saikawa, Y; Takahashi, T | 1 |
| Akiyama, N; Arai, F; Funakoshi, K; Ikarashi, S; Ito, H; Kato, T; Motoyama, H; Sasaki, S | 1 |
| Akagi, J; Fukami, K; Masuda, Y; Takai, E; Takemoto, T; Yagishita, Y | 1 |
| Kawano, I; Yufu, M | 1 |
| Hara, K; Maruyama, T; Ohkohchi, N; Takagaki, T | 1 |
| Adachi, M; Hirose, T; Hosaka, T; Ishida, H; Nakashima, M; Okuda, K; Sugiyama, T; Yamaoka, T | 1 |
| Aoyagi, Y; Azuma, M; Kougo, H; Minobe, S; Takagi, K; Yamaguchi, T; Yonehara, T | 1 |
| Akiya, T; Hara, T; Kobayashi, O; Koizumi, W; Miyashita, K; Nagaie, T; Narahara, H; Nishizaki, T; Orita, H; Takagane, A; Takagi, M; Takagi, S; Takeuchi, M; Takiyama, W; Toh, Y; Yamamura, Y; Yanaoka, K | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Shien, T; Shimizu, C; Yonemori, K | 1 |
| Cascinu, S | 1 |
| Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M | 1 |
| Aikou, T; Aridome, K; Etoh, T; Hamanoue, M; Hokita, S; Ishigami, S; Iwashita, T; Komatsu, H; Maehara, Y; Maenohara, S; Miyazono, F; Morita, S; Nakajo, A; Nakano, S; Natsugoe, S; Sakamoto, J; Satoh, K; Takiuchi, H | 1 |
| Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J | 1 |
| Dono, K; Kobayashi, S; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Takeda, Y; Umeshita, K; Wada, H | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Hirao, M; Imano, M; Ishihara, R; Narahara, H; Taguchi, T; Takiuchi, H; Tsujinaka, T; Tsukuma, H; Uedo, N | 1 |
| Mori, K; Murata, K; Saito, K; Terao, K | 1 |
| Imaizumi, T; Kizaki, J; Koga, A; Miyagi, M; Shirouzu, K; Yano, S | 1 |
| Iino, K; Morita, M; Sasaki, H; Tomita, K; Toyoshima, H | 1 |
| Furukawa, H; Nishioka, T; Saito, A; Saito, N; Suzuki, K; Tsutsumida, A; Yamamoto, Y | 1 |
| Matsui, K; Nakagawa, S; Nashimoto, A; Nomura, T; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H | 1 |
| Adachi, A; Hashimoto, H; Uchisako, H; Uchiyama, T | 1 |
| Matsuda, T; Shikata, S | 1 |
| Doi, K; Kudoh, K; Matsuo, A; Ogata, K; Ohchi, T; Ohtao, R; Sugimura, H | 1 |
| Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Manoh, M; Mishima, H; Miyazaki, M; Nakamori, S; Ogawa, H; Takeda, M; Tsujinaka, T; Yasui, M | 1 |
| Aoyama, I; Arai, O; Doi, A; Hata, T; Hirao, K; Jinno, A; Katayama, S; Kikuchi, O; Kiyosuke, Y; Maeda, Y; Matsueda, K; Miyoshi, M; Mouri, H; Sakai, A; Tanabe, W; Terashima, Y; Tsuji, Y; Yamamoto, H; Yamamoto, N | 1 |
| Chiba, T; Doi, R; Fukushima, M; Ishiguro, H; Kami, K; Kanai, M; Kawaguchi, Y; Kitano, T; Matsumoto, S; Misawa, A; Nishimura, T; Yamauchi, J; Yanagihara, K; Yasuda, H; Yazumi, S; Yoshikawa, K | 1 |
| Bae, JM; Choi, IJ; Kim, CG; Kim, HK; Kim, NK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW | 1 |
| Ahn, JB; Chung, HC; Jeung, HC; Jung, JY; Noh, SH; Rha, SY; Yang, WI | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Fukunari, H; Hatano, T; Hayashi, T; Inada, S; Kawauchi, Y; Nikkuni, K; Nishimura, A; Sato, T; Shimizu, T; Sugita, M; Takahashi, S; Tomidokoro, T; Yanagi, M; Yoshida, H | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W | 1 |
| Fujita, K; Ichikawa, W; Sasaki, Y | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
| Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y | 1 |
| Aizawa, T; Anami, K; Kimura, Y; Kubo, N; Noguchi, T; Tokuishi, K | 1 |
| Ikebe, T; Kaneko, M; Tanaka, H; Terakura, M; Yoshioka, H | 1 |
| Inagaki, D; Katayama, K; Oosawa, H; Shiraishi, R; Tanabe, H; Tani, K; Wada, H; Yasuda, S | 1 |
| Kono, T; Noguchi, T; Nohara, J; Sakaguchi, Y; Terada, Y | 1 |
| Akiyama, S; Fukushima, M; Oka, T; Ooyama, A; Yamamoto, M; Zhao, HY | 1 |
| Hayashi, K; Kamikozuru, H; Kuramochi, H; Nakajima, G; Yamamoto, M | 1 |
| Ahn, JB; Baik, SH; Cheon, SH; Choen, JH; Choi, HJ; Chung, HC; Jeung, HC; Keum, KC; Kim, NK; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Anami, S; Furukawa, H; Hasegawa, K; Imamura, H; Kitada, N; Miyabe, T; Morimoto, S; Morita, S; Tabuse, K; Watari, M; Yamasaki, H | 1 |
| Ikeda, S; Ikegami, N; Murayama, J; Sakamaki, H; Shimizu, H; Tanaka, K; Yajima, S | 1 |
| Furuse, J; Ioka, T; Ishii, H; Ito, Y; Okusaka, T; Shibuya, K; Shinchi, H; Yamada, S | 1 |
| Hwang, SW; Jang, KM; Jung, JY; Kim, HJ; Kim, JH; Kim, MJ; Kwon, JH; Lee, BH; Lee, HW; Park, CK; Park, SR; Song, HH; Yang, DH; Zang, DY | 1 |
| Ikeda, Y; Ishitoya, J; Mitake, D; Tanigaki, Y; Tsukuda, M; Yabuki, K | 1 |
| Abe, S; Kondo, H; Kukitsu, T; Mizushima, T; Nagashima, H; Oura, K; Sumiyoshi, T; Tamura, F; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Iwata, S; Katoh, H; Kitaoka, A; Masumoto, H; Ohtsuka, K; Yamaki, S | 1 |
| Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K | 1 |
| Ishida, T; Kameyama, T; Matsuyama, A; Okamoto, M; Okazaki, J; Tsutsui, S; Utsunomiya, T; Yamamoto, M | 1 |
| Kuwahara, A; Masuda, T | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Matsunaga, N; Nakagawa, Y; Yanagawa, K | 2 |
| Baba, E; Fujihara, M; Kaji, Y; Kusaba, H; Nagashima, R; Nakano, S | 1 |
| Jeen, YT; Kim, HK; Kim, YH; Seo, HY; Shim, BY; Yang, J | 1 |
| Inaba, K; Isogaki, J; Kamoshida, S; Komori, Y; Sakurai, Y; Tsutsumi, Y; Uyama, I; Yoshida, I | 1 |
| Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB | 1 |
| Chida, K; Fujii, M; Inui, N; Nagayama, M; Naitoh, T; Nakamura, H; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Yasuda, K | 1 |
| Aikou, T; Arigami, T; Arima, H; Ishigami, S; Kita, Y; Matsumoto, M; Nakajo, A; Natsugoe, S; Sasaki, K; Setoyama, T; Uchikado, Y; Uenosono, Y | 1 |
| Ahn, JS; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SR; Nam, TK; Shim, HJ; Yang, DH | 1 |
| Fujitani, K; Furukawa, H; Inoue, K; Narahara, H; Sugimoto, N; Taguchi, T; Takiuchi, H; Tsujinaka, T; Tsukuma, H; Uedo, N | 1 |
| Nishiyama, M | 1 |
| Ichikawa, W; Sasaki, Y | 1 |
| Inamine, S; Miyata, M; Sunagawa, H; Takeshima, M; Zaha, H | 1 |
| Cao, J; Li, J; Liu, Y; Lu, F; Yin, J; Zhu, X; Zuo, Y | 1 |
| Masai, Y; Nakagawa, T; Nibu, K; Otsuki, N; Sasaki, R; Tsukuda, M | 1 |
| Barone, C; Pozzo, C | 1 |
| Akiyama, I; Fujita, Y; Hasegawa, K; Morimoto, S; Shono, Y; Tabuse, K; Tsuji, T | 1 |
| Aoki, Y; Furuta, R; Hibi, S; Ina, K; Kabeya, M; Kataoka, T; Kawai, M; Kayukawa, S; Kojima, S; Masaki, A; Mori, F; Nagao, S; Yamada, K | 1 |
| Hirose, N; Kawano, T; Matsusaki, K; Minamisono, Y; Miura, O; Morita, M; Nagasaki, S; Okamoto, F; Okazaki, Y; Toda, T; Yamada, T | 1 |
| Saitou, T; Sasaki, H; Tokunaga, Y | 1 |
| Fujimori, N; Fujimoto, C; Funakoshi, A; Maruyama, Y; Niina, Y; Sumii, T | 1 |
| Furuta, S; Inaba, K; Isogaki, J; Kamoshida, S; Komori, Y; Sakurai, Y; Sunagawa, R; Tsutsumi, Y; Uyama, I | 1 |
| Aragane, K; Furukawa, M; Hoshino, S; Kitamura, T; Sugano, T | 1 |
| Igarashi, T; Imai, H; Iwabuchi, T; Matsumoto, H; Obana, N; Ooyauchi, M; Sakamoto, K; Satou, Y | 1 |
| Itoh, K; Konishi, T; Minami, K; Murata, K; Nakajima, K; Noie, T; Tanishima, Y | 1 |
| Arai, H; Kashiwabara, M; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Mizutani, T; Nishi, Y; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T | 1 |
| Aikou, T; Arigami, T; Hamada, T; Ishigami, S; Matsumoto, M; Nakajo, A; Natsugoe, S; Setoyama, T; Uchikado, Y; Uenosono, Y | 1 |
| Fujii, Y; Goto, T; Hara, T; Katayama, K; Kimura, S; Okitsu, H; Ozaki, K; Yamashita, M | 1 |
| Abe, Y; Mitsuyama, S; Nasu, T; Tanabe, Y; Tokunaga, M; Toyoshima, S | 1 |
| Fujimoto, K; Hara, T; Kurahashi, T; Muraki, Y; Nagata, M; Yamashita, Y; Yasuda, Y | 1 |
| Hirata, K; Kawasaki, H; Kukita, K; Mizushima, Y | 1 |
| Ando, T; Fukuoka, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Miwa, T; Mori, F; Nagao, S; Nishio, T; Takeuchi, Y | 1 |
| Baek, JH; Chang, HM; Kang, HJ; Kang, WK; Kang, YK; Kim, JG; Kim, TW; Lee, JL; Lee, KH; Min, YJ; Park, SR; Ryoo, BY; Ryu, MH; Shin, DB; Zang, DY | 1 |
| Hizawa, K; Iida, M; Matsumoto, T; Nagata, Y; Nakamori, M; Taniguchi, M | 1 |
| Ebi, N; Fukuoka, M; Katakami, N; Kubo, A; Miyazaki, M; Nakagawa, K; Nishimura, T; Okamoto, I; Sugawara, S; Takeda, K; Yoshioka, H | 1 |
| Anami, S; Furukawa, H; Imamura, H; Kato, H; Kishimoto, T; Masutani, S; Miyazaki, Y; Tomotsu, K; Usui, T; Watanabe, M | 1 |
| Anami, S; Azuma, J; Fujii, C; Fujino, M; Furukawa, H; Matsumura, T; Nishiguchi, T; Ohno, M; Ohsato, H; Tsuge, M; Yamamoto, A; Yasui, Y | 1 |
| Fukuda, N; Niki, M; Nomoto, T; Sugiyama, Y; Wada, J | 1 |
| Akutsu, N; Iwashita, C; Kenmochi, T; Maruyama, M; Otsuki, K; Saigo, K | 1 |
| Kondou, K; Noda, K; Tanabe, D; Uchiyama, T | 1 |
| Fujimura, M; Fukushima, W; Hirosawa, H; Ichihashi, K; Ishida, Y; Ishiura, Y; Izumi, R; Kasahara, K; Kodama, K; Maruyama, K; Miyazu, M; Motoi, I; Saito, K; Tanikawa, F; Terasaki, Y; Yamamoto, H; Yokawa, S; Yoneda, K | 1 |
| Fukao, K; Irabu, S; Kasagawa, T; Kusashio, K; Matsumoto, M; Nobumoto, D; Suzuki, M; Tashima, Y; Tonooka, T; Udagawa, I; Yasutomi, J | 1 |
| Iizaka, M; Inoue, K; Kinoshita, K; Tanaka, E; Uto, N; Yoshida, Y | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Wada, H; Yamamoto, Y | 1 |
| Akaike, H; Fujii, H; Kawaguchi, Y; Kono, K; Mimura, K; Mizukami, Y; Sugai, H | 1 |
| Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Takagi, S; Tanabe, S | 1 |
| Aikata, H; Azakami, T; Chayama, K; Jeong, SC; Kawakami, Y; Kawaoka, T; Mori, N; Takahashi, S; Takaki, S; Uka, K | 1 |
| Komatsu, Y; Munakata, M; Muto, O; Sakata, Y; Shimaya, S; Shitara, K; Yuki, S | 1 |
| Atagi, S; Fukai, S; Kawaguchi, T; Kawahara, M; Komatsu, H; Kubo, A; Kusunoki, Y; Okishio, K; Saito, R; Takada, M; Tomizawa, Y; Uehira, K; Yumine, K | 1 |
| Naito, T; Ono, A; Yamamoto, N | 1 |
| Azuma, M; Futawatari, N; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Saegusa, M; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
| Hara, H; Kajikawa, S; Mochizuki, T; Mukawa, K; Nakamura, T; Oguchi, H; Ohta, H; Shimada, K; Shinji, A; Yamamura, N; Yazawa, K | 1 |
| Adachi, K; Arimoto, Y; Nishio, K; Ohba, H; Ohtani, H; Shintani, M; Yui, S | 1 |
| Hirai, T; Idenoue, S; Kaizu, T; Kamiya, N; Kondo, Y; Naito, M; Nishi, Y; Shiraishi, H; Tsuchihashi, S; Yasogawa, Y | 1 |
| Horiuchi, H; Kashihara, M; Kishimoto, Y; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Ureshino, M | 1 |
| Hashida, H; Kanai, M; Tada, M; Takabayashi, A; Ueda, S; Yoshida, M | 1 |
| Ishii, Y; Mado, K; Manmoto, J; Masuda, H; Mazaki, T; Okame, H; Suzuki, K; Takayama, T | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Tsuchiya, T; Utsugi, M; Yanagitani, N | 1 |
| Shiba, E; Takahara, S; Tokushima, H; Yamamoto, H | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osaki, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Choi, IS; Choi, JH; Chung, HC; Hong, YS; Kang, WK; Kim, SY; Lee, JJ; Lee, KH; Lee, YY; Song, HS; Woo, IS | 1 |
| Choi, HS; Hong, CW; Hong, YS; Jeong, SY; Jung, KH; Kim, BC; Kim, DY; Kim, SY; Park, JW; Sohn, DK | 1 |
| Harada, H; Hiraoka, M; Itasaka, S; Kizaka-Kondoh, S; Morinibu, A; Ou, G; Shibuya, K; Shinomiya, K; Xie, X; Zeng, L | 1 |
| Bang, S; Chung, JB; Kim, HM; Park, JY; Park, SW; Seong, J; Song, SY | 1 |
| Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Lee, GW; Oh, SY | 1 |
| Bekaii-Saab, T; Haghighat, P | 1 |
| Ebara, T; Hara, K; Hisada, T; Ishikawa, H; Ishizuka, T; Kaira, K; Kawamura, H; Kawata, T; Mori, M; Nakano, T; Nonaka, T; Sakurai, H; Shimizu, K; Suga, T; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Kishimoto, K; Nishiyama, A; Ono, T; Sasaki, A; Yoshida, S; Yoshihama, Y | 1 |
| Hirata, E; Komatsu, M; Nagai, N; Shiroyama, Y; Yunokawa, M | 1 |
| Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H | 1 |
| Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Nakashima, K; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Kim, GH; Seol, YM; Shin, HJ; Song, GA; Song, MK | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| Akiho, H; Goto, A; Itaba, S; Murao, H; Nagai, E; Nakamura, K; Segawa, Y; Takayanagi, R; Tokunaga, N; Yoshinaga, S | 1 |
| Fujii, Y; Ishiguro, H; Kimura, M; Kuwabara, Y; Mitsui, A; Ogawa, R | 1 |
| Fujii, S; Imada, T; Kanazawa, A; Kunisaki, C; Makino, H; Masuda, M; Murakami, H; Nagano, Y; Ohshima, T; Rino, Y; Sato, T; Tsukahara, T; Yamada, T; Yamamoto, N; Yukawa, N | 1 |
| Shimizu, Y; Tanaka, N; Tsunezuka, Y | 1 |
| Goto, S; Hatanaka, N; Hirose, M; Itoi, H; Kamiyama, J; Kubota, T; Matsumura, A; Okamoto, K; Otsuji, E; Oyamada, Y; Sakurai, K; Taiyoh, H | 1 |
| Hatakeyama, K; Hirota, M; Kanda, T; Kobayashi, T; Kosugi, S; Ohashi, M; Yajima, K | 1 |
| Shirasaka, T | 1 |
| Chikamori, K; Gemba, K; Hotta, K; Kamei, H; Kanazawa, S; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Tabata, M; Takata, S; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Bae, SH; Eun, JR; Hyun, MS; Jang, BI; Kim, MK; Kim, TN; Lee, KH; Lee, SA; Ryoo, HM | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY | 1 |
| Chung, H; Hagiwara, S; Hatanaka, K; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takahashi, S; Tatsumi, C; Ueda, T; Ueshima, K | 1 |
| Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Yasuda, Y; Yokoyama, T; Zuiki, T | 1 |
| Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M | 1 |
| Aiba, K; Ishida, Y; Kawakami, M; Kitajima, K; Kobayashi, S; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Amatsu, H; Iguchi, H; Kanazawa, A; Kusuki, M; Nakamura, A; Uyama, T; Yamane, H | 1 |
| Ishikawa, T; Isozaki, Y; Kiyota, K; Kokura, S; Matsuyama, R; Nagao, Y; Okita, M; Oyamada, H; Suzuki, K; Yoshikawa, T | 1 |
| Harafuji, I; Mitsuoka, S; Onoda, T; Tabuchi, Y | 1 |
| Hara, A; Watanabe, H | 1 |
| Fujimoto, H; Harada, E; Horiuchi, N; Iwasaka, N; Kashima, M; Kimura, S; Masuda, K; Matsushita, T; Nakamura, S; Oshima, Y; Shichijo, K; Shinomiya, S; Takeichi, T; Tamaki, Y; Yoshida, S | 1 |
| Doki, Y; Fujiwara, Y; Miyata, H; Nakajima, K; Nishida, T; Takiguchi, S; Yamazaki, M | 1 |
| Iwagami, S; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Nunobe, S; Ohashi, M; Takahashi, K; Yamaguchi, T | 1 |
| Ami, K; Ando, M; Fukuda, A; Ganno, H; Maruyama, M; Nagahama, T | 1 |
| Agata, T; Aoyama, H; Funahashi, M; Hanai, T; Honda, K; Katsuno, H; Koide, Y; Maeda, K; Matsuoka, H; Noro, T; Sato, H; Shiota, M | 1 |
| Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Aoki, T; Igarashi, Y; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanida, T; Tsukao, Y; Uemura, Y | 2 |
| Baba, H; Fujiwara, N; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Shimoda, S; Tamai, S; Tanaka, K | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ohzato, H; Takemoto, H; Tatsuta, M; Yamamoto, T | 1 |
| Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ota, K; Tatsuta, M | 1 |
| Doi, K; Kawasaki, Y; Kudo, K; Maeda, T; Ogata, K; Ohchi, T; Suzuki, S | 1 |
| Doi, M; Egawa, T; Hayashi, S; Ito, Y; Nagashima, A; Ohashi, M | 1 |
| Aoki, T; Hamada, H; Kenno, S; Oba, G; Okuda, K; Shimada, S; Shimokuni, T; Takada, J | 1 |
| Iida, M; Tokairin, Y; Yamazaki, S | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Akagi, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kato, H; Kawanishi, K; Kitada, M; Maeda, S; Nomura, M; Oshima, N; Sasaki, T; Shimano, T; Shimizu, J; Takamoto, K; Tsukahara, Y | 1 |
| Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N | 1 |
| Oka, M; Yoshino, S | 1 |
| Fujimoto, T; Nakamura, Y; Ogawa, K; Osawa, G; Otani, T; Tsunoda, T; Yokomizo, H; Yoshimatsu, K | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W | 1 |
| Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S | 1 |
| Fukumoto, T; Hachiya, O; Kamio, Y; Kimura, W; Nomura, T; Shibata, K; Takasu, N | 1 |
| Itakura, T; Sugimoto, T; Uesaka, K | 1 |
| Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Yahagi, N | 1 |
| Jeong, CY; Ju, JH; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Kim, TH; Lee, GW | 1 |
| Hanata, K; Ishikawa, K; Nanjo, H; Suzuki, S | 1 |
| Hwang, SW; Jang, KM; Jung, JY; Kim, HJ; Kim, HY; Kim, JH; Kim, KO; Kim, MJ; Kwon, JH; Lee, BH; Park, CH; Park, HC; Park, SR; Song, HH; Zang, DY | 1 |
| Chang, HM; Kim, EK; Kim, MH; Kim, TW; Lee, J; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, I; Ryu, MH; Sohn, BS; Suh, DW | 1 |
| Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T; Yoneoka, Y | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Nakagawa, K; Nishio, K; Okabe, T; Okamoto, I; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Han, T; Hwang, SW; Jang, KM; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Park, S; Song, HH; Yang, DH; Yoo, KS; Zang, DY | 1 |
| Hanauske, A; Hilger, RA; Krauss, J; Kredtke, S; Makris, L; Mende, B; Scheulen, ME; Scigalla, P; Strumberg, D; Thyssen, D; Urrea, PD | 1 |
| Ahn, JB; Chung, HC; Im, CK; Jeung, HC; Noh, SH; Park, CH; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Horiuchi, C; Ishitoya, J; Kawakami, M; Kawano, T; Komatsu, M; Matsuda, H; Mikami, Y; Nishimura, G; Sakuma, Y; Satake, K; Shiono, O; Taguchi, T; Takahashi, M; Tsukuda, M; Watanabe, M; Yamashita, Y | 1 |
| Maruya, S; Matsubara, A; Namba, A; Shinkawa, H; Shirasaki, T | 1 |
| Hidaka, A; Higashi, T; Iwanaga, Y; Kitamura, T; Kitasato, Y; Kuroda, H; Mizoguchi, A; Ogata, Y; Saruwatari, A; Shiota, K; Tanaka, M; Taniwaki, S; Yoshida, T | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Honda, Y; Ishida, T; Ishimoto, O; Munakata, M; Sugawara, S | 1 |
| Kanellos, D; Kanellos, I | 1 |
| Katirtzoglou, NA; Saif, MW; Syrigos, KN | 1 |
| Harada, K; Horinaga, D; Mano, T; Mihara, M; Okafuji, M; Uchida, K; Ueyama, Y; Wada, N | 1 |
| Fumoto, S; Iishi, H; Imamura, F; Narahara, H; Sakai, D; Sugimoto, N; Tatsuta, M; Yagi, T; Yamamoto, S | 1 |
| Fujii, H; Nakao, K | 1 |
| Danno, K; Imaoka, S; Iwazawa, T; Kano, T; Kimura, Y; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Tono, T; Yano, H | 1 |
| Endo, Y; Furuie, M; Inase, N; Ohba, T; Ohtani, Y; Yamasaki, T; Yoshizawa, Y | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Ono, A; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Fujiwara, M; Ito, S; Kodera, Y; Kojima, H; Kojima, T; Kondo, K; Koshikawa, K; Matsui, T; Mochizuki, Y; Nakao, A; Suzuki, N; Takase, T; Tsuboi, K | 1 |
| Shinden, S; Shiotani, A; Watabe, T; Yamashita, T | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Hayashi, M; Hoshino, T; Imizu, H; Kato, A; Kohashi, Y; Mieno, Y; Okazawa, M; Saito, Y; Sakakibara, H; Tada, T; Takeuchi, Y; Totani, Y; Uchiyama, Y; Yoneda, Y | 1 |
| Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S; Tanaka, S | 1 |
| Fujii, M; Hirota, M; Iwase, K; Kimura, T; Matsuda, C; Nasu, S; Nishikawa, K; Shimada, K; Tanaka, Y; Wada, D | 1 |
| Fujiwara, Y; Hayashi, C; Kobayashi, M; Koishi, K; Kojima, S; Matsumoto, T; Miwa, H; Sasako, M; Tanaka, J; Tomita, N; Yamamoto, N; Yamamura, T | 1 |
| Hashimoto, R; Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Mizuno, A; Okochi, O; Takami, Y; Takeda, S; Tsuboi, K | 1 |
| Fujii, Y; Kawano, O; Okuda, K; Sasaki, H; Yano, M; Yukiue, H | 1 |
| Imai, S; Kobayashi, A; Koyama, H; Matsuyama, T; Okubo, K; Tokugawa, T | 1 |
| Furukawa, H; Kaji, M; Katai, H; Kinoshita, T; Miyashiro, I; Ninomiya, M; Sano, T; Sasako, M; Tsuburaya, A | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Higashi, H; Ichinose, Y; Maehara, Y; Maruyama, R; Shoji, F; Takeo, S; Tokunaga, S; Yamazaki, K; Yano, T | 1 |
| Fukuoka, M; Kashii, T; Kobayashi, M; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Ozaki, T; Shibata, T; Takeda, K; Tamura, K | 1 |
| Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y | 1 |
| Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K | 1 |
| Akimoto, T; Boku, N; Fujii, M; Fukuda, H; Hayashi, R; Kiyota, N; Nakamura, K; Tahara, M | 1 |
| Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Harada, M; Kato, K; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Tanaka, R | 1 |
| Ikeda, M; Kagawa, T; Morise, Z; Okabe, Y; Sugioka, A; Takeura, C; Tanahashi, Y | 1 |
| Hayashi, Y; Horikoshi, K; Iguchi, K; Inagaki, M; Ogata, T; Ohtani, T; Onuki, T; Saito, K; Shinohara, Y; Suzuki, K; Takabe, K; Wakai, Y | 1 |
| Fujita, S; Hata, A; Higashi, Y; Kaji, R; Katakami, N; Kida, Y; Nanjo, S; Otsuka, K | 1 |
| Hamada, J; Hayashi, K; Munakata, Y; Okada, M; Okita, K; Sakon, M; Seki, H; Sekino, Y; Tagami, S; Takata, M | 1 |
| Kitajima, Y; Miyazaki, K; Nakafusa, Y; Ohtsuka, T; Sato, S; Tanaka, M; Yakabe, T | 1 |
| Ansai, M; Ichiki, M; Ichinose, A; Kamata, K; Kawamura, M; Miyazaki, S; Nakano, Y; Sai, K; Sugawara, H | 1 |
| Izumi, S; Ohashi, R; Oka, T; Onoda, Y; Shiota, K; Suzuka, I | 1 |
| Chatani, M; Kajikawa, H; Kamakura, T; Kitamura, T; Matsushiro, N; Okumura, S | 1 |
| Hyodo, I; Kobayashi, A; Ota, M | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Lee, SJ; Shim, HJ; Yoon, JY | 1 |
| Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y | 1 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Okita, NT; Shimada, Y; Shimoda, T; Shirao, K; Takahari, D; Taniguchi, H; Yamada, Y | 1 |
| Matsui, K; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H | 1 |
| Hashizume, T; Nakada, Y | 1 |
| Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T | 1 |
| Endo, M; Hasegawa, I; Kato, A; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Tanaka, Y; Tokuda, Y | 1 |
| Kira, M; Takizawa, H; Tangoku, A; Toba, H; Yamai, H; Yoshida, T | 1 |
| Hayashi, T; Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Mitani, T; Miyata, Y; Nakamura, M; Ochiai, Y; Sakurada, T; Yahagi, N | 1 |
| Fujimura, T; Fushida, S; Kinoshita, J; Ohta, T; Oyama, K; Yagi, Y | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C | 1 |
| Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Anegawa, E; Iwamoto, O; Koga, C; Koga, M; Kusukawa, J; Sakaino, H; Tsuyama, H; Yoh, J | 1 |
| Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Sasaki, T; Tanabe, S | 1 |
| Kameda, A; Minami, K; Miyahara, E; Noso, Y; Ohara, M; Suzuki, T; Tsutani, Y | 1 |
| Endo, M; Gomi, K; Harada, H; Horai, T; Horiike, A; Kozuka, T; Morota, M; Murakami, H; Nakamura, Y; Nishimura, T; Nishio, M; Ohyanagi, F; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Choi, IJ; Kim, NK; Kim, YW; Kong, SY; Kook, MC; Lee, JH; Lee, JS; Lim, HS; Nam, BH; Park, SR; Park, YI; Ryu, KW | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H | 2 |
| Kang, EM; Kang, WK; Kim, HS; Lee, HY; Lee, J; Lee, Y; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE | 1 |
| Chijiiwa, K; Hidaka, H; Hotokezaka, M; Maehara, N; Nagaike, K; Nakashima, S | 1 |
| Furuya, A; Kobayashi, S; Monden, T; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H | 1 |
| Fujita, M; Matsuura, O; Morohashi, H; Yamada, K; Yamazaki, S | 1 |
| Ando, N; Haruki, N; Kurehara, H; Maeda, Y; Sato, A; Sugiura, M; Tatematsu, T; Tsuji, H; Yamakawa, Y | 1 |
| Inaba, K; Konno, H; Okamoto, N | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Hirai, T; Hiraki, A; Murakami, R; Nakahara, A; Nakayama, H; Nomura, T; Obayashi, T; Ota, K; Oya, N; Shinohara, M; Teshima, K; Toya, R; Yamashita, Y; Yoshitake, Y | 1 |
| Hisada, T; Iijima, H; Imai, H; Ishizuka, T; Iwasaki, Y; Kaira, K; Mori, M; Saito, R; Shimizu, K; Sunaga, N; Tomizawa, Y; Tsurumaki, H; Utsugi, M; Yanagitani, N | 1 |
| Fukuoka, M; Okamoto, I | 1 |
| Fujino, N; Kobayashi, S; Suzuki, S; Yanai, M | 1 |
| Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Seki, Y; Ueno, H | 1 |
| Fujita, M; Miyazaki, M; Moriya, T; Nakagawa, K; Nakamura, Y | 1 |
| Fukuda, K; Igarashi, T; Ito, R; Kitagawa, Y; Kumagai, K; Nakamura, R; Saikawa, Y; Takahashi, T; Takeuchi, H; Tsuwano, S | 1 |
| Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I | 1 |
| Ando, Y; Hatori, M; Kurihara, Y; Sato, H; Shintani, S; Shirota, T; Tachikawa, T; Takayama, S | 1 |
| Akiya, T; Fujimori, M; Hamada, T; Kikuchi, Y; Koizumi, W; Kurihara, M; Mine, T; Sakuyama, T; Sasaki, E; Sasaki, T; Sato, A; Shimada, K; Tomidokoro, T; Yamaguchi, K | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Gemma, A; Hino, M; Kudoh, S; Nagao, K; Niitani, H; Tada, Y; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Imamoto, R; Kanbe, T; Kishimoto, Y; Kojo, H; Mukouyama, T; Nishimuki, E; Shabana, M; Tsunoda, H | 1 |
| Andou, T; Haneda, S; Kakyou, M; Kinouchi, M; Miura, K; Ogawa, H; Okabe, M; Saijou, F; Sasaki, I; Shibata, C; Unno, M | 1 |
| Furuta, R; Hibi, S; Ina, K; Kataoka, T; Kawai, M; Kojima, S | 1 |
| Abe, M; Doiguchi, M; Hasuo, T; Miyamoto, Y; Sakamoto, F; Tanigawa, T | 1 |
| Morio, A; Nakahara, K; Ninomiya, H; Sunada, K; Tomioka, K | 1 |
| Fujii, S; Fukahori, M; Imada, T; Kunisaki, C; Makino, H; Masuda, M; Nagano, Y; Oshima, T; Rino, Y; Sato, T; Yamamoto, N | 1 |
| Futagawa, S; Kitajima, M; Konishi, N; Marusasa, T; Nishimura, K; Ochiai, T; Satoh, G; Watanabe, T | 1 |
| Inokuchi, M; Kawano, T; Kojima, K; Otsuki, S; Sugihara, K; Sugita, H; Yamada, H | 1 |
| Hoshino, S; Ishii, F; Maki, K; Naito, M; Shibata, R; Shinohara, T; Tanaka, S; Yamaguchi, R; Yamashita, Y | 1 |
| Hamasaki, K; Nakazaki, T; Sano, I; Shimizu, K; Shindo, H; Taniguchi, H | 1 |
| Kubota, Y; Marutaka, M; Orita, Y; Yoshida, R | 1 |
| Kang, SM; Murata, A; Nishino, Y; Tendou, M; Tezuka, K | 1 |
| Ashida, A; Cho, H; Fujii, K; Fujii, Y; Fujikawa, H; Hayashi, T; Ike, H; Kojima, Y; Makino, T; Masuda, M; Matsuzu, K; Narui, K; Rino, Y; Saito, B; Wada, N | 1 |
| Hosogi, H; Obama, K; Okabe, H; Sakai, Y; Ueda, S | 1 |
| Cho, C; Choi, C; Kang, H; Kim, J; Kim, MS; Kim, Y; Lee, D; Seo, Y; Yang, K; Yoo, H; Yoo, S | 1 |
| Chen, FG; Wang, JJ; Xue, Q | 1 |
| Teng, KY; Xu, RH | 1 |
| Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S | 1 |
| Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K | 1 |
| Chiba, A; Fujii, T; Habiro, A; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Sasajima, J; Sugiyama, Y; Tanno, S | 1 |
| Ban, T; Fujiwara, K; Hayashi, K; Hori, Y; Iwasaki, H; Kurimoto, T; Nemoto, A; Nishiwaki, H; Orito, E; Shiroko, J; Tachi, K; Umemura, S; Yamada, T; Yamakawa, Y | 1 |
| Bessho, T; Egawa, T; Hashimoto, O; Koyanagi, K; Seki, H; Tokuhara, H; Yokoyama, T | 1 |
| Abo, H; Horiuchi, C; Matsuda, H; Niho, T; Taguchi, T; Tsukuda, M; Watanabe, M | 1 |
| Iwashima, Y; Kutsuna, T; Maeno, K; Miyazaki, M; Nakamura, A; Nakao, M; Oguri, T; Ohta, C; Sato, S; Takakuwa, O; Ueda, R | 1 |
| Hara, Y; Kawano, T; Maekawa, K; Minami, Y; Ueda, S | 1 |
| Fukada, I; Ikeda, H; Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Ikeda, H; Kanagawa, T; Katoh, H; Kobayashi, K; Kodera, M; Oishi, M; Seshimo, K; Takita, K; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Asada, T; Chijiiwa, K; Eto, TA; Futami, S; Hidaka, H; Imada, S; Shibata, N; Shimayama, T; Takaya, T; Tanaka, S | 1 |
| Fujii, S; Hiroshima, Y; Kimura, J; Kunisaki, C; Makino, H; Nagano, Y; Oshima, T; Takagawa, R | 1 |
| Ichikawa, M; Iwakawa, K; Matsumoto, T; Miyauchi, S; Seike, H; Tanaka, Y; Tanisaka, Y; Tsubouchi, E | 1 |
| Ishikawa, K; Suzuki, S | 1 |
| Boku, N; Fuse, N; Koizumi, W; Komatsu, Y; Muro, K; Takiuchi, H; Tsuburaya, A; Yamada, Y | 1 |
| Kubo, T; Mihara, K; Ohuchi, K; Seyama, T; Takigahira, M; Tsumuraya, M; Yanagihara, K | 1 |
| Nishida, T | 1 |
| Abe, K; Kanno, Y; Katsushima, F; Monoe, K; Ohira, H; Takahashi, A; Wakatsuki, T; Yokokawa, J | 1 |
| Azuma, M; Ishido, K; Koizumi, W; Okayasu, I; Sakuramoto, S; Takeuchi, A; Watanabe, M | 1 |
| Arai, H; Imada, T; Masuda, M; Matsuura, H; Murakami, H; Oshima, T; Rino, Y; Sugano, N; Wada, N; Yukawa, N | 1 |
| Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S | 1 |
| Aizaki, K; Fujihira, D; Funatsu, K; Hokari, T; Kawakami, S; Kazama, A; Kohno, S; Koike, T; Matsushita, T; Norimatsu, T; Ohya, Y; Sasaki, K; Shino, M; Takano, S; Tanaka, T; Yoshida, T | 1 |
| Fukumoto, R; Hashimoto, M; Hirabayashi, S; Honda, I; Mase, T; Morioka, Y; Nagata, J; Nakanishi, K; Nishi, T; Onishi, E; Oya, H | 1 |
| Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Ikeda, N; Saito, H; Sakano, T; Tabira, Y; Urakawa, M; Watanuki, A | 1 |
| Egi, H; Itamoto, T; Kadoya, T; Kohashi, T; Matsugu, Y; Nakahara, H; Ohmori, I; Okajima, M; Takakura, Y; Urushihara, T | 1 |
| Arita, M; Kuga, Y; Miwata, T; Moriya, T; Murakami, E; Nishida, T; Numata, Y; Ohya, T; Okanobu, H; Tanaka, T; Usui, Y; Yoshimi, S | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Otsuka, K; Sakayori, N; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, S; Yoshioka, T | 1 |
| Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Amano, R; Hirakawa, K; Kawajiri, H; Komoto, M; Nakata, B; Nishii, T; Shinto, O; Yamada, N; Yashiro, M | 1 |
| Fujii, M; Hasegawa, Y; Homma, A; Ishitoya, J; Nishijima, W; Tomita, K; Tomita, T; Tsukuda, M; Yamane, H | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Hashiguchi, K; Hiraki, M; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Nakamura, J; Noshiro, H; Sumi, K | 1 |
| Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kawashima, M; Kinoshita, T; Mitsunaga, S; Nakachi, K; Shimizu, S | 1 |
| Arisawa, T; Sato, K; Shiroeda, H; Shiroeda, S; Tsutsumi, M; Yamada, M | 1 |
| Furuya, A; Kaburagi, A; Kamakazu, K; Kobayashi, S; Monden, T; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H | 3 |
| Kakizaki, T; Kaseda, S; Sugiura, Y; Takeuchi, K | 1 |
| Akiya, T; Hosaka, H; Kon, Y; Motegi, K; Nogawa, H; Tagaya, R | 1 |
| Fujishima, Y; Fukuda, T; Fukunaga, H; Iwai, M; Koide, M; Miura, M; Yoneda, R | 1 |
| Kadono, K; Kawamoto, K; Park, T | 1 |
| Itoh, Y; Takahashi, T | 1 |
| Nakagawa, S; Nashimoto, A; Otsuo, T; Takii, Y; Tsuchiya, Y; Yabusaki, H | 1 |
| Hokama, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kubota, S; Miyazaki, T; Okada, N; Sakimoto, T; Yamada, H; Yokoyama, M; Yokoyama, Y | 1 |
| Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kaida, Y; Kubota, H; Matsumoto, H; Murakami, H; Oka, Y; Okumura, H; Saito, A; Uragami, A; Yamashita, K; Yoden, E | 1 |
| Fukuda, K; Ikeguchi, M; Kuroda, H; Matsunaga, T; Saito, H; Tatebe, S | 1 |
| Doi, K; Hirano, Y; Ishihara, A; Kojima, K; Kudo, K; Ochi, T; Ogata, K | 1 |
| Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Ohashi, M; Takahashi, K; Yamaguchi, T | 1 |
| Baba, H; Fujiwara, N; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Tamai, S | 1 |
| Inoue, S; Nasu, K; Noda, K; Umekita, N | 1 |
| Aoki, T; Igarashi, Y; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanida, T; Tanizaki, K; Uemura, Y; Yamanaka, C | 1 |
| Ikari, H; Izumino, K; Kajihara, K; Kunizaki, T; Sasaki, N; Shigemasa, Y; Shimizu, T; Yonemitsu, N | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N | 1 |
| Iwanaga, T; Iwasaki, Y; Matsumoto, H; Matsumura, H; Nakano, D; Ohashi, M; Takahashi, K; Yamaguchi, T | 1 |
| Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T | 1 |
| Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, N; Nagahama, T; Ohara, T; Tei, S | 1 |
| Fukushima, Y; Hashimoto, K; Hiraki, M; Matsumoto, S; Matsuyama, J; Morimoto, T; Morita, S; Naitou, A; Nishishou, I; Nomura, T; Sasaki, Y; Yokoyama, S | 1 |
| Furuya, T; Hayashi, H; Inoue, Y; Ishigaki, N; Saeki, T; Yahara, N; Yanai, H | 1 |
| Kataoka, M; Kawamoto, J; Oeda, Y; Tonooka, T; Wakatsuki, K; Yoshioka, S | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Ohzato, H | 1 |
| Dan, N; Fukuoka, T; Hirakawa, K; Hori, T; Ikehara, T; Nishino, H; Takatsuka, S; Tendou, M; Tezuka, K | 1 |
| Aoki, T; Igarashi, Y; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanizaki, K; Uemura, Y; Yamanaka, C | 2 |
| Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ookubo, K; Ootsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S | 1 |
| Hashimoto, K; Suzuki, M | 1 |
| Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ohtsuka, M; Okubo, K; Taniguchi, M; Tsujie, M; Yamanaka, C; Yoshioka, S | 1 |
| Ami, K; Andou, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kurokawa, T; Nagahama, T; Ohara, T; Tei, S | 1 |
| Kametaka, H; Koyama, T; Makino, H; Seike, K | 5 |
| Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K | 1 |
| Doki, Y; Dono, K; Eguchi, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomokuni, A | 1 |
| Kirihara, M; Nagashima, M; Ogura, T; Tahira, H; Tajima, M | 1 |
| Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K | 1 |
| Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T | 1 |
| Funada, N; Honda, G; Kurata, M; Tokashiki, T; Tsuruta, K; Watanabe, F | 1 |
| Fukunaga, M; Furukawa, H; Ikeda, H; Mabuchi, E; Matsumura, T; Miwa, H; Ohzato, H; Ota, K; Yamamoto, T | 1 |
| Aramaki, N; Iizuka, M; Kuranami, M; Kurita, A; Miyauchi, K; Nakakuma, T; Sengoku, N; Shiozawa, K; Ueno, S | 1 |
| Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K | 1 |
| Arimori, K; Hanada, N; Hidaka, H; Hidaka, M; Kawaguchi, H; Kawano, Y; Nakamura, C; Tomiyama, N | 1 |
| Hirata, K; Kato, J; Kida, M; Kobune, M; Miyanishi, K; Niitsu, Y; Ohnuma, H; Ohta, H; Okubo, S; Sagawa, T; Sato, T; Sato, Y; Shintani, N; Takahashi, Y; Takayama, T; Takimoto, R; Tanaka, S; Yamaguchi, K | 1 |
| Chang, HM; Hong, YS; Kang, YK; Kim, KP; Kim, TW; Lee, HJ; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Yoon, DH | 1 |
| Chikama, T; Nishida, T; Takahashi, N; Wakuta, M | 1 |
| Fukushima, M; Tanaka, F; Wada, H | 1 |
| Chiba, Y; Misawa, M; Sakai, H; Yu, Y | 1 |
| Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mio, T; Misawa, A; Niimi, M; Nishimura, T; Sasaki, T; Tada, H; Teramukai, S; Yanagihara, K; Yasuda, H; Yoshimura, K | 1 |
| Choi, IS; Kim, JH; Kim, KH; Kim, YJ; Lee, JS; Lee, KW | 1 |
| Nakayama, T; Noguchi, S | 1 |
| Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yanagi, M | 1 |
| Amano, S; Furuichi, M; Ishimoto, S; Morooka, H; Muramatsu, T; Nishii, T; Ohmori, I; Sakurai, K; Shimamura, M; Shiono, M; Sodeyama, M; Takeshita, S | 1 |
| Hyodo, M; Morishima, K; Nihei, Y; Sata, N; Yasuda, Y | 1 |
| Aragane, H; Kan, K; Katano, T; Shimomura, M; Suchi, K; Yasui, H | 1 |
| Aoki, T; Ishizaki, T; Ito, K; Katayanagi, S; Nomura, T; Ogata, T; Shimazu, M; Sonoda, I; Sumi, T; Suzuki, Y; Tsuchida, A; Yasuda, Y | 1 |
| Inokuchi, M; Kato, K; Kawano, T; Kojima, K; Sugihara, K; Yamada, H | 1 |
| Akagi, S; Kanou, M; Kurisu, Y; Tanaka, T; Toge, K | 1 |
| Hasegawa, H; Kijima, T; Kitahara, M; Kubo, H; Miyahara, M; Tada, K | 1 |
| Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Funai, S; Hatabe, S; Inoue, K; Kitano, Y; Tanaka, A | 1 |
| Kitagawa, M; Koh, T; Kondo, Y; Nakagawa, N; Nanri, M; Oguro, A; Yamasaki, J | 1 |
| Kubo, N; Matuoka, T; Nobuhara, Y; Yo, T | 1 |
| Abe, M; Abe, S; Ishii, T; Kogawa, T; Kondo, H; Kukitsu, T; Mizushima, T; Onodera, Y; Sumiyoshi, T; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Akagi, Y; Ishibashi, N; Mori, S; Ogata, Y; Sasatomi, T; Shirouzu, K | 1 |
| Chen, X; Liu, K; Zhong, D; Zou, H | 1 |
| Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S | 1 |
| Ariyoshi, Y; Fukuoka, M; Ichinose, Y; Kubota, K; Kunitoh, H; Nakagawa, K; Saijo, N; Sakai, H; Takeda, K; Yamamoto, N | 1 |
| Furuta, R; Hibi, S; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Takeuchi, Y | 1 |
| Endo, A; Harada, A; Kikuchi, S; Kodama, H; Ooshio, H; Saito, T; Takeda, K; Teshima, S; Yunome, G | 1 |
| Emi, M; Hamai, Y; Hihara, J; Okada, M; Suzuki, T; Tanabe, K; Taomoto, J; Yoshida, K | 1 |
| Fujimoto, H; Hashimoto, K; Ishizuka, H; Kameyama, Y; Oyama, T; Suito, T; Yasuda, H | 1 |
| Ikeda, H; Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Ogasahara, K; Ohyama, M; Okabe, M; Paku, T; Sano, K; Yamaguchi, K; Yoshida, Y | 1 |
| Chatani, T; Doi, Y; Fukuda, H; Horiki, M; Iwasaki, R; Kashihara, T; Kitada, M; Kondo, S; Murayama, Y; Okuno, M; Sano, I | 1 |
| Fukuoka, T; Ikehara, T; Kanazawa, A; Nishiguchi, Y; Sakurai, K; Shimizu, S; Takemura, M; Tsukamoto, T; Xiang, Z; Yamamoto, A; Yamamoto, S; Yamashita, Y; Yoshida, K | 1 |
| Fujita, H; Ichimura, K; Ikeda, H; Katoh, H; Kawai, Y; Kodera, M; Maejima, R; Oishi, M; Seshimo, K; Shibagaki, K; Takita, K; Tanaka, N; Toshima, T; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Higaki, K; Kikuno, M; Matsuyama, S; Mori, N; Murakami, S; Nasu, K; Sonoda, K; Yamamoto, K | 1 |
| Akaza, H; Fujimoto, H; Naito, S; Tsukamoto, T; Usami, M | 1 |
| Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I | 1 |
| Asada, Y; Fujisawa, K; Iida, Y; Kawaguchi, M; Mitsui, T; Miura, S; Munemoto, Y; Sudo, Y; Takehara, A; Terada, T | 1 |
| Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Todaka, A; Tomita, H; Yamazaki, K; Yasui, H | 1 |
| Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Ui, T; Yasuda, Y; Yokoyama, T; Zuiki, T | 1 |
| Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Goto, K; Kenmotsu, H; Koga, Y; Kuroda, J; Matsumura, Y; Nagano, T; Nishimura, Y; Nishiwaki, Y; Sugino, T; Yasunaga, M | 1 |
| Miyade, Y; Okano, K; Okita, A | 1 |
| Aka, H; Hanashiro, N; Kiyuna, M; Matsuura, F; Miyahira, T; Murayama, S; Nishihara, M; Okushima, N; Teruya, J; Teruya, N; Toda, Y | 1 |
| Ahn, JB; Baik, SH; Choen, JH; Choi, HJ; Chung, HC; Im, JS; Jeung, HC; Keum, KC; Kim, HG; Kim, NK; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Chìn, K; Hatake, K; Matsusaka, S; Mishima, Y; Mizunuma, N; Ogura, M; Shinozaki, E; Suenaga, M; Terui, Y | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N | 1 |
| Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY | 1 |
| Cho, H; Ito, S; Kodera, Y; Miyashita, Y; Morita, S; Sakamoto, J; Tsuburaya, A; Yoshikawa, T | 1 |
| Ahn, JB; Jeong, JH; Kim, TW; Kim, YH; Kim, YT; Lee, KH; Lee, MA; Oh, DY; Park, YS; Roh, JK; Shim, BY; Shin, SJ; Zang, DY | 1 |
| Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M | 1 |
| Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Sugiyama, A; Tanemura, H; Tomita, E; Yamada, M; Yamada, T | 1 |
| Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S | 1 |
| Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H | 1 |
| Hirai, K; Kato, Y; Kawate, S; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Yoshinari, D | 1 |
| Akamoto, S; Hagiike, M; Inoue, T; Izuishi, K; Kakinoki, K; Okano, K; Sano, T; Suzuki, Y; Takebayashi, R; Usuki, H | 1 |
| Arita, M; Kuga, Y; Miwata, T; Moriya, T; Murakami, E; Nishida, T; Numata, Y; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Denda, T; Hara, T; Ishihara, T; Nakamura, K; Sudo, K; Yamaguchi, T; Yokosuka, O | 1 |
| Awaya, H; Ishida, T; Kuwata, T; Ohta, M; Tagawa, T | 1 |
| Ariga, H; Fujimoto, K; Jingu, K; Kaneta, T; Katja, L; Koto, M; Matsufuji, N; Metoki, T; Mitsuya, M; Narazaki, K; Nemoto, K; Ogawa, Y; Takahashi, S; Takai, Y; Takeda, K; Umezawa, R; Yamada, S | 1 |
| Ito, S; Kodera, Y; Kojima, T; Mochizuki, Y; Nakanishi, H; Yamamura, Y | 1 |
| Gemma, A; Kataoka, K; Matsuda, K; Minegishi, Y; Miyanaga, A; Noro, R; Okano, T; Seike, M; Soeno, C; Yoshimura, A | 1 |
| Harada, H; Omura, K | 1 |
| Hashimoto, M; Matsuda, M; Sasaki, K; Watanabe, G | 1 |
| Imawari, M; Ito, N; Kiuchi, Y; Kobayashi, M; Kogo, M; Konishi, K; Kurihara, T; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Bando, E; Boku, N; Kawamura, T; Motegi, Y; Oshima, N; Sasaki, K; Sugisawa, N; Taki, Y; Tanizawa, Y; Terashima, M; Tokunaga, M | 1 |
| Saito, T; Sasaki, H; Tokunaga, Y | 1 |
| Kinoshita, K; Kondo, K; Watanabe, K | 1 |
| Egawa, H; Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K | 1 |
| Aiki, F; Hattori, A; Kakisaka, T; Kazui, K; Matsuhisa, T | 1 |
| Fukuoka, M; Kiniwa, M; Nakagawa, K; Okamoto, I; Takezawa, K; Tanizaki, J; Tsukioka, S; Uchida, J | 1 |
| Hiraki, M; Kai, K; Kobayashi, K; Miyazaki, K; Morito, K; Noshiro, H; Sato, S; Tanaka, M; Tokunaga, O | 1 |
| Doi, T; Handa, R; Hoshi, M; Iijimal, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Ooshima, S | 1 |
| Aoe, K; Fujiwara, K; Fujiwara, Y; Gemba, K; Harita, S; Himei, K; Hosokawa, S; Hotta, K; Kanazawa, S; Kiura, K; Nogami, N; Shinkai, T; Tabata, M; Takata, S; Takemoto, M; Takigawa, N; Tanimoto, M | 1 |
| Hong, YS; Jang, SJ; Kim, JC; Kim, JH; Kim, MJ; Kim, TW; Lee, JL; Lee, JS; Lim, SB; Park, JH; Yoon, SN; Yu, CS | 1 |
| Bae, SH; Baek, JH; Chae, YS; Do, YR; Kim, JG; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Tsujino, T | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Kim, SB; Yoon, DH | 1 |
| Ohdan, H; Suzuki, T; Tanabe, K; Tokumoto, N; Yamamoto, H; Yoshida, K | 1 |
| Hayakawa, K; Ishiyama, H; Kotani, S; Nakayama, M; Niibe, Y; Okamoto, M | 1 |
| Ito, D; Iwai, M; Kimura, M; Morihata, K; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Horiike, M; Ikebe, T; Kaneko, M; Nishioka, T; Terakura, M | 1 |
| Kaisaki, S; Kato, M; Kitayama, J; Nagawa, H; Sanuki, J; Yamaguchi, H | 1 |
| Aoki, Y; Funakoshi, M; Kameda, A; Miyahara, E | 1 |
| Oka, T; Onoda, Y; Shiota, K; Suzuka, I; Tokumo, M; Yamakawa, T | 1 |
| Fukumoto, I; Fukumoto, K; Imada, N; Itani, K; Kanemitsu, D; Kassai, K; Kobayashi, Y; Koyama, M; Miyagaki, T; Nakase, Y; Onishi, A; Sakamoto, K; Takagi, T; Takenaka, S | 1 |
| Abe, N; Atomi, Y; Masaki, T; Mizuno, H; Mori, T; Sugiyama, M; Suzuki, Y | 1 |
| Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A | 1 |
| Hirakawa, K; Kawajiri, H; Miwa, A; Shimizu, K; Shimizu, T; Shinto, O; Yashiro, M | 1 |
| Dogru, M; Ibrahim, OM; Matsumoto, Y; Ogawa, Y; Sato, EA; Tatematsu, Y; Tsubota, K | 1 |
| Kawai, K; Kitayama, J; Nagawa, H; Sunami, E; Yasuda, K | 1 |
| Araki, K; Doi, T; Fuse, N; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Minashi, K; Ogino, T; Ohtsu, A; Okano, S; Tahara, M; Yoshino, T; Zenda, S | 1 |
| Doki, Y; Fujiwara, Y; Miyata, H; Moon, JH; Mori, M; Nakajima, K; Nishida, T; Takiguchi, S; Yamamoto, K; Yamasaki, M | 1 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Choi, IS; Kim, H; Kim, JH; Kim, KH; Kim, WH; Kim, YJ; Lee, HS; Lee, JS; Lee, KW | 1 |
| Chin, K; Hatake, K; Hijioka, S; Seto, Y; Yamamoto, N | 1 |
| Fujii, M; Kobayashi, O; Nakajima, T; Nashimoto, A; Omura, K; Takabayashi, A; Yamada, T; Yamaguchi, T; Yamaue, H; Yoshikawa, T | 1 |
| Cao, Y; Gao, F; He, Y; Huang, J; Liao, C; Wu, L | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Bergmann, L; Graeven, U; Hanauske, A; Lipp, R; Scheulen, ME; Schuette, J; Schultheis, B; Scigalla, P; Strumberg, D; Urrea, P | 1 |
| Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Yuki, S | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Fujikuni, N; Hashimoto, M; Iwako, H; Kuranishi, F; Kuroda, Y; Moriyuki, T; Niitsu, H | 1 |
| Imai, T; Kanematsu, M; Kawai, M; Kunieda, K; Matsuhashi, N; Nagao, N; Nishina, T; Sakuratani, T; Sasaki, Y; Tajima, JY; Tanaka, C; Yamada, A | 1 |
| Aizawa, K; Kasuga, Y; Kumaki, T; Matsushita, A; Muramatsu, S; Sakaguchi, H | 1 |
| Furuya, T; Hirao, H; Nagai, M; Nakamura, H; Nomura, Y; Ogura, M; Suzuki, Y; Takahashi, M; Takayama, T; Tanaka, N | 1 |
| Matsunaga, N; Nakagawa, Y; Noda, S; Yanagawa, K | 1 |
| Aoki, T; Fujimori, A; Kusano, M; Kusano, T; Murakami, M; Shimizu, Y; Taka, J | 1 |
| Miyagawa, K; Sagara, Y; Yamaoka, N; Yata, Y | 1 |
| Kameda, R; Kobayashi, S; Miyagawa, K; Morinaga, S; Okawa, S; Ueno, M | 1 |
| Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K | 1 |
| Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H; Tokunaga, O | 1 |
| Fujii, Y; Iino, Y; Isayama, H; Kamimura, H; Kihara, K | 1 |
| Asai, K; Honda, H; Nakamura, K; Nakashima, T; Nonoshita, T; Ohga, S; Ohnishi, K; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A | 1 |
| Boku, N; Hironaka, S; Kojima, T; Machida, N; Muro, K; Shitara, K; Taku, K; Ueda, S; Yamazaki, K; Yokota, T | 1 |
| Araki, H; Denda, T; Hara, T; Hatano, K; Imagumbai, T; Ishihara, T; Ito, H; Kawakami, H; Nakamura, K; Sakai, M; Sudo, K; Tawada, K; Uno, T; Yamaguchi, T; Yokosuka, O | 1 |
| Egashira, N; Kubota, T; Nonaka, T; Oishi, R; Sonoda, M; Takada, A; Watanabe, H; Yamada, T; Yano, T | 1 |
| Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Tsuchida, K; Yamamoto, N | 1 |
| Ibusuki, A; Kanekura, T; Kawai, K; Kubo, H; Matsushita, S; Mera, K; Tada, K; Yoshii, N | 1 |
| Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A | 1 |
| Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Aomatsu, N; Hirata, K; Kimura, K; Kosaka, K; Lee, T; Lee, WH; Nishii, T; Okita, Y; Sim, JK; Takeuchi, K; Tei, S; Uchima, Y | 1 |
| Fujiwara, I; Ichida, M; Matsumoto, M; Mizuta, M; Mizuta, N; Nishiyama, A; Ohashi, M; Sakaguchi, K; Umeda, Y | 1 |
| Arai, T; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kaze, C; Miwa, H; Ohsato, H; Sohta, Y | 1 |
| Hasegawa, H; Kijima, D; Kubo, H; Miyahara, M; Tada, K | 1 |
| Arakawa, A; Hisama, S; Kimura, M; Matsushita, H; Nishimura, T; Okamura, S; Saitoh, S; Shimokawa, Y; Tanaka, Y; Toyama, H | 1 |
| Kinoshita, E; Kosaka, T; Minato, H; Motoo, Y; Nakajima, H; Nakaya, N; Ohno, K; Sato, I; Shimasaki, T; Ueda, N | 1 |
| Egawa, S; Furuya, A; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H | 1 |
| Kito, F; Kunisaki, C; Matsuda, S; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T | 1 |
| Gon, H; Hamabe, Y; Ishida, T; Iwasaki, T; Kanemitsu, K; Nakajima, T; Nishioka, N; Okuda, T; Takahashi, T; Tanaka, K; Tani, S; Tomono, A; Toyokawa, A; Tsukamoto, T; Wakahara, T; Yamamichi, T; Yamashita, H | 1 |
| Akazawa, N; Imai, A; Iwaki, H; Kikuchi, H; Minato, M; Taguchi, K | 1 |
| Ako, E; Enomoto, J; Hasegawa, T; Hirakawa, T; Kanehara, I; Morisaki, T; Nakazawa, K; Nishimura, S; Tachimori, A; Taenaka, N; Yamagata, S; Yamaki, K | 1 |
| Egashira, Y; Gotoh, M; Higuchi, K; Kawabe, S; Kii, T; Kojima, Y; Kuwakado, S; Takiuchi, H; Tanigawa, N; Yoshida, M | 1 |
| Doi, T; Horiuchi, A; Ishida, N; Sato, K; Sugishita, H; Watanabe, Y; Yoshida, M | 1 |
| Hama, T; Horiuchi, T; Ishida, K; Miyagawa, Y; Sakaguchi, S; Shono, Y; Tabuse, K; Tamagawa, K; Tanishima, H; Tsubakihara, H; Tsujimoto, T; Uemura, R | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Harada, K; Itashiki, Y; Takenawa, T; Ueyama, Y | 1 |
| Cho, KJ; Cho, Y; Choi, SH; Kim, JS; Kim, SB; Kim, SY; Lee, JH; Lee, SW; Nam, SY; Roh, JL; Song, SY; Yoon, DH | 1 |
| Fukuoka, M; Gemma, A; Ichinose, Y; Kubota, K; Niitani, H; Saijo, N; Sakai, H; Yamamoto, N; Yamanaka, T | 1 |
| Arao, T; Chung, H; Hagiwara, S; Haji, S; Kimura, M; Kudo, M; Munakata, H; Nishio, K; Park, AM; Takita, M; Ueshima, K; Yamaguchi, M | 1 |
| Atsumi, K; Higaki, Y; Hirata, H; Honda, H; Nakamura, K; Ohnishi, K; Ohura, H; Sasaki, T; Shinoto, M; Shioyama, Y; Toh, Y; Yamaguchi, T | 1 |
| Imai, T; Machida, T; Shima, Y; Uemura, Y | 1 |
| Akaza, H; Fujimoto, H; Ikemoto, I; Kobayashi, M; Naito, S; Namiki, M; Tsukamoto, T; Usami, M | 1 |
| Cho, Sh; Go, SI; Jeong, SH; Joo, YT; Kang, JH; Kang, MH; Kim, Hg; Kwon, HC; Lee, GW; Lee, YJ; Oh, SY | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K | 1 |
| Chao, TY; Chao, Y; Chen, JS; Chen, LT; Chen, PM; Cheng, AL; Chiou, TJ; Hsieh, RK; Whang-Peng, J; Yeh, KH | 1 |
| Inokuchi, A; Kuratomi, Y; Monji, M; Satoh, S; Shimazu, R; Suzuki, K; Tokumaru, S; Yokogawa, K | 1 |
| Hatakeyama, K; Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T | 1 |
| Egawa, S; Furuya, A; Kaburagi, A; Kamakazu, K; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H | 1 |
| Aomatsu, N; Hirata, K; Kimura, K; Kosaka, K; Nishii, T; Ohkita, H; Takeuchi, K; Tanaka, H; Tei, S; Uchima, Y | 1 |
| Hachisuka, T; Hattori, K; Kinoshita, T; Miyauchi, M; Mori, T; Shikano, T; Shinohara, M; Yamamoto, T | 1 |
| Akagi, T; Eguchi, H; Etoh, T; Hiroishi, K; Kitano, S; Noguchi, T; Shiraishi, N; Ueda, Y; Yasuda, K | 1 |
| Akiyama, N; Ayata, S; Maruyama, Y; Tsukada, Y | 1 |
| Ajiki, T; Fujita, T; Ku, Y | 1 |
| Kanematsu, S; Kasahara, N; Kwon, AH; Nakatake, R; Okukawa, H; Shoji, T; Tanaka, K; Ueyama, Y; Yamamoto, D; Yoshida, H | 1 |
| Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T | 1 |
| Bang, YJ; Choi, IS; Ham, HS; Han, SW; Hong, J; Im, SA; Kang, GH; Kim, BS; Kim, TY; Oh, DY | 1 |
| Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY | 1 |
| Akiyama, H; Endo, I; Fujii, S; Kameda, K; Kimura, J; Kito, F; Kosaka, T; Kunisaki, C; Makino, H; Morita, S; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M | 1 |
| Arai, H; Fujimura, M; Mikami, K; Nishikawa, R; Sekita, N; Shibata, N; Sugano, I | 1 |
| Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Kinoshita, T; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K | 1 |
| Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J | 1 |
| Fukushima, M; Nakagawa, F; Ohshimo, H; Sakamoto, K; Taguchi, T | 1 |
| Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K | 1 |
| Araida, T; Ariizumi, S; Hayashi, K; Suzuki, R; Yamamoto, M | 1 |
| Schmoll, HJ | 1 |
| Iwanaga, T; Iwasaki, Y; Kanda, T; Nunobe, S; Ohashi, M; Okumura, Y | 1 |
| Aragane, H; Ichikawa, D; Itokawa, Y; Kakihara, N; Koizumi, K; Morii, J; Morita, S; Nishi, H; Okamoto, K; Otsuji, E; Sakamoto, J; Shimotsuma, M; Taniguchi, F; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y | 1 |
| Ishiyama, A; Ito, H; Ito, S; Kinoshita, T; Kodera, Y; Mochizuki, Y; Nakao, A; Sakamoto, J; Tsuburaya, A; Yokoyama, H; Yoshikawa, T | 1 |
| Kamijo, A; Kanoda, H; Maeda, Y; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Atsumi, H; Kuze, S; Kyokane, T; Nakamura, H; Shibahara, H; Takamizawa, J | 1 |
| Asano, T; Doi, K; Kinoshita, T | 1 |
| Higuchi, M; Ishii, S; Mima, T; Ueda, T; Yakushiji, N | 1 |
| Fukui, H; Kou, C; Matsumoto, M; Matsumoto, T | 1 |
| Hashimoto, M; Matsuda, M; Sasaki, K; Sawada, T; Tomizawa, K; Udagawa, H; Watanabe, G | 1 |
| Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T | 1 |
| Spiliotis, J; Zoras, O | 1 |
| Harada, Y; Kawai, T; Miyazaki, I; Moriyasu, F | 1 |
| Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kong, SY; Lee, JH; Lee, JY; Park, SR; Park, YI; Rhee, J; Ryu, KW | 1 |
| Fukushima, M; Nakagawa, F; Saito, H; Sakamoto, K; Sakata, M; Sakata, Y | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Kitagawa, Y; Nakamura, R; Oyama, T; Saikawa, Y; Takahashi, T; Takaishi, H; Takeuchi, H; Wada, N | 1 |
| Iwase, S; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D; Yoshida, H | 1 |
| Furuse, J; Kaneko, S; Kudo, M; Nakachi, K; Okusaka, T; Ueno, H; Ueshima, K; Yamashita, T | 1 |
| Morimoto, M; Sanbe, T; Suzaki, H; Suzuki, T; Takemura, H; Yui, T | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kitagawa, M; Kokuba, Y; Kuriu, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A; Sonoyama, T | 1 |
| Kimura, H; Kobayashi, W; Kon, T; Kubota, K; Nakagawa, H; Narita, N; Sakaki, H; Sato, H | 1 |
| Kobayashi, N; Kubo, M; Mizuta, M; Otani, H; Shirakawa, K; Udaka, T | 1 |
| Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Aoki, M; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Ando, T; Fujii, M; Komatsu, Y; Matsuoka, A; Nagahori, J; Ogasawara, T; Sato, H; Tsujii, S | 1 |
| Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Akaza, H; Eto, M; Fujisawa, M; Naito, S; Namiki, M; Nishikido, M; Shinohara, N; Tomita, Y; Tsukamoto, T; Usami, M | 1 |
| Vogelzang, NJ | 1 |
| Amaya, S; Fujisawa, K; Iida, Y; Ishii, H; Koizumi, H; Mitsui, T; Miura, S; Munemoto, Y; Sato, Y; Terada, T | 1 |
| Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T | 1 |
| Ando, M; Asami, K; Fukuoka, M; Hirashima, T; Ikeda, N; Iwamoto, Y; Kudoh, S; Kurata, T; Miyazaki, M; Morita, S; Nakagawa, K; Okamoto, I; Saka, H; Satouchi, M; Sawa, T; Seto, T; Takeda, K; Tamura, K; Yamamoto, N; Yoshioka, H | 1 |
| Akiyama, S; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Mitsuhashi, A; Nishioka, Y; Sato, S; Sone, S; Van, TT | 1 |
| Inaba, K; Ishida, Y; Isogaki, J; Kanaya, S; Komori, Y; Sakurai, Y; Taniguchi, K; Uyama, I; Yoshimura, F | 1 |
| Katsuno, M; Sato, N; Sugio, Y; Tachibana, S; Tani, Y; Watanabe, N; Zusho, H | 1 |
| Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S | 1 |
| Iijima, H; Kamide, Y; Mori, M; Saito, R; Sato, K; Suzuki, J; Tomizawa, Y; Tsuchiya, T; Tsurumaki, H; Watanabe, S; Yoshii, A | 1 |
| Kanda, T; Katayama, M; Matsumoto, H; Nishikawa, A; Okajima, T; Shigematsu, T; Tanaka, M | 1 |
| Atsukawa, K; Honda, T; Hoshino, G; Imai, S; Imajyo, K; Kanai, T; Kumamoto, Y; Nagase, T; Nakagawa, M; Nonaka, T; Ogawa, Y; Sakaguchi, T; Shiba, T; Wada, O | 1 |
| Fukuyama, S; Funayama, Y; Kakita, T; Matsumura, N; Musya, H; Sasaki, H; Takahashi, K; Tokumura, H; Toshima, T; Yasumoto, A | 1 |
| Fujitani, K; Hasegawa, H; Hirao, M; Kurokawa, Y; Mita, E; Nakazuru, S; Tsujinaka, T | 1 |
| Karaho, T; Kogashiwa, Y; Kohno, N; Maruyama, T; Matsuda, T; Nagafuji, H; Tsubosaka, T; Yamauchi, K | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Murai, M; Ohashi, T; Ohnishi, M; Tanahashi, S | 1 |
| Hirabayashi, N; Kitano, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Mitsugi, K; Morikita, T; Nakano, S | 1 |
| Kang, WK; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, SY | 1 |
| Bou, H; Kanno, H; Kiyama, T; Maejima, K; Suzuki, H; Tokunaga, A; Uchida, E; Watanabe, M | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T | 1 |
| Hayashi, R; Kawada, K; Kawashima, M; Matsuura, K; Minami, H; Mukai, H; Ogino, T; Ohtsu, A; Sakuraba, M; Tahara, M | 1 |
| Chuah, B; Dinolfo, M; Furuie, T; Goh, BC; Lau, F; Lee, SC; Lim, SE; Mulay, M; Rosen, LS; Saito, K; Soo, R; Soong, R; Zergebel, C | 1 |
| Arita, M; Iwasaki, T; Kawasaki, N; Kitajima, M; Kuroda, H; Noro, T; Ohara, T; Ohdaira, H; Suzuki, Y; Tsutsui, M; Yoshino, K | 1 |
| Asano, K; Ikemura, S; Kawada, I; Morosawa, M; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Ah, K; Kanematsu, S; Tanaka, K; Yamamoto, D; Yoshida, H | 1 |
| Inoue, H; Murakami, M; Nishizaki, T; Shimabukuro, R; Shiraishi, T; Takahashi, I; Yano, H | 1 |
| Furuichi, N; Imai, T; Kanematsu, M; Kawai, M; Kunieda, K; Matsuhashi, N; Nagao, N; Nishina, T; Sakuratani, T; Sasaki, Y; Tajima, JY; Tanaka, C; Yamada, A; Yanagawa, S | 1 |
| Guillén-Ponce, C; Molina-Garrido, MJ | 1 |
| Haba, R; Huang, CL; Kadota, K; Liu, D; Wada, H; Yokomise, H | 1 |
| Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S | 1 |
| Bang, YJ; Han, SW; Im, SA; Jang, JJ; Kang, GH; Kim, SJ; Kim, TY; Kim, YJ; Oh, DY; Suh, KS; Yi, NJ; Yoon, JH | 1 |
| Honda, H; Komune, S; Nakamura, K; Nakashima, T; Nonoshita, T; Ohga, S; Ohnishi, K; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Egawa, C; Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Yanai, A; Yoshioka, Y | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Moon, JH; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M | 1 |
| Ikeda, J; Itokawa, Y; Koide, K; Otsuji, E; Shimizu, H; Shioaki, Y; Sonoda, H; Takashina, K; Taniguchi, F; Ueshima, Y | 1 |
| Akagi, K; Douno, K; Fujino, S; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Miyake, M; Munakata, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yanagawa, T | 1 |
| Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N | 1 |
| Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kawaguchi, T; Kokuba, Y; Komatsu, S; Konishi, H; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T; Yoshikawa, T | 1 |
| Amano, R; Doi, Y; Hirakawa, K; Iwauchi, T; Nakamoto, K; Ohira, G; Ohira, M; Yamada, N | 1 |
| Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kojima, O; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T; Yamaguchi, M | 1 |
| Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S | 1 |
| Fukumoto, I; Fukumoto, K; Ishida, E; Itani, K; Kanemitsu, D; Kassai, K; Kobayashi, Y; Miyagaki, T; Nakase, Y; Sakamoto, K; Soga, K; Takagi, T; Takenaka, S; Yanagida, K | 1 |
| Baba, H; Beppu, T; Okabe, K; Sano, O; Sugiyama, S; Wada, A; Yamanaka, T | 1 |
| Funaki, H; Hosokawa, K; Kinami, S; Kosaka, T; Nakano, Y; Ohnishi, T; Ohno, Y; Omote, K; Tomita, Y; Ueda, N; Yokoi, M; Yoshitani, S | 1 |
| Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Morimoto, J; Muguruma, K; Nakamura, M; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yamashita, Y; Yashiro, M | 1 |
| Akatsu, T; Amemiya, T; Fukushima, H; Hasegawa, H; Ishida, T; Kitagawa, Y; Mitsugi, Y; Murai, S; Shimizu, H; Shoji, T; Yabe, N | 1 |
| Iwanaga, T; Iwasaki, Y; Kadono, M; Matsumoto, H; Nakano, D; Ohashi, M; Ohinata, R; Takahashi, K; Yamaguchi, T | 1 |
| Hamada, H; Hayashi, S; Katsuki, Y; Kina, M; Kuraya, D; Takada, J; Watanabe, K | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, N; Kurokawa, T; Nagahama, T; Ohhara, T; Watayo, Y | 1 |
| Kataoka, M; Kawamoto, J; Nishida, T; Oeda, Y; Tonooka, T; Wakatsuki, K; Washiro, M; Yoshioka, S | 1 |
| Iwanaga, T; Iwasaki, Y; Koizumi, S; Matsumoto, H; Nakano, D; Ohashi, M; Ohinata, R; Takahashi, K; Tateishi, Y; Yamaguchi, T | 1 |
| Egawa, T; Hayashi, S; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Nagashima, A; Ohashi, M; Okamura, A | 1 |
| Asami, S; Idani, F; Kin, H; Komoto, S; Kubo, S; Kubota, T; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yoshioka, T | 1 |
| Hamatsu, T; Hasegawa, H; Honboh, T; Ikebe, M; Kitamura, M; Minagawa, R; Ushijima, C | 1 |
| Maeda, Y; Oka, M; Shindo, Y; Suzuki, N; Yoshino, S | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Miwa, H; Miyanishi, K; Ohzato, H; Yamamoto, T | 1 |
| Danno, K; Fujiwara, Y; Imaoka, S; Kagara, N; Kagawa, K; Kanoh, T; Kim, C; Kimura, Y; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tohno, T | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, N; Kurokawa, T; Nagahama, T; Watayo, Y | 1 |
| Doi, K; Hirano, Y; Kudo, K; Narita, Y; Ogata, K; Ohchi, T | 1 |
| Akabane, H; Inagaki, M; Nakano, S; Shomura, H; Yanagida, N | 1 |
| Iwanaga, T; Iwasaki, Y; Maeda, Y; Matsumoto, H; Nakano, D; Ohashi, M; Ohhinata, R; Sasaki, E; Takahashi, K; Yamaguchi, T | 1 |
| Akaike, M; Mikayama, Y; Morinaga, S; Shiozawa, M; Tamagawa, H; Tamura, S; Watanabe, T; Yamamoto, N | 1 |
| Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ohkubo, K; Ohtsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M | 1 |
| Fujiwara, Y; Ikeda, M; Inoue, K; Inoue, M; Ishikawa, K; Iwama, M; Kimura, H; Kitani, K; Murata, M; Nakayama, T; Okajima, K; Ota, Y; Yukawa, M | 1 |
| Fujita, S; Ikeda, N; Kanamura, T; Kojima, Y; Nakagawa, K; Ueno, M | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamada, D | 1 |
| Akagi, K; Dono, K; Fujino, S; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Miyake, M; Munakata, K; Nagai, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yanagawa, T | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tanida, T; Umeshita, H; Wada, H | 1 |
| Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T | 1 |
| Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Lee, T; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Asukai, K; Fujimoto, T; Hama, N; Hata, T; Kashiwazaki, M; Konishi, M; Maekawa, T; Nakanishi, M; Okubo, K; Taniguchi, M; Tsujie, M; Yano, K; Yoshioka, S | 1 |
| Chika, N; Dan, N; Goto, H; Hosokawa, T; Kakimoto, M; Kato, H; Koshiishi, H; Masuda, T; Matsuyama, T; Mitsuhashi, Y; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H; Yoshimura, T | 1 |
| Agatsuma, T; Koizumi, T; Komatsu, Y; Kubo, K | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
| Akazawa, Y; Ichikawa, T; Isomoto, H; Miyaaki, H; Morisaki, T; Nakao, K; Ohnita, K; Takeshima, F; Taura, N; Toriyama, H; Yamaguchi, N | 1 |
| Baba, K; Hasegawa, Y; Imaizumi, K; Kondo, M; Kondoh, Y; Nishiyama, O; Ogasawara, T; Saito, H; Shimokata, K; Sugino, Y; Suzuki, R; Takada, K; Taniguchi, H; Yamamoto, M | 1 |
| Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N | 1 |
| Gandhi, J; Govindan, R; Herbst, RS; Kommor, MD; Morgensztern, D; Saito, K; Schaefer, P; Schiller, J; Zergebel, C | 1 |
| Bae, KS; Chang, HM; Hong, YS; Jang, G; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Lim, HS; Ryu, MH; Shin, JG | 1 |
| Eguchi Nakajima, T; Fukagawa, T; Hamaguchi, T; Iwasa, S; Katai, H; Kato, K; Morita, S; Saka, M; Shimada, Y; Yamada, Y | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T | 3 |
| Chon, HJ; Chung, HC; Jeung, HC; Kim, HS; Noh, SH; Park, HS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Chin, K; Esaki, T; Furukawa, H; Hamada, C; Iishi, H; Imamoto, H; Imamura, H; Narahara, H; Sakata, Y; Tsuburaya, A | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Shiroyama, T; Tachibana, I | 1 |
| Katsahian, S; O'Quigley, J; Zohar, S | 1 |
| Hatae, M; Hirai, Y; Kamiura, S; Katsumata, N; Kokawa, K; Nishimura, R; Ochiai, K; Sugiyama, T | 1 |
| Hoshika, T; Kamei, H; Shiote, Y; Shirakawa, A; Suwaki, T; Takigawa, N; Umemura, S; Yamane, H; Yano, T | 1 |
| Hasegawa, M; Ide, H; Kikuchi, E; Kosaka, T; Maeda, T; Miyajima, A; Oya, M; Shirotake, S; Tanaka, N; Yasumizu, Y | 1 |
| Chikakiyo, M; Hirose, T; Satake, N; Suzuki, Y; Yagi, T | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kong, SY; Lee, JH; Lee, JY; Nam, BH; Park, SR; Park, YI; Rhee, J; Ryu, KW | 1 |
| Imai, Y; Kirita, T; Sasahira, T; Shimomura, H; Tamaki, S; Yamanaka, Y | 1 |
| Fujita, Y; Kaneko, K; Kobayashi, S; Miyazaki, M; Nakagawa, K; Nakamura, J; Tanaka, K | 1 |
| Adachi, A; Azuma, K; Inoue, N; Kuriyama, D; Nakamura, T; Noguchi, M; Sawada, M; Someda, H; Uose, S; Yoshioka, M | 1 |
| Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K | 1 |
| Egawa, S; Kamakazu, K; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T | 1 |
| Asaumi, Y; Douden, K; Fujita, M; Hashidume, Y; Hattori, M; Hayashi, H; Hayashida, Y; Hirano, Y; Ito, H; Kitamura, H; Maeda, K; Miyanaga, T; Miyazaki, M; Ota, K; Sasaki, T; Shin, H; Yagi, D | 1 |
| Doi, F; Ishikawa, N; Kusumoto, C; Kusumoto, M; Matsumoto, T; Toyoda, S | 1 |
| Hayashi, H; Miyanaga, K; Tabo, T | 1 |
| Dan, N; Fukuoka, T; Hirakawa, K; Hori, T; Ikehara, T; Nishino, H; Takatsuka, S; Tendo, M; Tezuka, K | 1 |
| Shoji, T | 1 |
| Hatano, E; Ikeda, K; Kamo, N; Mitsuyoshi, H; Mori, A; Nitta, T; Uemoto, S | 1 |
| Fukuoka, J; Hosokawa, A; Ishizawa, S; Itaya, Y; Kajiura, S; Kawai, K; Minemura, M; Nakayama, Y; Nishimizu, T; Sawasaki, T; Shimizu, S; Sugiyama, T; Tajiri, K; Takahara, T; Tokimitsu, Y; Yamawaki, H; Yanagisawa, A; Yasumura, S | 1 |
| Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S | 1 |
| Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Kamiya, K; Kobashi, H; Shimizu, K | 1 |
| Matsui, K; Nagata, T; Shimada, K; Shimada, Y; Shinbo, M; Tazawa, K; Tsuchiya, Y; Tsukada, K; Yamagishi, F | 1 |
| Kishi, S; Matsumoto, A; Morise, M; Suzuki, H; Suzuki, T; Takeshita, T; Tsutsui, A; Yoneyama, K | 1 |
| Amano, S; Fujii, S; Fukahori, M; Godai, T; Imada, T; Kunisaki, C; Makino, H; Masuda, M; Numata, M; Oshima, T; Rino, Y; Sato, T | 1 |
| Kameda, R; Kanazawa, A; Kobayashi, S; Miyakawa, K; Morinaga, S; Ohkawa, S; Tamura, S; Ueno, M; Yamamoto, N | 1 |
| Arita, M; Fujino, H; Kuga, Y; Miwata, T; Moriya, T; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Aoki, M; Ikarashi, M; Ishibashi, Y; Itoh, Y; Iwama, A; Omori, K; Wakabayashi, K | 1 |
| Aw, CW; Lee, SC; Lim, R; Lim, TC; Tan, CS; Yeo, SW | 1 |
| Hirakawa, K; Kamano, T; Kambe, M; Mitachi, Y; Morita, S; Nakata, B; Oikawa, K; Onoda, N; Saji, S; Sakamoto, J; Shirasaka, T; Taenaka, N; Takahashi, M; Tanaka, Y; Tsuji, A | 1 |
| Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H | 1 |
| Fukuda, H; Hamaguchi, T; Ito, Y; Moriya, Y; Nakamura, K; Nakano, A; Shibata, T; Shimada, Y; Takashima, A | 1 |
| Daimon, Y; Kito, F; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T; Yoshida, S | 1 |
| Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C | 1 |
| Akiyama, H; Endo, I; Fujii, S; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Nagano, Y; Ono, HA; Takagawa, R | 1 |
| Bergmann, L; Graeven, U; Hanauske, AR; Lipp, R; Saito, K; Scheulen, ME; Schuette, J; Schultheis, B; Scigalla, P; Strumberg, D | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Miyazaki, T; Takayama, T; Takayama, Y; Tamegai, H; Watanabe, M | 1 |
| Akiyama, R; Egawa, S; Hayashi, T; Ikeda, K; Ikenoya, Y; Kobayashi, S; Sanbe, T; Shimane, T; Sugimoto, A; Suzaki, H; Uzuki, A | 1 |
| Danno, K; Imaoka, S; Kanou, T; Kimura, Y; Miyazaki, S; Monden, T; Nakano, H; Onishi, T; Tono, T; Yano, H | 1 |
| Akiyama, R; Egawa, S; Hayashi, T; Ikeda, K; Ikenoya, Y; Kobayashi, S; Sanbe, T; Shimane, T; Sugimoto, A; Uzuki, A | 1 |
| Andou, M; Baba, S; Matsukata, A; Rai, Y; Sagara, Y; Tamada, S; Yotsumoto, D | 1 |
| Hadano, N; Imamura, Y; Koyama, M; Kuwada, A; Nakamitsu, A; Taogoshi, H; Uegami, S | 1 |
| Hirota, N; Kawai, Y; Matsumura, M; Sato, M; Shimizu, K; Tagi, T; Takebayashi, K; Tani, T; Yamamoto, H | 1 |
| Fujimura, M; Kou, K; Nagashima, T; Shibuya, M; Suganuma, Y | 1 |
| Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T | 1 |
| Fukumoto, M; Hayashi, T; Ito, H; Kagaya, T; Kikuchi, H; Koizumi, K; Mita, K; Murabayashi, R | 1 |
| Ahn, JB; Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ; Yang, WI | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
| Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S | 1 |
| Fujisawa, K; Iwamoto, S; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D | 1 |
| Anami, S; Fujii, C; Fujino, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Sumida, R; Yasui, Y | 1 |
| Kayata, Y; Kikawa, Y; Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Gon, H; Ishida, T; Iwasaki, T; Kanemitsu, K; Nakajima, T; Okuda, T; Tanaka, K; Toyokawa, A; Yamashita, H | 1 |
| Hirano, T; Matsumoto, K; Morisaki, T; Sada, M | 1 |
| Ishii, Y; Okada, R; Onozawa, H; Takenoshita, S; Yamada, M | 1 |
| Kakisaka, T; Kamachi, H; Kamiyama, T; Matsushita, M; Mizukami, T; Nakanishi, K; Tahara, M; Taniguchi, M; Todo, S; Yokoo, H | 1 |
| Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y | 1 |
| Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Chung, HC; Jeung, HC; Lim, SJ; Noh, SH; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Hiraki, Y; Kurahara, H; Maemura, K; Mataki, Y; Nakajo, M; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S | 1 |
| Goto, H; Haruta, J; Ina, K; Iwase, H; Kumada, T; Shimada, M; Shinoda, M; Sugihara, M; Tsuzuki, T | 1 |
| Fukushima, M; Hasegawa, S; Okabe, H; Ozaki, N; Sakabayashi, S; Sakai, Y; Satoh, S; Teramukai, S; Tsuji, A; Ueda, S | 1 |
| Chiba, F; Kiyozaki, H; Konishi, F; Saito, M; Shuto, C; Takata, O; Yamada, S; Yoshida, T | 1 |
| Baggstrom, M; Graham, C; Herbst, R; Jones, D; Saito, K; Sandler, A; Zergebel, C | 1 |
| Ajani, JA; Blum, M; Suzuki, A | 1 |
| Kawasaki, G; Mizuno, A; Yamada, S; Yanamoto, S; Yoshitomi, I | 1 |
| Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T | 1 |
| Fujisaka, M; Maruyama, M; Naruse, A; Shojaku, H; Tachino, H; Takakura, H; Tsubota, M; Watanabe, Y; Yasumura, S | 1 |
| Amano, S; Fukino, N; Kano, H; Kawasaki, A; Kida, K; Kuboi, Y; Mimatsu, K; Oida, T | 1 |
| Horiba, T; Inoue, T; Masubuchi, M; Matsumura, T; Oomoto, K; Orihara, A; Sato, E; Yagi, Y | 1 |
| Nakano, S; Nishida, T; Ogasawara, T; Ootsuka, T; Shida, T; Takahashi, M | 1 |
| Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Ishida, M; Morita, S | 1 |
| Kaino, S; Kuramitsu, Y; Murakami, K; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Yoshida, K; Zhang, X | 1 |
| Handa, K; Hatogai, K; Hibi, T; Higuchi, H; Iwasaki, E; Izumiya, M; Kishino, R; Maeda, N; Mizuki, A; Mukai, K; Nakazawa, A; Seki, E; Shimoyama, Y; Takaishi, H; Takita, M; Tsukada, N | 1 |
| Hamada, Y; Horie, A; Iketani, S; Kanai, I; Kawaguchi, K; Nakatani, Y; Nomura, T; Sato, K; Suzuki, S; Yamada, H | 1 |
| Ishii, Y; Kikuchi, D; Saitou, M; Takenoshita, S; Yamada, M | 1 |
| Matsueda, S; Sasaki, H; Tokunaga, Y | 1 |
| Araya, J; Matsuoka, K; Nakajima, F; Nomura, H; Ogawa, T | 1 |
| Asaumi, Y; Doden, K; Fujita, M; Hashizume, Y; Hattori, M; Hayashi, H; Hayashida, Y; Hirano, M; Ito, H; Kaizaki, Y; Kitamura, H; Maeda, K; Miyanaga, T; Miyazaki, M; Ohta, K; Shin, H; Yagi, D | 1 |
| Hamada, J; Ikeda, J; Itokawa, Y; Lee, C; Shimomura, K; Shioaki, Y; Sonoda, H; Takashina, K; Taniguchi, F; Ueshima, Y | 1 |
| Akamatsu, H; Ei, S; Handa, K; Ishimaru, N; Koshida, Y; Masai, K; Mito, M; Mizuno, K; Motegi, K; Mukai, K; Okada, R; Shimoyama, Y; Tajima, T; Takahashi, H; Toriumi, F; Yamanashi, T | 1 |
| Hirai, K; Hirano, T; Kawate, S; Ogawa, H; Sunose, Y; Takahashi, N; Takase, Y; Takeyoshi, I; Tanaka, K; Totsuka, O; Toya, H; Yoshinari, D | 1 |
| Fujii, M; Hasegawa, T; Hayashi, I; Kasakura, Y; Kinukawa, N; Murayama, I; Nemoto, N; Okaniwa, A; Watanabe, Y | 1 |
| Goto, T; Hibi, K; Ishibashi, K; Kigawa, G; Kitamura, Y; Matsubara, T; Nemoto, H; Saito, M; Sakuraba, K; Shinmura, K; Soda, H; Yokomizo, K | 1 |
| Ishi, Y; Kikuchi, D; Saito, M; Takenoshita, S; Yamada, M | 1 |
| Fujitani, K; Furukawa, H; Iijima, S; Imamura, H; Inoue, K; Kimura, Y; Kobayashi, K; Kurokawa, Y; Matsuyama, J; Tamura, S; Tsuji, T | 1 |
| Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y | 1 |
| Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Naruke, A; Nishimura, K; Sasaki, T; Takagi, S; Tanabe, S | 1 |
| Okamura, T; Oshitanai, R; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Akiyama, R; Egawa, S; Hayashi, T; Ikeda, K; Ikenoya, Y; Sanbe, T; Shimane, T; Sugimoto, A; Uzuki, A | 1 |
| Asaumi, Y; Doden, K; Fujita, M; Hashizume, Y; Hattori, M; Hayashi, H; Hayashida, Y; Hirano, M; Ito, H; Kaizaki, Y; Kitamura, H; Maeda, K; Miyanaga, T; Miyazaki, M; Ohta, K; Sawada, K; Yagi, D | 1 |
| Kobayashi, T; Kubota, Y; Ogino, T; Satomoto, K; Ueyama, S | 1 |
| Fujii, Y; Hamano, K; Hanashima, M; Kuga, T; Oka, K; Yamashita, A | 1 |
| Ando, J; Endo, Y; Koyama, Y; Nakamura, I; Ohki, S; Sassa, M; Sato, Y; Suzuki, S; Tachibana, K; Takenoshita, S | 1 |
| Dan, N; Hori, T; Nishino, H; Tendo, M; Tezuka, K | 1 |
| Gotoh, M; Higuchi, M; Kitamura, M; Satoh, Y; Shio, Y; Suzuki, H | 1 |
| Ikeda, O; Kitajima, Y; Miyoshi, A; Noshiro, H; Satoh, S; Yakabe, T | 1 |
| Chae, YS; Chung, HY; Jang, YJ; Jeon, SW; Jung, MK; Kang, BW; Kim, JG; Kwon, O; Lee, SJ; Lee, YH; Lee, YJ; Moon, JH; Seo, J; Sohn, SK; Yu, W | 1 |
| Boku, N; Brown, KH; Hayashi, H; Muro, K; Nakajima, TE; Satoh, T; Shi, X; Shimada, Y; Takahari, D; Taku, K; Yamada, Y | 1 |
| Ito, T; Kamigaki, S; Morita, S; Nakayama, T; Noguchi, S; Sakamoto, J; Taguchi, T; Takashima, T; Yoshidome, K | 1 |
| Fukada, J; Fukuda, K; Kawaguchi, O; Kitagawa, Y; Oyama, T; Saikawa, Y; Shigematsu, N; Takahashi, T; Takaishi, H; Takeuchi, H; Wada, N | 1 |
| Fujitani, K; Hasegawa, H; Hirao, M; Kurokawa, Y; Tsujinaka, T | 1 |
| Jin, ZM; Zhu, QC | 1 |
| Jiang, J; Ju, J; Lu, B; Wu, C; Xu, X; Yan, H; Zhang, X; Zheng, X; Zhou, Q | 1 |
| Abu Lila, AS; Doi, Y; Ishida, T; Kiwada, H; Matsunaga, M; Nakamura, K | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Shimada, Y | 1 |
| Goto, A; Hamaguchi, T; Ichikawa, Y; Kato, K; Matsumoto, H; Shimada, Y; Yamada, Y; Yamaguchi, T | 1 |
| Hanayama, H; Hori, T; Kaibe, N; Kikuchi, S; Matsumoto, T; Oshima, T; Ozawa, R; Sasako, M; Takemura, M; Yamashita, H | 1 |
| Akizuki, M; Fujii, K; Fukutomi, T; Kobayashi, K; Kosaka, J; Mouri, Y; Nakano, S; Yorozuya, K; Yoshida, M | 1 |
| Furumoto, K; Ito, D; Kogire, M; Mori, T; Yoshimura, G | 1 |
| Aono, K; Sato, T; Yasui, A | 1 |
| Enomoto, N; Hosoya, N; Motoyama, K; Oono, R; Otsuki, S; Ueda, Y | 1 |
| Aoki, Y; Arimura, Y; Goto, A; Igarashi, H; Itoh, M; Kaneto, H; Kobayashi, T; Matsunaga, Y; Okuda, H; Onodera, K; Shimizu, H; Shinomura, Y; Sukawa, Y; Suzuki, K; Wakasugi, H; Yawata, A; Yonezawa, K | 1 |
| Abadie, E; Calvo Rojas, G; Camarero, J; Garcia-Carbonero, R; Matt, P; Pignatti, F; Ter Hofstede, H; van Zwieten-Boot, B | 1 |
| Akie, K; Dosaka-Akita, H; Fujita, Y; Fukumoto, S; Harada, M; Harada, T; Isobe, H; Kikuchi, E; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Ohsaki, Y; Oizumi, S; Shinagawa, N | 1 |
| Chung, KY; Hollywood, E; Saito, K; Saltz, LB; Segal, M; Zergebel, C | 1 |
| Hamatake, M; Hirai, F; Ichinose, Y; Kometani, T; Maruyama, R; Ondo, K; Seto, T; Sugio, K | 1 |
| Fujita, K; Imamura, I; Kakeji, Y; Kubo, N; Maehara, Y; Morita, M; Ohgaki, K; Oki, E; Sadanaga, N; Shibahara, K; Tsujitani, S | 1 |
| Murakami, Y; Sudo, T; Uemura, K | 1 |
| Kanekura, T; Kawai, K; Matsushita, S; Mera, K; Yonekura, K | 1 |
| Enomoto, M; Hirakawa, K; Kawada, N; Kawajiri, H; Morikawa, H; Motoyama, H; Takashima, T; Tamori, A | 1 |
| Boku, N; Fukutomi, A; Hamauchi, S; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Fujitani, K; Fukushima, R; Hirabayashi, N; Kadowaki, S; Morita, S; Munakata, Y; Nishikawa, K; Sakamoto, J; Sekishita, Y; Shitara, K; Takagane, A; Takagi, M; Takahashi, M; Takiguchi, N; Tanaka, T; Tokunaga, Y; Tsuburaya, A | 1 |
| Fujita, I; Furukawa, K; Kanazawa, Y; Kato, S; Shirakawa, T; Uchida, E; Yamada, T; Yokoi, K | 1 |
| Asaka, S; Isohata, N; Katsube, T; Kuhara, K; Miyaki, A; Murayama, M; Naritaka, Y; Ogawa, K; Usuda, A; Yamaguchi, K | 1 |
| Fujiwara, H; Hosoi, N; Koeda, K; Konosu, M; Sase, M; Taguchi, M; Tamasawa, Y; Tsukahara, T; Ushio, A; Wakabayashi, G | 1 |
| Homma, K; Maruyama, S; Matsuki, A; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tsuchiya, Y; Usuda, A; Yabusaki, H | 1 |
| Egawa, C; Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Teramoto, A; Uji, K; Yanai, A; Yoshioka, Y | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Hayashi, H; Kinoshita, J; Kitagawa, H; Makino, I; Nakagawara, H; Nakamura, K; Ninomiya, I; Ohta, T; Oyama, K; Tajima, H; Takamura, H; Tani, T | 1 |
| Fujii, M; Furukawa, H; Katai, H; Kinoshita, T; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T | 1 |
| Hori, S; Kondo, G; Maeda, T; Miki, A; Satoh, H; Sawada, Y; Yamamuro, F | 1 |
| Hilger, RA; Mende, B; Saito, K; Scheulen, ME; Strumberg, D; Zergebel, C | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Ajioka, Y; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Yajima, K | 1 |
| Fukuoka, M; Ichinose, Y; Katakami, N; Kudoh, S; Nakagawa, K; Nishimura, Y; Okamoto, I; Saka, H; Sasaki, T; Sawa, T; Seto, T; Takeda, K; Tanaka, M; Yamanaka, T | 1 |
| Ashida, C; Higashida, A; Kawara, F; Kondo, T; Mamori, S; Okutani, T; Onishi, K; Takeda, A; Yamada, H | 1 |
| Akiyama, J; Asayama, N; Fujiya, K; Gotoda, T; Kobayakawa, M; Kojima, Y; Nagata, N; Nakajima, R; Nishimura, S; Ogami, T; Sakurai, T; Shimbo, T; Uemura, N; Yokoi, C; Yokota, E | 1 |
| Amano, K; Aratake, K; Hashimoto, T; Hirosawa, T; Itabashi, M; Kameoka, S; Narita, T; Ogawa, S; Seshimo, A | 1 |
| Aoki, M; Iwamoto, O; Koga, C; Koga, M; Kusukawa, J; Nakamura, M | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kuzushita, N; Mita, E; Mitsuta, C; Nakazuru, S; Ohta, T; Ota, M; Suemura, S; Sueyoshi, Y; Tatsumi, K; Toyama, T; Yoshio, T | 1 |
| Kinoshita, S; Kyoda, S; Morikawa, T; Okamoto, T; Takeyama, H; Uchida, K; Yamashita, A | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Cho, H; Fukunaga, T; Ito, S; Kunisaki, C; Matsui, T; Morita, S; Nishikawa, K; Sakuramoto, S; Taguri, M; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Fukusato, T; Kobunai, T; Watanabe, T | 1 |
| Deguchi, T; Fujisaki, M; Kadomura, T; Kato, A; Kato, Y; Kitajima, M; Kojima, M; Kubota, K; Kuroda, J; Nitori, N; Okada, A; Origuchi, N | 1 |
| Furuse, J; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shinichi, O; Suzuki, E; Ueno, H; Ueno, M; Yamaguchi, T | 1 |
| Fukuda, K; Kawakubo, H; Kitagawa, Y; Saikawa, Y; Takahashi, M; Takahashi, T; Takeuchi, H; Wada, N | 1 |
| Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kuwabara, H; Mikayama, Y; Ogata, T; Tsuburaya, A; Yoshikawa, T | 2 |
| Fukumoto, T; Ishida, T; Kitanaka, A; Kubota, Y; Matsumoto, K; Ohnishi, H; Uemura, M; Waki, F | 1 |
| Fujitani, K; Furukawa, H; Imamura, H; Inoue, K; Kimura, Y; Kogire, M; Kurokawa, Y; Kwon, AH; Nakane, Y; Okano, S; Shimokawa, T; Takiuchi, H; Tamura, S; Tsujinaka, T | 1 |
| Akiba, T; Kamijo, A; Murayama, C; Nakayama, Y; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Chang, HM; Kang, YK; Kim, TW; Koo, DH; Lee, JL; Lee, SS; Moon, JH; Ryoo, BY; Ryu, MH | 1 |
| Hayashi, N; Igawa, S; Katagiri, M; Katono, K; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Nagashima, Y; Otani, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yokoba, M | 1 |
| Inoue, K; Kamata, M; Kitade, H; Kwon, AH; Matsui, Y; Ohe, C; Sakaida, N; Satoi, S; Tanigawa, N; Toyokawa, H; Uemura, Y; Yamamoto, T; Yanagimoto, H | 1 |
| Fujimura, T; Fukushima, N; Fushida, S; Kawachi, Y; Kuwabara, S; Musha, N; Nashimoto, A | 1 |
| Ando, M; Atagi, S; Fujita, Y; Hayashihara, K; Kawaguchi, T; Matsumura, A; Okano, Y; Okishio, K; Saito, R; Takada, M; Takahashi, F; Tamura, A; Tomizawa, Y | 1 |
| Fukumoto, S; Higuchi, T; Horinouchi, Y; Uehara, S; Yamamoto, C; Yasumori, K; Yoshida, M; Yoshikawa, H | 1 |
| Osada, S; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Aoyama, T; Hasegawa, S; Kanemoto, A; Saze, Z; Tahara, H; Terashima, M; Tsuburaya, A; Yoshikawa, T | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kuwabara, H; Masuda, M; Mikayama, Y; Ogata, T; Rino, Y; Tsuburaya, A; Yoshikawa, T | 2 |
| Aoki, T; Chono, T; Hyuga, S; Kato, A; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanizaki, K; Uemura, Y; Watanabe, R | 1 |
| Danno, K; Imaoka, S; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tohno, T | 1 |
| Ishii, Y; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Ohashi, M; Ohinata, R; Takahashi, K; Yamaguchi, T | 1 |
| Akagi, K; Dono, K; Fujino, S; Fujita, J; Hata, T; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Masuike, Y; Miyake, M; Morita, S; Nagai, K; Noda, T; Ohara, N; Okamoto, K; Oshima, K; Yanagawa, T | 1 |
| Fujiwara, Y; Ikeda, M; Inoue, K; Inoue, M; Isono, S; Iwama, M; Kimura, H; Kitani, K; Murata, M; Nakayama, T; Okajima, K; Ota, Y; Sato, K; Tsujie, M; Yukawa, M | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Munakata, S; Ohzato, H; Takemoto, H; Yamamoto, T | 1 |
| Ebisui, C; Ide, Y; Kinuta, M; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Tamai, M; Yanagisawa, T; Yokouchi, H | 1 |
| Aoyagi, H; Hasegawa, K; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Takahata, T; Yoshida, T | 2 |
| Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
| Babaya, A; Hamanaka, M; Kamikonya, N; Kuno, T; Matsubara, N; Noda, M; Tomita, N; Tsukamoto, K; Yamagishi, D; Yamano, T | 1 |
| Kamiya, A; Kawachi, Y; Maruyama, H; Nagano, H; Nakajima, Y; Ohtsukasa, S; Okazaki, S; Takamatsu, S | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Sanada, T; Wakabayashi, M | 2 |
| Ikehara, T; Ikeya, T; Inoue, T; Kanazawa, A; Kodai, S; Komatsu, H; Morimoto, J; Nishiguchi, Y; Shimizu, S; Tsukamoto, T; Yamamoto, A; Yamashita, Y; Yamazoe, S | 1 |
| Dok, Y; Hamakawa, T; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Ebisui, C; Kato, R; Kinuta, M; Makino, S; Murakami, M; Murata, K; Nishigaki, T; Okada, K; Okamura, S; Owada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Amano, R; Hirakawa, K; Ito, G; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Egawa, T; Irino, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, Y; Nagashima, A; Yamamuro, W | 1 |
| Egawa, T; Eto, E; Hayashi, S; Inaba, Y; Irino, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Okamura, A; Segami, K | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Okada, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Yoneda, M | 1 |
| Akagi, K; Dono, K; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Miyake, M; Nagai, K; Shimano, T; Shimizu, J | 1 |
| Doki, Y; Eguchi, H; Katsura, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H; Wakasa, K | 1 |
| Doki, Y; Eguchi, H; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Adachi, T; Fukushima, M; Habuchi, Y; Hirajima, S; Komatsu, S; Otsuj, E; Sakuyama, A | 1 |
| Hasegawa, Y; Itou, N; Nishizuka, S; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
| Kume, H | 1 |
| Kato, K | 1 |
| Ding, KL; Feng, XS; Gao, SG; Jia, RN; Pan, LX; Shan, TY; Song, NS; Wang, LD; Wang, YF; Xie, XH | 1 |
| Fukunaga, M; Furukawa, H; Imamura, H; Ohzato, H; Yamamoto, T | 1 |
| Miura, K; Sasaki, I; Shirasaka, T; Yamaue, H | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D | 1 |
| Anami, S; Fujii, C; Fujino, M; Furukawa, H; Hachino, Y; Imamura, H; Kawabata, R; Kishimoto, T; Sumida, R | 1 |
| Chiba, T; Fujiwara, H; Koeda, K; Mitomo, S; Sugai, T; Takahashi, M; Uesugi, N; Wakabayashi, G | 1 |
| Hashizume, E; Narita, T; Suzuki, A; Yajima, M | 1 |
| Harada, N; Hayashi, T; Imaizumi, T; Kaji, S; Koike, N; Morishita, K; Suzuki, M; Suzuki, S; Takeo, Y | 1 |
| Iizawa, H; Kakizaki, Y; Motoi, F; Okada, T; Sakurai, N; Tamura, G; Unno, M; Yamamoto, K | 1 |
| Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N | 1 |
| Chung, HC; Jeung, HC; Jung, I; Kim, GM; Kim, HS; Lee, KH; Nam, BH; Rha, SY | 1 |
| Egawa, N; Hanada, K; Hijioka, S; Hirose, Y; Ikari, T; Ikeda, T; Ishii, H; Itoi, T; Kimura, Y; Maetani, I; Matsumura, Y; Mouri, H; Nakajima, T; Ohoka, S; Okabe, Y; Omuro, Y; Ozaka, M; Sofuni, A; Suyama, M; Tani, M; Watanabe, R | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Baba, H; Kakeji, Y; Kobayashi, M; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Sato, S; Takahashi, I; Takeuchi, Y; Tsuburaya, A | 1 |
| Edagawa, A; Ikeda, Y; Itoh, S; Kakeji, Y; Kawanaka, H; Korenaga, D; Maehara, Y; Oki, E; Okuyama, T; Takenaka, K; Tateishi, M; Tsujitani, S | 1 |
| Lordick, F | 1 |
| Kaneda, H; Nakagawa, K; Nishio, K; Okamoto, I; Sakai, K; Takeda, M; Tanizaki, J | 1 |
| Chang, JS; Chung, Y; Koom, WS; Seong, J; Song, SY; Wang, ML; Yoon, HI | 1 |
| Ebi, M; Joh, T; Kamiya, T; Kataoka, H; Kitagawa, M; Mizoshita, T; Shimura, T; Tanida, S; Yamada, T | 1 |
| Akamatsu, H; Endo, M; Harada, H; Imai, H; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Sakaguchi, C; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Abu Lila, AS; Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Okada, T | 1 |
| Ahn, HK; Bae, JM; Choi, DI; Choi, MG; Kang, WK; Kim, KM; Kim, S; Lee, DJ; Lee, J; Lim, DH; Lim, HY; Min, BH; Noh, JH; Park, JO; Park, SH; Park, YS; Sohn, TS | 1 |
| Hamaguchi, T; Hashimoto, J; Kato, K; Nakajima, TE; Okazaki, S; Shimada, Y; Takahari, D; Tamura, K; Yamada, Y; Yamamoto, S | 1 |
| Ariga, H; Fujimoto, K; Hagiwara, Y; Ichikawa, M; Kenjo, M; Kuroda, Y; Murakami, M; Nemoto, K; Nomiya, T; Ogawa, K; Ota, I; Suzuki, M; Takai, K; Takeda, K; Wada, H | 1 |
| Fang, WJ; Huang, MZ; Jin, DZ; Mao, CY; Mou, HB; Peng, L; Xu, N; Zhao, P; Zheng, YL | 1 |
| Hashimoto, Y; Hiyama, E; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Kawahara, H; Kobayashi, S; Toyama, Y; Watanabe, K; Yanaga, K; Yanagisawa, S | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Hayashi, K; Kuramochi, H; Nakamura, T; Narumiya, K; Ota, M; Sato, T; Shirai, Y; Yamamoto, M | 1 |
| Hirai, K; Katoh, R; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D | 1 |
| Kondo, F; Miyazaki, M; Nakano, S; Nomura, S; Ogasawara, T; Otsuka, Y; Shida, T; Takahashi, M | 1 |
| Aizawa, H; Aizawa, S; Hakamada, K; Ishizawa, Y; Kasai, M; Munakata, M; Okudera, D; Sakata, Y; Satoh, Y; Yokoyama, M | 1 |
| Higashiyama, M; Kato, T; Nakamura, Y; Nakayama, H; Nobutou, Y; Okamura, R; Wada, S; Yoh, T | 1 |
| Endo, S; Hidaka, E; Ikehara, K; Ishida, F; Kudo, SE; Omoto, T; Tanaka, J | 1 |
| Asanuma, F; Atsuda, K; Morimoto, Y; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoneyama, H | 1 |
| Fukuda, Y; Ito, S; Morisue, R; Munakata, K; Ogaw, Y; Yamaguchi, T | 1 |
| Bando, T; Chen, F; Date, H; Fujinaga, T; Miyahara, R; Sakai, H; Sato, T; Shoji, T; Sonobe, M; Wada, H | 1 |
| Kondo, C; Matsuo, K; Mizota, A; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y | 1 |
| Cho, H; Fukushima, R; Hiki, N; Morita, S; Nunobe, S; Sano, T; Taguri, M; Taniguchi, H; Tsuburaya, A; Yoshikawa, T | 1 |
| Miyanaga, T; Miyashita, H; Sasaki, T; Sugiyama, K; Yamamoto, K | 1 |
| Ishigami, H; Kaisaki, S; Kitayama, J | 1 |
| Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T | 1 |
| Kawai, Y; Matsumura, M; Mekata, E; Sato, M; Shimizu, K; Tagi, T; Takebayashi, K; Tani, T; Yamamoto, H | 1 |
| Asano, K; Betsuyaku, T; Ikemura, S; Naoki, K; Ogura-Tomomatsu, H; Sato, T; Soejima, K; Terai, H | 1 |
| Higashi, Y; Hiraide, T; Kubota, H; Maruo, H; Shoji, T; Suzuki, K; Takeda, M; Taniguchi, M; Yamazaki, M; Yonekawa, H | 1 |
| Ikeda, T; Minamoto, K; Yuasa, I | 1 |
| Adachi, T; Hara, N; Kashima, Y; Shirasaka, T; Sohtome, I | 1 |
| Akamine, S; Hisano, H; Matsumoto, K; Minami, H; Miyazaki, T; Nagayasu, T; Nakamura, A; Tagawa, T; Taniguchi, H; Taniguchi, Y; Tsuchiya, T; Yamasaki, N | 1 |
| Hagiike, M; Inoue, T; Kimura, T; Okano, K; Suzuki, Y; Usuki, H; Yachida, S | 1 |
| Abe, S; Harada, M; Hiura, M; Kihara, Y; Miyagawa, K; Shimajiri, S; Taguchi, M; Yamamoto, M | 1 |
| Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H | 1 |
| Fukuoka, J; Hori, R; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Watanabe, T; Yoshioka, I | 1 |
| Furusawa, M; Hirai, T; Hiraki, A; Murakami, R; Nakaguchi, Y; Nakayama, H; Shinohara, M; Teshima, K; Tomitaka, E; Tsujita, N; Yamashita, Y; Yoshida, R | 1 |
| Abe, S; Hashida, H; Hattori, K; Inoue, Y; Kadono, K; Miyake, M; Nomura, A; Osaki, N; Terajima, H; Ueda, S; Yoshida, M; Yoshimura, M; Yoshitomi, M | 1 |
| Hosone, M; Katayama, H; Maruyama, H; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Yokoyama, T; Yoshida, H | 1 |
| Azuma, T; Inoue, T; Mori, Y; Ohtani, H; Tamamori, Y | 1 |
| Hasegawa, H; Kubo, H; Miyahara, M; Nishiyama, M; Tada, K; Yamashita, Y | 1 |
| Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S | 1 |
| Gomi, K; Hachiya, T; Hama, M; Honda, T; Komatsu, Y; Nakamura, T; Shinagawa, Y; Yamashita, K; Yoshikawa, S | 1 |
| Boku, N; Ito, S; Katayama, H; Mizusawa, J; Sano, T; Sasako, M; Takahari, D; Terashima, M; Tsuburaya, A | 1 |
| Fujiwara, M; Ito, S; Kobayashi, D; Kodera, Y; Kojima, H; Kondo, K; Matsui, T; Mochizuki, Y; Ohashi, N; Tanaka, C | 1 |
| Kondo, C; Matsuo, K; Muro, K; Niwa, Y; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T | 1 |
| Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S | 1 |
| Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Ryoo, BY; Ryu, MH; Shin, JG | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T | 1 |
| Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW | 1 |
| Fukushima, J; Komune, S; Nakamura, K; Nakashima, T; Shioyama, Y; Shiratsuchi, H; Toh, S; Yasumatsu, R | 1 |
| Doyama, H; Hayashi, T; Inagaki, S; Inaki, N; Ito, R; Kaneko, Y; Katayanagi, K; Kitou, Y; Kurumaya, H; Nakanishi, H; Niwa, H; Takeda, Y; Takemura, K; Tominaga, K; Tsuji, K; Tsuji, S; Yamada, S; Yamada, T; Yamamoto, M | 1 |
| Inoue, K; Kawaguchi, Y; Kwon, AH; Michiura, T; Nakai, K; Nakane, Y; Ozaki, T; Takada, H; Ueyama, Y; Yamada, M | 1 |
| Fujii, K; Fujii, N; Haradai, K; Iizuka, R; Ikawa, O; Ishii, W; Izumi, H; Kakihara, N; Kobayashi, T; Matsumura, H; Morimura, R; Nakase, K; Ohgaki, M; Okajima, W; Sakaki, M; Takenaka, A; Taniguchi, H; Yamada, K | 1 |
| Ishihara, S; Kimura, K; Kishi, M; Kobayashi, M; Kokudo, Y; Kurosaki, T; Miyake, S; Mizobuchi, K; Mori, Y; Muraoka, A; Nagasaka, T; Tatemoto, A; Tsumura, M; Watanabe, N | 1 |
| Ishibashi, N; Kibe, S; Murakami, N; Ogata, Y; Shirouzu, K; Takahashi, K; Takeuchi, M; Uchida, S; Yahara, T | 1 |
| Anan, T; Eto, K; Hayashi, T; Kobayashi, T; Mitsuyama, Y; Oda, A; Ogawa, M; Watanabe, M; Yanaga, K | 1 |
| Bang, YJ; Choung, H; Khwarg, SI; Kim, HH; Kim, JH; Kim, N; Kim, S; Kim, YJ; Lee, JS; Lee, KW; Lee, MJ; Park, C; Park, DJ | 1 |
| Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kitagawa, M; Mizoshita, T; Shimura, T; Tanida, S; Yamada, T | 1 |
| Aihara, R; Ando, H; Asao, T; Fukai, Y; Haga, N; Kuwano, H; Mochiki, E; Ogata, K; Ohno, T; Toyomasu, Y; Uchida, N | 1 |
| Azuma, K; Fukuoka, M; Hasegawa, Y; Kudoh, T; Kurata, T; Miyazaki, M; Morinaga, R; Nakagawa, K; Nishikawa, T; Nishimura, Y; Okamoto, I; Takezawa, K; Terashima, M; Tsurutani, J; Tsuya, A; Yonesaka, K | 1 |
| Egawa, Y; Futami, K; Higashi, D; Hirano, K; Ishibashi, Y; Koga, M; Maekawa, T; Mikami, K; Sasaki, T; Seki, K; Sudo, M | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Ito, Y; Miyakawa, H; Nagase, M; Okusaka, T; Sato, K; Sato, T; Yamao, K; Yonemoto, N | 1 |
| Fujii, C; Fujino, M; Fukunaga, M; Furukawa, H; Hachino, Y; Imamura, H; Kawabata, R; Kishimoto, T; Matsushima, Y; Ohzato, H; Yasui, Y | 1 |
| Fujioka, Y; Kuraya, D; Nakata, H; Shinano, H | 1 |
| Enomoto, K; Ito, M; Matsumoto, S; Migita, K; Nakajima, Y; Takayama, T; Tanaka, T; Wakatsuki, K | 1 |
| Kusano, F; Masuishi, T; Nagayama, K; Sakai, Y; Soma, T; Tazawa, J | 1 |
| Ando, Y; Fujimoto, Y; Fujita, K; Hiramatsu, M; Inada, M; Kawada, K; Mitsuma, A; Morita, S; Yasuda, Y | 1 |
| Edagawa, A; Eguchi, D; Ikeda, Y; Itoh, S; Kawanaka, H; Kawasaki, K; Korenaga, D; Koushi, K; Okuyama, T; Shinohara, S; Takenaka, K | 1 |
| Cho, EK; Chung, M; Hong, J; Jung, M; Kim, HS; Lee, JH; Lee, WK; Park, J; Shin, DB; Sym, SJ | 1 |
| Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J | 1 |
| Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Matsuno, Y; Mihara, Y; Miyazaki, T; Takayama, T | 1 |
| Doi, T; Fuse, N; Hayashi, R; Kawashima, M; Ogino, T; Ohtsu, A; Okano, S; Tahara, M; Yoshino, T; Zenda, S | 1 |
| Ando, T; El-Omar, EM; Goto, H; Morise, K; Murayama, M; Shinoda, M; Suzuki, T; Takashi, H | 1 |
| Kidani, K; Kodani, I; Ogawa, N; Ryoke, K; Tamura, T; Tanio, K | 1 |
| Asukai, K; Hasegawa, I; Horiguchi, N; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Shimizu, S; Togawa, S | 1 |
| Goto, M; Hirata, Y; Kawahara, Y; Kitamura, M; Nakayama, M; Ohta, R; Oneyama, M; Sekikawa, K; Shimoda, Y; Takahashi, Y | 1 |
| Akamatsu, S; Hashida, S; Inamoto, S; Komatsubara, T; Lee, J; Teramura, Y; Yasuda, S | 1 |
| Endo, M; Hatano, M; Hirata, Y; Imamura, T; Inaba, T; Isayama, H; Kinugawa, K; Koike, K; Maki, H; Mohri, D; Nagai, R; Shiga, T; Yao, A | 1 |
| Kobayashi, M; Kodera, Y; Morita, S; Sakamoto, J; Shitara, K; Tsuburaya, A; Yamaguchi, K; Yoshida, K; Yoshikawa, T; Yoshino, S | 1 |
| Andou, T; Kameda, R; Kobayashi, S; Morinaga, S; Ohkawa, S; Ueno, M; Yamamoto, N | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Masuzawa, T; Miyata, H; Mori, M; Nakajima, K; Nakamura, A; Nakamura, Y; Okada, K; Osawa, R; Takeda, K; Takiguchi, S; Tsunoda, T; Yamasaki, M; Yoshida, K | 1 |
| Aoki, Y; Emi, M; Hamai, Y; Hihara, J; Kushitani, K; Okada, M; Tanabe, K | 1 |
| Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N | 1 |
| Sakata, Y; Satoh, T | 1 |
| Aikata, H; Arihiro, K; Chayama, K; Hiramatsu, A; Honda, Y; Hyogo, H; Kagawa, K; Kawakami, Y; Kawaoka, T; Miyaki, D; Naeshiro, N; Nagaoki, Y; Nakahara, T; Sanetou, H; Takahashi, S; Takaki, S; Tanaka, M; Waki, K | 1 |
| Jeong, JH; Kang, YK; Kim, BS; Kim, KC; Lee, SH; Lee, SS; Oh, ST; Park, I; Ryoo, BY; Ryu, MH; Yook, JH | 1 |
| Cho, BC; Choi, EC; Hong, YK; Kim, GM; Kim, HR; Kim, HS; Kim, JH; Kim, SH; Kim, SM; Koh, YW; Sung, JH | 1 |
| Araki, K; Ishida, M; Kaneta, T; Matsunaga, M; Miwa, K; Nakayama, H; Narabayashi, M; Noguchi, T; Onishi, H; Sasaki, Y; Shimada, K; Sunakawa, Y | 1 |
| Akiyama, H; Endo, I; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M | 1 |
| Fujii, C; Fujino, M; Fukunaga, M; Furukawa, H; Hachino, Y; Imamura, H; Kawabata, R; Kishimoto, T; Ohzato, H; Yasui, Y | 1 |
| Ito, D; Iwai, M; Kimura, M; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Hirata, Y; Itagaki, T; Kameda, A; Miyahara, E; Okamura, K; Sasaki, T; Teramoto, S; Ukon, K | 1 |
| Aoki, Y; Higashiguchi, T; Iwakura, S; Kunimoto, H; Nakase, T; Shimada, K; Shimamoto, T | 1 |
| Abe, T; Fujikawa, T; Kawashima, T; Maekawa, H; Shimoike, N; Shiraishi, K; Tada, S; Tanaka, A; Tanaka, H; Yoshimoto, Y | 1 |
| Doi, T; Fuse, N; Kojima, T; Nagahisa-Oku, E; Nomura, S; Ohtsu, A; Sasaki, T; Tahara, M; Yano, T; Yoshino, T | 1 |
| Baek, JH; Cho, SH; Choi, YH; Chung, IJ; Hong, YS; Jeung, HC; Kang, HJ; Kim, BS; Kim, JS; Nam, SH; Oh, SC; Song, EK; Yang, SH; Yim, CY | 1 |
| Agatsuma, T; Goya, H; Hirai, K; Ichiyama, T; Kanda, S; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Tateishi, K; Yamamoto, H; Yoshiike, F | 1 |
| Chi, Y; Cui, CX; Li, YS; Lü, N; Song, Y; Sun, YK; Wang, JW; Yang, L; Yuan, XH; Zhang, W; Zhou, AP | 1 |
| Endo, K; Kondo, S; Murono, S; Wakisaka, N; Yoshizaki, T | 1 |
| Bae, HI; Chae, YS; Choi, JY; Chung, HY; Jeon, SW; Jeong, JY; Kang, BW; Kim, JG; Kwon, OK; Lee, DK; Lee, IK; Lee, SJ; Lee, YJ; Yu, W | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Ogata, Y; Okafuji, K; Shiroyama, T; Tachibana, I; Yamamoto, S | 1 |
| Ebata, T; Hiramatsu, K; Maeda, A; Nagino, M; Sakaguchi, K; Sakamoto, E; Takahashi, Y; Takeuchi, E; Tojima, Y; Uehara, K | 1 |
| Harada, T; Isogai, M; Kamei, K; Kaneoka, Y; Maeda, A; Sunagawa, M; Takayama, Y | 1 |
| Kogashiwa, Y; Kohno, N; Nagafuji, H | 1 |
| Furukawa, H; Imamoto, H; Imano, M; Inoue, K; Itoh, T; Kato, H; Nishida, S; Nishikawa, M; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Goto, A; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Shimada, Y; Yamada, Y | 1 |
| Arihiro, K; Emi, A; Haruta, R; Kadoya, T; Kajitani, K; Kanno, E; Kataoka, T; Kobayashi, Y; Masumoto, N; Okada, M; Sasada, T; Shigematsu, H | 1 |
| Kiyokawa, T; Nishida, M; Seto, Y; Shimoyama, S | 1 |
| Aramaki, T; Bando, E; Goto, H; Kanemoto, H; Kawamura, T; Tanizawa, Y; Terashima, M; Tokunaga, M; Uesaka, K; Yasui, H | 1 |
| Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Sakai, A; Shimakami, T; Sunagozaka, H; Terashima, T; Yamashita, T | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yamamoto, N | 1 |
| Eguchi, K; Hoshi, E; Kasai, T; Kikuchi, K; Kobayashi, K; Komiyama, K; Kotajima, F; Koyama, S; Minezaki, S; Mori, K; Nakayama, M; Sutani, A; Takayanagi, N | 1 |
| Andou, A; Fujiwara, K; Kayatani, H; Matsuo, K; Matsushita, M; Sato, T; Shigematsu, H; Ueda, Y; Yamadori, I; Yonei, T | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
| Choi, DH; Hong, YS; Kim, AY; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, EM; Lee, JH; Lee, JL; Lim, SB; Park, YS; Yu, CS | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Grothey, A | 1 |
| Asai, J; Katoh, N; Nakai, N; Okuzawa, Y; Takenaka, H; Wakabayashi, Y; Yamamoto, Y | 1 |
| Fujimoto, H; Kameyama, Y; Nakayama, S; Oyama, T; Suito, T | 1 |
| Adachi, T; Goto, A; Itoh, M; Kanno, S; Kondo, Y; Mitsuhashi, K; Shinomura, Y; Suzuki, T; Wakasugi, H; Yabana, T | 1 |
| Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y | 1 |
| Kim, HH; Kim, JH; Kim, SJ; Kim, YJ; Lee, JS; Lee, KW; Park, DJ | 1 |
| Hirashima, Y; Shirao, K | 1 |
| Harita, S; Kiguchi, T; Kimura, K; Kubo, T; Mannami, T; Masunari, T; Nakata, Y; Ninomiya, K; Okada, T; Seno, S; Sezaki, N; Sonobe, H; Suzuki, Y; Tamura, T | 1 |
| Fujioka, M; Fukui, H; Kou, C | 1 |
| Ebi, M; Hirata, Y; Inagaki, H; Joh, T; Kamiya, T; Kataoka, H; Mizoshita, T; Okamoto, Y; Shimura, T; Tanida, S; Tsukamoto, H; Yamada, S | 1 |
| Higuchi, K; Katano, M; Kato, M; Matsumoto, K; Motoshita, J; Onishi, H; Tsuruta, N | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M; Nakashima, H; Oka, Y; Okumura, H; Tsutsumi, K | 1 |
| Akiba, T; Kamata, H; Kamijo, A; Kawada, S; Murayama, C; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Baba, H; Baba, Y; Beppu, T; Chikamoto, A; Iwatsuki, M; Miyamoto, Y; Okabe, H; Sakamoto, Y; Watanabe, M | 1 |
| Akiyama, H; Endo, I; Fujii, S; Hasegawa, S; Izumisawa, Y; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Oshima, T; Takagawa, R; Tokuhisa, M | 1 |
| Abu Lila, AS; Ishida, T; Kiwada, H; Nagao, A | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K | 2 |
| Hirayama, M; Kato, J; Kawano, Y; Kobune, M; Kuroiwa, G; Miyanishi, K; Sato, T; Sato, Y; Takada, K; Takahashi, S; Takimoto, R | 1 |
| Shimada, Y; Terazawa, T | 1 |
| Fukuda, K; Funakoshi, S; Kawakubo, H; Kitagawa, Y; Saikawa, Y; Takahashi, T; Takaishi, H; Takeuchi, H | 1 |
| Higashida, M; Hirai, T; Kawabe, Y; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M; Nakashima, H; Oka, Y; Okumura, H | 1 |
| Fujitani, K; Furukawa, H; Imamura, H; Imano, M; Kimura, Y; Kurokawa, Y; Matsuoka, M; Shimokawa, T; Takiuchi, H; Tokunaga, Y; Tsujinaka, T; Yano, H | 1 |
| Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K | 1 |
| Bando, H; Inaki, N; Ishiyama, Y; Kitamura, H; Kotake, M; Kurokawa, M; Matsunaga, M; No, H; Yamada, T; Yamamoto, M | 1 |
| Amakata, Y; Amano, I; Hashimoto, H; Horimoto, R; Kato, R; Matsumoto, J; Mizuno, C; Mizuno, M; Nishiwaki, M; Okanoue, T; Oya, H; Sawai, N; Seki, K; Shaura, Y; Shima, T; Tanaka, I | 1 |
| Kawai, T; Kinoshita, K; Kobayashi, S; Kusano, M; Miyagishima, T; Nagasako, Y; Ogasawara, K; Sunahara, M; Takahashi, M | 1 |
| Kawamura, M; Kawamura, T; Nyumura, Y; Sasaki, K; Sato, R; Ushigome, T | 1 |
| Aoyama, T; Cho, H; Hasegawa, S; Hayashi, T; Masuda, M; Oshima, T; Rino, Y; Shirai, J; Tsuburaya, A; Tsuchida, K; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H | 2 |
| Amano, R; Hirakawa, K; Ishikawa, T; Kimura, K; Kubo, N; Lee, T; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kitani, Y; Masuda, M; Ogata, T; Oshima, T; Ozawa, Y; Rino, Y; Shirai, J; Tsuburaya, A; Wada, H; Yoshikawa, T; Yukawa, N | 1 |
| Ajiki, T; Fukumoto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Otsubo, I; Sawa, H; Shinzeki, M; Shirakawa, S; Tanaka, M; Toyama, H; Ueno, K; Yamashita, H | 1 |
| Aoyama, T; Cho, H; Hasegawa, S; Hayashi, T; Kitani, Y; Masuda, M; Ogata, T; Oshima, T; Ozawa, Y; Rino, Y; Shirai, J; Tsuburaya, A; Tsuchida, K; Wada, H; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Enomoto, K; Sakurai, K | 1 |
| Hirai, R; Ikeda, E; Kuroda, M; Takagi, S; Tsuji, H; Yamano, T; Yoshitomi, S | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Akita, H; Doki, Y; Eguchi, H; Furukawa, K; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Umeshita, K; Wada, H | 1 |
| Arai, I; Inoue, S; Ohashi, I; Tamura, C; Wakasa, K | 1 |
| Ebisui, C; Kato, R; Kinuta, M; Makino, S; Murakami, M; Murata, K; Nishigaki, T; Ohwada, Y; Okada, K; Okamura, S; Wada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Fujii, C; Fukunaga, M; Imamura, H; Kawabata, R; Kimura, Y; Kishimoto, T; Ohzato, H | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Sato, A; Umakoshi, T; Yamamuro, W | 1 |
| Egawa, T; Etoh, E; Inaba, Y; Irino, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Okamura, A; Segami, K | 1 |
| Fujii, C; Fujino, M; Furukawa, H; Hachino, Y; Imamura, H; Iseki, C; Kawabata, R; Kawase, T; Sumida, R | 1 |
| Danno, K; Fujita, S; Imaoka, S; Kagawa, K; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Ohnishi, T; Taniguchi, H; Tono, T; Yamada, Y; Yoshida, T | 1 |
| Amano, R; Asano, Y; Hirakawa, K; Kimura, K; Kubo, N; Kuroda, K; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Takii, M; Tanaka, H; Yamada, N | 1 |
| Hosaka, S; Inada, K; Kawamoto, S; Kikutake, T; Maeno, H; Nagao, S; Okubo, S; Umemoto, S; Yoshida, T | 1 |
| Fujii, C; Fukunaga, M; Imamura, H; Izeki, C; Kawabata, R; Kawase, T; Ohzato, H | 1 |
| Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Oohashi, M; Oohinata, R; Takahashi, K; Yamaguchi, T | 1 |
| Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Nagase, H; Oshima, S; Sakamoto, T | 1 |
| Akagi, T; Etoh, T; Fujii, K; Inomata, M; Kinoshita, T; Kitano, S; Kubo, N; Matsumoto, T; Nakajima, K; Shiraishi, N; Shiromizu, A; Tahara, K | 1 |
| Ando, M; Atagi, S; Hirashima, T; Ikeda, N; Iwamoto, Y; Kudoh, S; Morita, S; Nakagawa, K; Nakanishi, Y; Okamoto, I; Saka, H; Satouchi, M; Sawa, T; Seto, T; Takeda, K; Yamamoto, N; Yoshioka, H | 1 |
| Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H | 1 |
| Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y | 1 |
| Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX | 2 |
| Hareyama, M; Hayashi, J; Himi, T; Hori, M; Kondo, A; Miura, K; Nakata, K; Sakata, K; Someya, M; Takagi, M | 1 |
| Akashi, T; Hashiguchi, M; Itsui, Y; Kaneko, S; Watanabe, M; Yauchi, T; Yoshida, R | 1 |
| Haruta, J | 1 |
| Aga, K; Hosaka, M; Matsumoto, H; Onishi, T; Seki, H; Shimada, A; Shimada, S; Yamachika, D; Yasui, N | 1 |
| Hirano, T; Inoue, T; Kitamura, S; Kuga, Y; Moriya, T; Nakamura, Y; Ohya, T; Okanobu, H; Yoshifuku, Y | 1 |
| Hagiwara, S; Hirai, K; Miyamae, Y; Ogawa, H; Sunose, Y; Takahashi, N; Takeyoshi, I; Tanaka, K; Totsuka, O; Toya, H; Tsukagoshi, H; Yoshinari, D | 1 |
| Bando, E; Goto, H; Kawamura, T; Makuuchi, R; Miki, Y; Sugisawa, N; Tanizawa, Y; Terashima, M; Tokunaga, M; Uesaka, K; Yamakawa, Y | 1 |
| Kawai, S; Kobayashi, S; Kyokane, T; Maeda, A; Mokuno, Y; Nagino, M; Tojima, Y; Uehara, K; Yoshimura, K; Yoshioka, Y | 1 |
| Chiba, T; Fukui, H; Maruo, T; Miwa, H; Okabe, Y; Osaki, Y; Oshima, T; Sekikawa, A; Tomita, T; Tsumura, T; Wakasa, T; Watari, J; Zhang, X | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N | 1 |
| Harada, K; Hayashi, T; Hirakawa, M; Hirata, K; Hirayama, M; Kato, J; Katsuki, S; Kobune, M; Maeda, M; Miyamoto, H; Miyanishi, K; Nobuoka, T; Ohnuma, H; Ono, M; Sagawa, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takahashi, Y; Takayama, T; Takimoto, R | 1 |
| Fujimura, T; Fushida, S; Hirono, Y; Hirosawa, H; Kaji, M; Kimura, H; Kinami, S; Kinoshita, J; Nakano, T; Ohta, T; Oyama, K; Takai, Y; Takeda, T; Tsukada, T; Tsuneda, A; Yabushita, K; Yasui, T; Yoshimoto, K | 1 |
| Asaishi, K; Goto, M; Higuchi, K; Kawabe, S; Kii, T; Kuwakado, S; Miyamoto, T; Nishitani, H; Yoshida, M | 1 |
| Morimoto, M; Nakagawa, M; Tangoku, A | 1 |
| Kaneoka, Y; Kimura, M; Sugiyama, T; Teramachi, H; Tsuchiya, T; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Akamine, S; Ebi, N; Ichinose, Y; Kato, M; Kishimoto, J; Maruyama, R; Nagamatsu, Y; Saeki, S; Tsukamoto, S; Yano, T | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Kimura, T; Kishimoto, H; Ninomiya, M; Nishizaki, M; Nonaka, Y; Shigeyasu, K; Takahata, T; Uno, F | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I | 1 |
| Harada, H; Hiraki, A; Nakayama, H; Omura, K; Shinohara, M; Shintani, S; Tomioka, H; Yoshihama, Y | 1 |
| Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY | 1 |
| Yano, S | 1 |
| Akazawa, Y; Aono, N; Imamura, F; Ito, Y; Kumagai, T; Nishino, K; Okuyama, T; Uchida, J; Yoshinami, T | 1 |
| Akiyama, H; Endo, I; Fukushima, T; Hasegawa, S; Izumisawa, Y; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Oshima, T; Ota, M; Takagawa, R; Takahashi, M; Tokuhisa, M; Tsuchida, K | 1 |
| Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX | 1 |
| Fukushima, N; Iwasaki, Y; Katai, H; Nakamura, K; Nashimoto, A; Sano, T; Sasako, M; Tsuburaya, A; Tsujinaka, T; Yamamoto, S | 1 |
| Kaneko, M; Murata, T; Yamada, T; Yoshino, H | 1 |
| Ishii, R; Kawamura, M; Kodama, H; Machida, T; Nakamura, Y; Ogino, T; Sakamoto, N; Takahashi, T; Takanashi, S; Tsutsumi, K | 1 |
| Hamada, K; Imataka, H; Nemoto, H; Sato, A; Takeda, N | 1 |
| Ayaki, M; Horie, S; Kashiwagi, R; Mitsuda, A; Tanaka, H | 1 |
| Fujimura, T; Fushida, S; Goda, F; Hirono, Y; Kaji, M; Kinoshita, J; Oyama, K; Sudo, Y; Watanabe, Y; Yagi, Y | 1 |
| Bando, E; Kawamura, T; Sasaki, K; Tanizawa, Y; Terashima, M; Tokunaga, M | 1 |
| Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ | 1 |
| Enomoto, K; Ito, M; Kurumatani, N; Matsumoto, S; Migita, K; Nakajima, Y; Saeki, K; Takayama, T; Tanaka, T; Wakatsuki, K | 1 |
| Chaulagain, CP; Goodman, MD; Ng, J; Saif, MW | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Harada, N; Hayashi, T; Kaji, S; Koike, N; Ozaki, Y; Saida, S; Suzuki, M; Suzuki, S | 1 |
| Kawamura, M; Matsutani, N | 1 |
| Kagabu, M; Kaido, Y; Miura, Y; Niinuma, H; Shoji, T; Suga, Y; Sugiyama, T; Takada, A; Takatori, E; Takeuchi, S | 1 |
| Bae, WK; Cho, IS; Cho, SH; Chung, IJ; Chung, WK; Han, HS; Hwang, JE; Lee, JK; Lee, KH; Lim, SC; Shim, HJ; Song, EK; Yun, HJ | 1 |
| Asaumi, Y; Doden, K; Hashizume, Y; Hattori, M; Hirano, Y; Hosokawa, O; Ito, T; Maeda, K; Matsunaga, T; Miyanaga, T; Nishida, Y; Ota, K; Sato, Y; Shimizu, S; Tanaka, N | 1 |
| Daga, H; Miyamoto, N; Nishijima, M; Okada, H; Sumitani, M; Syoji, S; Taira, K; Takeda, K; Tokunaga, S; Tsuda, M | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kameda, Y; Masuda, M; Miyagi, Y; Oshima, T; Rino, Y; Shirai, J; Tsuburaya, A; Yoshikawa, T; Yukawa, N | 1 |
| Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H | 1 |
| Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y | 1 |
| Ezaki, H; Hayashi, Y; Iijima, H; Kawai, S; Miyazaki, M; Nakai, K; Nishida, K; Nishida, T; Shinzaki, S; Takehara, T; Tsujii, M; Watabe, K; Yakushijin, T; Yamada, T | 1 |
| Harada, H; Horiike, A; Ishikura, S; Kaira, K; Kozuka, T; Murakami, H; Naito, T; Nishimura, T; Nishio, M; Ohyanagi, F; Takahashi, T; Yamamoto, N | 1 |
| Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H | 1 |
| Baba, H; Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fukutomi, A; Funakoshi, A; Furuse, J; Hatori, T; Ikeda, M; Ioka, T; Kitano, M; Mizumoto, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Shimamura, T; Sho, M; Sugimori, K; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K; Yanagimoto, H | 1 |
| Kobayashi, R; Nakagawa, K; Ohtomo, K; Okuma, K; Shiraishi, K; Yamashita, H | 1 |
| Endoh, T; Ikeda, K; Iwata, N; Minami, T; Sasano, H; Sugawara, N; Yoshida, Y | 1 |
| Hattori, Y; Kaneda, H; Kurata, T; Miyazaki, M; Morita, S; Nakagawa, K; Negoro, S; Okamoto, I; Okuno, K; Satouchi, M; Shimada, T; Takeda, M; Tanaka, K; Terashima, M; Urata, Y | 1 |
| Morioka, T; Niikura, N; Ogiya, R; Okamura, T; Oshitanai, R; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kodaira, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Akiyama, H; Endo, I; Hasegawa, S; Kosaka, T; Kunisaki, C; Makino, H; Momiyama, M; Ono, HA; Oshima, T; Takagawa, R; Wada, T | 1 |
| Akiba, T; Kawahara, H; Neki, K; Toyama, Y; Watanabe, K; Yanaga, K | 1 |
| Ilson, DH | 3 |
| Benson, AB | 1 |
| Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M | 1 |
| Chen, L; Chen, YX; Hao, LH; Jiang, XJ; Li, ZY; Lin, HZ; Song, MQ | 1 |
| Ito, S; Nakamura, Y; Noumi, T; Sasaki, Y | 1 |
| Boku, N; Hashigaki, S; Kimura, N; Lechuga, M; Machida, N; Miyata, Y; Muro, K; Suzuki, M | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Kubo, H; Mikoshiba, Y; Okuyama, R; Uhara, H | 1 |
| Esaki, M; Hibino, Y; Hirashima, N; Iwase, H; Kato, B; Kato, E; Kida, Y; Kuno, T; Okeya, M; Ryuge, N; Shimada, M; Tanaka, Y; Tsuzuki, T; Urata, N; Yokoi, M | 1 |
| Ferdous, T; Harada, K; Harada, T; Kin, T; Ueyama, Y | 1 |
| Sanford, M | 1 |
| Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Konishi, M; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K | 1 |
| Aoki, K; Kirita, T; Kuniyasu, H; Kurihara, M; Obata, K; Takaki, M | 1 |
| Fujitani, K; Furukawa, H; Iijima, S; Imamura, H; Inoue, K; Kimura, Y; Kobayashi, K; Kurokawa, Y; Matsuyama, J; Shimokawa, T; Tamura, S; Tsuji, T; Tsujinaka, T | 1 |
| Ishiguro, H; Takeuchi, M; Tanaka, S; Toi, M; Tsuji, W; Ueno, T | 1 |
| Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K | 1 |
| Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Ema, A; Katada, N; Kikuchi, S; Mieno, H; Nemoto, M; Sakuramoto, S; Shibata, T; Wang, G; Watanabe, M; Yamashita, K | 1 |
| Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z | 1 |
| Fujie, T; Furuiye, M; Inase, N; Jin, Y; Kojima, K; Komazaki, Y; Miyazaki, Y; Sakashita, H; Sumi, Y; Tamaoka, M | 1 |
| Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U | 1 |
| Fukushima, R; Hirabayashi, N; Ito, Y; Iwahashi, M; Kimura, Y; Matsui, T; Mikata, S; Miyashiro, I; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Takiguchi, N; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
| Chaulagain, CP; Rothschild, J; Saif, MW | 1 |
| Gemma, A | 1 |
| Fukunaga, M; Imamura, H; Kawabata, R; Kimura, Y; Kishimoto, T; Ohzato, H | 1 |
| Fukumoto, M; Irei, Y; Maruyama, S; Matsuki, A; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tsuchiya, Y; Yabusaki, H | 1 |
| Ishikawa, H; Ishioka, K; Ko, S; Matsusaka, M; Mukogawa, T; Nishiwada, S; Watanabe, A; Yoshikawa, T | 1 |
| Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y | 1 |
| Amagai, K; Hirai, S; Hironaka, S; Hirose, M; Hyodo, I; Mamiya, T; Matsuda, K; Moriwaki, T; Murashita, T; Nihei, T; Ohkawara, A; Ozeki, M; Sato, M; Soeda, A; Yamaguchi, T | 1 |
| Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M | 1 |
| Doyama, H; Endo, N; Kadoya, S; Kurumatani, H; Murakami, N; Shimada, M; Tanada, Y; Yamada, T | 1 |
| Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T | 1 |
| Ohishi, K; Ori, T; Sunayama, K; Takeda, M | 1 |
| Okazaki, A; Okazaki, M; Sato, F; Watanabe, Y; Yamagishi, H | 1 |
| Kato, R; Maeshima, A; Oyamada, Y; Takeuchi, K | 1 |
| Ikeda, S; Ito, T; Kanazawa, H; Katada, N; Morita, K; Narita, M; Nishimura, D; Okubo, K; Shibahara, H; Takeuchi, A | 1 |
| Eshita, Y; Ogawa, F | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Hayashi, H; Inokuchi, M; Kinoshita, J; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, N; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Saito, H; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Fujiyama, Y; Kaneko, H; Kikuchi, M; Kinoshita, S; Nishizawa, T; Sakuno, T; Suzuki, H; Takahashi, M | 1 |
| Ito, N; Kubo, N; Masahiro, O; Nakayama, A; Ogiwara, H; Takeuchi, N; Tsujimoto, K | 1 |
| Kato, T; Kobayashi, A; Nakamura, Y; Nakayama, H; Okamura, R; Wada, S; Yoh, T | 1 |
| Hosomi, Y; Ikeda, N; Kaburagi, T; Kato, T; Kunitoh, H; Michimae, H; Minato, K; Niho, S; Okamoto, H; Oshita, F; Sakai, H; Seto, T; Shimizu, K; Suzuki, K; Takeuchi, M; Tsuboi, M; Watanabe, K | 1 |
| Eguchi, T; Fujitake, S; Fujiwara, M; Ishigure, K; Ito, S; Kinoshita, T; Kodera, Y; Kojima, H; Mochizuki, Y; Ohashi, N | 1 |
| Amagai, K; Boku, N; Denda, T; Fujita, Y; Hamamoto, Y; Kawai, H; Konishi, K; Mizusawa, J; Nakamura, K; Nishina, T; Nishisaki, H; Ohkawa, S; Ohtsu, A; Takashima, A; Tsuji, A; Tsuji, Y; Yamada, Y; Yamaguchi, K | 1 |
| Araki, K; Maeda, M; Matsunobu, T; Shiotani, A; Tomifuji, M; Yamashita, T | 1 |
| Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R | 1 |
| Atsumi, K; Hirata, H; Honda, H; Matsumoto, K; Nakamura, K; Nonoshita, T; Ooga, S; Sasaki, T; Shioyama, Y; Uehara, S; Yoshitake, T | 1 |
| Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH | 1 |
| Fueki, N; Hisada, T; Ishihara, S; Iwasaki, Y; Kaira, K; Kazama, T; Koga, Y; Kohyama, K; Minato, K; Miura, Y; Ono, A; Saito, R; Sato, K; Sunaga, N; Tomizawa, Y; Yoshii, A; Yoshino, R | 1 |
| And, RN; Iwata, T; Komatsu, M; Kurita, N; Miyatani, T; Morimoto, S; Nishioka, M; Sato, H; Shimada, M; Yoshikawa, K | 1 |
| Cai, JP; Chen, W; Hao, XY; Hou, X; Liang, LJ; Yin, XY | 1 |
| Ikeguchi, M; Kanayama, H; Kurisu, Y; Nakamura, S; Nishidoi, H; Ogawa, H; Shimizu, T; Tatebe, S; Tsujitani, S; Yamane, N | 1 |
| Baek, JY; Jung, KH; K Shim, E; Kim, SY; Kong, SY; S Hong, Y; Shin, A | 1 |
| Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Fukuoka, M; Goto, I; Kurata, T; Matsumoto, K; Nakagawa, K; Okamoto, I; Sakai, D; Sugimoto, N; Tamiya, A; Tsuya, A; Ueda, S; Yamamoto, N | 1 |
| Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
| Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW | 1 |
| Aishima, S; Ando, K; Kakeji, Y; Kitahara, H; Kounoe, S; Maehara, Y; Oki, E; Saeki, H; Shirabe, K | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Yamamoto, N | 1 |
| Hamatake, M; Hirai, F; Ichinose, Y; Kometani, T; Ohba, T; Sasaki, T; Seto, T; Sugio, K; Taguchi, K; Takenoyama, M; Toyokawa, G; Yamaguchi, M; Yamanaka, T | 1 |
| Fukuda, H; Iwasaki, Y; Kurokawa, Y; Sano, T; Sasako, M; Shibata, T; Tsuburaya, A | 1 |
| Ando, M; Kadowaki, S; Komori, A; Kondo, C; Muro, K; Narita, Y; Nitta, S; Takahari, D; Taniguchi, H; Ura, T; Yamaguchi, K | 1 |
| Chung, HY; Han, JH; Kang, BW; Kim, YB; Lee, D | 1 |
| Gabata, T; Ikeda, H; Ishikawa, D; Iwakami, S; Matsui, O; Mouri, H; Nanjo, S; Ohtsubo, K; Takamatsu, Y; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K | 2 |
| Baba, H; Esaki, T; Fuse, N; Gotoh, M; Hara, T; Hosaka, H; Koizumi, W; Muro, K; Nakayama, N; Nishina, T; Sasaki, T; Sasaki, Y; Takagi, M; Takinishi, Y; Yamaguchi, K | 1 |
| Horiguchi, J; Kikuchi, M; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takata, D; Takeyoshi, I; Tokiniwa, H | 1 |
| Enomoto, T; Kobayashi, T; Takeda, A; Yokosuka, T | 1 |
| Kanagawa, T; Kobatake, T; Nogami, H; Ookawa, T | 1 |
| Atsumi, Y; Hasegawa, S; Imada, T; Masuda, M; Nemoto, H; Oshima, T; Rino, Y; Sato, T; Tamagawa, H; Uchiyama, M; Yoshikawa, T; Yukawa, N | 1 |
| Ichihara, T; Muto, T; Nomura, N; Okamoto, K; Sato, T; Uchida, H; Yamashita, K | 1 |
| Hisashige, A; Nakajima, T; Sasako, M | 1 |
| Furukawa, H; Iijima, S; Imamura, H; Imano, M; Kimura, Y; Kishimoto, T; Kurokawa, Y; Maruyama, K; Morimoto, T; Otsuji, T; Takiuchi, H; Yamashita, K | 1 |
| Ebara, T; Hisada, T; Ishizuka, T; Iwasaki, Y; Kaira, K; Kamide, Y; Koga, Y; Matsuura, M; Nakano, T; Nishioka, M; Ono, A; Saitoh, J; Shirai, K; Sunaga, N; Tomizawa, Y; Yoshii, A; Yoshino, R | 1 |
| Aoyagi, K; Hashimoto, K; Isobe, T; Kizaki, J; Koufuji, K; Miyagi, M; Shirouzu, K | 1 |
| Horie, T; Ishibashi, Y; Mizumoto, K; Noso, Y; Yamagata, S | 1 |
| Qi, JL; Shi, SB; Tang, XY; Tian, J; Wang, M | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nishitani, H; Shimada, Y; Takashima, A; Terazawa, T; Yamada, Y | 1 |
| Chijiiwa, K; Egawa, S; Hayashi, K; Hirono, S; Kanbe, T; Kato, J; Kawai, M; Kwon, AH; Miyazawa, M; Mukouyama, T; Ohuchida, J; Okada, K; Satoi, S; Shirasaka, T; Tani, M; Tsunoda, H; Ueda, K; Yamaguchi, T; Yamaue, H; Yanagimoto, H | 1 |
| Hasegawa, M; Hattori, S; Ide, H; Kikuchi, E; Miyajima, A; Oya, M; Yasumizu, Y | 1 |
| Boku, N; Fukuda, H; Kato, K; Mizusawa, J; Nakamura, K; Ohtsu, A; Shimada, Y; Shirao, K; Takashima, A | 1 |
| Chang, CL; Chen, JS; Cheng, WH; Chou, WC; Hsu, HC; Hsu, JT; Hung, YS; Liu, KH; Shen, WC | 1 |
| Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E | 1 |
| Fujiwara, M; Inoue, K; Ito, N; Karasawa, F; Maruyama, A; Nakayama, A; Shirozaki, T; Takeuchi, N; Yoshizawa, J | 1 |
| Ishida, K | 1 |
| Asano, T; Ishii, M; Iwata, K; Kobayashi, H; Kobayashi, S; Koizumi, S; Okamura, R; Otsubo, T; Saji, O; Sumiyoshi, K | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Kushima, R; Sekine, S; Shimada, Y; Takashima, A; Taniguchi, H; Yamada, Y | 1 |
| Baba, H; Iwamoto, S; Komatsu, Y; Matsumoto, H; Mishima, H; Morita, S; Muro, K; Nakamura, M; Sakata, Y; Sasaki, Y; Satoh, T; Shimada, K; Shimada, Y; Sugihara, K; Takahari, D; Takahashi, K; Watanabe, M; Yamada, Y; Yoshida, K; Yoshida, M | 1 |
| Hashimoto, T; Ishii, F; Kuramochi, H; Matsumoto, H; Naito, M; Nakagawa, M; Shinohara, T; Yamashita, Y | 1 |
| Akiyama, H; Endo, I; Fujii, S; Hasegawa, S; Kaida, S; Kosaka, T; Kunisaki, C; Makino, H; Ono, H; Oshima, T; Tamura, S; Wada, T | 1 |
| Akao, T; Fukai, Y; Fukuda, T; Ojima, H; Sano, A; Sohda, M; Tanabe, A | 1 |
| Doki, Y; Fukunaga, M; Hasegawa, J; Hata, T; Ide, Y; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohashi, I; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H; Yasumasa, K | 1 |
| Akiyama, H; Endo, I; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, H; Takagawa, R | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Isohashi, F; Kawamoto, K; Kobayashi, S; Kudo, T; Mori, M; Nagano, H; Sakai, D; Satoh, T; Tomimaru, Y; Wada, H | 1 |
| Akaza, H; Fujisawa, M; Hashine, K; Mizokami, A; Naito, S; Nakagawa, M; Nishikido, M; Shinohara, N; Tatsugami, K; Tomita, Y; Tsukamoto, T | 1 |
| Furuse, J | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J | 1 |
| Fukuoka, J; Kawabe, A; Nagata, T; Nakajima, S; Okumura, T; Omura, T; Shimada, Y; Tajika, S; Tsukada, K; Yamagishi, F | 1 |
| Inoue, K; Kobayashi, H; Murata, S; Naitoh, H; Tani, T; Yamamoto, H | 1 |
| Azemoto, R; Hara, T; Hirata, N; Ishihara, T; Mikata, R; Nakagawa, A; Nakaji, S; Nakamura, K; Nihei, T; Nishino, T; Ohshima, T; Ozawa, F; Shimura, K; Sudo, K; Tada, M; Tawada, K; Yamaguchi, T; Yokosuka, O | 1 |
| Doi, K; Fujisaka, Y; Hayashi, H; Kawakami, H; Nakagawa, K; Nishimura, Y; Nishina, S; Okamoto, I; Okamoto, K; Satoh, T; Takeda, M; Tanaka, K; Terao, K; Ueda, S | 1 |
| Hatanaka, N; Hirabayashi, N; Matsuda, H; Ninomiya, M; Shinozaki, K; Tanabe, K; Yamaguchi, K | 1 |
| Ishiguro, M; Kudo, H; Nishidoi, H; Ozaki, Y; Shibata, S; Ueta, T; Yamaguchi, Y; Yamashiro, Y | 1 |
| Chen, G; Li, J; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X; Zhao, Z | 1 |
| He, MM; Luo, HY; Qiu, MZ; Ren, C; Wang, F; Wang, FH; Wang, ZQ; Wu, WJ; Xu, RH; Zeng, ZL; Zhang, DS | 1 |
| Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y | 1 |
| Abu Lila, AS; Doi, Y; Ishida, T; Kiwada, H; Nagao, A; Nakamura, H | 1 |
| Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K | 1 |
| Chen, SY; Chen, X; Deng, Y; He, Y; Li, S; Li, TJ; Peng, QL; Qin, X; Tang, WZ; Wang, J; Wu, JR; Xie, L; Xie, YT | 1 |
| Cao, C; Chen, J; Chen, Y; Gong, Y; Gu, D; Shen, Y; Tang, C; Zhang, Q; Zhang, X | 1 |
| Arase, H; Doi, T; Eriguchi, K; Kawashima, T; Koyama, T; Makidono, K; Miyamoto, K; Ohishi, T; Sakahira, H; Takahashi, O; Ueda, Y | 1 |
| Ishimoto, T; Kinoshita, O; Kishimoto, M; Konishi, E; Kuriu, Y; Masuzawa, N; Murayama, Y; Nakanishi, M; Otsuji, E; Yanagisawa, A; Yasukawa, S | 1 |
| Desaki, R; Higashi, M; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Hasuike, Y; Hirao, S; Ishida, K; Iwagami, Y; Koshino, T; Tomoda, K; Toyomasu, T; Yoshikawa, S | 1 |
| Aoyama, T; Cho, H; Fujikawa, H; Hayashi, T; Kitani, Y; Masuda, M; Ogata, T; Oshima, T; Ozawa, Y; Rino, Y; Wada, H; Yoshikawa, T; Yukawa, N | 2 |
| Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Tomita, Y; Ueda, N | 1 |
| Kaiho, T; Kobayashi, S; Nishimura, M; Okamoto, R; Okaniwa, A; Shimizu, W; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Ohira, M; Otani, H; Tanaka, H; Toyokawa, T | 1 |
| Aoki, S; Egawa, S; Fukase, K; Hayashi, H; Katayose, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, T; Sakata, N; Unno, M; Yoshida, H | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tanizaki, K; Tomimaru, Y; Wada, H | 1 |
| Doi, T; Fujishima, F; Kawaguchi, K; Kuroda, F; Motoi, F; Nozawa, Y; Takemura, S; Unno, M; Yokoyama, S | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Toyoki, Y; Wakiya, T | 1 |
| Hakamada, K; Koyama, M; Morohashi, H; Murata, A; Muroya, T; Sakamoto, Y; Takahashi, S; Terui, K; Yokoyama, H | 1 |
| Kwon, AH; Motohiro, T; Nakatake, R; Saito, T; Tanaka, H; Ueda, A; Yamamichi, K | 1 |
| Akami, T; Matsumura, A; Matsuyama, T; Mugitani, T; Nishibeppu, K; Ogino, S; Shimode, Y; Takemura, M | 1 |
| Kondo, J; Nagashima, Y; Nakamura, M; Nisimura, T; Okada, T; Sakata, K; Setoguchi, M; Yoshino, S | 2 |
| Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T | 2 |
| Aono, T; Deguchi, K; Deguchi, T; Endo, S; Fujitani, K; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H | 2 |
| Hasegawa, J; Hirota, M; Kim, HM; Kubota, M; Matsunami, N; Matsuura, Y; Mikata, S; Miwa, H; Miyake, Y; Morishima, H; Murakami, M; Nezu, R; Soma, Y; Watase, C; Yasuyama, A; Yoshikawa, Y | 1 |
| Doi, K; Furuhashi, S; Inoue, K; Iwatsuki, M; Ogata, K; Ogawa, K; Sugiyama, S; Takamori, H; Tanaka, H | 1 |
| Hoshino, S; Ito, K; Katayanagi, S; Kawachi, S; Nomura, T; Shimazu, M; Suda, T; Sumi, T; Takagi, Y; Tsuchida, A | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Kamikozuru, H; Nagahama, T; Seki, R; Takasaki, J; Tei, S | 1 |
| Egawa, C; Hashimoto, T; Kagawa, Y; Kato, T; Katsura, Y; Kawashima, H; Kimura, K; Kusama, H; Matsushita, K; Morimoto, Y; Mukai, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Fushida, S; Kita, I; Mukubo, H; Sato, N; Yasui, T | 1 |
| Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 2 |
| Fujino, M; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Matsuo, M; Seike, K; Yokoyama, M | 1 |
| Amagasa, H; Ami, K; Ando, M; Aoki, N; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Imai, K; Kamikozuru, H; Nagahama, T; Ohbu, M; Takeuchi, S; Tei, S | 1 |
| Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Hanada, S; Ichioka, M; Kondo, M; Ochi, J; Okamoto, E; Sakuranaka, H; Shibayama, T; Takagi, K; Tamura, A; Tanaka, M; Tei, S | 1 |
| Aoki, T; Chono, A; Hyuga, N; Kobayashi, K; Matsumoto, T; Nishioka, K; Takachi, K; Takemoto, H; Uemura, Y; Watanabe, R; Yoshida, K | 1 |
| Hosaka, S; Inada, K; Kawamoto, S; Matsuoka, T | 1 |
| Endo, W; Hamano, R; Nakano, H; Shirakawa, M; Taniguchi, M; Tsujie, M; Watanabe, Y; Yano, H | 1 |
| Hakamada, K; Kawasaki, H; Kimura, A; Muroya, T; Nagase, H; Nakai, M; Nakayama, Y; Okano, K; Wajima, N; Yonaiyama, S | 1 |
| Hatano, K; Ikari, H; Kajihara, K; Kunizaki, T; Kusaba, T; Nagamatsu, M; Ooshima, K; Sasaki, N; Shigemasa, Y; Takeoka, Y; Yonemitsu, N | 1 |
| Fukunaga, M; Kaido, M; Kawabata, R; Kawase, T; Kimura, Y; Nakajima, Y; Ninomiya, H; Ohzato, H | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Kuroda, K; Lee, T; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Tanaka, H | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishigami, H; Kishi, K; Kitayama, J; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sasaki, K; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Aoki, T; Chono, T; Hyuga, S; Kobayashi, K; Matsumoto, T; Moon, JH; Nishioka, K; Takachi, K; Takemoto, H; Tsukao, Y; Uemura, Y; Watanabe, R | 1 |
| Fukuoka, M; Nishizawa, Y; Omura, N; Tachibana, S; Tatara, T; Tatsumi, Y; Yoshida, T; Yoshimura, H | 1 |
| Fukada, J; Fukuda, K; Kawaguchi, O; Kawakubo, H; Kitagawa, Y; Matsuda, S; Saikawa, Y; Shigematsu, N; Takahashi, T; Takeuchi, H | 1 |
| Guan, Y; Ju, Y; Li, F; Zhao, H | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K | 1 |
| Fujimoto, Y; Itoh, Y; Kato, S; Naganawa, S; Nakashima, T | 1 |
| Chen, J; Li, P; Liu, GF; Long, AH; Tang, D; Wang, S; Xiang, XX; Xu, YX; Zhang, LL; Zhou, NL | 1 |
| Kanazawa, Y; Uchida, E; Yamada, T; Yokoi, K | 1 |
| Goto, M; Nakayama, Y; Yamashita, Y | 1 |
| Ishikawa, T; Kanda, T; Kosugi, S; Okabe, Y; Sakamoto, K; Sato, Y; Wakai, T; Yajima, K | 1 |
| Kanazawa, H; Matsumoto, N; Nagano, I; Niwa, M; Sato, T; Yamada, I; Yoshinaka, H | 1 |
| Duh, D; Warnez, M | 1 |
| Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z | 1 |
| Doki, Y; Furukawa, H; Gamoh, M; Imamura, H; Komatsu, Y; Kurokawa, Y; Miwa, H; Nishina, S; Okuda, H; Sakai, D; Shimokawa, T; Sugimoto, N; Tsuda, M; Tsujinaka, T | 1 |
| Mukai, H; Ohashi, Y; Ohno, S | 1 |
| Katagiri, Y; Kawaguchi, M; Murata, I; Okamura, K; Suzuki, T; Yaguchi, Y | 1 |
| Kogashiwa, Y; Kohno, N; Sato, D; Tsukahara, K; Yamauchi, K | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Shimizu, S; Shoji, H; Ueno, H | 1 |
| Choi, HJ; Choi, JH; Eum, JB; Jang, JW; Kim, HJ; Kim, MH; Lee, JB; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, SE; Seo, DW | 1 |
| Fujimoto, M; Fujisawa, Y | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Iijima, S; Imamura, H; Imano, M; Kurokawa, Y; Shimokawa, T; Sugimoto, N; Uedo, N | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Abe, M; Hamada, H; Higaki, J; Ito, R; Kadowaki, T; Katayama, H; Miyoshi, S; Okura, T; Watanabe, A; Yano, S | 1 |
| Bae, MK; Cha, J; Chang, H; Cho, BC; Chung, H; Hur, J; Kim, CB; Kim, DJ; Kim, HI; Kim, HR; Kim, JH; Lee, CG; Lee, CY; Lee, H; Lee, JG; Lee, SK; Lee, YC; Park, JC; Shin, SK | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS | 1 |
| Aoyama, T; Hasegawa, S; Hayashi, T; Ito, Y; Kimura, Y; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Hiraoka, M; Itasaka, S; Kawaguchi, Y; Matsuo, Y; Mizowaki, T; Nakamura, A; Shibuya, K; Takaori, K; Uemoto, S; Yoshimura, M | 1 |
| Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O | 1 |
| Aishima, S; Baba, H; Emi, Y; Hirabayashi, N; Kakeji, Y; Kusumoto, T; Maehara, Y; Morita, M; Oki, E; Orita, H; Sadanaga, N; Saeki, H; Sakaguchi, Y; Sakai, K; Shimokawa, M; Takahashi, I; Yamaguchi, K; Yamamoto, M; Yamanaka, T; Yoshida, K | 1 |
| Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q | 1 |
| Wang, M; Wang, Q; Wang, W; Wang, Y; Wu, M | 1 |
| Liu, Z; Lu, Y; Zhang, J | 1 |
| Kimura, T; Maruo, T; Nishikawa, H; Okabe, Y; Osaki, Y; Sekikawa, A; Takeda, H; Tsumura, T; Wakasa, T | 1 |
| Higashino, M; Ichihara, S; Kawata, R; Lee, K; Nishikawa, S; Uesugi, Y | 1 |
| Fujii, M; Funada, T; Kanamori, N; Kochi, M; Mihara, Y; Suda, H; Takayama, T; Takayama, Y; Tamegai, H; Watanabe, M | 1 |
| Fukushima, N; Mizusawa, J; Nashimoto, A; Sasako, M; Tanaka, Y; Tsuburaya, A | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Harada, N; Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Matsuura, H; Morita, M; Okadome, K; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Uchiyama, H; Yamashita, Y; Yoshizumi, T | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Morita, S; Nishikawa, K; Ogata, T; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Cao, W; Cheng, C; Huo, BL; Wang, YH; Zhang, E | 1 |
| Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH | 1 |
| Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y | 1 |
| Hori, Y; Itagaki, R; Iwata, H; Maekawa, S | 1 |
| Ishizuka, D; Kano, Y; Tada, T; Ueki, K; Wakai, T; Yajima, K | 1 |
| Enjoji, M; Ishida, T; Ishimaru, S; Kobayashi, K; Murase, H; Obara, M; Oono, R; Ueda, Y | 1 |
| Baba, H; Fujimura, Y; Goto, H; Nakahara, O; Otao, R | 1 |
| Hasegawa, Y; Hatanaka, M; Iwata, H | 1 |
| Goto, T; Sasaki, K; Shimao, K; Yano, M | 1 |
| Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Nishimura, K; Ueda, N; Yamanaka, K; Yoshida, Y | 1 |
| Chikamatsu, K; Ishioka, NS; Kaira, K; Kanai, Y; Nagamori, S; Ohshima, Y; Oriuchi, N; Oyama, T; Sakakura, K; Shino, M; Takahashi, K; Takayasu, Y; Tominaga, H; Toyoda, M | 1 |
| Misawa, S; Miyamoto, M | 1 |
| Iida, T; Nakabayashi, Y; Okui, N; Otsuka, M; Shiba, H; Yanaga, K | 1 |
| Hosoi, H; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Okusaka, T; Shimizu, S; Terazawa, T; Ueno, H | 1 |
| Fujishima, F; Haneda, S; Kajiwara, T; Kohyama, A; Komura, T; Kudoh, K; Miura, K; Musha, H; Naitoh, T; Nakagawa, K; Ohnuma, S; Philchenkov, A; Shibata, C; Shimada, M; Shirasaka, T; Toshima, M; Unno, M | 1 |
| Akashi, Y; Atagi, S; Ebi, N; Fujii, S; Hirashima, T; Kaneda, H; Kimura, T; Kogure, Y; Maeda, T; Morita, S; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishino, K; Nishio, K; Oizumi, S; Okamoto, I; Okuno, M; Sakai, K; Satouchi, M; Sawa, T; Seto, T; Takahashi, T; Takayama, K; Takeda, K; Tomii, K; Yamamoto, M; Yoshioka, H | 1 |
| Nakamura, Y; Teramoto, Y; Yamada, K; Yamamoto, A | 1 |
| Akazawa, K; Funakoshi, K; Hasegawa, J; Hatakeyama, K; Maruyama, S; Okada, T; Takii, Y; Tani, T; Yamazaki, T | 1 |
| Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H | 1 |
| Ishigure, K; Ishiyama, A; Ito, S; Kobayashi, D; Kodera, Y; Kurimoto, K; Matsui, T; Mochizuki, Y; Nakao, A; Nakayama, H; Sakamoto, J; Tanaka, N | 1 |
| Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y | 1 |
| An, HX; Li, DH; Pan, ZK; Wu, JX; Ye, F | 1 |
| Cabalag, CS; Chan, ST; Duong, CP; Kaneko, Y | 1 |
| Shi, L; Tang, Y; Teng, XZ; Wang, W | 1 |
| Fukui, H; Hirota, S; Kaibe, N; Kikuchi, S; Maeyama, Y; Matsumoto, M; Miwa, H; Morimoto, K; Nakamori, S; Niwa, H; Sasako, M; Takemura, M | 1 |
| Akai, T; Endo, M; Hirayama, N; Matsubara, H; Nakano, A | 1 |
| Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K | 1 |
| Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R | 1 |
| Ide, T; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, J; Noshiro, H | 1 |
| Katsuno, A; Matsushita, A; Nakamura, Y; Sumiyoshi, H; Uchida, E; Yamahatsu, K | 1 |
| Katolická, J; Rotnáglová, S; Vaníček, J | 1 |
| Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K | 1 |
| Ikari, T; Ioka, T; Isayama, H; Ishii, H; Koike, K; Kwon, AH; Nakai, Y; Okusaka, T; Ozaka, M; Satoi, S; Shimokawa, T; Sho, M; Tanaka, M; Ueno, H; Yanagimoto, H | 1 |
| Ema, A; Naito, M; Nakamura, T; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Boku, N; Endo, T; Ikejiri, K; Ishiguro, M; Kameoka, S; Kinugasa, Y; Kotake, K; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Nakatani, E; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takii, Y; Tomita, N; Watanabe, M; Watanabe, T; Yoshida, M | 1 |
| He, S; Li, M; Li, Z; Lin, J | 1 |
| Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S | 1 |
| Castro-Rojas, C; Ortiz-Lópezj, R; Rojas-Martínez, A | 1 |
| Cao, C; Chen, J; Gu, D; He, M; Kuang, M; Tang, C; Zhang, X | 1 |
| Arai, T; Doi, T; Ito, T; Kamigaki, S; Kawajiri, H; Komoike, Y; Masuda, N; Miyauchi, K; Miyoshi, Y; Morita, S; Nakayama, T; Sakamoto, J; Taguchi, T; Takashima, T; Tsurutani, J; Yoshidome, K | 1 |
| Haruma, K; Higashida, M; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Nakamura, M; Yoden, E | 1 |
| Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y | 1 |
| Guo, H; Jin, M; Li, J; Liu, X; Lv, F; Shen, L; Wang, B | 2 |
| Baba, H; Miyamoto, Y; Sakamoto, Y; Yoshida, N | 1 |
| Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Shen, L; Su, J; Sun, L; Wu, Y; Xia, M; Xiang, X; Xu, Y; Yang, X | 1 |
| Boku, N; Endo, M; Fukutomi, A; Funakoshi, T; Kenmotsu, H; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S | 1 |
| Chikakio, M; Eto, S; Higashigima, J; Iwata, T; Kashihara, H; Kurita, N; Matsumoto, N; Sato, H; Shimada, M; Takasu, C; Yoshikawa, K | 1 |
| Hong, YS; Jeon, EK; Kim, HK; Ko, YH; Park, JC; Park, SY; Shim, BY; Sun, DS; Won, HS | 1 |
| Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Kawahara, M | 1 |
| Ichikawa, W; Imamura, H; Katai, H; Kitada, K; Kurahashi, I; Ochiai, A; Sakuramoto, S; Sano, T; Sasako, M; Terashima, M | 2 |
| Hiraga, M; Omura, N; Ono, F; Onochi, S; Sato, H; Takano, N; Toyama, S; Yamamura, A | 1 |
| Bang, S; Cha, J; Chung, MJ; Kim, HM; Lee, KJ; Park, SW; Seong, J; Song, SY | 1 |
| Hirano, M; Ichinose, M; Mizumoto, A; Ozamoto, Y; Takao, N; Tatsuno, M; Togawa, T; Yamamoto, Y; Yonemura, Y | 1 |
| Akasaka, Y; Iwasaki, S; Katayama, T; Koike, M; Kon, H; Konishi, Y; Kuwahara, H; Mino, K; Shoji, H; Suzuki, A; Tamura, M | 1 |
| Ishikawa, M; Miyoshi, K; Murakami, S; Nakano, R; Ohuchi, K; Sozaki, M; Uchiyama, A; Umeda, S | 1 |
| Hanyu, T; Ichikawa, H; Ishikawa, T; Kosugi, S; Muneoka, Y; Sakamoto, K; Sato, Y; Wakai, T; Yajima, K | 1 |
| Ishibashi, Y; Ito, Y; Omori, K; Wakabayashi, K | 1 |
| Imaida, K; Kagawa, I; Kishi, S; Matsumoto, Y; Mitan, M; Miyamoto, M; Nishiwaki, K; Saoo, K; Tsuda, H; Yokohira, M | 1 |
| Endo, Y; Inoue, M; Kakimoto, Y; Kato, Y; Kimura, T; Matsuda, Y; Matsuoka, N; Murakami, O; Sasakabe, H; Suzuki, H; Toyoda, A; Ushimaru, Y | 1 |
| Arakawa, A; Date, K; Kawada, K; Kimura, M; Kuroda, D; Matsushita, H; Nishimura, T; Shimokawa, Y; Soh, M | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
| Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY | 1 |
| Beppu, N; Doi, H; Kamikonya, N; Matsubara, N; Noda, M; Tomita, N; Yamanaka, N; Yamano, T; Yanagi, H | 1 |
| Aoe, K; Fujiwara, K; Gemba, K; Harita, S; Hosokawa, S; Hotta, K; Kanazawa, S; Kato, Y; Katsui, K; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Maeda, T; Nogami, N; Okada, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yasugi, M | 1 |
| Lin, RF; Luo, WH; Su, M; Wei, HP; Zhu, LC; Zou, CL | 1 |
| Arakawa, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T | 1 |
| Min, K; Xu, CN; Yang, J; Yao, Q; Zhou, Y | 1 |
| Ahn, JB; Bello, M; Charoentum, C; Chen, LT; Cheng, AL; Ciardiello, F; de Lima Lopes, G; Ho, GF; Kim, TW; Köhne, CH; Kong, HL; Lam, KO; Li, J; Liu, TS; Ma, BB; Park, YS; Shaw, M; Sriuranpong, V; Sudoyo, AW; Teh, C; Vaid, AK; Wang, JY; Zhang, J; Zhang, SZ | 1 |
| Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H | 1 |
| Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y | 1 |
| Ito, A; Kawanishi, J; Sakakima, Y; Sueoka, S | 1 |
| Hara, Y; Minami, Y; Nakamura, T; Ueda, S | 1 |
| Fukuda, N; Niki, M; Ogura, R; Sano, M; Wada, J | 1 |
| Guo, Z; Hong, L; Li, B; Liu, C; Si, T; Yu, H | 1 |
| Hata, M; Komatsu, M; Kubota, A; Nishimura, G; Oridate, N; Sakuma, Y; Sano, D; Shiono, O; Taguchi, T; Taguri, M; Takahashi, M; Tanigaki, Y | 1 |
| Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Nosaki, K; Seto, T; Takenaka, T; Takenoyama, M; Toyokawa, G; Yamaguchi, M; Yoshida, T | 1 |
| Akiba, T; Kamijo, A; Kawada, S; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Akaike, M; Aoyama, T; Asari, M; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Ohkawa, S; Rino, Y; Shiozawa, M; Ueno, M; Yamamoto, N; Yoshikawa, T | 1 |
| Hong, WD; Huang, QK; Liu, Y; Sun, XC; Wu, JM | 1 |
| Ishiguro, M; Sugihara, K; Yoshida, M | 1 |
| Abali, H; Calıkusu, Z; Seyrek, E; Yavuz, S | 1 |
| Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hamada, C; Higuchi, K; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Du, W; Ke, QH; Lei, Y; Liang, G; Luo, F; Yang, JY; Zhou, SQ | 1 |
| Hayashi, K; Iwase, H; Kawano, I; Kuramoto, M; Nishimura, R; Tanigawa, T; Yamamoto, Y; Yamamoto-Ibusuki, M | 1 |
| Baba, H; Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Mochiki, E; Sobajima, J; Suzuki, O; Tsuji, Y | 1 |
| Murahashi, K; Okuno, T; Sawada, T; Shirotsuki, J | 1 |
| Fujiwara, M; Kobayashi, D; Kodera, Y; Tanaka, C | 1 |
| Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
| Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS | 1 |
| Furukawa, K; Izumo, W; Katsuragawa, H; Komatsu, A; Shigematsu, K | 1 |
| Doki, Y; Ezoe, S; Hata, T; Kudo, T; Matsumoto, K; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Takemasa, I; Uemura, M; Yamamoto, H | 1 |
| Abei, M; Fukuda, K; Hashimoto, T; Ishikawa, H; Mizumoto, M; Ohkawa, A; Okumura, T; Sakae, T; Sakurai, H; Tsuboi, K | 1 |
| Nakamura, K; Sudo, K; Yamaguchi, T | 1 |
| Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Itoyama, R | 1 |
| Fujino, H; Kenzaki, K; Kondo, K; Matsuoka, H; Sakamoto, E; Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H; Uchida, J; Uyama, K | 1 |
| Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Endo, K; Kita, M; Kondo, S; Muramatsu, M; Murono, S; Tsuji, A; Wakisaka, N; Yoshida, S; Yoshizaki, T | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Ikeguchi, M; Kurisu, Y; Kuroda, H; Nagai, S; Osaki, T; Takahashi, S; Watanabe, H; Yamamoto, M | 1 |
| Chen, X; Gao, P; Liu, H; Lu, X; Song, Y; Sun, J; Wang, Z; Xu, H; Zhang, N | 1 |
| Goto, K; Murakami, H; Naito, T; Nakagawa, K; Ohba, T; Okamoto, I; Seto, T; Takahashi, T; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H | 1 |
| Akiyama, K; Hoshikawa, H; Inamoto, R; Indo, K; Kishino, T; Miyashita, T; Mori, N; Mori, T | 1 |
| Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Ohtsuka, K; Okuda, C; Takeshita, J | 1 |
| Aoyama, T; Cho, H; Fujikawa, H; Hayashi, T; Kawabe, T; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Tsuchida, K; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Bu, ZD; Ji, JF; Ji, X; Li, SX; Li, ZY; Shan, F; Wu, AW; Wu, XJ; Zhang, LH; Zong, XL | 1 |
| Cai, J; Li, T; Wu, B; Xu, Y; Zhao, G | 1 |
| Aoe, K; Gemba, K; Harita, S; Hosokawa, S; Hotta, K; Inoue, K; Kanazawa, S; Kato, Y; Kishino, D; Kiura, K; Kozuki, T; Kuyama, S; Nogami, N; Okada, T; Oze, I; Segawa, Y; Shibayama, T; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Naruge, D; Okano, N; Takasu, A | 1 |
| Endo-Sakamoto, Y; Ishige, S; Kasama, H; Kasamatsu, A; Minakawa, Y; Ogawara, K; Shiiba, M; Takiguchi, Y; Tanzawa, H; Uzawa, K | 1 |
| Fukuda, K; Kawakubo, H; Kitagawa, Y; Nakamura, R; Saikawa, Y; Takahashi, T; Takaishi, H; Takeuchi, H; Wada, N | 1 |
| Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I | 1 |
| Iwata, J; Kozuki, A; Morita, S; Nakamura, T; Okabayashi, T; Saisaka, Y; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Sun, D; Wang, J; Xu, J; Xu, S; Yang, C; Yao, L | 1 |
| Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M | 1 |
| Boku, N; Denda, T; Esaki, T; Hyodo, I; Kato, T; Kuwano, H; Nishina, T; Ohishi, T; Ojima, H; Otsuji, T; Shimada, K; Shirao, K; Takeuchi, M; Yamazaki, K | 1 |
| Hirakawa, K; Hori, T; Inaba, M; Ishikawa, T; Kuroda, K; Nakao, S; Nakata, B; Tendo, M | 1 |
| Akiyama, H; Endo, I; Kanazawa, A; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Ota, M; Takagawa, R | 1 |
| Kamijo, A; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Futagami, K; Nakagawa, T; Nomoto, S; Ogata, K; Takase, H; Tokunaga, S; Yonekita, H; Yoshimitsu, K | 1 |
| Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Tsuji, E; Ueda, Y; Yamagishi, H | 1 |
| Higashi, Y; Ishikawa, S; Maruo, H; Murakami, T; Nishiyama, R; Shoji, T; Suzuki, K; Taniguchi, M; Yamazaki, M | 1 |
| Iwanaga, T; Iwasaki, Y; Ohashi, M; Oohinata, R; Takishita, C; Yajima, K | 1 |
| Hirakawa, K; Kanehara, I; Kitayama, K; Nishimura, J; Nishino, H; Noda, E; Nomura, S; Teraoka, H | 1 |
| Kawamura, A; Kobayashi, M; Maeda, H; Okamoto, K; Sakamoto, J; Takeshita, A; Tamura, S; Usui, T | 1 |
| Endo, S; Hiraoka, K; Kim, C; Konishi, K; Nakagawa, T; Nishijima, J; Okuyama, M; Yamada, T | 1 |
| Imai, H; Nishi, K; Ohori, H; Sasaki, T; Sato, A; Sawada, K; Takahashi, T | 1 |
| Itoh, H; Jinbu, Y; Kusama, M; Miyagi, N; Nakai, Y; Noguchi, T; Shinozaki, Y; Sugiyama, T; Tsuchiya, Y; Watanabe, H | 1 |
| Hashiguchi, Y; Horie, H; Ishihara, S; Ishikawa, Y; Kato, D; Kawai, K; Kondo, K; Matsusaka, S; Mizunuma, N; Murofushi, K; Nakajima, T; Nakazawa, M; Oguchi, M; Okada, T; Okuda, J; Shinbo, T; Sunami, E; Uehara, K; Ueno, M; Watanabe, T; Yamashita, H | 1 |
| Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kabata, H; Kamata, H; Kawada, I; Miyata, J; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Atagi, S; Hirashima, T; Kurata, K; Minomo, S; Nakatani, T; Okamoto, N; Okishio, K; Omachi, N; Saijo, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Lv, JQ; Wang, HF | 1 |
| Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
| Chen, L; Feng, D; Leong, M; Li, T | 1 |
| Chen, Q; Huang, XB; Lan, YQ; Lin, MX; Wang, XL; Wu, RP; Zhong, DT | 1 |
| Haneda, S; Kajiwara, T; Kohyama, A; Komura, T; Kudoh, K; Miura, K; Musha, H; Naitoh, T; Ohnuma, S; Shimada, M; Shirasaka, T; Toshima, M; Unno, M | 1 |
| Fujisaka, Y; Iwasa, T; Kawakami, H; Komoike, Y; Kurata, T; Nakagawa, K; Nishio, K; Nonagase, Y; Sakiyama, T; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, O | 1 |
| Kogashiwa, Y; Kohno, N; Matsumoto, Y; Moro, Y; Nakamura, T; Sakurai, H; Sato, D; Yamauchi, K | 1 |
| Beppu, T; Fujii, M; Fukushima, M; Hanamure, Y; Hasegawa, Y; Higaki, Y; Iwae, S; Kawabata, K; Kohno, N; Kubota, A; Nagahara, K; Nakatani, H; Taguchi, T; Takemura, H; Terada, T; Teramukai, S; Tomita, K; Tsukahara, K; Yoshino, K | 1 |
| Cho, KJ; Jang, G; Jung, HY; Kim, HR; Kim, JH; Kim, JY; Kim, SB; Kim, YH; Lee, GH; Ryu, JS; Song, HY; Yoon, DH | 1 |
| Fuse, N; Kadowaki, S; Kajiura, S; Kimura, T; Kuboki, Y; Kuwata, T; Machida, N; Nagatsuma, AK; Nishina, T; Ochiai, A; Ohtsu, A; Ooki, A; Shinozaki, E; Shitara, K; Yamanaka, T; Yoshino, T; Yuki, S | 1 |
| Li, WP; Mu, LJ; Shi, M; Sun, J; Wang, XB; Xue, ZG | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M | 1 |
| Komune, S; Nakashima, T; Toh, S; Yamauchi, M; Yasumatsu, R | 1 |
| Ajani, JA; Bodoky, G; Carrato, A; Cascinu, S; Jassem, J; Moiseyenko, V; Prausová, J; Rivera, F; Scheulen, ME; Van Laethem, JL; Vynnychenko, I | 1 |
| Hishida, T; Kunitoh, H; Ohashi, Y; Sakurai, H; Shukuya, T; Takamochi, K; Tsuboi, M; Yoh, K | 1 |
| Katayose, Y; Morikawa, T; Otsuka, H; Shirasaki, K; Unno, M | 1 |
| Abe, T; Aoki, T; Karasawa, H; Katayose, Y; Kimura, S; Kudoh, K; Morikawa, T; Motoi, F; Musha, H; Nagao, M; Naitoh, T; Ohnuma, S; Tanaka, N; Unno, M; Watanabe, K | 1 |
| Adachi, E; Funahashi, T; Ikeda, Y; Kabashima, A; Kitagawa, D; Kondo, N; Nakamura, T; Saito, G; Teramoto, S | 1 |
| Fujiyama, J; Fukuda, K; Kiuchi, J; Konishi, T; Masuyama, M; Nakashima, S; Umehara, S | 1 |
| Fujita, Y; Ishikawa, F; Ito, H; Kamata, S; Nitta, H; Omoto, H; Yamada, C | 1 |
| Araki, H; Choda, Y; Harano, M; Idani, H; Kanazawa, T; Kato, T; Matsukawa, H; Mimura, N; Miyake, S; Miyoshi, H; Ninomiya, M; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Taguchi, K; Takahashi, K; Tokumoto, N; Toshima, T; Yamaguchi, K; Yoshida, K | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Hata, T; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takiguchi, S; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
| Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Ishida, J; Ito, T; Kido, M; Kokubun, M; Ku, Y; Kuramitsu, K; Matsumoto, I; Nanno, Y; Okazaki, T; Okuno, T; Shinzeki, M; Takebe, A; Tanaka, M; Toyama, H; Tsugawa, D; Ueta, A | 1 |
| Deguchi, S; Goto, W; Inoue, T; Ishikawa, A; Kanazawa, A; Kotsuka, M; Kurihara, S; Mori, Y; Nakajima, T; Nishiguchi, Y; Ohira, G; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tashima, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y; Yoshii, M | 1 |
| Ishii, J; Kaneko, H; Katagiri, T; Koda, T; Kubota, Y; Maeda, T; Otsuka, Y; Shibuya, K; Tamura, A; Tsuchiya, M | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Osawa, S; Sawada, S; Shibuya, K; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Aisu, Y; Andoh, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Nakayama, A; Ohta, T; Shoji, M; Tajima, H; Takamura, H | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nagata, H; Nakanishi, M; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A | 1 |
| Fukushima, T; Imada, T; Kunisaki, C; Masuda, M; Ono, H; Oshima, T; Rino, Y; Tsuchida, K; Watanabe, T; Yoshikawa, T | 1 |
| Ito, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakajima, Y; Takayama, T; Tanaka, T; Wakatsuki, K | 1 |
| Fujino, M; Inaba, S; Ito, N; Kitai, S; Mochizuki, S; Nagata, T; Nakase, Y; Yamazato, Y | 1 |
| Adachi, S; Akagi, K; Dono, K; Hatano, H; Hirota, M; Hokonohara, K; Imamura, H; Iwazawa, T; Komori, T; Morita, S; Noda, T; Oshima, K; Takata, A; Tanida, T | 1 |
| Abe, T; Aoki, T; Kajiwara, T; Karasawa, H; Katayose, Y; Kimura, S; Kono, E; Kudo, K; Miyachi, T; Morikawa, T; Motoi, F; Musha, H; Nagao, M; Naito, T; Nakagawa, K; Ohnuma, S; Tanaka, N; Tsuchiya, T; Unno, M; Yoshida, H | 1 |
| Fujiwara, T; Kagawa, S; Kikuchi, S; Kubota, T; Kuroda, S; Kuwada, K; Nishizaki, M; Tanaka, T | 1 |
| Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K | 1 |
| Asao, Y; Furuyama, H; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Hayashida, H; Higaki, N; Miyake, Y; Nakane, S; Nezu, R; Oka, Y; Okada, K; Omura, Y; Uemura, H | 1 |
| Ishiyama, S; Iwasaki, Y; Maeda, Y; Natsume, S; Oohinata, R; Takahashi, K; Yajima, K; Yuu, K | 1 |
| Aoyama, T; Kitani, Y; Kumazu, Y; Masuda, M; Ozawa, Y; Rino, Y; Wada, H; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Akita, H; Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Gokita, K; Imai, K; Kawai, Y; Kodaka, F; Matsunaga, Y; Nagahama, T; Ohshima, N; Okada, Y; Takagi, M; Tei, S; Yamada, Y | 1 |
| Fujita, S; Hirose, H; Michiura, T; Miyazaki, S; Miyazaki, Y; Nagaoka, M; Sugimoto, S; Yamabe, K | 1 |
| Choda, Y; Harano, M; Idani, H; Kanazawa, T; Kato, T; Matsukawa, H; Nagai, Y; Ninomiya, M; Ohno, S; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Tokumoto, N | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N | 1 |
| Ebisui, C; Fukuchi, N; Kinuta, M; Murata, K; Nushijima, Y; Okada, K; Okamura, S; Yanagisawa, T; Yokouchi, H | 1 |
| Asaoka, T; Fukuda, Y; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Kanzawa, M; Kodama, Y; Maeda, S; Mano, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Yamamoto, K | 1 |
| Iijima, S; Kobayashi, K; Matsumoto, T; Nakao, E; Nishioka, K; Oshima, S; Otsuru, T; Takachi, K; Takemoto, H; Tsujimura, N; Uemura, Y; Yoshida, K | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Miyamoto, M; Tanigawa, T; Yamamoto, M | 1 |
| Kin, M; Komatsu, T; Nakano, S; Nomura, S; Ogasawara, T; Ootsuka, Y; Shida, T; Takahashi, M | 1 |
| Hirai, K; Igarashi, T; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yamazaki, H; Yokoo, H; Yoshinari, D | 1 |
| Kim, KH; Kim, WS | 1 |
| Chung, KY; Kim, DS; Kim, J; Kim, SH; Lee, MG | 1 |
| Akimoto, T; Fujii, H; Fujii, M; Fukuda, H; Hasegawa, Y; Hayashi, R; Homma, A; Iwae, S; Kiyota, N; Kubota, A; Matsuura, K; Mizusawa, J; Monden, N; Nakamura, K; Onozawa, Y; Tahara, M | 1 |
| Aruga, T; Iwasa, T; Komoike, Y; Kuroi, K; Makimura, C; Miyazaki, M; Nakagawa, K; Nishina, S; Okamoto, K; Saeki, T; Shigekawa, T; Tanizaki, J; Tsurutani, J; Yamashita, T | 1 |
| Du, Z; He, X; Li, Q; Tang, R; Wen, F; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Aoi, J; Fukushima, S; Ihn, H; Jinnin, M; Kajihara, I; Kanemaru, H; Masuguchi, S; Miyake, T | 1 |
| Jiang, Z; Li, Y; Liu, G; Sun, J; Zhang, L | 1 |
| Chen, D; Hu, J; Huang, W; Li, N; Wan, Z; Wang, L; Xue, P; Yang, H; Zhu, L | 1 |
| Ahn, SH; Bang, SM; Kim, HH; Kim, JH; Kim, JW; Kim, JY; Kim, SH; Kim, YJ; Lee, DW; Lee, HS; Lee, JO; Lee, JS; Lee, KW; Park, DJ; Shin, E | 1 |
| Akamaru, Y; Fujitani, K; Inagaki, H; Ishiguro, T; Miyashita, Y; Morita, S; Nakamura, M; Nishikawa, K; Sakamoto, J; Shigematsu, T; Sugimoto, N; Takagi, M; Tamura, S; Tokunaga, S; Tsuburaya, A; Tsujinaka, T; Yoshikawa, T | 1 |
| Hwang, A; Ju Choi, I; Kim, MJ; Kim, YW; Lee, JH; Lim, HS; Park, SR; Park, YI; Ryu, KW | 1 |
| Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H | 1 |
| Fujii, K; Iwai, N; Kataoka, K; Masuzawa, A; Matsumoto, N; Morita, Y; Takada, R; Takami, S; Takaya, H; Tanaka, N; Wakabayashi, N; Yoriki, H | 1 |
| Ito, S; Ito, Y; Kurahashi, S; Misawa, K; Niwa, Y; Shimizu, Y; Yatabe, Y | 1 |
| Endo, T; Homma, Y; Numata, T; Osawa, H; Yanai, H | 1 |
| Aoyama, T; Atsumi, Y; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Oshima, T; Rino, Y; Shiozawa, M; Ueno, M; Yamamoto, N; Yamaoku, K; Yoshikawa, T | 1 |
| Kase, S | 1 |
| Nishikawa, K; Shirao, K; Watanabe, K | 1 |
| Katoh, M; Kubota, K; Shimizu, T; Shimoda, M | 1 |
| Hamamoto, Y; Miyata, Y; Muro, K; Ohtsu, A; Shirao, K; Takahari, D; Takahashi, T; Tsuji, A; Yoshida, K; Yoshida, M; Yoshino, T | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Beppu, N; Doi, H; Kakuno, A; Kamikonya, N; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, MJ; Kim, SK; Kim, YW; Kong, SY; Kook, MC; Lee, JH; Lee, JS; Lee, JY; Lim, HS; Park, SR; Park, YI; Ryu, KW | 1 |
| Motoi, F; Unno, M | 1 |
| Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D | 1 |
| Doki, Y; Hamakawa, T; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Fujimoto, Y; Hiramatsu, M; Itoh, J; Itoh, Y; Kawamura, M; Kimura, K; Kubota, S; Naganawa, S; Nakahara, R; Okada, T; Shibata, T | 1 |
| Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S | 1 |
| Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
| Hirokawa, E; Kanbayashi, C; Nakamiya, N; Osaki, A; Saeki, T; Sano, H; Sato, N; Sekine, H; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S | 1 |
| Fukudome, I; Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Ogawa, M; Shiga, M | 1 |
| Dong, WG; He, AB; Luo, RF; Peng, XL; Song, J; Tang, Y; Zhang, JX | 1 |
| Ando, Y; Hayashi, M; Kamiya, H; Kobayashi, R; Maruyama, S; Matsuo, S; Nakao, M; Shibata, K; Shimokata, T; Teramachi, H; Tsuchiya, T; Yasuda, Y | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Chen, MW; Huang, HQ; Huang, JJ; Jiang, DK; Lu, DC; Wu, FL; Yang, X; Ying, YP; Zeng, HY; Zhou, AM; Zhou, J | 1 |
| Fukuda, M; Gemma, A; Inoue, A; Isobe, H; Katakami, N; Kobayashi, K; Kubota, K; Kudoh, S; Kunitoh, H; Michimae, H; Minato, K; Nakamura, Y; Nishio, M; Ohmatsu, H; Okamoto, H; Sakai, H; Sugawara, S; Takeuchi, M; Takiguchi, Y; Yokoyama, A | 1 |
| Hirashiki, A; Hirooka, Y; Murohara, T; Yamada, K; Yamamura, K; Yano, K | 1 |
| Egawa, S; Hiramoto, Y; Ishiyama, M; Kimura, S; Kira, S; Kiyota, H; Koide, H; Moritake, J; Sakata, A; Suzuki, K; Tomita, M; Yoshida, K | 1 |
| Goto, H; Hiramatsu, K; Kato, T; Maeda, A; Nagino, M; Sakamoto, E; Takeuchi, E; Tojima, Y; Uehara, K; Yatsuya, H | 1 |
| Gao, C; Li, X; Liu, D; Sun, L; Tong, J; Wu, D; Yang, D; Zhang, Q; Zheng, H | 1 |
| Baba, H; Komatsu, Y; Mishima, H; Morita, S; Muro, K; Nakamura, M; Sakata, Y; Sasaki, Y; Satoh, T; Shimada, Y; Sugihara, K; Takahashi, K; Watanabe, M; Yamada, Y | 1 |
| Fujino, Y; Goji, T; Kimura, T; Kitamura, S; Miyamoto, H; Miyoshi, J; Muguruma, N; Okahisa, T; Okamoto, K; Sogabe, M; Takayama, T; Taniguchi, T; Tomonari, T | 1 |
| Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K | 1 |
| Furuya, T; Hayashi, H; Murakami, T; Shimokawa, Y; Sugihara, S; Yahara, N; Yanai, H | 1 |
| Gomi, A; Kosugi, K; Miyazaki, H; Negishi, A; Ogawa, M; Takayama, Y; Yokoo, S | 1 |
| Hirose, T; Ishikawa, Y; Kitamura, K; Miki, A; Minami, T; Morioka, H; Nishihira, T; Otani, T; Suzuki, T; Yoshitani, S | 1 |
| Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T | 1 |
| Edagawa, H; Fujii, Y; Goto, M; Hamada, Y; Itoh, K; Kuramoto, S; Masuda, Y; Matsumoto, D; Mori, O; Okitsu, H; Tani, R; Tomibayashi, A; Yamashita, M; Yuasa, Y | 1 |
| Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J | 1 |
| Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H | 1 |
| Cho, JW; Choi, DR; Han, B; Jung, JY; Kang, YK; Kim, HS; Kim, JH; Kim, MJ; Lim, MS; Park, CK; Ryoo, BY; Ryu, MH; Song, H; Yang, DH; Zang, DY | 1 |
| Fuji, S; Hirai, M; Makihara, S; Marunaka, H; Miki, K; Nishizaki, K; Noyama, Y; Orita, Y; Sato, Y; Tachibana, T; Takao, S; Torigoe, A | 1 |
| Chen, L; Fang, W; Jiang, H; Mao, C; Mou, H; Qian, J; Teng, L; Wang, Y; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Aizawa, M; Matsuki, A; Migita, K; Nashimoto, A; Yabusaki, H | 1 |
| Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H | 1 |
| Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Doki, Y; Hasegawa, J; Hata, T; Ikeda, M; Ikenaga, M; Kato, T; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nakata, K; Nezu, R; Nishimura, J; Ohue, M; Satoh, T; Sekimoto, M; Shingai, T; Takemasa, I; Uemura, M; Yamamoto, H | 1 |
| Andratschke, N; Duma, MN; Hadjamu, M; Oechsner, M; Schönknecht, C | 1 |
| Chiba, Y; Furukawa, H; Imamoto, H; Imano, M; Itoh, T; Nishida, S; Peng, YF; Satoh, T; Tsubaki, M; Yasuda, T | 1 |
| Chi, Y; Du, F; Jiang, Z; Qu, T; Shi, S; Song, Y; Sun, Y; Wang, J; Yang, L; Yuan, X; Zhao, J; Zheng, Z | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaneda, T; Katakami, N; Kumagai, T; Morita, S; Negoro, S; Nishimura, T; Nishino, K; Okuda, C; Satouchi, M; Tachihara, M; Urata, Y; Yokota, S | 1 |
| Fujino, Y; Hirakawa, M; Hirata, K; Kagawa, M; Kato, J; Katsuki, S; Kobune, M; Kubo, T; Mitsui, Y; Miyamoto, H; Miyoshi, J; Nobuoka, T; Ohnuma, H; Okuda, T; Osuga, T; Sagawa, T; Sato, Y; Takahashi, Y; Takaoka, T; Takayama, T; Takimoto, R | 1 |
| Choo, SP; Chua, C; Iwasa, S; Lim, HY; Ng, M; Ong, WS; Rha, SY; Tai, DW; Tan, IB; Tham, CK; Yamada, Y; Yong, WP | 1 |
| Chin, K; Fujii, M; Ichikawa, W; Kakeji, Y; Kawase, T; Kochi, M; Kunisaki, C; Matsuhashi, N; Nakajima, T; Nishikawa, K; Ohno, T; Takagane, A; Takeuchi, M; Tanabe, K; Terashima, M; Tsuji, A; Yoshida, K | 1 |
| Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y | 1 |
| Fujii, T; Fujiwara, M; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Murotani, K; Nakayama, G; Sugimoto, H; Tanaka, C; Yamada, S | 1 |
| Furukawa, K; Sakamoto, T; Shiba, H; Tsutsumi, J; Uwagawa, T; Yanaga, K | 1 |
| Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K | 1 |
| Bai, C; Liu, W; Lu, M; Shen, L; Wang, Y; Xu, J | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Azuma, T; Ikeda, A; Kutsumi, H; Miki, I; Okuno, T; Yokozaki, H | 1 |
| Fujita, Y; Muranishi, Y; Nakayama, I | 1 |
| Boku, N; Esaki, T; Hyodo, I; Kato, T; Miyata, Y; Moriwaki, T; Nishina, T; Yamazaki, K; Yoshino, T | 1 |
| Baba, M; Furuta, M; Katayama, M; Matsumoto, H; Murai, K; Okajima, T; Shigematsu, T; Tanaka, M | 1 |
| Kurashima, Y; Miyazaki, T; Ohata, K; Ohno, K; Okawa, M; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
| Hanaki, K; Higaside, S; Kanda, Y; Mise, M; Morimoto, T; Noda, H; Yata, Y; Yonenaga, Y | 1 |
| Baba, E; Boku, N; Cho, SH; Esaki, T; Hyodo, I; Kang, WK; Kang, YK; Lee, KH; Nam, BH; Park, SR; Park, YI; Ryoo, BY; Ryu, MH; Shin, DB; Shinozaki, K; Song, EK; Takano, T; Yang, SH; Yoo, C; Zang, DY | 1 |
| Ikarashi, S; Katanuma, A; Kin, T; Maguchi, H; Matsumori, T; Minami, R; Sano, I; Sen-yo, M; Shinohara, T; Takahashi, K; Tomonari, A; Yamazaki, H; Yane, K | 1 |
| Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H | 1 |
| Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K | 1 |
| Skoropad, VY | 1 |
| Boku, N; Fuse, N; Kanato, K; Kato, K; Mizusawa, J; Muro, K; Nihei, K; Ohtsu, A; Sato, A; Tahara, M; Takaishi, H; Yamazaki, K | 1 |
| Hoshi, K; Hosoda, K; Katada, N; Kikuchi, S; Mieno, H; Moriya, H; Ushiku, H; Watanabe, M; Yamashita, K | 1 |
| Atagi, S; Ichinose, Y; Iwamoto, Y; Kawaguchi, T; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Nishio, K; Ohta, M; Okada, M; Saka, H; Sakai, K; Sugawara, S; Takahama, M; Takahashi, T; Takeda, M; Yamanaka, T; Yoshimura, M; Yoshino, I; Yoshioka, H | 1 |
| Eto, S; Higashijima, J; Hotchi, M; Iwata, T; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Teraoku, H; Yoshikawa, K | 1 |
| Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K | 1 |
| Han, S; Li, Z; Lin, N; Mao, W | 1 |
| Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sakamoto, K; Takeshima, N; Tanigawa, T; Yamamoto, A | 1 |
| Andoh, M; Igarashi, Y; Kadowaki, S; Komori, A; Mori, K; Muro, K; Narita, Y; Nitta, S; Nomura, M; Takahari, D; Taniguchi, H; Ura, T; Yamaguchi, K | 1 |
| Akagi, K; Dono, K; Fujita, J; Hatano, H; Hirota, M; Hokonohara, K; Ikeda, A; Imamura, H; Iwazawa, T; Kameyama, A; Kawanishi, K; Komori, T; Morita, S; Noda, T; Oshima, K; Shinke, G; Takata, A; Tanida, T; Yoneyama, C | 1 |
| Hokama, Y; Ogata, D; Tsuchida, T | 1 |
| Akagi, Y; Baba, H; Beppu, T; Eguchi, S; Emi, Y; Higashi, H; Ikebe, M; Kabashima, A; Kakeji, Y; Maehara, Y; Miyamoto, Y; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Sakoda, M; Shirabe, K; Takatsuki, M; Tokunaga, S; Uchida, S | 1 |
| Bi, Z; Chen, C; Chen, R; Fan, X; Li, D; Li, Z; Liu, Y; Zhou, Y | 1 |
| Akaike, M; Aoyama, T; Cho, H; Hayashi, T; Imada, T; Kunisaki, C; Masuda, M; Numata, K; Oshima, T; Rino, Y; Sakamaki, K; Sato, T; Shiozawa, M; Yamada, T; Yoshihara, K; Yoshikawa, T | 1 |
| Ohi, H; Ozaki, T; Seki, H; Yabusaki, H | 1 |
| Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Boku, N; Kataoka, K; Katayama, H; Machida, N; Mizusawa, J; Nakamura, K; Sano, T; Sasako, M; Shitara, K; Terashima, M; Tokunaga, M; Tomita, T | 1 |
| Boku, N; Fukutomi, A; Hamauchi, S; Ichinose, M; Kashiwagi, H; Machida, N; Mori, K; Onozawa, Y; Tabuse, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Aihara, T; Beppu, N; Doi, H; Kamikonya, N; Kimura, F; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H; Yoshie, H | 2 |
| Chin, K; Fujii, M; Inada, T; Kitagawa, Y; Kodera, Y; Lee, SW; Nakajima, T; Nashimoto, A; Nomura, E; Ohyama, S; Omura, K; Sakata, Y; Sakuramoto, S; Takeuchi, M; Tanigawa, N; Terashima, M; Yamaguchi, T; Yamaue, H | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Asao, T; Hisada, T; Imai, H; Kaira, K; Motegi, M; Naruse, I; Sunaga, N; Yamada, M | 1 |
| Cheng, Y; Guan, ZG; Guo, ZQ; Hu, XH; Li, W; Li, YH; Liu, YP; Lu, HS; Qiu, MZ; Sun, GP; Wang, JJ; Xu, JM; Xu, RH; Yu, SY; Zhang, HL; Zhong, MZ; Zhou, JT | 1 |
| Egashira, A; Ikeda, Y; Kinjo, N; Minami, K; Morita, M; Okamura, T; Sakaguchi, Y; Toh, Y; Yamaguchi, S; Yamamoto, M | 1 |
| He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H | 1 |
| Fukusumi, M; Hamamoto, Y; Honma, C; Ibe, T; Kameyama, N; Kamimura, M; Mouri, A; Takeoka, S | 1 |
| Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y | 1 |
| Amagai, K; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tanabe, S; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Chen, X; Li, W; Liu, S; Liu, Y; Ma, R; Sun, L | 1 |
| Hasegawa, T; Himuro, N; Hirata, K; Ishikawa, K; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Mori, M; Murase, K; Nobuoka, T; Sato, T; Sato, Y; Sugita, S; Takada, K; Takayama, T; Takimoto, R | 1 |
| Hijikawa, T; Kitade, H; Kon, M; Nakatani, K; Shikata, N; Tokuhara, K; Yamada, M; Yoshida, R; Yoshioka, K | 1 |
| Hijikawa, T; Inoue, K; Kitade, H; Kon, M; Nakai, K; Yamada, M; Yoshioka, K | 1 |
| Fang, Y; Han, X; Jin, DY; Li, JA; Lou, WH; Shi, CY; Xu, XF | 1 |
| Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K | 1 |
| Abdel-Rahman, O; ElHalawani, H; Essam-Eldin, S | 2 |
| Cao, C; Chen, J; Kuang, M; Tang, C; Xu, W; Zhang, X | 1 |
| Fujitake, S; Ishigure, K; Ishiyama, A; Ito, S; Kobayashi, D; Kodera, Y; Kojima, H; Mochizuki, Y; Morita, S; Nakanishi, K; Shikano, T | 1 |
| Fukagawa, T; Hamaguchi, T; Honma, Y; Iwasa, S; Katai, H; Kato, K; Machida, N; Morita, S; Ohashi, M; Shimada, Y; Takashima, A; Terazawa, T; Yamada, Y | 1 |
| Ahn, JB; Baik, SH; Hong, SP; Hur, H; Jung, I; Jung, M; Keum, KC; Kim, H; Kim, NK; Kim, TI; Koom, WS; Lim, JS; Min, BS; Park, YS; Roh, JK; Shin, SJ | 1 |
| Hata, H; Kinjo, Y; Okabe, H; Ota, S; Sakai, Y; Tokuka, A; Ueda, S; Yoshimura, K; Yoshimura, T; Zaima, M | 1 |
| Akamine, S; Arai, J; Hisano, H; Honda, S; Matsumoto, K; Miyazaki, T; Muraoka, M; Nagayasu, T; Nakamura, A; Sano, I; Tagawa, T; Taniguchi, H; Tsuchiya, T; Yamasaki, N | 1 |
| Fukuda, M; Ikeda, T; Kasai, T; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Oka, M; Takatani, H; Tsukamoto, K; Yamaguchi, H | 1 |
| Lopez-Tarruella, S; Martin, M | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Ashida, R; Ioka, T; Katayama, K; Sakon, M; Takahashi, H; Teshima, T | 1 |
| Baba, H; Bando, H; Boku, N; Emi, Y; Esaki, T; Gotoh, M; Hironaka, S; Hyodo, I; Komatsu, Y; Machida, N; Matsumoto, S; Moriwaki, T; Nakajima, TE; Nishina, T; Sekikawa, T; Sugimoto, N; Takeuchi, M; Tsuji, A; Yamaguchi, K | 1 |
| Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Baba, H; Boku, N; Fukutomi, A; Fukuzawa, K; Furukawa, M; Furuse, J; Hyodo, I; Iguchi, H; Ikeda, M; Ioka, T; Isayama, H; Komatsu, Y; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Shimada, K; Sugimori, K; Takeuchi, M; Ueno, M | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Ahn, Y; Jeong, JH; Kang, YK; Kim, BS; Kong, SY; Park, SR; Ryoo, BY; Ryu, MH; Yoo, MW; Yook, JH | 1 |
| Natsui, M; Seino, S; Tsuchiya, A | 1 |
| Amagai, K; Azuma, M; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Deng, YH; Li, YH; Luo, DY; Luo, HY; Qiu, MZ; Wang, FH; Wang, ZQ; Xu, N; Xu, RH; Zhang, DS | 1 |
| Egawa, S; Hara, K; Hijioka, S; Imaoka, H; Kou, T; Mizuno, N; Shimizu, Y; Tanaka, M; Yamao, K; Yazumi, S | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Lodder, P; Mohammad, NH; Ngai, LL; Samaan, M; Ter Veer, E; van Laarhoven, HW; van Oijen, MG | 1 |
| Fukahori, M; Matsunaga, M; Miwa, K; Ushijima, T | 1 |
| Haga, A; Kiritoshi, T; Nakagawa, K; Ohtomo, K; Okuma, K; Takenaka, R; Yamashita, H | 1 |
| Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Mazaki, J; Omori, K; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Hara, T; Kobayashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Asano, T; Kanomata, H; Matsuoka, Y; Miyamoto, Y; Murayama, M; Seyama, Y; Takahashi, M; Tani, K; Tanizawa, T; Umekita, N; Warabi, M | 1 |
| Abe, T; Aoki, S; Hayashi, H; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, R; Okada, Y; Oyauchi, M; Sakata, N; Unno, M; Yoshida, H | 1 |
| Hishikawa, H; Matsuura, T; Ozaki, T; Saito, T; Sakaguchi, T; Sueyoshi, H; Tanaka, Y; Ueda, A; Yamamichi, K | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 4 |
| Hamakawa, T; Hoshino, H; Ikeda, N; Kamigaki, S; Kawase, T; Kimura, Y; Makari, Y; Mikami, J; Munakata, S; Nakata, K; Ohzato, H; Tsujie, M; Yamamoto, T; Yamamura, J | 1 |
| Goto, H; Hirano, T; Hoshino, M; Imaizumi, K; Kakimoto, M; Koshiishi, H; Matsuyama, T; Murata, T; Nakata, T; Okuno, K; Tokura, M; Yoshimura, T | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Morioka, E; Nakano, Y; Noguchi, M; Ohonishi, T; Ohono, Y; Sakata, N; Tomita, Y; Ueda, N | 1 |
| Dono, K; Hatano, H; Hirabuki, N; Hirota, M; Imamura, H; Nakata, S; Noda, T; Oh, RJ; Ohara, N; Ohira, R; Yakushiji, H; Yasumoto, T | 1 |
| Asai, K; Baba, M; Hiratsuka, M; Katsuyama, S; Murata, M; Saso, K; Sawami, H; Takahashi, H; Takayama, O; Tanaka, N; Yagi, T; Yamada, M; Yamamoto, M | 1 |
| Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M; Yasui, M | 1 |
| Fukada, T; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
| Ebihara, K; Fujimori, M; Gobaru, A; Hamakawa, T; Kato, F; Kawase, T; Kimura, Y; Kitamura, S; Makari, Y; Mikami, J; Mitsudo, D; Nakata, K; Ohzato, H; Tsujie, M; Tsukamoto, Y; Yabuta, T | 1 |
| Kawamoto, S; Mase, T; Nagao, S; Nomi, M; Tanaka, K; Yoshida, T | 1 |
| Fushimi, K; Omori, T | 1 |
| Danno, K; Fujitani, K; Iwase, K; Kawada, J; Kitagawa, A; Kubota, M; Matsuda, C; Matsuura, N; Miyazaki, S; Motoori, M; Nakatsuka, R; Nishimura, M; Nomura, M; Okumura, Y | 1 |
| Hasegawa, J; Kobayashi, T; Naito, T; Sakata, J; Shimada, T; Shimakage, N; Tani, T; Usui, K; Wakai, T; Yamamoto, J | 1 |
| Ando, T; Hirose, Y; Ishikawa, H; Kameyama, H; Kobayashi, T; Kosugi, S; Miura, K; Nagahashi, M; Ohashi, T; Sakata, J; Soma, D; Takizawa, K; Tatsuda, K; Wakai, T; Yuza, K | 1 |
| Iijima, S; Matsumoto, T; Nakao, E; Nishioka, K; Oshima, S; Takachi, K; Takemoto, H; Tsujimura, N; Uemura, Y; Yoshida, K | 1 |
| Hasegawa, J; Hirota, M; Ikenaga, M; Kameda, C; Kawabata, R; Koga, C; Miwa, H; Murakami, M; Noura, S; Ozato, Y; Shimizu, J; Yoshikawa, M | 1 |
| Furuya, K; Hazama, S; Iida, M; Inoue, Y; Nagano, H; Takeda, S; Tamesa, T; Tokumitsu, Y; Ueno, T; Yoshino, S | 1 |
| Ishigami, E; Kawamoto, J; Miyazaki, M; Nakada, S; Shinoda, K; Teranaka, R; Yoichi, T | 1 |
| Hayashida, H; Higaki, N; Miyake, Y; Nakane, S; Nezu, R; Oka, Y; Okada, K; Ueshima, S | 1 |
| Endo, S; Fujitani, K; Fushimi, H; Hama, N; Haraguchi, N; Hirao, M; Ikeda, M; Kawada, J; Maeda, S; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Sekimoto, M; Yamamoto, K | 1 |
| Fukunari, H; Hayashi, T; Kato, T; Nakao, K; Okajima, C; Shitara, K; Watanabe, G; Yamamoto, Y | 1 |
| Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H | 1 |
| Akasaka, H; Hakamada, K; Kubo, N; Muroya, T; Okano, K; Sakuraba, S; Uchida, C; Wajima, N; Yoshida, T | 1 |
| Ako, E; Hirakawa, T; Kametani, N; Kanehara, I; Kato, Y; Komoto, M; Nakazawa, K; Nishimura, S; Taenaka, N; Tanaka, R; Yamada, N; Yamagata, S | 1 |
| Inagaki, M; Inatsugi, N; Kuge, H; Kurisaki, M; Masuda, T; Miyazawa, Y; Shimobayashi, T; Sho, M; Uchida, H; Yamaoka, K; Yokoo, T; Yokotani, T; Yoshikawa, S | 1 |
| Kawamoto, S; Maeno, H; Munechika, T; Nagao, S; Nomi, M; Okamoto, T; Sasaguri, T; Sueishi, K; Tanaka, K; Yonemitsu, K | 1 |
| Hosoda, Y; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yasui, M | 1 |
| Kunisaki, C; Masuda, M; Ohshima, T; Rino, Y; Suzuki, Y; Tsuburaya, A; Yukawa, N | 1 |
| Akiyama, H; Endo, I; Kimura, J; Kunisaki, C; Makino, H; Minami, Y; Suzuki, Y; Takagawa, R; Tsuburaya, A; Yazawa, K | 1 |
| Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakajima, Y; Nakatani, M; Tanaka, T; Wakatsuki, K | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Koga, Y; Kudoh, K; Ogata, K; Ohchi, T; Ootao, R | 1 |
| Hanazaki, K; Kitagawa, H; Kobayashi, M; Kumon, M; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Okamoto, K; Shiga, M | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Okubo, S; Takahashi, T; Takiguchi, S; Yamazaki, M | 1 |
| Ando, K; Kubosawa, H; Miyazaki, M; Oda, K; Shimizu, Y | 1 |
| Arai, S; Kataoka, M; Miyazawa, K; Oeda, Y; Shiobara, M; Suda, K; Takagi, T; Wakatsuki, K; Yoshioka, S | 1 |
| Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S | 1 |
| Akagi, Y; Arai, S; Horiuchi, H; Ishikawa, H; Kawahara, R; Muroya, D; Naito, Y; Nakama, Y; Nomura, Y; Okabe, Y; Okuda, K; Tanaka, H; Torimura, T; Yasumoto, M; Yasunaga, M | 1 |
| Fujiwara, H; Hatakeyama, T; Ichikawa, D; Ikoma, H; Imamura, T; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyahara, Y; Miyazaki, M; Nishida, T; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Hirose, Y; Kameyama, H; Kobayashi, T; Kosugi, S; Minagawa, M; Miura, K; Morimoto, Y; Nagahashi, M; Sakata, J; Sato, R; Soma, D; Takano, K; Takizawa, K; Wakai, T; Yuza, K | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
| Goto, Y; Inagaki, S; Kaneko, S; Kobayashi, T; Wakita, S; Yoshimitsu, M | 1 |
| Fujimoto, Y; Fujiwara, N; Harita, S; Ikeda, G; Kambara, T; Kenmotsu, M; Komoda, M; Kurimoto, E; Mannami, T; Ohtawa, Y; Okada, T; Sato, N; Senoo, S; Sonobe, H; Tamura, T; Waku, T | 1 |
| Fuse, N; Ikegawa, K; Nomura, H; Saito, S; Suzuki, S; Yamamoto, K | 1 |
| Hayashi, Y; Iwase, H; Maeda, M; Makino, Y; Saito, Y | 1 |
| Eto, R; Nakatsu, H; Ozasa, H; Shimizu, R | 1 |
| Akashi, Y; Inagaki, Y; Inagawa, S; Kemmochi, A; Ohkohchi, N; Satomi, K | 1 |
| Abdel-Rahman, O; ElHalawani, H | 1 |
| Hirabatake, M; Kurimoto, Y; Nakamura, T; Nakanishi, S; Nishida, A; Sotozono, C; Tsuji, A; Yamada, R | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, KR; Nam, TK; Park, YK; Ryu, SY; Shim, HJ | 1 |
| Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S | 1 |
| Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M | 1 |
| Cho, BC; Choi, EC; Kim, HR; Kim, JH; Koh, YW; Lee, CG | 1 |
| Katsui, K; Kiura, K; Maki, Y; Miyoshi, S; Soh, J; Torigoe, H; Toyooka, S | 1 |
| Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
| Hishima, T; Hosomi, Y; Miyamoto, S; Okamura, T; Okuma, Y; Shibuya, M | 1 |
| Cheng, Y; Guan, S; Huang, X; Jia, Y; Ma, Y; Song, Q; Sun, Y; Tan, B; Wang, C; Wang, J; Yao, B | 1 |
| Inagaki, M; Iwagaki, H; Nonoshita, T; Otsuka, S | 1 |
| Ishiguro, M; Ishikawa, T; Kobunai, T; Matsui, S; Murotani, K; Sugihara, K; Uetake, H | 1 |
| Adachi, K; Hirano, A; Hirata, Y; Joh, T; Kataoka, H; Kawai, T; Kitagawa, M; Mizuno, Y; Mizushima, T; Mochizuki, H; Mori, Y; Nakamura, M; Natsume, M; Nishie, H; Sano, H; Seno, K; Shimura, T; Sobue, S; Tsuchida, K | 1 |
| Aga, M; Endo, K; Hirai, N; Kondo, S; Murono, S; Nakanishi, Y; Tsuji, A; Wakisaka, N; Yoshizaki, T | 1 |
| Wang, D; Wang, X; Yu, X | 1 |
| Fukuda, H; Furuse, J; Ishii, H; Katayama, H; Mizusawa, J; Morizane, C; Okusaka, T | 1 |
| Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
| Hwang, SH; Kim, SG | 1 |
| Abe, T; Akahori, D; Hasegawa, H; Koda, K; Matsui, T; Niwa, H; Ozawa, Y; Suda, T; Tanahashi, M; Yamada, K; Yokomura, K | 1 |
| Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K | 1 |
| Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ | 1 |
| Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Hasegawa, M; Ichikawa, K; Kokado, Y; Koshiba, T; Kusama, T; Sone, N; Yamagami, K | 1 |
| Kakiuchi, Y; Takashima, H; Urano, S | 1 |
| Amada, E; Baba, S; Kameyama, N; Mitsuhashi, H; Miyata, R; Tomita, M | 1 |
| Abe, Y; Hagiwara, H; Kamata, A; Kano, T; Koizumi, M; Miyamae, T; Natori, J; Sarukawa, H; Takahashi, K; Uchiyama, K; Wada, Y | 1 |
| Iwata, J; Morikawa, T; Shima, Y; Teraishi, F | 1 |
| Li, QL; Qiu, MQ; Wang, T; Zhang, SF | 1 |
| Asai, K; Asayama, Y; Honda, H; Matsumoto, K; Nakamura, K; Nishie, A; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Kim, C; Kim, HR; Kim, JH; Lee, H; Noh, SH; Rha, SY; Rhee, Y; Song, S; Song, SE | 1 |
| Fujii, T; Fujiwara, M; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Suenaga, M; Sugimoto, H; Tanaka, C; Yamada, S | 1 |
| Koike, T; Nagasawa, A; Namura, O; Okamoto, T; Tsuchida, M | 1 |
| Hashimoto, K; Kogo, R; Nakagawa, T; Nakano, T; Nakashima, T; Sato, M; Sawatsubashi, M; Yasumatsu, R | 1 |
| Kokuryo, T; Nagino, M; Uehara, K; Yamaguchi, J; Yamauchi, K; Yokoyama, Y | 1 |
| Katata, Y; Okawaki, M; Sawaki, A; Yamaguchi, Y; Yamamura, M | 1 |
| Kamijo, A; Nagase, H; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Anan, T; Hasegawa, T; Ichihara, K; Ogawa, M; Okuma, M; Suzuki, T; Yanaga, K; Yoshida, K | 1 |
| Baba, T; Hagiwara, E; Ikeda, S; Iwasawa, T; Kato, T; Komatsu, S; Ogura, T; Okuda, R; Satoh, H; Sekine, A; Shinohara, T | 1 |
| Esaki, T; Fujiya, T; Furukawa, H; Horita, Y; Imamoto, H; Imamura, H; Kimura, Y; Morita, S; Ninomiya, M; Nishikawa, K; Oono, R; Sasako, M; Sugimoto, N; Taguri, M; Takayama, O; Tan, P; Tsuburaya, A; Tsujinaka, T; Yabusaki, H; Yamada, Y | 1 |
| Arita, J; Hasegawa, K; Kokudo, N; Matsuyama, Y; Mizunuma, N; Oba, M; Saiura, A; Sakamoto, Y; Shinozaki, E; Takahashi, M | 1 |
| Batlett, D; Canbay, E; Coccolini, F; Deraco, M; Elias, D; Glehen, O; Gonzaletz-Moreno, S; Ishibashi, H; Li, Y; Mahtem, H; Mizumoto, A; Moran, B; Morris, D; Piso, P; Sugarbaker, PH; Verwaal, V; Yonemura, Y | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Jensen, HA; Krogh, M; Pfeiffer, P; Qvortrup, C; Sorbye, H; Vestermark, LW; Winther, SB; Zubcevic, K | 1 |
| Aoe, M; Date, H; Fukuda, M; Hotta, K; Kajiwara, S; Kataoka, K; Kataoka, M; Matsuo, K; Nakamura, H; Nakata, M; Okumura, N; Sano, Y; Soh, J; Toyooka, S | 1 |
| Asaoka, T; Fujitani, K; Hara, H; Hirao, M; Ikeda, M; Ikenaga, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Saito, Y; Sekimoto, M; Tsujie, M; Yamamoto, K | 1 |
| Arigami, T; Baba, K; Ishigami, S; Kita, Y; Maemura, K; Matsushita, D; Mori, S; Natsugoe, S; Okumura, H; Tsuruda, Y; Uchikado, Y; Uenosono, Y; Yanagita, S | 1 |
| Kabashima, A; Maekawa, S; Sanefuji, K; Tanaka, S | 1 |
| Fukunaga, M; Kagimura, T; Matsumoto, H; Miyake, Y; Nagata, N; Ogata, Y; Otsuka, K; Sato, A; Shimada, K; Takagane, A; Takahashi, T; Tsuji, A; Yoshida, M | 1 |
| Liu, J; Ma, S; Zhu, L | 1 |
| Aoyama, T; Cho, H; Fujita, J; Fujitani, K; Hayashi, T; Ito, Y; Kimura, Y; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T | 1 |
| Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
| Hirooka, S; Inoue, K; Kon, M; Matsui, Y; Michiura, T; Miyasaka, C; Ohe, C; Ryota, H; Satoi, S; Tanigawa, N; Uemura, Y; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Ko, AH | 1 |
| Hamauchi, S; Iida, Y; Kamijo, T; Nakagawa, M; Nishimura, T; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Tanuma, A; Todaka, A; Yamashita, A; Yasui, H; Yokota, T; Yurikusa, T | 1 |
| Date, K; Fujimoto, T; Kimura, H; Matsunaga, T; Miyasaka, Y; Mochidome, N; Mori, Y; Nakamura, M; Oda, Y; Ohtsuka, T | 1 |
| Asada, K; Enomoto, N; Fujisawa, T; Imokawa, S; Inui, N; Karayama, M; Koshimizu, N; Kuroishi, S; Masuda, M; Matsuda, H; Nakamura, Y; Suda, T; Suzuki, S; Toyoshima, M; Watanabe, H; Yamada, T; Yokomura, K | 1 |
| Goda, Y; Hara, H; Irie, K; Kobayashi, S; Morimoto, M; Moriya, S; Ohkawa, S; Okusaka, T; Tanaka, M; Tezuka, S; Ueno, M | 1 |
| Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T | 1 |
| Hisamatsu, A; Inoue, H; Matsukawa, M; Saito, M; Shimada, K; Suzuki, M; Toshima, H | 1 |
| Kato, T; Nakamura, Y; Nakayama, H; Okamura, R; Yoh, T | 1 |
| Emi, M; Hirabayashi, N; Ibuki, Y; Kagimoto, A; Kaneko, M; Mukaida, H; Takiyama, W; Yoshimitsu, M | 1 |
| Fukuda, S; Kuga, Y; Moriya, T; Nishida, T | 1 |
| Chen, M; Chen, XD; He, FQ; Tang, LC; Tang, XL | 1 |
| Baba, H; Hayakawa, K; Hiraoka, M; Ikushima, H; Kamikonya, N; Kato, D; Nemoto-Murofushi, K; Noda, M; Oya, M; Oya, N; Sakai, Y; Sato, T; Shimada, M; Takeuchi, M; Tomita, N; Watanabe, M; Watanabe, T | 1 |
| Kanemoto, H; Kyoden, Y; Nagai, E; Oba, N; Ohata, K; Sato, S; Suzuki, M; Takagi, M; Takahashi, M; Taki, Y; Taku, K; Watanabe, M | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Yamamoto, H | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Goda, F; Goji, T; Kawamoto, S; Kimura, M; Kimura, T; Kitamura, S; Miyamoto, H; Muguruma, N; Negoro, Y; Niitsu, Y; Okahisa, T; Okamoto, K; Sakamoto, K; Shimoyama, R; Takaoka, T; Takayama, T; Tsuji, A; Yano, H; Yoshizaki, K | 1 |
| Furukawa, D; Hirabayashi, K; Izumi, H; Mashiko, T; Nakagohri, T; Ozawa, S; Sadahiro, S; Tomioku, M; Yasuda, S; Yazawa, N | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nishikawa, T; Nozawa, H; Otani, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Azuma, K; Hisamatsu, Y; Hoshino, T; Ichiki, M; Ishii, H; Nishikawa, K; Shukuya, T; Takahashi, K; Takeoka, H; Tokito, T; Yamada, K | 1 |
| Akiyama, H; Arisaka, S; Endo, I; Furuya, M; Ichikawa, Y; Kosaka, R; Kunisaki, C; Ohashi, K | 1 |
| Fujii, T; Hara, R; Hashiyata, H; Ikeda, A; Nakamoto, K; Takeshige, M; Yoshida, K | 1 |
| Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Mochiki, E; Ogura, T; Sobajima, J | 2 |
| Akagi, Y; Baba, H; Emi, Y; Kobayashi, K; Maehara, Y; Natsugoe, S; Ogata, Y; Oki, E; Shimokawa, M; Takahashi, T; Tanaka, T; Tsuji, A; Yoshida, K | 1 |
| Azakami, T; Eguchi, N; Hayashi, H; Matsumoto, K; Shimamoto, F; Sumida, T; Sumii, M; Sumimoto, K; Tamura, T; Uraoka, N | 1 |
| Gochi, A; Hasegawa, H; Imano, M; Matsuda, T; Morita, S; Murakami, N; Nagao, J; Naitoh, H; Nemoto, H; Nishikawa, K; Oka, M; Osanai, H; Saji, S; Sakamoto, J; Sakata, K; Shimizu, R; Suzuki, M; Tajiri, T; Takahashi, T; Tanaka, A; Yoshikawa, T; Yoshino, S | 1 |
| Akabane, H; Doihara, H; Fukuda, T; Hagiwara, Y; Kashiwaba, M; Mouri, M; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Watanabe, T | 1 |
| Amaki, M; Imamura, A; Iwasaki, Y; Ken, Y; Oohinata, R; Yajima, K | 1 |
| Kurono, Y; Matushita, K; Nagano, H | 1 |
| Ikegawa, K; Saito, S; Suzuki, S; Yamamoto, K | 1 |
| Hattori, Y; Itoh, S; Kawa, Y; Kiriu, T; Negoro, S; Satouchi, M; Shimada, T; Soejima, T; Takase, N; Tsujino, K; Urata, Y; Yamamoto, M | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
| Feng, J; Wang, X; Xu, J; Zhao, D | 1 |
| Amaki, M; Iwasaki, Y; Oohinata, R; Suzuki, K; Yajima, K; Yuu, K | 1 |
| Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E | 1 |
| Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K | 1 |
| Lijun, X; Weidong, C | 1 |
| Kimura, M | 1 |
| Hirata, Y; Homma, Y; Honda, G; Honjo, M; Kurata, M; Sakamoto, K; Shinya, S | 1 |
| Akase, T; Arakawa, I; Inoue, T; Iyoda, T; Kanno, H; Nagase, S; Uetsuka, Y | 1 |
| Hanada, S; Kanazawa, G; Kinoshita, M; Kiyota, S; Matsuda, Y; Nishizawa, S; Tanaka, H | 1 |
| Cho, H; Hayashi, T; Ikeda, K; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Ohshima, T; Rino, Y; Sato, T; Segami, K; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Aoyama, T; Atsumi, Y; Kazama, K; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Rino, Y; Shiozawa, M; Ueno, M; Washimi, K; Yukawa, N | 1 |
| Altan, B; Asao, T; Bai, T; Bao, P; Handa, T; Ide, M; Kaira, K; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Yanoma, T; Yokobori, T | 1 |
| Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N | 1 |
| Alemdar, A; Bas, K; Ilhan, E; Ureyen, O | 1 |
| Amagai, K; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Ishido, K; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X | 1 |
| Abu Lila, AS; Fukushima, M; Huang, CL; Ishida, T; Moriyoshi, N; Wada, H | 1 |
| Boku, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishimura, T; Okita, N; Shimada, Y; Takashima, A; Yamada, Y | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Egashira, S; Fukushima, S; Ihn, H; Inoue, Y; Jinnin, M; Kajihara, I; Kanemaru, H; Nagamoto, E; Nakahara, S; Uemura-Kiyohara, M; Yamada-Kanazawa, S | 1 |
| Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Dai, X; Jiang, J; Wang, C; Wu, C; Zhang, X | 1 |
| Chen, DL; Guo, P; Hao, YT; He, MM; He, YY; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Wang, ZX; Xu, RH; Yuan, SQ; Zeng, YX; Zeng, ZL; Zhang, DS | 1 |
| Honda, M; Kim, DH; Nishiguchi, R; Sakamoto, T | 1 |
| Boku, N; Hyodo, I; Narahara, H; Nishina, T; Sugimoto, N; Yoshino, T; Yoshisue, K | 1 |
| Au, KH; Chiang, CL; Lam, KC; Lam, KO; Law, AL; Lee, CC; Li, L; Mo, FK; Ng, WT; So, TH; Yeo, W | 1 |
| Han, CB; Ma, JT; Sun, L; Sun, X; Xiong, ZC; Zhang, SL | 1 |
| Arigami, T; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Mori, S; Natsugoe, S; Sakoda, M; Shinchi, H; Uchikado, Y; Ueno, S; Uenosono, Y | 1 |
| Kadowaki, S; Muro, K; Narita, Y; Sugiyama, K; Tajika, M; Ura, T | 1 |
| Asakage, M; Ishigami, H; Kitayama, J; Yamaguchi, H; Yamashita, H | 1 |
| Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H | 1 |
| Geng, C; Ji, Y; Liu, S; Nie, K; Wang, R; Zhang, L; Zhang, Z; Zou, X | 1 |
| Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
| Ci-Ren, BS; Duo-Ji, MM; Long, ZW; Luo, DL; Zhang, XH | 1 |
| Baars, A; Boot, H; Kwakman, JJM; Pfeiffer, P; Pruijt, JFM; Punt, CJA; Winther, SB | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, DW; Lee, KH; Na, II; Oh, DY; Rhee, J; Yang, Y | 1 |
| Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Tomita, Y; Ueda, N | 1 |
| Chida, S; Fujita, S; Hayase, S; Kase, K; Kono, K; Monma, T; Ohki, S; Ohtake, T; Sakamoto, W; Takawa, M; Takenoshita, S; Yamauchi, N | 1 |
| Akamatsu, H; Furukawa, K; Ikehara, M; Kishi, K; Koh, M; Masuzawa, T; Suzuki, Y; Tanemura, M; Tei, M; Tsukada, R | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Kawamoto, K; Mori, M; Noda, T; Ueno, G; Wada, H; Yamada, D | 1 |
| Akasaka, H; Hakamada, K; Ichinohe, D; Jin, H; Kimura, T; Miura, T; Morohashi, H; Odagiri, T; Saito, T; Sakamoto, Y; Suto, A; Umetsu, S; Wakasa, Y; Yoshida, E; Yoshida, T | 1 |
| Fukushima, T; Hasegawa, S; Hayashi, T; Ike, H; Masuda, M; Minamizawa, K; Murakami, H; Nemoto, D; Rino, Y; Shibuya, T; Shimada, Y; Takagawa, R; Wada, T; Watanabe, T; Yokoi, H | 1 |
| Fujita, H; Funaki, H; Kinami, S; Koda, W; Kosaka, T; Miura, S; Nishino, R; Sakata, N; Ueda, N | 1 |
| Hagihara, K; Hama, N; Hirao, M; Ikeda, M; Kobayashi, N; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K | 1 |
| Hanyu, T; Hishiki, M; Ichikawa, H; Ishikawa, T; Kameyama, H; Kano, Y; Kobayashi, T; Kosugi, S; Muneoka, Y; Nagahashi, M; Otani, T; Sakata, J; Sato, Y; Usui, K; Wakai, T | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 2 |
| Earashi, M; Fujii, H; Munemoto, M; Neduka, H; Nonomura, A; Ojima, T | 1 |
| Hatanaka, N; Hirao, T; Iwamoto, K; Kono, E; Mizuno, H; Morimoto, Y; Noro, H; Son, C; Takaichi, S; Yamasaki, Y; Yasumasa, K | 1 |
| Fujii, C; Fujita, J; Hayashi, H; Ishizaka, T; Kamigaki, S; Kimura, Y; Makari, Y; Mikami, J; Yanagishita, Y; Yasui, Y | 1 |
| Abe, T; Fukase, K; Hayashi, H; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Otsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Akiyama, Y; Egawa, C; Inatome, J; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Murakami, K; Naito, A; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Fukuda, S; Harada, T; Hiraki, S; Kanesada, K; Tada, K | 1 |
| Choda, Y; Idani, H; Ishida, M; Matsukawa, H; Mimura, N; Miyake, S; Nagai, Y; Ninomiya, M; Ogawa, T; Ojima, Y; Okajima, M; Shiozaki, S | 1 |
| Fukuchi, M; Ishida, H; Ishiguro, T; Mochiki, E; Muta, Y; Ogura, T | 1 |
| Katayanagi, S; Kawachi, S; Makuuchi, Y; Osakabe, H; Shigoka, M; Sumi, T; Tsuchida, A | 1 |
| Akai, T; Higashi, Y; Kojima, T; Maruo, H; Nakamura, K; Nishiyama, R; Shoji, T; Taniguchi, M; Yamazaki, M | 1 |
| Akamatsu, H; Furukawa, K; Kishi, K; Masuzawa, T; Mori, K; Otsuka, M; Suzuki, Y; Tanemura, M; Tei, M; Tsukada, R | 1 |
| Hagihara, K; Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Uemura, M; Yamamoto, K | 1 |
| Akasaka, H; Hakamada, K; Ichinohe, D; Jin, H; Miura, T; Morohashi, H; Nagase, H; Okano, K; Sakamoto, Y; Yoshida, E; Yoshida, T | 1 |
| Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E | 1 |
| Ito, F; Kaneta, A; Miura, J; Otani, S; Saito, T; Tsuchiya, T | 1 |
| Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Miwa, H; Murakami, M; Noura, S; Shimizu, J; Takata, A; Yasuyama, A; Yoshikawa, M | 1 |
| Hanyu, T; Hishiki, M; Ichikawa, H; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Muneoka, Y; Nagahashi, M; Otani, T; Sakai, T; Sakata, J; Usui, K; Wakai, T | 1 |
| Endo, S; Fujitani, K; Hama, N; Hirao, M; Ikeda, M; Kawada, J; Maeda, S; Matsuda, C; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K | 1 |
| Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, K; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K | 1 |
| Fujii, N; Hashimoto, T; Kogo, M; Nagatani, A; Naito, Y; Ogawa, Y; Okabe, T; Sasaki, T; Sunaga, T; Tomura, K | 1 |
| Akimoto, T; Arahira, S; Enokida, T; Motegi, A; Tahara, M; Wakasugi, T; Yamazaki, T; Yoshisue, K; Zenda, S | 1 |
| Futawatari, H; Hasegawa, S; Hashiguchi, M; Higashi, M; Hijikuro, K; Ido, A; Nasu, Y; Sasaki, F; Shigeta, K; Tamai, T | 1 |
| Abe, Y; Endo, T; Nakanishi, K; Ohsaki, Y; Sugiyama, K | 1 |
| Kamiyama, Y; Kasai, T; Mori, K; Nakamura, Y; Sugiyama, T | 1 |
| Iida, S; Kurihara, N; Matsuura, Y; Tsutsui, R | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M | 1 |
| Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K | 1 |
| Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
| Arigami, T; Kijima, Y; Kurahara, H; Maemura, K; Mataki, Y; Matsushita, D; Natsugoe, S; Okubo, K; Sakoda, M; Uenosono, Y; Yanagita, S | 1 |
| Hagiwara, Y; Hashimoto, D; Imaoka, H; Isayama, H; Ishii, H; Kitano, M; Maguchi, H; Nagakawa, T; Nakamori, S; Nebiki, H; Ohashi, Y; Ohkawa, S; Shimizu, A; Shirasaka, T; Sho, M; Sugimori, K; Ueda, K; Ueno, H; Yamaue, H; Yanagimoto, H; Yokota, I | 1 |
| Lee, ES; Park, YJ; Soh, BW | 1 |
| Ahn, S; Ahn, SH; Baek, JH; Bang, YJ; Choung, HK; Chung, JY; Khwarg, SI; Kim, HH; Kim, JS; Kim, JW; Kim, N; Kim, TY; Lee, KH; Lee, KW; Park, DJ | 1 |
| Azuma, M; Goto, H; Hanibuchi, M; Kakiuchi, S; Kawano, H; Nishioka, Y; Ogushi, F; Otsuka, K; Saijo, A; Sakaguchi, S; Tezuka, T; Toyoda, Y | 1 |
| Hu, S; Jiang, Y; Sun, Y; Xue, L; Xue, X; Yang, L; Yue, J; Zhu, Y | 1 |
| Ikeda, H; Kakegawa, S; Matsumoto, I; Saito, D; Takata, M; Takemura, H; Tamura, M; Tanaka, Y; Yoshida, S | 1 |
| Asakawa, H; Fujino, K; Hashimoto, M; Hayashi, T; Ito, H; Mita, K; Ota, E; Takahashi, K | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Okada, K; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Azuma, M; Higuchi, K; Hosoda, K; Katada, N; Koizumi, W; Komori, S; Mieno, H; Moriya, H; Tanabe, S; Watanabe, M; Yamashita, K; Yoshida, T | 1 |
| Imamura, F; Inoue, T; Kimura, M; Kumagai, T; Nishino, K; Tamiya, M | 1 |
| Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
| Creemers, GJM; Hendriks, MP; Koopman, M; Kwakman, JJM; Los, M; Mol, L; Muller, EW; Polée, MB; Punt, CJA; Simkens, LHJ; Ten Tije, AJ; van Alphen, RJ; van de Wouw, AJ; van der Velden, AMT; van Rooijen, JM; van Voorthuizen, T; van Werkhoven, E | 1 |
| Ebata, T; Goto, H; Hiramatsu, K; Kobayashi, S; Maeda, A; Mukai, T; Nagino, M; Okada, Y; Sakamoto, E; Takeuchi, E; Uehara, K | 1 |
| Hanafusa, T; Hashimoto, T; Matsuda, K; Namiki, T; Ueno, M; Yokozeki, H | 1 |
| Fang, M; Jia, Y; Li, J; Liang, X; Luo, L; Lv, S; Song, T; Xu, H | 1 |
| Bian, W; Chen, H; Chen, WQ; Liu, XL; Song, GM; Tian, X; Zhou, JG | 1 |
| Miyakita, H; Nagase, H; Ogimi, T; Okada, K; Sadahiro, S; Saito, G; Suzuki, T; Tanaka, A | 1 |
| Akiyama, H; Endo, I; Ishibe, A; Kogure, Y; Momiyama, M; Sato, K; Suwa, Y | 1 |
| Fushida, S; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohta, T; Oyama, K; Saito, H; Tajima, H; Tsukada, T; Yamaguchi, T | 1 |
| Futami, S; Higashiguchi, M; Hirashima, T; Kijima, T; Koba, T; Komuta, K; Minami, S; Nishijima-Futami, Y; Suzuki, H; Tamiya, M | 1 |
| Aoyama, T; Cho, H; Ikeda, K; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T | 1 |
| Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
| Endo, I; Kubota, K; Kumamoto, T; Matsuyama, R; Mori, R; Sakamaki, K; Taniguchi, K; Yabushita, Y | 1 |
| Go, T; Liu, D; Matsuura, N; Nakano, J; Nakano, T; Nakashima, N; Nii, K; Tarumi, S; Tokunaga, Y; Yokomise, H | 1 |
| Aoyama, T; Fujitani, K; Fukunaga, T; Hirabayashi, N; Ito, S; Kimura, Y; Matsui, T; Miki, A; Nemoto, H; Nishikawa, K; Sakamaki, K; Tanabe, K; Yoshikawa, T | 1 |
| Fujieda, M; Hakoi, K; Hitotsumachi, T; Kanie, S; Morita, F; Suzuki, S; Yasui, H | 1 |
| Boku, N; Hironaka, S; Hyodo, I; Ito, M; Kimura, Y; Miura, Y; Miyata, Y; Mori, M; Moriwaki, T; Musha, N; Negoro, Y; Nishikawa, K; Nosho, K; Okuda, H; Sakamoto, T; Shinozaki, H; Shinozaki, K; Shirakawa, T; Sugimoto, N; Sukawa, Y; Takano, T; Taku, K; Tokunaga, S; Tsuda, T; Uchino, K; Yonesaka, K; Yoshimura, K; Yoshiyama, H | 1 |
| Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H | 1 |
| Aoyagi, E; Kimura, T; Kitamura, S; Mitsui, Y; Miyamoto, H; Muguruma, N; Nakagawa, T; Okamoto, K; Rokutan, K; Takayama, T; Tanahashi, T | 1 |
| Franck, C; Malfertheiner, P; Venerito, M | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Muguruma, K; Nagahara, H; Ohira, G; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Yamazoe, S; Yashiro, M | 1 |
| Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T | 1 |
| Ikeyama, M; Ishizone, S; Nakayama, J; Yoshizawa, J | 1 |
| Hara, R; Kita, E; Nakamura, K; Sudo, K; Tsujimoto, A; Yamaguchi, T | 1 |
| Aoi, J; Fukushima, S; Igata, T; Ihn, H; Jinnin, M; Johno, T; Kajihara, I; Maeda-Otsuka, S; Masuguchi, S; Nakamura, Y; Yamada-Kanazawa, S | 1 |
| Doki, Y; Hirota, M; Kawabata, R; Kurokawa, Y; Masuzawa, T; Mikami, J; Mori, M; Takiguchi, S; Yamamoto, K; Yamashita, K | 1 |
| Kakinoki, K; Kamada, H; Maeda, E; Masaki, T; Okano, K; Oshima, M; Shibata, T; Suto, H; Suzuki, Y; Takahashi, S; Yamamoto, N | 1 |
| Baars, A; de Mol, P; Kok, WEM; Koopman, M; Kwakman, JJM; Punt, CJA; van Zweeden, AA | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K | 1 |
| Suga, Y; Takehana, K | 1 |
| Fan, QX; Han, DM; Lu, H; Song, NS; Wang, F; Wang, HH | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Inadomi, K; Kusaba, H; Makiyama, A; Makiyama, C; Mitsugi, K; Shibata, Y; Shinohara, Y; Shirakawa, T; Takayoshi, K; Tsuchihashi, K; Uchino, K; Uenomachi, M | 1 |
| Domae, S; Ono, T; Sasaki, A; Takakura, H | 1 |
| Hirakawa, K; Hosoya, Y; Kanda, M; Kitajima, M; Kobayashi, M; Koeda, K; Konno, H; Morita, S; Muguruma, K; Nakamori, M; Nishikawa, K; Okajima, M; Saji, S; Sakamoto, J; Shimada, M; Shirasaka, T; Sowa, M; Taguri, M; Takahashi, M; Tanaka, H; Tsuji, A; Yamamitsu, S | 1 |
| Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R | 1 |
| Furukawa, M; Hatakeyama, H; Hori, Y; Kitani, Y; Kubota, A; Mizoguchi, N; Nakayama, Y; Nonaka, T; Oridate, N | 1 |
| Handa, S; Kato, Y; Moriya, K; Nakamura, S; Sasaki, T; Sasaki, Y; Shimizu, H; Takahashi, H; Yoshida, H | 1 |
| Adachi, Y; Mizukami, Y; Nomura, H; Okamura, M; Ota, S; Sumii, A; Tsuboi, K | 1 |
| Ito, J; Kato, H; Kubo, T; Kurayama, E; Miyachi, K; Nakajima, M; Onodera, S; Otsuka, K; Sasaki, K; Satomura, H; Takahashi, M; Yamaguchi, S | 1 |
| Cho, SJ; Kim, CG; Kim, MJ; Kong, SY; Lee, JY; Nam, BH; Park, SR; Park, YI | 1 |
| Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
| Ishigami, H; Kitayama, J; Kurihara, M; Satoh, Y; Yamaguchi, H; Yatomi, Y | 1 |
| Boku, N; Iizumi, S; Kawai, S; Matsushima, T; Muro, K; Nagashima, K; Narita, Y; Tajika, M; Takahari, D; Takashima, A; Yasui, H | 1 |
| Ge, L; Qie, S; Wang, Z; Yan, Q; Yang, L; Zhong, S | 1 |
| Chin, K; Hiroki, O; Ichimura, T; Matsushima, T; Nakayama, I; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Baba, H; Denda, T; Ikejiri, K; Kato, T; Li, J; Mishima, H; Sakai, K; Shen, L; Shimada, K; Toh, Y; Wang, J; Xu, J; Xu, R; Yamamoto, M | 1 |
| Anderegg, MCJ; Mohammad, NH; Ngai, LL; Ter Veer, E; Valkenhoef, GV; van Laarhoven, HWM; van Oijen, MGH | 1 |
| Hu, S; Shu, C; Song, Y; Sun, YK; Yang, L; Yang, Y; Yuan, X; Zhang, W; Zhou, A; Zou, S | 1 |
| Chi, Y; Zhao, H; Zhao, J | 1 |
| Hagiwara, Y; Imi, K; Isaka, H; Matsuyama, Y; Mukai, H; Watanabe, K | 1 |
| Hata, Y; Ikeda, S; Iyoda, A; Kadokura, M; Kiribayashi, T; Kishi, K; Murakami, Y; Nagashima, M; Nakayama, T; Otsuka, H; Ozeki, Y; Takagi, K | 1 |
| Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N | 1 |
| Bulitta, JB; Jeong, SW; Kim, TH; Kwon, DR; Min, BS; Park, GY; Shin, BS; Shin, JC; Shin, S; Weon, KY; Woo, MH; Yoo, SD | 1 |
| Abdalla, K; Abramov, M; Ajani, JA; Alsina, M; Aoyama, T; Benedetti, F; Bondarenko, I; Elme, A; Esko, V; Feliu, J; Gorbunova, V; Hontsa, A; Lazarev, S; Makris, L; Mizuguchi, H; Otchenash, N; Rosati, G; Shparyk, Y; Verma, U | 1 |
| Hara, H; Hori, M; Ohashi, M; Sakuraya, M; Shatari, T; Shimizu, Y; Tachikawa, N | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Mihara, H; Ogawa, K; Origasa, H; Sugiyama, T; Ueda, A; Yabushita, K; Yoshioka, A; Yoshita, H | 1 |
| Asami, S; Fujii, M; Furukawa, H; Hatachi, Y; Kimura, Y; Kunisaki, C; Masuishi, T; Matsusaka, S; Nagao, N; Nakajima, T; Nakamura, M; Nishikawa, K; Sasaki, K; Segawa, Y; Takeuchi, M; Yuasa, Y | 1 |
| Doki, Y; Endoh, S; Fujita, J; Fujitani, K; Kurokawa, Y; Mori, M; Ohmori, T; Takeno, A; Takiguchi, S; Yamasaki, M | 1 |
| Che, X; Chen, J; Miao, Q; Wang, J; Weng, M; Wu, X; Zheng, Q; Zou, Y | 1 |
| Cho, JH; Cho, JY; Lim, JY | 1 |
| Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T | 2 |
| Chang, J; Cheng, Y; Goto, K; Ichinose, Y; Lim, WT; Lu, S; Maemondo, M; Mok, TSK; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Shi, YK; Soo, RA; Sugawara, S; Takahashi, T; Tamura, T; Yamamoto, N; Yang, JC; Zhang, L | 1 |
| Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K | 1 |
| Akimoto, T; Ikeda, M; Kobayashi, T; Kojima, M; Konishi, M; Ohno, I; Takahashi, S; Uesaka, K | 1 |
| Hachimine, T; Hijikawa, T; Inoue, K; Kon, M; Nakai, K; Uemura, Y; Yamada, M; Yasuda, K; Yoshioka, K | 1 |
| Goto, M; Harada, S; Higuchi, K; Kodama, K; Kojima, Y; Nouda, S; Ota, K; Ozaki, H; Takeuchi, T | 1 |
| Itai, R; Yamashita, Y; Yokode, M; Zen, Y | 1 |
| Fukuda, T; Hagiwara, Y; Hozumi, Y; Kawahara, T; Mouri, M; Mukai, H; Ohashi, Y; Ohsumi, S; Sagara, Y; Shimozuma, K; Shiroiwa, T | 1 |
| Furuta, R; Ina, K | 1 |
| Arakawa, Y; Hayashi, K; Nagasaki, E; Nakada, K; Tamura, M; Uwagawa, T; Yano, S | 1 |
| Iiyama, T; Iwata, J; Morita, S; Okabayashi, T; Shima, Y; Shimada, Y; Sui, K; Sumiyoshi, T | 1 |
| Kim, MJ; Kim, S; Kong, SY; Nam, BH; Park, SR; Park, YI | 1 |
| Cai, H; Huang, D; Huang, H; Li, G; Liu, X; Long, Z; Sheng, W; Wang, Y; Yin, J; Zhang, Z; Zhao, G; Zhou, Y; Zhu, H; Zhu, X | 1 |
| Kabashima, A; Kimura, K; Maekawa, S; Sanefuji, K | 1 |
| Chen, XS; Chi, Y; Fang, H; Jin, J; Li, N; Li, YX; Liu, WY; Liu, YP; Ren, H; Song, YW; Tang, Y; Wang, JY; Wang, SL; Wang, WH; Wang, X; Yang, L; Zhang, T; Zhao, DB | 1 |
| Du, X; Gui, Y; Jia, Q; Liao, D; Miao, J; Sun, M; Tian, H; Wen, Y; Yang, C; Yang, Q; Zhao, Z | 1 |
| Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K | 1 |
| Fujiwara, T; Hamano, R; Kagawa, S; Kambara, T; Kikuchi, S; Kishimoto, H; Kuroda, S; Kuwada, K; Muraoka, A; Nakayama, H; Nishizaki, M; Noma, K; Shigeyasu, K; Shirakawa, Y; Tanaka, N; Tanakaya, K | 1 |
| Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Goto, H; Haku, T; Hanibuchi, M; Hatakeyama, N; Kakiuchi, S; Kanematsu, T; Machida, H; Nishioka, Y; Ogushi, F; Okano, Y; Sone, S; Urata, T | 1 |
| Chang, HM; Choi, DR; Ha, HI; Han, B; Jeong, JH; Kim, D; Kim, HS; Kim, JH; Kim, KP; Kim, TW; Lee, JL; Ryoo, BY; Seo, J; Yoo, C; Zang, DY | 1 |
| Baba, E; Boku, N; Ebi, M; Esaki, T; Hironaka, S; Honda, T; Hyodo, I; Kajiwara, T; Kashiwada, T; Kunieda, K; Makiyama, A; Matsushita, Y; Minashi, K; Moriwaki, T; Muro, K; Nagase, M; Negoro, Y; Noguchi, M; Nozaki, A; Okano, N; Okuda, H; Okuno, T; Otsu, S; Sakai, D; Shimodaira, H; Shimokawa, M; Sugimoto, N; Sugiyama, J; Takeda, K; Tamura, S; Tamura, T; Tsuda, T; Tsuji, A; Ueda, S; Yanagihara, K | 1 |
| Fukushima, N; Iwaya, T; Koeda, K; Nakatochi, M; Nishizuka, SS; Ohmori, Y; Sumida, C; Takahashi, T; Tamura, G | 1 |
| Chochi, K; Morita, D; Muto, Y; Oka, A; Rikiyama, T | 1 |
| Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T | 1 |
| Chino, S; Kaida, T; Kondo, Y; Kubo, H; Naito, M; Nishi, Y; Takahashi, Y; Ushiku, H; Watanabe, M; Yamashita, W | 1 |
| Fujii, T; Horiguchi, J; Ikeda, F; Kimura, M; Koibuchi, Y; Uchida, N; Yanagita, Y | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Dong, X; Du, F; Tang, S; Wei, H; Wei, J | 1 |
| Nagase, H; Nakagawa, F; Uchida, J | 1 |
| Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S | 1 |
| Chikugo, T; Imai, H; Kamata, K; Kamei, K; Kawaguchi, K; Makutani, Y; Matsumoto, I; Matsumoto, M; Murase, T; Nakai, T; Satoi, S; Takeyama, Y | 1 |
| Hirano, Y; Hosoda, Y; Ishii, Y; Maeno, H; Munechika, T; Noritomi, T; Okamoto, T; Shibata, R; Shimaoka, H; Sueishi, K; Yonemitsu, K; Yoshida, T | 1 |
| Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Ueno, T; Yoshino, S | 1 |
| Ebisui, C; Fukuchi, N; Hamano, R; Kinuta, M; Kitahara, T; Minoji, T; Murata, K; Ohishi, K; Okamura, S; Yanagisawa, T; Yokouchi, H | 1 |
| Hiranuma, A; Kadoya, K; Kato, R; Kawamitsu, K; Kitahara, T; Nabekura, D; Nagashima, M; Okazumi, S; Ooshiro, T; Sato, A; Sato, Y; Takagi, R; Tanaka, H; Urita, T; Yoshida, Y | 1 |
| Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Kinami, S; Kosaka, T; Miura, S; Motoo, Y; Nakano, Y; Ohnishi, T; Omote, K; Tomita, Y; Ueda, N | 1 |
| Fujieda, Y; Fujisawa, K; Hanazaki, K; Kawanishi, Y; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Munekage, M; Namikawa, T | 1 |
| Aratani, K; Chuman, M; Gunji, H; Koyama, I; Miyawaki, Y; Okamoto, K; Sakuramoto, S; Sato, H; Wakata, M; Yamaguchi, S | 1 |
| Choda, Y; Harano, M; Idani, H; Ishida, M; Kubota, T; Matsukawa, H; Miyake, S; Morito, T; Nakano, K; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Sumitani, D | 1 |
| Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T | 1 |
| Choda, Y; Fujita, S; Harano, M; Idani, H; Ishida, M; Kubota, T; Matsukawa, H; Miyake, S; Nakano, K; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Sumitani, D | 1 |
| Fujita, H; Kinami, S; Kosaka, T; Miura, S; Nakano, Y; Nishino, R; Sakata, N; Ueda, N | 1 |
| Fujiwara, T; Kagawa, S; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Nishizaki, M; Noma, K; Shirakawa, Y; Tanabe, S | 1 |
| Doki, Y; Gakuhara, A; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Tanaka, K; Yamasaki, M | 1 |
| Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
| Kawamoto, S; Kuroki, N; Maekawa, K; Terashima, T | 1 |
| Furuke, Y; Ikeda, J; Imura, K; Komatsu, S; Kumano, T; Nakatsugawa, Y; Shimomura, K; Shioaki, Y; Tanaka, Y; Taniguchi, F | 1 |
| Akagi, K; Dono, K; Hamabe, A; Hirota, M; Imamura, H; Iwazawa, T; Kawase, T; Morita, S; Nagase, H; Noguchi, K; Oshima, K; Tanida, T; Tomimaru, Y | 1 |
| Cheong, JH; Chung, HC; Hyung, WJ; Jung, I; Jung, M; Kang, SY; Kim, BS; Kim, HS; Kim, KH; Lee, CK; Lee, KH; Lee, MH; Noh, SH; Rha, SY; Shin, DB; Zang, DY | 1 |
| Fan, L; Huang, J; Jiao, Z; Li, Y; Liu, Y; Tan, B; Tian, Y; Wang, D; Yang, P; Zhang, Z; Zhao, Q; Zhao, X | 1 |
| Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS | 1 |
| Eba, J; Fukuda, H; Furuse, J; Ikeda, M; Ishii, H; Konishi, M; Mizusawa, J; Nakachi, K; Okusaka, T | 1 |
| Liu, D; Lu, J; Song, J; Zhang, H; Zhang, Y; Zhu, X | 1 |
| Boku, N; Fukutomi, A; Hagiwara, Y; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Fujii, M; Imai, A; Imai, Y; Kamoshida, S; Katakami, N; Konishi, M; Sugimoto, K | 1 |
| Cui, J; Nan, KJ; Ren, MZ; Song, LP; Wang, MC; Wang, SX; Zhang, YM | 1 |
| Fujii, H; Masubuchi, M; Mikame, Y; Mori, M; Nishijima, H; Okuda, Y; Shinada, M; Sudoh, T; Watano, R | 1 |
| Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Nishikura, K; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A; Watanabe, G | 1 |
| Akabori, H; Iida, H; Kaida, S; Kitamura, N; Miyake, T; Murata, S; Naka, S; Shimizu, T; Sonoda, H; Takebayashi, K; Tani, M; Terada, Y; Ueki, T; Yamaguchi, T; Zen, Y | 1 |
| Baba, T; Ebata, T; Kokuryo, T; Nagino, M; Uehara, K; Yamaguchi, J; Yokoyama, Y | 1 |
| Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y | 1 |
| Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K | 1 |
| Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T | 1 |
| Liu, F; Song, Y; Wang, W; Xing, D | 1 |
| An, JY; Kim, S; Kim, SM; Lee, J; Sohn, TS | 1 |
| Fusumae, T; Kawakita, R; Oda, S; Takasugi, A; Takeuchi, A; Yoshida, T | 1 |
| Ishikura, H; Kawakami, Y; Kawakita, N; Kimura, S; Kondo, K; Sawada, T; Takizawa, H; Tangoku, A; Toba, H; Tsuboi, M; Yoshida, M | 1 |
| Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Aoyama, T; Bando, E; Inano, T; Kawamura, T; Makuuchi, R; Tanizawa, Y; Terashima, M; Tokunaga, M; Yasui, H | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Hu, T; Liu, F; Wang, C; Wang, W | 1 |
| Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y | 1 |
| Ariizumi, Y; Enomoto, T; Hiwatari, M; Kitajima, M; Kobayashi, S; Koizumi, S; Matsushita, T; Mikami, S; Nakajima, T; Ono, T; Otsubo, T; Saji, O; Sasaki, N | 1 |
| Kaibe, N; Kikuchi, S; Kurahashi, Y; Nakao, E; Niwa, H; Oshima, T; Ozawa, R; Sasako, M; Shinohara, H; Takii, M | 1 |
| Horiuchi, T; Hoshida, Y; Iwakura, S; Kimura, M; Tanishima, H; Tatsubayashi, T; Tominaga, T | 1 |
| Agawa, S; Aoki, H; Itoh, K; Kondou, N; Kuroda, J; Sumita, T | 1 |
| Akagi, K; Dono, K; Hamabe, A; Hirota, M; Imamura, H; Iwazawa, T; Kawase, T; Morita, S; Nagase, H; Noguchi, K; Oshima, K; Tanida, T; Tomimaru, Y; Yokota, Y | 1 |
| Cho, H; Ikeda, K; Kano, K; Maezawa, Y; Nakajima, T; Ogata, T; Okubo, Y; Yamada, T; Yoshikawa, T | 1 |
| Hasegawa, H; Kakeji, Y; Kanaji, S; Matsuda, T; Matsuda, Y; Nakamura, T; Oshikiri, T; Sumi, Y; Suzuki, S; Ueta, K; Yamamoto, M; Yamashita, K | 1 |
| Fujita, R; Fukuda, S; Hirayama, R; Kataoka, R; Kuwamoto, N; Miura, Y; Otsuka, R; Saito, S; Shindo, Y; Takaishi, H | 1 |
| Izumiya, Y; Kawakami, S; Kimura, Y; Kin, S; Komiyama, S; Nakashima, S | 1 |
| Hu, X; Li, J; Liu, Y; Wang, Y; Yang, L; Yang, S; Zhang, Y | 1 |
| Bai, XL; Chen, W; Liang, TB; Ma, T; Tu, JJ; Zhang, XZ | 1 |
| Ito, S; Ohashi, Y; Sasako, M | 1 |
| Ahmad, R; Cao, Y; Du, F; Jiang, J; Ma, X; Ren, D; Shen, G; Wang, Z; Zhang, H; Zhang, S; Zhao, F; Zhao, J; Zheng, F | 1 |
| Chin, K; Eto, K; Hiki, N; Ida, S; Kano, Y; Kumagai, K; Nunobe, S; Ohashi, M; Sano, T; Shoji, Y; Takahari, D; Tsuda, Y; Yamaguchi, K; Yasufuku, I | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Konishi, M; Nakachi, K; Ohta, T; Okusaka, T; Saiura, A; Sakamoto, H; Shimada, K; Shimamura, T; Sugiyama, M | 1 |
| Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y | 1 |
| Cai, Z; Chen, Z; Shen, C; Wang, J; Yin, X; Yin, Y; Zhang, B; Zhou, Y | 1 |
| Hayata, K; Katsuda, M; Maruoka, S; Nakamori, M; Nakamura, M; Ojima, T; Shimokawa, T; Yamaue, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
| Boku, N; Fujitani, K; Fukushima, N; Nishida, Y; Okumura, N; Takeno, A; Takiguchi, N; Tanahashi, T; Terashima, M; Yamaguchi, K; Yoshida, K; Yoshikawa, T | 1 |
| Fujimoto, Y; Hirakawa, A; Hiramatsu, M; Itoh, Y; Kawamura, M; Kimura, K; Kozai, Y; Kubota, S; Mizutani, T; Naganawa, S; Nakahara, R; Nishio, N; Oie, Y; Okada, T; Takase, Y; Tsuzuki, H | 1 |
| Hirakawa, K; Kubo, N; Miki, Y; Muguruma, K; Ohira, M; Sakurai, K; Tamura, T; Tanaka, H; Toyokawa, T | 1 |
| Feng, JF; Wang, XH; Zhao, D | 1 |
| Li, H; Liu, JM; Ma, L; Zhang, J | 1 |
| Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
| Beppu, T; Fujii, M; Hanamure, Y; Hasegawa, Y; Higaki, Y; Iwae, S; Kawabata, K; Kohno, N; Kubota, A; Nagahara, K; Nakatani, E; Nakatani, H; Taguchi, T; Takemura, H; Terada, T; Teramukai, S; Tomita, K; Tsukahara, K; Yoshino, K | 1 |
| Akune, Y; Shigeyasu, C; Yamada, M | 1 |
| Huang, C; Huang, Y; Huang, Z; Wu, B; Xu, Z; Yin, Y; Zhang, J; Zhuang, W | 1 |
| Amagai, K; Azuma, M; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Kageyama, H; Mitome, T; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamaguchi, K; Yasui, H | 1 |
| Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y | 1 |
| Li, L; Pan, C; Wang, Y; Wei, J; Yao, T; Zhang, N | 1 |
| Hara, R; Hashimoto, Y; Ikeda, M; Kobayashi, S; Kondo, S; Mitsunaga, S; Morizane, C; Nakamura, O; Ohno, I; Okusaka, T; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H | 1 |
| Deguchi, T; Hanaki, T; Ichikawa, T; Kobayashi, D; Masubuchi, M; Shibata, A; Takase, T; Yaguchi, T | 1 |
| Kawai, K; Kiriyama, M; Kobayashi, S; Kurumiya, Y; Sekoguchi, E; Tominaga, K | 1 |
| Nishibuchi, I; Wadasaki, K | 1 |
| Saito, K; Sato, A; Takahata, T; Yu, C | 1 |
| Kou, K; Maruyama, T; Morishita, Y; Nishida, K; Shimazaki, J; Shimoda, M; Suzuki, K; Suzuki, S; Tago, T | 1 |
| Doi, T; Okino, T; Sakamoto, T | 1 |
| Aoki, D; Aoki, Y; Cha, SD; Chang, TC; Chung, HH; Fujiwara, K; Hirashima, Y; Kamiura, S; Kamura, T; Kang, SB; Katsumata, N; Kim, BG; Kim, JH; Kim, SM; Kim, YT; Lim, S; Lin, H; Ochiai, K; Takeuchi, M; Takizawa, K | 1 |
| Hamada, S; Hongo, S; Kanno, A; Kikuta, K; Kume, K; Masamune, A; Miura, S; Nabeshima, T; Shimosegawa, T; Takikawa, T; Ueno, M; Yoshida, N | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Harada, H; Ichinose, Y; Kataoka, M; Kitajima, H; Kodaira, T; Kozuka, T; Kunitake, N; Nakagawa, K; Nakanishi, Y; Nishimura, Y; Nishio, M; Sasaki, T; Seto, T; Shimizu, J; Takahashi, T; Tsutsumi, S; Yamamoto, N; Yamanaka, T; Yoshimura, N | 1 |
| Babazono, A; Fujita, T; Harano, Y; Jiang, P | 1 |
| Ichikawa, D; Inoue, S; Kimura, A; Matsuda, K; Mimura, K; Nakayama, Y; Nakazawa, T; Ohmori, M | 1 |
| Ryo, H; Sato, T; Shirai, Y; Yamashita, Y; Yoshida, K | 1 |
| Akahoshi, K; Ban, D; Kuboki, R; Kudo, A; Mitsunori, Y; Oba, A; Ono, H; Tanabe, M; Tanaka, S | 1 |
| Fujii, M; Matsuura, D; Morikawa, H; Ochiai, T; Onoe, A; Terui, T | 1 |
| Emi, Y; Fukuyama, Y; Hamatake, M; Kometani, T; Maehara, Y; Motohiro, A; Nagashima, A; Okamoto, T; Osoegawa, A; Saito, G; Shimokawa, M; Shoji, F; Sugio, K; Tagawa, T; Takenoyama, M; Takeo, S; Toyokawa, G; Tsukamoto, S; Ueda, H; Yamazaki, K; Yano, T; Yokoyama, H | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Feng, Q; Li, SL; Zhang, AX; Zhao, JR | 1 |
| Gou, H; Yi, C; Zhao, Y; Zhu, H | 1 |
| Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y | 1 |
| Achiwa, K; Ando, M; Hashimoto, S; Hattori, M; Hirai, T; Hiramatsu, T; Hirooka, Y; Ishikawa, T; Kanamori, A; Kawashima, H; Kuroiwa, M; Maruta, S; Matsubara, H; Nonogaki, K; Ohno, E; Sasaki, Y; Sumi, H; Tsuzuki, T | 1 |
| Aomatsu, N; Hirakawa, T; Iwauchi, T; Kurihara, S; Miyamoto, H; Morimoto, J; Nakazawa, K; Nobori, C; Okada, T; Takeuchi, K; Uchima, Y; Wang, E; Yamagata, S | 1 |
| Amano, S; Aoyama, T; Maezawa, Y; Masuda, M; Morita, J; Numata, M; Oshima, T; Ozawa, Y; Rino, Y; Sato, T; Sawazaki, S; Yukawa, N | 1 |
| Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N | 1 |
| Atagi, S; Azuma, M; Goto, H; Haku, T; Hanibuchi, M; Kakiuchi, S; Kawano, H; Kondo, M; Nishioka, Y; Nokihara, H; Ogushi, F; Otsuka, K; Sakaguchi, S; Shimizu, E; Toyoda, Y | 1 |
| Chiba, Y; Imano, M; Iwama, M; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Fujikawa, K; Hamaguchi, K; Okagawa, Y; Sagawa, T; Sakurada, A; Takahashi, Y; Tamura, F; Uemura, N | 1 |
| Abe, T; Higaki, E; Ito, S; Ito, Y; Kinoshita, T; Komori, K; Misawa, K; Natsume, S; Oshiro, T; Senda, Y; Shigeyoshi, I; Shimizu, Y; Uemura, N | 1 |
| Bando, H; Chin, K; Cho, H; Emi, Y; Fukunaga, T; Gotoh, M; Hirao, M; Ishibashi, T; Katai, H; Kawashima, Y; Misawa, K; Nakamura, Y; Oki, E; Sasako, M; Shitara, K; Terashima, M; Yamanaka, T; Yoshida, K | 1 |
| Feng, Y; Liu, Y; Zhang, K; Zhang, R; Zhou, C | 1 |
| Cui, S; Sun, Y; Ye, M; You, D; Zhao, Q | 1 |
| Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
| Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, J; Song, Y; Wang, S; Wang, X; Xia, X; Yi, X; Zhao, L; Zhou, L; Zhou, X | 1 |
| Guo, X; Li, Y; Sui, Y; Tan, X; Wang, M; Yang, H | 1 |
| Chai, C; Chao, P; Li, D; Wang, B; Wang, X; Yang, L | 1 |
| Li, Y; Qie, S; Shi, HY; Yuan, L; Zhang, X | 1 |
| Hayashi, H; Koda, K; Kosugi, C; Matsubara, H; Mori, M; Narushima, K; Shuto, K | 1 |
| Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Furuse, J; Honda, G; Kosuge, T; Matsumoto, I; Matsuyama, Y; Motoi, F; Satoi, S; Sho, M; Ueno, H; Unno, M; Wada, K; Yamaue, H | 1 |
| Liu, L; Liu, P; Lou, P; Lv, T; Ou, D; Qin, S; Wang, X; Wang, Y | 1 |
| Bian, NN; Min, GT; Wang, YH | 1 |
| Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Wu, J; Yang, Y; Yi, C | 1 |
| Aiba, S; Fujimura, T; Haga, T | 1 |
| Fukuoka, J; Matsumoto, K; Miyazaki, T; Nagayasu, T; Nakamura, Y; Sano, I; Tsuchiya, T; Yamaguchi, H; Yamasaki, N; Yamazaki, T | 1 |
| Boku, N; Choda, Y; Fukuda, H; Fukushima, N; Hato, S; Ito, S; Kaji, M; Katayama, H; Kawachi, Y; Mizusawa, J; Nishida, Y; Nunobe, S; Sano, T; Sasako, M; Takeno, A; Terashima, M; Yabusaki, H; Yamada, T; Yasuda, T; Yoshida, K; Yoshikawa, T | 1 |
| Kamata, T; Kanno, M; Kono, T; Nakayama, A; Sato, N; Takai, Y | 1 |
| Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T | 1 |
| Akabane, S; Hadano, N; Hinoi, T; Ishiyama, K; Kojima, M; Kubota, H; Misumi, T; Onoe, T; Shimizu, W; Shimizu, Y; Sudo, T; Suzuki, T; Tashiro, H; Tazawa, H | 1 |
| Adachi, S; Hayashida, H; Higaki, N; Kawanaka, S; Nezu, R; Oka, Y; Okada, K; Taniguchi, S; Ueshima, S; Yoshioka, S | 1 |
| Cho, H; Okamoto, S | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Sawano, T; Suto, A; Tsuruta, S; Wakasa, Y | 1 |
| Fujimura, T; Hagino, S; Izumi, R; Kitagawa, H; Kurata, T; Saito, K; Sasaki, S; Shoji, Y; Terada, I; Yoshikawa, A | 1 |
| Arita, T; Fujiwara, H; Ikoma, H; Kobayashi, T; Konishi, H; Kosuga, T; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Okamoto, K; Otsuji, E; Shiozaki, A; Shoda, K | 1 |
| Fujiwara, A; Hama, N; Hamakawa, T; Hirao, M; Kato, S; Kato, T; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takami, K; Uemura, M | 1 |
| Ajioka, Y; Alexey, A; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A | 1 |
| Endo, S; Gamoh, M; Kawabata, R; Kawada, J; Kimura, Y; Kobayashi, K; Kurokawa, Y; Masuzawa, T; Matsuyama, J; Sakai, D; Satoh, T; Shimokawa, T; Takeno, A; Taniguchi, H; Yamamoto, K | 1 |
| Hirashima, T; Kijima, T; Koba, T; Komuta, K; Minami, S; Mori, M; Morimura, O; Niki, M; Shiroyama, T; Sugimoto, H; Torii, Y; Yokoi, T | 1 |
| Asada, T; Fujiwara, M; Iizuka, A; Ishigure, K; Ishiyama, A; Ito, S; Kanda, M; Kobayashi, D; Kodera, Y; Matsushita, H; Mochizuki, Y; Murai, T; Murotani, K; Tanaka, C; Teramoto, H | 1 |
| Chen, L; Cong, X; Hao, Y; Li, S; Song, H; Xue, Y; Zhu, L; Zou, M | 1 |
| Kawai, S; Nagase, M; Ono, K; Takehana, T; Yamamoto, K | 1 |
| Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I | 1 |
| Aoyama, K; Hayashi, D; Kajiwara, Y; Mikane, Y; Miyake, T; Nishikawa, H; Nogami, T; Nonaka, Y; Shigemitsu, K; Shinoura, S; Syoji, R; Watanabe, M | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Noma, T; Takahashi, T; Tanaka, K; Yamasaki, M | 1 |
| Akamatsu, H; Furukawa, K; Kishi, K; Mikamori, M; Ohtsuka, M; Saito, T; Suzuki, Y; Tamaoka, K; Tanemura, M; Tei, M | 1 |
| Honda, M; Ishibashi, K; Kataoka, M; Kato, T; Kobayashi, K; Matsuda, C; Mishima, H; Morita, Y; Munemoto, Y; Nakata, K; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Tanaka, C; Tanioka, H | 1 |
| Creemers, GM; Hendriks, MP; Koopman, M; Kwakman, JJM; Los, M; Mol, L; Muller, EW; Polée, MB; Punt, CJA; Simkens, LHJ; Tije, AJT; van Alphen, RJ; van de Wouw, YAJ; van der Velden, AMT; van Rooijen, JM; van Voorthuizen, T; van Werkhoven, E | 1 |
| Akiyama, N; Asada, K; Enomoto, N; Fujii, M; Fujisawa, T; Furuhashi, K; Hozumi, H; Inami, N; Inui, N; Kaida, Y; Karayama, M; Matsuda, H; Matsui, T; Matsuura, S; Nakamura, Y; Suda, T; Suzuki, Y; Toyoshima, M; Uto, T; Yasui, H | 1 |
| Chang, J; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, H | 1 |
| Venerito, M | 1 |
| Boku, N; Hirao, M; Ito, Y; Iwasaki, Y; Kaji, M; Katai, H; Katayama, H; Kimura, Y; Kurita, A; Mizusawa, J; Nakamura, K; Sano, T; Sasako, M; Takagi, M; Terashima, M; Yamada, M; Yoshikawa, T | 1 |
| Gemma, A; Goto, K; Ichinose, Y; Imamura, F; Inoue, A; Kiura, K; Maemondo, M; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Ohe, Y; Okamoto, I; Saka, H; Sakai, H; Seto, T; Shingyoji, M; Sugawara, S; Takahashi, T; Takeda, K; Tamura, T; Yamamoto, N | 1 |
| Chin, K; Hiki, N; Ida, S; Kano, Y; Kumagai, K; Nagino, M; Nunobe, S; Ohashi, M; Sano, T; Takahashi, R; Yamaguchi, K | 1 |
| Boku, N; Iwatani, T; Kanemaki, Y; Kawamoto, H; Kojima, Y; Motoyoshi, A; Shimo, A; Tsugawa, K; Uejima, T; Yoshie, R | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Matsumoto, Y; Murakami, S; Ohe, Y; Sekine, K; Tamura, N; Yamamoto, N | 1 |
| Hata, M; Hoshino, H; Imamoto, H; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Ogino, T; Okano, M; Okuyama, M; Tanizaki, K; Tsujinaka, T | 1 |
| Masai, Y; Shimizu, H; Suwa, H; Taji, T; Yamaguchi, A | 1 |
| Akimoto, T; Goto, K; Hida, T; Hosomi, Y; Nihei, K; Niho, S; Ohe, Y; Okamoto, H; Tanaka, H; Umemura, S | 1 |
| Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X | 1 |
| Fujii, M; Ichikawa, W; Ito, S; Kaji, M; Kakeji, Y; Kochi, M; Kodera, Y; Matsui, T; Matsuyama, J; Nagao, N; Nomura, T; Okitsu, H; Sano, T; Takagane, A; Takahashi, M; Takeuchi, M; Watanabe, T; Yamada, M; Yoshida, K; Yoshikawa, T | 1 |
| Hosokawa, H; Ishii, T; Shimoda, H | 1 |
| Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S | 1 |
| Han, L; Jiang, AY; Lv, YF; Wei, ZX | 1 |
| Bao, TT; Cao, Y; Chen, D; Chen, W; Hoffman, RM; Jian, T; Li, WB; Liu, HX; Liu, JB; Yang, Z; Yu, C; Yue, C | 1 |
| Fukumitsu, K; Ishii, T; Kaido, T; Morino, K; Nishino, H; Okajima, H; Seo, S; Taura, K; Uemoto, S; Yamanaka, K; Yoh, T | 1 |
| Akahoshi, S; Beppu, T; Kinoshita, K; Kitaoka, M; Nasu, J; Saito, S; Sato, N; Yoshida, Y; Yuki, H | 1 |
| Asada, T; Fujiwara, M; Ishigure, K; Ishiyama, A; Ito, S; Kanda, M; Kobayashi, D; Kodera, Y; Matsushita, H; Mochizuki, Y; Murai, T; Murotani, K; Nakanishi, K; Tanaka, C; Teramoto, H | 1 |
| Han, X; Huang, G; Li, W; Meng, M; Ni, Y; Wang, J; Wei, Z; Yang, X; Ye, X | 1 |
| Milano, G | 1 |
| Gunji, H; Hanari, N; Hayano, K; Hayashi, H; Kano, M; Matsubara, H; Murakami, K; Ota, S; Toyozumi, T; Uesato, M | 1 |
| Chang, PH; Chen, JS; Chen, PT; Chen, YY; Chou, WC; Hsu, HC; Hung, CY; Hung, YS; Kuo, YC; Lai, HL; Lu, CH | 1 |
| Fukutomi, A; Kasai, J; Kashiwagi, H; Kawahira, M; Kawakami, T; Machida, N; Mori, K; Omae, K; Tsushima, T; Yamaguchi, K; Yasui, H; Yoshisue, K | 1 |
| Adachi, T; Akahori, T; Asahara, S; Endo, I; Fujii, T; Furukawa, M; Hakamada, K; Hara, K; Ioka, T; Katanuma, A; Katsuda, M; Kitano, M; Miyazawa, M; Nagano, H; Ohira, M; Ojima, T; Satoi, S; Sudo, K; Ueno, M; Yamada, S; Yamaue, H | 1 |
| Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z | 1 |
| Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H | 1 |
| Aono, H; Fujimoto, S; Gemma, A; Hosomi, Y; Isobe, H; Kubota, K; Minato, K; Miyanaga, A; Okamoto, H; Okuma, Y; Satouchi, M; Takiguchi, Y | 1 |
| Amagai, K; Bando, Y; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Maeba, T; Morimoto, M; Moriwaki, T; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y | 1 |
| Jiang, H; Mao, C; Qian, J; Song, F; Wang, Q; Xiao, C; Xu, N; Zheng, Y | 1 |
| Amagai, K; Boku, N; Chin, K; Goto, M; Hironaka, S; Ishizuka, N; Kadowaki, S; Machida, N; Minashi, K; Nakajima, TE; Nishina, T; Shoji, H; Takahari, D; Takashima, A; Taku, K; Wakatsuki, T; Yamaguchi, K | 1 |
| Chishima, T; Doihara, H; Hozumi, Y; Ishikawa, T; Miyoshi, Y; Morimoto, T; Mukai, H; Narui, K; Nishimura, R; Ohashi, Y; Ohno, S; Suto, A; Tamura, M; Uemura, Y; Yoshino, H; Zaha, H | 1 |
| Komune, N; Matsuo, M; Nakagawa, T; Taura, M; Uchi, R; Wakasaki, T; Yasumatsu, R | 1 |
| Chin, K; Hara, H; Hasegawa, H; Hirao, M; Kadowaki, S; Mitani, S; Muro, K; Nishikawa, K; Tajika, M; Takahari, D; Wakatsuki, T | 1 |
| Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H | 1 |
| Egawa, H; Fukunaga, T; Ishibashi, Y; Kaji, S; Kajiyama, Y; Kanda, S; Kohira, Y; Oka, S; Sakamoto, K; Yube, Y | 1 |
| Fujii, M; Kano, H; Kawai, T; Kochi, M; Masuda, S; Matsuno, Y; Nishimaki, H; Shimizu, H; Sugitani, M; Takayama, T; Tamegai, H; Watabe, M | 1 |
| Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T | 1 |
| Cai, H; Du, C; Fang, Y; Huang, D; Huang, H; Jin, J; Li, G; Liu, X; Long, Z; Lu, Q; Ma, M; Sheng, W; Wang, Y; Wu, J; Xie, L; Yin, J; Zhang, Z; Zhao, G; Zhou, M; Zhou, Y; Zhu, H; Zhu, J; Zhu, X | 1 |
| Xu, X; Zhang, T; Zhao, Y; Zheng, G; Zheng, Z | 1 |
| Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
| Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A | 1 |
| Fukushima, N; Imamura, H; Katai, H; Katayama, H; Mizusawa, J; Nakamura, K; Nashimoto, A; Sano, T; Sasako, M; Tsuburaya, A | 1 |
| Ariake, K; Hata, T; Hayashi, H; Kamei, T; Mitachi, K; Mizuma, M; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Unno, M | 1 |
| Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H | 1 |
| Amino, K; Imai, T; Iwai, S; Kanesaki, T; Katou, I; Matsumiya, Y; Meshii, N; Nakazawa, M; Niki, A; Omae, M; Onishi, T; Ota, Y; Suematsu, M; Sumi, T; Takeshita, A; Ueda, M | 1 |
| Goya, T; Hanaka, J; Kobayashi, A; Takahashi, S | 1 |
| Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K | 1 |
| Koshi, H; Oyama, T; Sano, T; Seki-Soda, M; Yokoo, S | 1 |
| Chen, J; Wang, J; Xu, T | 1 |
| Endo, I; Hata, M; Homma, Y; Ito, E; Kaizu, H; Koike, I; Kumamoto, T; Matsuyama, R; Mukai, Y; Sato, M; Sawada, Y; Sugiura, M; Takano, S; Yabushita, Y | 1 |
| Chang, CF; Chang, PH; Chen, JS; Chen, YY; Chou, WC; Hsueh, SW; Huang, PW; Hung, CY; Hung, YS; Lu, CH; Yeh, KY | 1 |
| Lu, Y; Sun, Y; Wang, Z; Zheng, S; Zhou, Y | 1 |
| Higashiyama, M; Inoue, M; Kusumoto, H; Okami, J; Ose, N; Sakamaki, Y; Shintani, Y; Shiono, H; Takeuchi, Y | 1 |
| Mini, E; Nobili, S; Roviello, G | 1 |
| Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y | 1 |
| Hiki, N; Hosoda, K; Ishii, S; Katoh, H; Soeno, T; Ushiku, H; Watanabe, M; Yamashita, K | 1 |
| Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H | 1 |
| Ikushima, H; Okuda, J; Tamura, K; Terashima, H; Tsukui, H; Yamasawa, K | 1 |
| Gemma, A; Hirose, T; Kobayashi, Y; Murata, Y; Shimizu, M; Taniuchi, N | 1 |
| Aizawa, M; Boku, N; Fukagawa, T; Hata, H; Higuchi, K; Hihara, J; Katai, H; Kawabata, R; Kawachi, Y; Kinoshita, T; Makuuchi, R; Nagashima, K; Ohashi, M; Sakamoto, T; Takashima, A; Tashiro, K; Tsuji, T; Yamada, T; Yamaguchi, T | 1 |
| Asada, T; Fujiwara, M; Ishigure, K; Ishiyama, A; Ito, S; Kanda, M; Kobayashi, D; Kodera, Y; Matsushita, H; Mochizuki, Y; Murai, T; Murotani, K; Tanaka, C; Teramoto, H; Tsutsuyama, M | 1 |
| Cho, K; Cho, S; Gwon, MR; Kang, WY; Kim, BK; Kim, JG; Lee, HW; Ohk, B; Seong, SJ; Sung, YK; Yoon, YR | 1 |
| Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S | 1 |
| Fushida, S; Gabata, R; Harmon, JW; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Shimbashi, H; Tajima, H; Takamura, H | 1 |
| Akamatsu, Y; Fukushima, S; Ihn, H; Kajihara, I; Kimura, T | 1 |
| Hata, T; Ito, S; Ito, Y; Kaneda, N; Kuriki, R; Misawa, K; Nakayama, K; Tatematsu, M | 1 |
| Gou, H; Huang, J; Li, Q; Liao, W; Wang, X; Wen, F; Wu, Q; Zhang, P; Zhou, J; Zhou, K; Zhu, G | 1 |
| Aburatani, T; Kinugasa, Y; Matsuyama, T; Nakagawa, M; Nakajima, Y; Sato, Y; Tokunaga, M | 1 |
| Chen, BB; Chen, HW; Kuo, HY; Kuo, SH; Tien, YW; Yang, SH | 1 |
| Ando, F; Kawano, Y; Matsuda, A; Matsumoto, S; Miyashita, M; Sakurazawa, N; Suzuki, H; Yamahatsu, K; Yoshida, H | 1 |
| Fujimoto, H; Fuse, A; Isobe, H; Ito, S; Kawaguchi, K; Ota, K; Urayama, M | 1 |
| Chen, B; Chen, C; Guo, Q; Lin, S; Pan, J; Weng, Y; Xu, H; Xu, Y; Zheng, W; Zong, J | 1 |
| Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J | 1 |
| Chu, Z; Diao, F; Lai, W | 1 |
| Akimoto, T; Fujii, M; Hanai, N; Hayashi, R; Imamura, Y; Iwae, S; Kiyota, N; Matsuura, K; Monden, N; Ogawa, G; Onozawa, Y; Tahara, M | 1 |
| Akazawa, Y; Ikoma, R; Kobayashi, S; Komatsu, M; Kubota, A; Miyamoto, S; Okami, K; Oridate, N; Sano, D; Suzuki, K; Tanabe, T; Tanigaki, Y; Yamada, Y | 1 |
| Bando, Y; Fujino, Y; Hirata, M; Kida, Y; Kitamura, S; Mitsui, Y; Miyamoto, H; Muguruma, N; Nakagawa, T; Okamoto, K; Sato, Y; Takayama, T; Tanahashi, T | 1 |
| Cao, T; Han, X; Li, G; Li, H; Liu, H; Wang, C; Yan, L | 1 |
| Bando, H; Demachi, K; Kawasaki, T; Nomura, H; Shitara, K; Yamaguchi, M; Yoshino, T | 1 |
| Aisu, N; Hasegawa, S; Kojima, D; Komono, A; Sakamoto, R; Yoshida, Y | 1 |
| Akashi, K; Ariyama, H; Baba, E; Isobe, T; Ito, M; Komoda, M; Kusaba, H; Kuwayama, M; Momosaki, S; Nakano, M; Oda, Y; Ohmura, H; Okada, C; Okumura, Y; Tanishima, S; Tsuchihashi, K; Uchino, K; Yamada, Y; Yamaguchi, K | 1 |
| Hamasu, S; Ikeda, Y; Konishi, S; Kudo, R; Manaka, D; Nishitai, R; Ota, T | 1 |
| Fujii, M; Harada, D; Harada, T; Hino, T; Ichinose, M; Inoue, A; Kuyama, S; Mori, Y; Nakagawa, T; Sugawara, S; Tanaka, H; Tsukita, Y; Watanabe, K | 1 |
| Aoyama, T; Cho, H; Hara, K; Hashimoto, I; Hiroshima, Y; Ito, H; Kano, K; Kimura, Y; Maezawa, Y; Masuda, M; Miyagi, Y; Morinaga, S; Ogata, T; Oshima, T; Oue, N; Rino, Y; Sakamaki, K; Shiozawa, M; Yamada, T; Yamamoto, N; Yasui, W; Yoshikawa, T | 1 |
| Chang, GC; Chen, JY; Chen, YM; Hsia, TC; Lai, CL; Wei, YF; Wu, JT | 1 |
| Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Kainuma, O; Kaneoka, Y; Konishi, M; Mori, K; Morinaga, S; Nagino, M; Nakamori, S; Narimatsu, H; Okamura, Y; Sata, N; Shimizu, Y; Takahashi, A; Toyama, H; Uesaka, K; Yamaguchi, R; Yamakita, K; Yanagisawa, A; Yasukawa, S | 1 |
| Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K | 1 |
| Aoyama, T; Cho, H; Fujikawa, H; Hara, K; Hashimoto, I; Hiroshima, Y; Ito, H; Kano, K; Kimura, Y; Maezawa, Y; Masuda, M; Miyagi, Y; Morinaga, S; Ogata, T; Oneyama, M; Oshima, T; Oue, N; Rino, Y; Sakamoto, N; Shiozawa, M; Tamagawa, H; Yamada, T; Yamamoto, N; Yasui, W; Yoshikawa, T; Yukawa, N | 1 |
| Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
| Akahoshi, K; Ban, D; Kudo, A; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S | 1 |
| Jung, YJ; Kim, IH; Lee, HH; Lee, J; Lee, SH; Park, CH; Park, JM; Park, SJ; Roh, SY; Seo, HS; Shin, K; Song, KY | 1 |
| Du, X; Geng, L; Wen, Y; Xiang, M; Yang, X | 1 |
| Liu, D; Yu, GM; Zhang, C; Zhang, M | 1 |
| Boku, N; Doki, Y; Katayama, H; Kurokawa, Y; Mizusawa, J; Sato, Y; Tanaka, K; Terashima, M; Yoshikawa, T | 1 |
| Liu, D; Wang, X; Yang, DP; Zhang, C; Zhang, M | 1 |
| Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M | 1 |
| Ashizawa, K; Fukuda, M; Fukuoka, J; Funaki, S; Hara, M; Mukae, H; Nabeshima, K; Okumura, M; Sato, S; Seto, T; Sugio, K; Takenoyama, M; Tateyama, H; Yamazaki, T | 1 |
| Abe, A; Aoki, T; Ishizuka, M; Iso, Y; Kubota, K; Mori, S; Sakuraoka, Y; Shimizu, T; Shiraki, T; Takagi, K | 1 |
| Gemma, A; Hosomi, Y; Imai, H; Kaburagi, T; Kasai, T; Kishi, K; Minato, K; Mori, K; Moriguchi, S; Seike, M; Yamada, Y; Yomota, M | 1 |
| Akazawa, Y; Chiba, Y; Ebi, N; Fujimoto, D; Hataji, O; Hayashi, H; Kato, R; Kozuki, T; Miyawaki, E; Nakagawa, K; Nakamura, A; Nishino, K; Okuno, M; Ota, K; Ozaki, T; Saeki, S; Shimizu, J; Tanaka, K; Teraoka, S; Toyozawa, R; Usui, K; Yamamoto, N | 1 |
| Cui, C; Jiang, Z; Sun, Y; Yang, L; Zhang, W; Zhou, A | 1 |
| Arita, T; Fujiwara, H; Imamura, T; Kishimoto, T; Kiuchi, J; Komatsu, S; Konishi, H; Kosuga, T; Kubota, T; Nishibeppu, K; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Aoyama, T; Cho, H; Fujikawa, H; Hara, K; Hayashi, T; Ito, H; Kano, K; Komori, K; Maezawa, Y; Masuda, M; Morinaga, S; Ogata, T; Oshima, T; Rino, Y; Shimoda, Y; Shiozawa, M; Watanabe, H; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Amagai, K; Azuma, M; Baba, H; Esaki, T; Han, SR; Hara, H; Hosaka, H; Kawakami, H; Kawazoe, A; Komatsu, Y; Machida, N; Negoro, Y; Nishina, T; Omuro, Y; Oshima, T; Shiratori, S; Shitara, K; Tsuda, M; Yamaguchi, K; Yasui, H; Yoshida, K | 1 |
| Gunji, H; Hoshino, I; Ikeda, A; Kawahara, K; Nabeya, Y; Soda, H; Takiguchi, N; Tonooka, T | 1 |
| Ando, S; Kamei, R; Kitamura, Y; Nabeya, M; Sakamoto, K; Tokuhisa, A; Yamamoto, T | 1 |
| Chihara, Y; Fukunaga, H; Hiraki, M; Kimura, H; Morita, S; Murakami, M; Sawada, G; Sawami, H; Urahigashi, A; Yamamoto, M | 1 |
| Akamaru, Y; Hokkoku, D; Ikeshima, R; Morimoto, O; Munakata, K; Ohash, H; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R | 1 |
| Akagi, K; Ando, K; Dono, K; Hirota, M; Imamura, H; Iwazawa, T; Kawase, T; Nagase, H; Noguchi, K; Noura, S; Ogino, T; Oshima, K; Tanida, T; Tomimaru, Y | 1 |
| Hasegawa, T; Hirakawa, K; Kinoshita, H; Mori, T; Nakamoto, K; Noda, E; Ohira, M; Teraoka, H | 1 |
| Deguchi, S; Hirakawa, K; Hori, T; Ishikawa, T; Masuda, G; Nakata, B; Sakimura, C; Tani, N; Tendo, M | 1 |
| Ishida, T; Kajiwara, T; Kamei, T; Karasawa, H; Kohyama, A; Naitoh, T; Ohnuma, S; Sato, K; Suzuki, H; Unno, M; Watanabe, K | 1 |
| Hamano, S; Hayashi, Y; Imafuji, H; Matsuo, Y; Morimoto, M; Oba, A; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Hiramatsu, S; Kashu, N; Kataoka, N; Makimoto, S; Shono, Y; Takami, T; Tomita, M; Yamaguchi, T; Yasuda, K; Yoshitake, H | 1 |
| Chino, S; Chuman, M; Ema, A; Hiki, N; Kondo, Y; Kubo, H; Naito, M; Nakamura, K; Nishi, Y; Takahashi, Y; Tokito, T; Ushiku, H | 1 |
| Kawaoka, T; Kubo, H; Miyahara, M; Nabeya, M; Nishida, Y; Saeki, S; Sasaki, S; Tamesa, T; Tokunou, K; Yamamoto, S; Yamashita, Y | 1 |
| Aomatsu, N; Hirakawa, T; Iwauchi, T; Kurihara, S; Miyamoto, H; Morimoto, J; Nakazawa, K; Okada, T; Takeuchi, K; Tsujio, G; Uchima, Y; Yamagata, S | 1 |
| Arai, S; Goseki, N; Koike, M; Kuwabara, H; Nakamura, N; Sanada, T; Sato, T; Tomi, Y; Yoshida, T | 1 |
| Ando, M; Ebata, T; Hiramatsu, K; Kurumiya, Y; Maeda, A; Mizuno, T; Nagino, M; Sakamoto, E; Seita, K; Yamaguchi, R | 1 |
| Bando, E; Fujiya, K; Furukawa, K; Hatakeyama, K; Hikage, M; Kamiya, S; Machida, N; Nakamura, K; Ohshima, K; Tanizawa, Y; Terashima, M; Urakami, K; Yamaguchi, K; Yasui, H | 1 |
| Akagi, Y; Ando, K; Baba, H; Emi, Y; Imamura, H; Kakeji, Y; Maehara, Y; Miyanari, N; Mori, M; Mori, S; Oki, E; Saeki, H; Sakai, K; Sawai, T; Tokunaga, S; Tsuji, A | 1 |
| Aida, T; Baba, T; Saito, T; Sasou, S; Shoji, T; Takeshita, R | 1 |
| Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N | 1 |
| Ebata, T; Mizuno, T | 1 |
| Cao, L; Li, S; Liu, J; Wang, C | 1 |
| Chin, K; Hiki, N; Ida, S; Kano, Y; Kumagai, K; Nunobe, S; Ohashi, M; Sano, T; Takahari, D; Yamaguchi, K | 1 |
| Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Arita, H; Hiraki, A; Hirayama, M; Hirosue, A; Kawahara, K; Kikuchi, K; Matsuoka, Y; Nagata, M; Nakamoto, M; Nakashima, H; Nakayama, H; Sakata, J; Shinohara, M; Takahashi, N; Yoshida, R | 1 |
| Ishioka, Y; Itoga, M; Kimura, D; Morimoto, T; Okumura, F; Shiratori, T; Tabe, C; Taima, K; Tanaka, H; Tasaka, S; Tsushima, T | 1 |
| Chen, C; Dai, N; Feng, Y; He, S; Li, C; Li, M; Shan, J; Wang, D; Wang, G; Xiao, H; Yang, B | 1 |
| Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M | 1 |
| Igai, H; Kamiyoshihara, M; Matsuura, N; Ohsawa, F; Yazawa, T; Yoshikawa, R | 1 |
| Akiyama, T; Fujiwara, Y; Higashida, M; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Okamoto, Y; Tsuruta, A; Ueno, M; Ueno, T; Watanabe, Y | 1 |
| Akamaru, Y; Hokkoku, D; Ikeshima, R; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R | 1 |
| Goto, A; Hanatate, F; Kimura, M; Matsumoto, K; Matsunami, H; Sekino, T; Tajirika, T; Tochii, K | 1 |
| Hong, XC; Hu, KH; Liang, QL; Luo, XB; Ou, WT; Yang, HX; Zhang, HJ | 1 |
| Feng, J; Feng, Z; He, X; Hou, X; Yan, P; Yang, K | 1 |
| Kanamori, M; Kobayashi, T; Maruyama, S; Matsuba, H; Mizuno, S; Tamauchi, T | 1 |
| Huang, H; Jin, H; Lou, Q; Shah, RJ; Wang, J; Wang, Y; Yang, J; Zhang, X; Zhou, H | 1 |
| Nakamura, T; Sakamoto, K; Takada, Y; Tamura, K; Tohyama, T; Wakisaka, H; Watanabe, J | 1 |
| Chan, LF; Kamei, Y; Miyakita, H; Ogimi, T; Okada, K; Sadahiro, S; Saito, G; Suzuki, T | 1 |
| Ando, M; Bessho, A; Daga, H; Hirano, K; Ishiguro, T; Iwamoto, Y; Ko, R; Miura, S; Morita, S; Nakagawa, K; Nakamura, A; Nakanishi, Y; Oguri, T; Okamoto, I; Tachihara, M; Tanaka, K; Toyozawa, R; Yamamoto, N; Yokoyama, T; Yoshioka, H | 1 |
| Ando, M; Kadowaki, S; Komori, A; Masuishi, T; Mitani, S; Muro, K; Narita, Y; Taniguchi, H; Ura, T | 1 |
| Ji, G; Meng, L; Wang, J; Wu, DX | 1 |
| Akashi, Y; Enomoto, T; Hisakura, K; Honda, M; Hori, S; Inagawa, S; Kaneda, A; Oda, T; Ogawa, K; Ohara, Y; Owada, Y; Shimomura, O; Takahashi, K | 1 |
| Chen, X; Ding, H; Ding, J; Luo, D; Wang, L; Wei, Y; Xiong, Y; Yi, F; Zhang, W | 1 |
| Mukai, H; Murata, T; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Suzukamo, Y; Taira, N | 1 |
| Fukuda, K; Funakoshi, T; Fusumae, T; Hirai, I; Kawakami, Y; Nakamura, Y; Tanese, K; Yaguchi, T | 1 |
| Akhoundova Sanoyan, D; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S | 1 |
| Fan, L; Guo, H; Huo, Z; Li, M; Li, Y; Lian, C; Liu, Y; Tan, B; Tian, Y; Wang, D; Yang, P; Zhang, Z; Zhao, Q; Zhao, X | 1 |
| Akashi, M; Demizu, Y; Matsuo, Y; Okimoto, T; Park, SC; Sulaiman, NS; Takahashi, D; Terashima, K; Tokumaru, S | 1 |
| Iede, K; Ikenaga, M; Kato, R; Matsuyama, J; Nakashima, S; Ohta, K; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 1 |
| Fukutani, M; Hirano, N; Ikeno, T; Kambe, M; Kawazoe, A; Keisho, C; Nakamura, Y; Nomura, S; Saito, Y; Sato, A; Shitara, K; Takahari, D; Tamura, H; Wakabayashi, M | 1 |
| Abe, Y; Aiura, K; Ei, S; Fujisaki, H; Hayatsu, S; Hori, S; Ikeda, K; Ishii, M; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Matsui, J; Minagawa, T; Oshima, G; Sakuragawa, T; Shinoda, M; Shinozaki, H; Shito, M; Suzuki, K; Takano, K; Takemura, Y; Tamagawa, E; Urakami, H; Yagi, H | 1 |
| Anan, K; Furusawa, H; Kai, Y; Kamada, Y; Mitsuyama, S; Miyara, K; Sagara, Y; Tamura, K; Tanaka, M; Tanaka, T; Uga, T | 1 |
| Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ | 1 |
| Harada, H; Hiki, N; Hosoda, K; Nishizawa, N; Soeno, T; Ushiku, H; Yamashita, K; Yokoi, K | 1 |
| Fujiwara, Y; Goto, Y; Horiike, A; Horinouchi, H; Hosomi, Y; Kanda, S; Kitazono, S; Kudo, K; Nakahara, Y; Nishio, M; Nokihara, H; Ohe, Y; Ohyanagi, F; Okuma, Y; Sunami, K; Tambo, Y; Yamamoto, N; Yanagitani, N | 1 |
| Goi, T; Hirono, Y; Katayama, H; Koneri, K; Kurebayashi, H; Morikawa, M; Murakami, M; Naruse, T; Sawai, K; Tamaki, M | 1 |
| Imai, H; Ishihara, S; Kaburagi, T; Kaira, K; Kanazawa, K; Kasahara, N; Kasai, T; Kishikawa, T; Minato, K; Minemura, H; Mori, K; Naruse, I; Shibata, Y; Suzuki, K; Uchino, J; Umeda, Y; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Hayata, K; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Chu, Z; Dai, X; Liu, Y; Ma, S; Ni, T; Qian, Y; Sunagawa, M; Wang, H; Wen, P; Xiang, L; Zhou, Z | 1 |
| Aoyama, T; Fujikawa, H; Hara, K; Hashimoto, I; Hiroshima, Y; Kano, K; Kimura, Y; Maezawa, Y; Masuda, M; Miyagi, Y; Morinaga, S; Numata, M; Ogata, T; Oshima, T; Oue, N; Rino, Y; Shiozawa, M; Tamagawa, H; Yamada, T; Yamamoto, N; Yasui, W | 1 |
| Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
| Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T | 1 |
| An, JY; Bae, JM; Choi, MG; Kang, M; Kim, S; Lee, JH; Sohn, TS; Youn, HG | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| Arai, T; Fukumura, Y; Hirabayashi, K; Kawanishi, A; Kojima, M; Matsuda, Y; Mino-Kenudson, M; Nakano-Narusawa, Y; Ohkubo, S; Sahara, Y; Takahashi, S; Yamaguchi, H | 1 |
| Fukuma, E; Haruyama, Y; Koshida, Y; Nakagawa, M; Nashimoto, M; Sakamoto, N | 1 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Dongping, F; Fujita, T; Iwabu, H; Kobayashi, M; Shimizu, Y; Tsuji, A; Yamamoto, N | 1 |
| Aoki, Y; Boku, N; Booka, E; Funakoshi, T; Hamamoto, Y; Imamura, CK; Kawakami, T; Kawakubo, H; Kitagawa, Y; Kitago, M; Mizukami, T; Takeuchi, H; Takeuchi, M; Tanigawara, Y; Wakuda, K | 1 |
| Aoyama, T; Atsumi, Y; Cho, H; Kano, K; Kazama, K; Maezawa, Y; Masuda, M; Murakami, H; Numata, M; Oshima, T; Rino, Y; Saeki, H; Sato, T; Tamagawa, H; Tsuchida, K; Yamada, T; Yamamoto, Y; Yukawa, N | 1 |
| Harada, D; Hosomi, Y; Kasai, T; Kato, T; Kishi, K; Kubota, K; Misumi, T; Nakamura, Y; Okamoto, H; Otani, S; Saito, H; Shimokawa, T; Takiguchi, Y; Tanaka, H; Yamada, K; Yamanaka, T | 1 |
| Egi, H; Imano, N; Kawahara, D; Kimura, T; Kochi, M; Kubo, K; Murakami, Y; Nagata, Y; Nishibuchi, I; Ohdan, H; Ohge, H; Shimizu, W; Takahashi, S; Takakura, Y; Takeuchi, Y; Uegami, S | 1 |
| Hua, YQ; Meng, ZQ; Ning, ZY; Shen, YH; Sheng, J; Wang, P; Xu, LT; Yan, X; Zhu, ZF; Zhuang, LP | 1 |
| Bai, LY; Chen, CY; Chen, LT; Chiang, NJ; Chiu, CF; Liang, SH; Su, YY; Wang, HC | 1 |
| Aogi, K; Haga, H; Ikeda, T; Imoto, S; Ishida, T; Ishiguro, H; Ito, Y; Iwata, H; Jimbo, K; Kai, Y; Kinoshita, T; Kitada, M; Masuda, N; Mukai, H; Ohashi, Y; Ohno, S; Saeki, T; Saji, S; Sato, N; Sato, Y; Shimizu, A; Sugie, T; Takada, M; Toi, M; Ueno, T | 1 |
| Chen, H; Chen, L; Fang, X; Fu, W; He, Y; Huang, H; Ji, J; Li, F; Li, G; Li, K; Li, S; Liang, H; Liang, P; Park, S; Shen, X; Sun, Y; Suo, J; Tian, Y; Wang, X; Xin, H; Xu, Z; Xue, Y; Yang, K; Ye, Y; Zhang, Z; Zhao, Q; Zheng, Z; Zhou, Y; Zhu, L | 1 |
| Akagi, Y; Ando, K; Baba, H; Enomoto, M; Fujita, F; Ihara, K; Miwa, K; Mori, M; Mori, S; Nakayama, G; Oki, E; Saeki, H; Shimokawa, M; Tominaga, M | 1 |
| Kim, EJ; Kim, M; Kim, MJ; Park, SR; Seo, S | 1 |
| Iwasaki, K; Kitamura, K; Koide, N; Koyama, M; Matsumura, T; Nomori, H; Obana, A; Sato, Y; Suwa, T; Usui, S; Yoshida, R | 1 |
| Itoi, T; Katsumata, K; Kondo, S; Makuuchi, Y; Nagakawa, Y; Okazaki, N; Ota, Y; Seshimo, A; Suda, T; Takahashi, K; Tsuchida, A; Watanabe, T; Yamamoto, A; Yamauchi, Y | 1 |
| Muguruma, K; Nagamori, M; Nakagawa, H; Nomura, S; Ohira, M; Ohtani, H; Tamura, T; Tanaka, H; Toyokawa, T; Yamakoshi, Y; Yoshii, M | 1 |
| Abe, T; Akazawa, N; Endo, R; Kakita, T; Oikawa, M; Okada, T; Sato, M; Sato, R; Tsuchiya, H; Tsuchiya, T; Yazawa, T | 1 |
| Akamaru, Y; Eguchi, S; Hokkoku, D; Ikeshima, R; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R | 1 |
| Aida, T; Miyazawa, K; Miyoshi, T; Shiobara, M; Suda, K; Wakatsuki, K; Watanabe, Y; Yamazaki, K; Yoneura, N; Yoshioka, S | 1 |
| Hara, S; Hatanaka, N; Hirao, T; Ide, Y; Iwasaki, T; Noro, H; Ohashi, T; Osawa, H; Sakai, K; Takayama, K; Yamasaki, Y; Yoneda, K; Yoshida, M; Yoshida, Y | 1 |
| Danno, K; Ikeda, K; Kawagishi, S; Nishigaki, T; Oka, Y; Sugimoto, K; Takahashi, K; Takeyama, H; Taniguchi, H; Tokunaga, T; Toyoda, Y; Yamamoto, H; Yamashita, M | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Fujii, H; Fuse, N; Hironaka, S; Komatsu, Y; Muro, K; Nishina, T; Ohtsu, A; Omuro, Y; Ueda, S; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Furukawa, T; Higuchi, R; Izumo, W; Matsunaga, Y; Shiihara, M; Uemura, S; Yamamoto, M; Yazawa, T | 1 |
| Fukumoto, T; Komatsu-Fujii, T; Nonoyama, S; Ogawa, M; Tanabe, H | 1 |
| Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M | 1 |
| Chen, J; Wang, J; Zou, Y | 1 |
| Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Noda, M; Ohtsuka, T; Okubo, K; Sasaki, K; Tanaka, T; Tsuruda, Y | 1 |
| Akabane, H; Hara, F; Hozumi, Y; Iwamoto, T; Mukai, H; Nishimura, R; Ohashi, Y; Ohsumi, S; Saito, T; Taira, N; Takashima, T; Toyama, T; Tsurutani, J; Uemura, Y; Watanabe, KI; Watanabe, T; Yotsumoto, D | 1 |
| Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y | 1 |
| Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Chen, CN; Lai, IR; Yeh, CC; Yen, HH | 1 |
| Ding, Y; Ge, Y; Liang, L; Liu, K; Rao, S; Yu, Y; Zeng, M | 1 |
| Chen, M; He, H; Qin, R; Qiu, ZY; Tian, GY; Wang, Y; Xi, Y; Zhang, Z | 1 |
| Hiramoto, H; Ishimoto, T; Kosuga, T; Masuyama, M; Matsui, T; Mochizuki, S; Nakamichi, N; Nakashima, S; Tsujiura, M | 1 |
| Ebihara, A; Hua, Z; Oyakawa, T; Shiga, T | 1 |
| Asaeda, K; Dohi, O; Doi, T; Inoue, K; Ishikawa, T; Itoh, Y; Kajiwara, M; Kamada, K; Kobayashi, R; Konishi, H; Miyazaki, H; Morita, R; Naito, Y; Sawai, Y; Takagi, T; Uchiyama, K; Yoshida, N | 1 |
| Gao, S; Guo, S; Jin, G; Li, B; Shen, S; Shi, X; Wang, H; Xu, X; Yin, X; You, S; Zhang, G | 1 |
| Hirokaga, K; Imamura, M; Konishi, M; Miki, M; Miyashita, M; Miyoshi, Y; Murase, K; Okuno, T; Shigeoka, Y; Suwa, H; Takao, S; Tanino, H; Yamagami, K; Yanai, A | 1 |
| Hashimoto, D; Hirooka, S; Inoue, K; Ishida, M; Ryota, H; Sakaguchi, T; Satoi, S; Sekimoto, M; Yamaki, S; Yamamoto, T | 1 |
| Kato, Y; Natsuki, S; Nishimura, S; Okuno, T; Taenaka, N | 1 |
| Chen, L; Chen, S; Lin, Z; Wang, Y; Wang, Z; Wei, S; Ye, Z; Zeng, Y | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
| Fukuyama, Y; Iwano, M; Kawarai, S; Kayanuma, H; Maruo, T; Nishiyama, Y; Orito, K; Yoda, S | 1 |
| Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M | 1 |
| Aoyama, T; Fujikawa, H; Hashimoto, I; Hatori, S; Hiroshima, Y; Kano, K; Kimura, Y; Komori, K; Masuda, M; Miyagi, Y; Morinaga, S; Numata, M; Ogata, T; Oshima, T; Rino, Y; Saeki, H; Sakamaki, K; Shizawa, M; Tamagawa, H; Watanabe, H; Yamada, T; Yamamoto, N; Yokohori, T; Yukawa, N | 1 |
| Chao, YJ; Chen, IS; Huang, HY; Liao, TK; Liu, IT; Shan, YS; Yen, CC; Yen, CJ | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Honda, N; Mukae, H; Nakatomi, K; Ogawara, D; Ono, S; Senju, H; Sugasaki, N; Suyama, T; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y; Yamaguchi, H | 1 |
| Qian, Y; Yin, Y; Zhang, Q | 1 |
| Hayashi, T; Kamiya, A; Katai, H; Otsuki, S; Sekine, S; Wada, T; Yamagata, Y; Yoshikawa, T | 1 |
| Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Doki, Y; Eguchi, H; Kitakaze, M; Miyoshi, N; Mizushima, T; Murata, K; Noura, S; Ohue, M; Takahashi, H; Tei, M; Uemura, M | 1 |
| Aoyama, T; Chin, K; Hama, T; Ide, T; Kawakami, K; Kobayashi, K; Machida, Y; Takahari, D; Yamaguchi, K; Yokokawa, T | 1 |
| Hara, K; Ide, M; Kuriyama, K; Nakazawa, N; Ogawa, H; Oyama, T; Saeki, H; Sakai, M; Sano, A; Shimoda, Y; Shirabe, K; Sohda, M; Ubukata, Y; Yokobori, T | 1 |
| Agarwal, R; Grieb, BC | 1 |
| Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M | 1 |
| Akabane, H; Fujisawa, T; Hozumi, Y; Kawahara, T; Mukai, H; Nishimura, R; Park, Y; Sagara, Y; Takahashi, M; Takashima, T; Uemura, Y; Watanabe, T | 1 |
| Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y; Takeuchi, S | 1 |
| Fukushima, K; Hayashi, H; Hosoda, K; Kobayashi, R; Kubota, K; Motoyama, H; Notake, T; Shimizu, A; Soejima, Y; Sugenoya, S; Yasukawa, K | 1 |
| Chen, C; Huang, SX; Shen, CL; Tang, CW | 1 |
| Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T | 1 |
| Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Ito, Y; Kadota, T; Kobayashi, S; Mizuno, N; Nakamori, S; Ogawa, G; Okusaka, T; Sata, N; Sato, T; Shimizu, K; Sugimori, K; Ueno, M | 1 |
| Dai, GH; Deng, GC; Han, QL; Lv, Y; Pan, YT; Qu, TT; Sun, DC; Yan, H | 1 |
| Kondo, T; Okada, T; Okamoto, I; Sato, H; Tokashiki, K; Tsukahara, K; Yoshino, K | 1 |
| Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z | 1 |
| Ye, Y; Zheng, S | 1 |
| Abdelmoneim, M; Bustos-Villalobos, I; Ichinose, T; Kasuya, H; Kikumori, T; Kodera, Y; Matsumura, S; Miyajima, N; Morimoto, D; Mukoyama, N; Naoe, Y; Ragab Eissa, I; Shibata, M; Takeuchi, D; Tanaka, M; Tsunoda, N | 1 |
| Fu, F; Huang, X; Liu, S; Wang, H; Wen, J | 1 |
| Cai, J; Liu, A; Luo, Y; Zhou, S | 1 |
| A Ono, H; Masui, H; Minami, Y; Mogaki, M; Nagahori, K; Nojiri, K; Suwa, H; Tsuura, Y | 1 |
| Demura, K; Hatanaka, N; Ide, Y; Morimoto, O; Murakami, K; Nishida, T; Ohashi, T; Osawa, H; Yoneda, K; Yoshida, M | 1 |
| Akamaru, Y; Eguchi, S; Hama, N; Harada, S; Ikeshima, R; Munakata, K; Ohashi, H; Ota, H; Shibata, K; Shimaoka, T; Takiuchi, D; Wada, N | 1 |
| Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okamura, K; Okano, N; Okusaka, T; Oono, T; Sekimoto, M; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamada, I; Yamaguchi, H; Yamashita, T | 1 |
| Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH | 1 |
| Hachiya, O; Kamio, Y; Motoi, F; Musha, H; Suzuki, T; Takahashi, K | 1 |
| Hata, T; Hiraki, M; Katsura, Y; Katsuyama, S; Kawai, K; Kitahara, T; Masuzawa, T; Murata, K; Ohmura, Y; Sakaue, M; Shinke, G; Takeda, Y; Takeno, A | 1 |
| Boku, N; Booka, E; Imamura, CK; Kawakubo, H; Kitagawa, Y; Takeuchi, H; Takeuchi, M; Tanigawara, Y | 1 |
| Cui, Y; Li, Q; Li, W; Liu, T; Wang, Y; Yu, S; Yu, Y; Zhang, J; Zhang, L | 1 |
| Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M | 1 |
| Eguchi, H; Fujii, T; Hattori, S; Hayashi, T; Higuchi, R; Hirooka, Y; Igarashi, H; Inoue, Y; Kawakatsu, S; Kitagawa, H; Kitano, M; Kuroki, T; Masamune, A; Nagakawa, Y; Ohba, A; Satoi, S; Shimizu, Y; Takami, H; Takeyama, Y; Tani, M; Tanno, S; Tomimaru, Y; Tsuji, Y; Unno, M; Yamamoto, T; Yamaue, H | 1 |
| Ishii, H; Ito, T; Izumi, H; Kawabata, K; Nakanishi, M; Okajima, W; Sudo, M; Takeshita, H; Yamaguchi, M; Yoshioka, A; Yutoku, Y | 1 |
| An, MS; Baik, H; Jeong, JY; Kang, SH; Kim, KH; Oh, SH; Seo, SH | 1 |
251 review(s) available for tegafur and oxonic acid
| Article | Year |
|---|---|
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorodeoxyuridylate; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Tegafur | 1993 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluorouracil; Immunologic Factors; Male; Mice; Mice, Nude; Oxonic Acid; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Vomiting | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
The oral fluorouracil prodrugs.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1998 |
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Combinations; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
[Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cycle; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Oxonic Acid; Pyridines; Rats; Tegafur | 1999 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Rectal Neoplasms; Tegafur | 2000 |
[S-1 for treatment of breast cancers].
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Combinations; Female; Humans; Oxonic Acid; Pyridines; Tegafur | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Synergism; Drug Therapy; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2000 |
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Humans; Leucovorin; Neoplasms; Oxidoreductases; Oxonic Acid; Pyridines; Radiation-Sensitizing Agents; Tegafur; Uracil | 2000 |
Oral DPD-inhibitory fluoropyrimidine drugs.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Oxonic Acid; Pyridines; Tegafur; Uracil | 2001 |
[TS-1 therapy for advanced gastric cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Humans; Oxidoreductases; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2001 |
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Drug Synergism; Head and Neck Neoplasms; Humans; Oxonic Acid; Pyridines; Rats; Stomach Neoplasms; Tegafur | 2001 |
[A complete response persisting for twelve months with the use of TS-1 in a patient with paraaortic lymph node metastasis of gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Aorta; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Oxonic Acid; Pyridines; Remission, Spontaneous; Stomach Neoplasms; Tegafur | 2001 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; Fluorouracil; Genes, ras; Humans; Imatinib Mesylate; Insect Proteins; Lung Neoplasms; Mice; Neoplasms; Neoplastic Syndromes, Hereditary; Oxonic Acid; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Signal Transduction; Tegafur; Tumor Cells, Cultured | 2002 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Patient Compliance; Prodrugs; Pyridines; Tegafur; Treatment Outcome | 2001 |
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Premedication; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
S-1 in gastric cancer: a comprehensive review.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
Current topics of S-1 at the 74th Japanese Gastric Cancer Congress.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Japan; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
[Controversial issues in chemotherapy for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Prognosis; Pyridines; Tegafur; Thymidylate Synthase; Uracil | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Meta-Analysis as Topic; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2003 |
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dosage Forms; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Oxonic Acid; Prodrugs; Pyridines; Pyrimidines; Tegafur | 2004 |
[Advanced gastric cancer successfully treated by TS-1--case report].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Aorta, Abdominal; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Neoplasms; Oxonic Acid; Prodrugs; RNA, Messenger; Tegafur; Thymidylate Synthase | 2004 |
[A case of liver metastasis of gastric cancer responding well to TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2004 |
[Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Humans; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2004 |
[Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Tegafur | 2005 |
[Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Infant; Middle Aged; Oxonic Acid; Pilot Projects; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Recent important insights into treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Intraoperative Care; Lymph Node Excision; Lymphatic Metastasis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyridines; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Treatment Outcome | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
[Anticancer immunotherapy with perorally effective lentinan].
Topics: Adjuvants, Immunologic; Administration, Oral; Antineoplastic Agents; beta-Glucans; Drug Combinations; Humans; Immunotherapy; Lentinan; Neoplasms; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2005 |
[An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[5 -fluoropyrimidines for treatment of biliary tract cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Pyridines; Pyrimidines; Tegafur; Uracil | 2006 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
[Non-surgical treatment for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Pharmaceutical Preparations; Prodrugs; Tegafur | 2006 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Humans; Kidney; Male; Middle Aged; Neoplasms; Oxonic Acid; Rats; Tegafur; Uracil | 2006 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Stomatitis; Tegafur | 2006 |
[Clinical development of S-1 (TS-1) for advanced gastric cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Oxonic Acid; Practice Guidelines as Topic; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[S-1+Low-Dose CDDP].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Combinations; Humans; Leukopenia; Neoplasm Transplantation; Neutropenia; Oxonic Acid; Quality of Life; Randomized Controlled Trials as Topic; Rats; Rats, Nude; Stomach Neoplasms; Stomatitis; Taxoids; Tegafur | 2006 |
[S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
[A recent trial of chemo-radiation with S-1 against gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Radiotherapy Dosage; Stomach Neoplasms; Tegafur; Treatment Outcome | 2006 |
[Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Humans; Meta-Analysis as Topic; Neoplasm Staging; Oxonic Acid; Registries; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Combinations; Gastrointestinal Neoplasms; Humans; Maximum Tolerated Dose; Multicenter Studies as Topic; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Remission Induction; Survival Rate; Tegafur | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Head and Neck Neoplasms; Humans; Oxonic Acid; Tegafur; Uracil | 2006 |
[Combination therapy with S-1 and CDDP for head and neck cancer].
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Tegafur; Thrombocytopenia | 2006 |
[Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Topics: Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Leukopenia; Multicenter Studies as Topic; Oxonic Acid; Randomized Controlled Trials as Topic; Survival Rate; Tegafur | 2006 |
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Neutropenia; Oxonic Acid; Remission Induction; Tegafur | 2006 |
[Combination therapy with S-1 plus docetaxel (DOC) for previously treated patients with non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Maximum Tolerated Dose; Oxonic Acid; Randomized Controlled Trials as Topic; Taxoids; Tegafur | 2006 |
[Clinical benefit of S-1 in metastatic breast cancer].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Mastectomy, Segmental; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomatitis; Survival Rate; Tegafur | 2006 |
[The possibility of S-1 for the treatment of patients with urological cancers].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Oxonic Acid; Prostatic Neoplasms; Tegafur; Urologic Neoplasms | 2006 |
[Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Oxonic Acid; Tegafur | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Clinical development of chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
[Diagnosis of and therapy for pancreatic neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
The role of S-1 in the treatment of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Japan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2008 |
Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients.
Topics: Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2A6; Drug Combinations; Humans; Orotate Phosphoribosyltransferase; Oxonic Acid; Pharmacogenetics; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
S-1: a promising new oral fluoropyrimidine derivative.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Evaluation, Preclinical; Humans; Neoplasms; Oxonic Acid; Tegafur | 2009 |
S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Combinations; Humans; Japan; Lung Neoplasms; Oxonic Acid; Tegafur | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
[A case of super advanced gastric cancer responding to S-1+CDDP and S-1 single regimen which led to a clinical complete response].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of advanced gastric cancer responding completely treated with S-1 therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
UFT and S-1 for treatment of primary lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Lung Neoplasms; Oxonic Acid; Radiotherapy, Adjuvant; Tegafur; Time Factors; Treatment Outcome; Uracil | 2010 |
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Japan; Methotrexate; Oxonic Acid; Tegafur; Uracil | 2010 |
Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations; Fatal Outcome; Fluorodeoxyglucose F18; Gastrectomy; Gastroscopy; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Splenectomy; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[A case of Stage IV AFP producing gastric cancer with long-term survival treated by adjuvant chemotherapy with S-1].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Cardia; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2010 |
S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Drug Combinations; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2011 |
[A case with multiple liver metastases of gastric cancer responding completely to S-1 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of scirrhous gastric carcinoma with peritoneal dissemination which was treated by curative gastrectomy after S-1/CDDP chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Female; Gastrectomy; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of locally advanced gastric cancer responding to pathological CR treated with S-1/CDDP neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Jejunal Neoplasms; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur; Uracil | 2010 |
[A case of AFP-producing gastric cancer resected after efficient S-1/CDDP combination chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Three cases of advanced gastric cancer successfully treated by combination therapy of biweekly S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Humans; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case report of primary duodenal adenocarcinoma responding to chemotherapy with S-1 and irinotecan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Duodenal Neoplasms; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2011 |
[A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Oxonic Acid; Prognosis; Tegafur | 2011 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Pathological complete response in advanced gastric carcinoma by S-1/CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Type 4 advanced gastric cancer responding to histological complete response after neoadjuvant S-1 combined with CDDP therapy-report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Recent advance of chemotherapy in gastric cancer].
Topics: Combined Modality Therapy; Drug Combinations; Evaluation Studies as Topic; Humans; Molecular Targeted Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Approval; European Union; Humans; Oxonic Acid; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Surgical resection following combination chemotherapy with oral S-1 and biweekly docetaxel in a patient with advanced gastric cancer and a prior coronary artery bypass graft with the right gastroepiploic artery: report of a case.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Docetaxel; Drug Combinations; Follow-Up Studies; Gastrectomy; Gastroepiploic Artery; Humans; Infusions, Intravenous; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Preoperative Care; Risk Assessment; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2011 |
[Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2011 |
[A very elderly case of advanced gastric cancer with disseminated carcinomatosis of bone marrow and multiple bone metastasis, diagnosed by extremely elevated serum alkaline phosphatase levels, and treated with low-dose S-1 to avoid disseminated intravascu
Topics: Aged, 80 and over; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Bone Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Combinations; Female; Humans; Imidazoles; Oxonic Acid; Stomach Neoplasms; Tegafur; Zoledronic Acid | 2011 |
[Squamous cell carcinoma of the anal canal showing pathological complete response after S-1 plus radiotherapy -a case report].
Topics: Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Grading; Oxonic Acid; Tegafur | 2011 |
[A case of long-term survival after undergoing S-1 based multidisciplinary therapy for liver metastasis of gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Liver Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
[A long-term survival case in advanced mucinous cystadenocarcinoma of the appendix using cytoreductive surgery and S-1/CDDP chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Cisplatin; Colonic Neoplasms; Cystadenocarcinoma, Mucinous; Drug Combinations; Female; Humans; Hyperthermia, Induced; Middle Aged; Oxonic Acid; Remission Induction; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
S-1 as a core anticancer fluoropyrimidine agent.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedule; Drug Combinations; Humans; Molecular Structure; Neoplasms; Oxonic Acid; Prodrugs; Tegafur | 2012 |
[A case of elderly advanced squamous cell lung carcinoma successfully treated with nedaplatin and S-1 combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Combinations; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of gastric cancer with rhabdoid features showing better prognosis through S-1/CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Humans; Male; Neoplasm Staging; Oxonic Acid; Rhabdoid Tumor; Stomach Neoplasms; Tegafur | 2012 |
S-1 for the treatment of gastrointestinal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Practice Guidelines as Topic; Tegafur | 2012 |
Hypomanic episode during recurrent gastric cancer treatment: report of a rare case and literature review.
Topics: Aged; Antineoplastic Agents; Bipolar Disorder; Cisplatin; Drug Combinations; Female; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Review Literature as Topic; Stomach Neoplasms; Tegafur | 2012 |
[A case report of a stage IV gastric cancer patient with rapid progression of liver metastases induced by postoperative anastomotic leakage].
Topics: Adult; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Medical Errors; Neoplasm Staging; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Failure | 2012 |
[Surgical resection and S-1 administration for the treatment of hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2012 |
[A case of peritoneal dissemination that exhibited a complete response to systemic chemotherapy following the resection of primary colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Quality of Life; Tegafur | 2012 |
[Locally recurrent case of gastric cancer with serosal invasion after four months of endoscopic submucosal dissection].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Endoscopy; Female; Gastric Mucosa; Humans; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Recurrence; Serous Membrane; Stomach Neoplasms; Tegafur | 2012 |
Adjuvant therapy of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans; Models, Biological; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tegafur | 2013 |
Second-line therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2013 |
Applications of oral fluoropyrimidines in colon cancer: their role and new directions.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxaloacetates; Oxonic Acid; Tegafur; Uracil | 2003 |
S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.
Topics: Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Combinations; European Union; Humans; Oxonic Acid; Quality of Life; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
[An autopsy of G-CSF-producing anaplastic carcinoma of the pancreas with impaired accumulation on FDG-PET after S-1 chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Autopsy; Carcinoma; Drug Combinations; Fatal Outcome; Female; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Oxonic Acid; Pancreatic Neoplasms; Pleurisy; Positron-Emission Tomography; Tegafur | 2013 |
[A case of gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Adenosquamous; Cisplatin; Docetaxel; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of liver metastasis from gastric cancer responding completely to S-1/docetaxel chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of gastric cancer with virchow and para-aortic node metastasis treated successfully by neo-adjuvant chemotherapy with S-1/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Curative resection of a case of advanced gastric cancer with peritoneal dissemination responding well to combination chemotherapy of docetaxel,cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Odds Ratio; Oxonic Acid; Publication Bias; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2013 |
S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Odds Ratio; Oxonic Acid; Proportional Hazards Models; Publication Bias; Tegafur; Treatment Outcome | 2014 |
[A case of jejnal cancer who was controlled peritoneal metastasis, successfully by combination therapy with docetaxel and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Jejunal Neoplasms; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Radiography; Taxoids; Tegafur; Treatment Outcome | 2013 |
[Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Tegafur; Treatment Outcome | 2013 |
[A case of locally advanced gastric cancer in which pathological complete response( PCR) was obtained after combination chemotherapy with S-1/cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastric Bypass; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2013 |
[A case of advanced gastric cancer with carcinomatous lymphangitis of the lung treated with docetaxel and S-1 combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Lung Neoplasms; Lymphangitis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of quadruple cancer of the liver, stomach, bladder, and ureter].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2013 |
S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Combinations; Humans; Odds Ratio; Oxonic Acid; Risk Factors; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
[Urgent gastrectomy in a patient who developed perforated gastric cancer during preoperative chemotherapy with S-1 plus cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced sigmoid colon cancer with metastases in the liver and the paraaortic lymph nodes successfully treated with 5-FU/l-LV and FOLFOX4 followed by S-1 leading to long-term complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Organoplatinum Compounds; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2014 |
[Gastrectomy for a patient with advanced gastric cancer with spleen metastases following induction chemotherapy with S-1 plus cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Induction Chemotherapy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Splenic Neoplasms; Stomach Neoplasms; Tegafur | 2014 |
[Case report of chemotherapeutic control of a gastric cancer producing granulocyte-colony stimulating factor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fatal Outcome; Gastroscopy; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Publication Bias; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur; Treatment Failure | 2014 |
A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Intraoperative Period; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Lavage; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur; Treatment Outcome | 2014 |
[Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers; Biotransformation; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Enzymes; Ethnicity; Fluorouracil; Gastrectomy; Humans; Mexico; Molecular Targeted Therapy; Organoplatinum Compounds; Oxonic Acid; Patient Selection; Pharmacogenetics; Precision Medicine; Prodrugs; Stomach Neoplasms; Tegafur | 2014 |
Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2014 |
Efficacy of S-1 in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectum; Tegafur | 2014 |
Efficacy of S-1 in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Combinations; Humans; Lung Neoplasms; Oxonic Acid; Tegafur | 2014 |
[A case of complete response to multiple liver metastasis of gastric cancer after discontinuation of S-1 administration].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
[A case of disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation caused by advanced colon cancer successfully treated with SOX/bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow Neoplasms; Chemotherapy, Adjuvant; Colonic Neoplasms; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2014 |
S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Drug Combinations; Humans; Oxonic Acid; Risk Factors; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur | 2015 |
[Advanced gastric cancer(Stage IV)leading to perforation during chemotherapy with S-1 plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Stomach Rupture; Tegafur | 2014 |
Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A case of advanced gastric cancer with tumor embolus in the portal vein and liver metastasis responding to S-1 plus cisplatin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur | 2014 |
S-1 in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Drug Combinations; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2014 |
The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Fluorouracil; Neoplasm Staging; Oxonic Acid; Risk Factors; Sex Factors; Stomach Neoplasms; Tegafur | 2014 |
Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2014 |
Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Drug Combinations; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Peritoneum; Tegafur | 2015 |
[A case of early gastric cancer with multiple synchronous bone metastases treated complete response with S-1+CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced gastric cancer responding to S-1/CDDP neoadjuvant chemotherapy, leading to a pathological complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[Reinforcement of warfarin action in a patient administered S-1].
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Cardiomyopathy, Hypertrophic; Cerebral Infarction; Drug Combinations; Drug Interactions; Humans; Male; Mouth Neoplasms; Neoplasms, Squamous Cell; Oxonic Acid; Tachycardia, Ventricular; Tegafur; Warfarin | 2015 |
[A case of surgical resection for liver metastasis of gastric cancer with portal vein tumor thrombus].
Topics: Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Portal Vein; Stomach Neoplasms; Tegafur; Venous Thrombosis | 2014 |
[A case of pancreatic cancer with distant metastasis successfully resected after neoadjuvant chemotherapy with a combination of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Pancreatic Neoplasms; Pleural Neoplasms; Stomach Neoplasms; Tegafur | 2014 |
[A case report of distal gastrectomy with thrombectomy after NAC for Gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Embolism; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Thrombectomy; Tomography, X-Ray Computed | 2014 |
[Curative resection for Stage IV advanced gastric cancer that responded to combination chemotherapy with docetaxel, cisplatin, and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2014 |
[A case of gastric cancer with liver metastases achieving a clinical complete response after S-1 plus CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Oxonic Acid; Positron-Emission Tomography; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Survival Rate; Tegafur; Treatment Outcome | 2015 |
[A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Drug Combinations; Hand-Foot Syndrome; Humans; Odds Ratio; Oxonic Acid; Risk Factors; Stomach Neoplasms; Survival Analysis; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2015 |
A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Topics: Capecitabine; China; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Oxonic Acid; Severity of Illness Index; Stomach Neoplasms; Tegafur | 2015 |
[Vesico-appendiceal fistula caused by appendiceal cancer: a case report].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Cystectomy; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Tegafur; Urinary Bladder Fistula | 2015 |
Long-term survival in metastasized leiomyosarcoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Oxonic Acid; Pyridines; Radiosurgery; Sigmoid Neoplasms; Tegafur; Treatment Outcome | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; Intestinal Mucosa; Mouth Mucosa; Neoplasms; Oxonic Acid; Randomized Controlled Trials as Topic; Stomatitis; Tegafur | 2016 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Odds Ratio; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Report; Tegafur; Treatment Outcome | 2015 |
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
Topics: Drug Combinations; Humans; Oxonic Acid; Safety; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of HER2-Positive Advanced Gastric Cancer with a Pathological Complete Response to Neoadjuvant Chemotherapy with S-1/CDDP/Trastuzumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2015 |
[Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2015 |
[A Case of Pancreatic Head Cancer Showing Pathological Complete Response to Neoadjuvant Chemoradiation Therapy].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2015 |
[Onset of Syndrome of Inappropriate Secretion of Antidiuretic Hormone in a Gastric Cancer Patient on SOX Treatment].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Humans; Inappropriate ADH Syndrome; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Advanced Gastric Cancer with a Complete Response to S-1 Neoadjuvant Chemotherapy in an Elderly Patient].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2016 |
S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Neoplasms; Neutropenia; Oxonic Acid; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Tegafur | 2016 |
S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Fluorouracil; Humans; Orotate Phosphoribosyltransferase; Oxonic Acid; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
[An Elderly Patient with Local Recurrence of Gastric Cancer Responding Completely to S-1 Monotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Recurrence; Remission Induction; Stomach Neoplasms; Tegafur | 2016 |
A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Drug Combinations; Humans; Hyperthermia, Induced; Infusions, Parenteral; Multivariate Analysis; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Middle Aged; Network Meta-Analysis; Oxonic Acid; Pyruvates; Stomach Neoplasms; Tegafur | 2016 |
Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Humans; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2016 |
Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Carcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Humans; Insulin; Oxonic Acid; Parenteral Nutrition, Total; Patient Compliance; Practice Guidelines as Topic; Stomach Neoplasms; Sulfates; Tegafur; Terminal Care | 2016 |
The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Infusions, Parenteral; Intraoperative Care; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2017 |
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2016 |
Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Humans; Lung Neoplasms; Oxonic Acid; Publication Bias; Tegafur; Treatment Outcome | 2017 |
[A Case of Gastric Cancer Responding to Neoadjuvant Chemotherapy Leading to Histological Change to Grade 3].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Stomach Neoplasms; Tegafur | 2016 |
[A Case of Simultaneous Multiple Gastric Cancers Showing Differences of Response after Neoadjuvant Chemotherapy with Docetaxel, CDDP, and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
A case of metachronous liver metastasis from neuroendocrine carcinoma of the stomach at 1 year and 10 months after endoscopic submucosal dissection.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Drug Combinations; Endoscopic Mucosal Resection; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2017 |
[Persistent Chemotherapy-Induced Hiccups Successfully Treated with Pregabalin].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Hiccup; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pregabalin; Tegafur; Treatment Outcome | 2017 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Oxonic Acid; Tegafur | 2017 |
[A Case of Rhabdomyolysis Related to SOX Therapy for Liver Metastasis of Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rhabdomyolysis; Stomach Neoplasms; Tegafur | 2017 |
Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature.
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritonitis; Pyridines; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Transcription Factors | 2017 |
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proportional Hazards Models; Publication Bias; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
[A Case of Advanced Neuroendocrine Cell Carcinoma of the Stomach Treated with S-1 and Cisplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Combinations; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Fistula; Esophageal Neoplasms; Female; Humans; Oxonic Acid; Taxoids; Tegafur | 2017 |
[A Case of Remnant Gastric Cancer That Completely Responded to Neoadjuvant S-1 and Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2017 |
[A Case of QOL Improvement after Intestinal Stenosis Due to Peritoneal Dissemination of Gastric Cancer in Elderly Patients].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Intestinal Obstruction; Intestine, Small; Oxonic Acid; Peritoneal Neoplasms; Quality of Life; Recurrence; Stents; Stomach Neoplasms; Tegafur | 2017 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; Oxonic Acid; Systematic Reviews as Topic; Tegafur | 2018 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Humans; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pneumonectomy; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Tegafur | 2018 |
[A Distal Bile Duct Carcinoma Patient Who Underwent Surgical Resection for Liver Metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2018 |
Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Staging; Neuroendocrine Tumors; Oxonic Acid; Pyrimidines; Tegafur; Treatment Outcome | 2018 |
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Lymph Node Excision; Network Meta-Analysis; Oxaloacetates; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur | 2018 |
Advances in the treatment of gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Gastrectomy; Humans; Nivolumab; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; China; Drug Combinations; Drug Therapy, Combination; Humans; Neoplasm Staging; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2018 |
The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review.
Topics: Antineoplastic Agents; Cisplatin; Drug Combinations; Humans; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2018 |
S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Humans; Oxonic Acid; Radiotherapy; Randomized Controlled Trials as Topic; Tegafur | 2018 |
S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hematologic Diseases; Humans; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2019 |
Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Neoplasm Metastasis; Oxonic Acid; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur | 2019 |
Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Japan; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Preoperative Care; Stomach Neoplasms; Tegafur | 2020 |
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2020 |
Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Lung Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Pneumonectomy; Pyridines; Tegafur | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Tegafur | 2020 |
The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Disease-Free Survival; Drug Combinations; Humans; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2020 |
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combinations; End Stage Liver Disease; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharyngeal Neoplasms; Pharynx; Positron Emission Tomography Computed Tomography; Sorafenib; Tegafur; Treatment Outcome | 2020 |
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Esophagogastric Junction; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Staging; Oxonic Acid; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Combinations; Humans; Hypertriglyceridemia; Male; Middle Aged; Oxonic Acid; Tegafur | 2021 |
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2020 |
Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Combinations; Humans; Leukopenia; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2021 |
Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
Topics: Humans; Hyperlipidemias; Hypertriglyceridemia; Oxonic Acid; Pyridines; Tegafur; Triglycerides | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
760 trial(s) available for tegafur and oxonic acid
| Article | Year |
|---|---|
[Phase I study of S-1. S-1 Study Group].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 1997 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Pyridines; Remission Induction; Survival Analysis; Tegafur | 1998 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomatitis; Tegafur | 1998 |
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 1998 |
[Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Rectal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 1999 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 1999 |
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 1999 |
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2000 |
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2000 |
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2000 |
Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Topics: Adult; Aged; Antibody Specificity; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Immunohistochemistry; Male; Middle Aged; Oxidoreductases; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Thymidylate Synthase; Treatment Outcome | 2000 |
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2001 |
[Late phase II study of S-1 in patients with advanced head and neck cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2001 |
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pilot Projects; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2001 |
Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2001 |
[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2002 |
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedule; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2002 |
[A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pilot Projects; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2002 |
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur; Time Factors | 2003 |
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2003 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Combinations; Female; Fluorouracil; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur; Tissue Distribution; Uracil | 2003 |
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Patient Compliance; Pyridines; Retrospective Studies; Severity of Illness Index; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2003 |
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Digestive System Surgical Procedures; Drug Combinations; Drug Evaluation; Female; Humans; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2003 |
Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Retrospective Studies; Severity of Illness Index; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Interventional | 2003 |
Development of clinical pathway in S-1 chemotherapy for gastric cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Critical Pathways; Disease Progression; Drug Combinations; Female; Humans; Japan; Male; Medical Records; Middle Aged; Oxonic Acid; Pyridines; Quality Assurance, Health Care; Safety Management; Self Administration; Stomach Neoplasms; Tegafur; Treatment Outcome; Withholding Treatment | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oxidoreductases; Oxonic Acid; Peritoneal Neoplasms; Predictive Value of Tests; Pyridines; Retrospective Studies; Statistics as Topic; Stomach Neoplasms; Survival Analysis; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome; Uracil | 2003 |
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Drug Hypersensitivity; Drug Resistance, Neoplasm; Drug Therapy; Female; Gene Expression; Gene Expression Profiling; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pilot Projects; Predictive Value of Tests; Prospective Studies; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2003 |
[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Lentinan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pilot Projects; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Postoperative Period; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
Pilot study of S-1 in patients with disseminated gastric cancer.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pilot Projects; Pyridines; Stomach Neoplasms; Survivors; Tegafur; Time Factors; Treatment Outcome | 2003 |
[A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Liver; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Vomiting, Anticipatory | 2004 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Thrombocytopenia | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Pyridines; Tegafur; Vomiting, Anticipatory | 2004 |
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2004 |
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Cross-Over Studies; Eating; Female; Fluorouracil; Food; Humans; Kinetics; Male; Middle Aged; Neoplasms; Oxonic Acid; Phosphorylation; Pyridines; Tegafur; Time Factors | 2004 |
Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Feasibility Studies; Female; Humans; Incidence; Male; Middle Aged; Oxonic Acid; Pyridines; Safety; Stomach Neoplasms; Tegafur | 2004 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Time Factors | 2004 |
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Predictive Value of Tests; Prognosis; Pyridines; Stomach Neoplasms; Tegafur; Thymidylate Synthase; Treatment Outcome | 2004 |
Phase II study of S-1 in patients with advanced biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Biliary Tract Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2004 |
A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2004 |
[Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2004 |
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Patient Compliance; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2005 |
Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cyclooxygenase 2; Drug Combinations; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Predictive Value of Tests; Prognosis; Prostaglandin-Endoperoxide Synthases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Tegafur; Treatment Outcome | 2005 |
[A phase I study of TS-1 and weekly cisplatin in patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur; Treatment Outcome | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Fluorouracil; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Radiotherapy Dosage; Tegafur; Vitamin A | 2005 |
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur; Treatment Outcome | 2005 |
Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2005 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2005 |
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2005 |
A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2005 |
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Endpoint Determination; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Pyrimidines; Stomach Neoplasms; Tegafur; Uracil | 2005 |
Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Pyridines; Risk; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
[Clinical phase trial of concurrent chemoradiotherapy combined TS-1 and nedaplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Pyridines; Radiotherapy Dosage; Tegafur | 2005 |
Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Preoperative Care; Pyridines; Tegafur | 2005 |
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2006 |
Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Combinations; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Administration Schedule; Female; Headache; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2006 |
[Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mitomycin; Mouth Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Tegafur | 2006 |
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survivors; Tegafur; Treatment Outcome | 2006 |
[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Leukopenia; Lung Neoplasms; Male; Neutropenia; Oxonic Acid; Pyridines; Tegafur | 2006 |
[Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia, Megaloblastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Leukopenia; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2006 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2006 |
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2006 |
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Upper Gastrointestinal Tract | 2007 |
A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Immunologic Factors; Immunotherapy; Middle Aged; Neoplasm Staging; Oxonic Acid; Proteoglycans; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Stomach Neoplasms; Stomatitis; Survival Rate; Tegafur | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capsules; Diarrhea; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Nausea; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2006 |
[Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Lentinan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Remission Induction; Tegafur | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur; Vomiting, Anticipatory | 2006 |
[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Endpoint Determination; Female; Humans; Lymph Node Excision; Male; Neoplasm Staging; Oxonic Acid; Proportional Hazards Models; Prospective Studies; Rectal Neoplasms; Survival Rate; Tegafur; Uracil | 2006 |
[Combination chemotherapy with S-1 and carboplatin for head and neck cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deglutition Disorders; Drug Administration Schedule; Drug Combinations; Female; Glottis; Humans; Laryngeal Neoplasms; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Radiation Injuries; Radiodermatitis; Radiotherapy Dosage; Stomatitis; Tegafur | 2006 |
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Radiation Injuries; Radiodermatitis; Radiotherapy Dosage; Tegafur | 2006 |
[Phase I study of concurrent radiotherapy with S-1 for oral squamous cell carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Nausea; Oxonic Acid; Quality of Life; Radiotherapy Dosage; Stomatitis; Tegafur | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mouth Neoplasms; Nausea; Neutropenia; Oxonic Acid; Preoperative Care; Survival Rate; Tegafur | 2006 |
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Oxonic Acid; Quality of Life; Remission Induction; Tegafur | 2006 |
[S-1 monotherapy for pancreatic cancer].
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Female; Humans; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2007 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Radiotherapy Dosage; Radiotherapy, Adjuvant; Taxoids; Tegafur | 2006 |
[A phase I study of postoperative combination therapy with TS-1 and low dose cisplatin against stage IV gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Period; Stomach Neoplasms; Tegafur | 2007 |
Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Tegafur | 2007 |
A late phase II study of S-1 for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2008 |
Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Asian People; Body Surface Area; DNA, Neoplasm; Drug Combinations; Drug Evaluation; Feasibility Studies; Female; Follow-Up Studies; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxonic Acid; Pharmacogenetics; Predictive Value of Tests; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
[Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Fever; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Computer Simulation; Drug Combinations; Fluorouracil; Humans; Kidney; Kinetics; Models, Biological; Oxonic Acid; Pyridines; Renal Insufficiency; Tegafur; Time Factors; Uracil | 2007 |
A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease Progression; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2007 |
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Vascular Endothelial Growth Factor A | 2007 |
Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2007 |
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Survival Analysis; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Salvage Therapy; Survival Analysis; Tegafur; Thrombocytopenia | 2008 |
Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Immunoenzyme Techniques; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2007 |
A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma.
Topics: Adult; Aged; Dermatitis; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Glottis; Humans; Laryngeal Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Oxonic Acid; Tegafur; Treatment Outcome | 2006 |
Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2007 |
[Unresectable gallbladder cancer with lymph node and liver metastases completely responding to S-1 monotherapy - a case report].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gallbladder Neoplasms; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Postoperative Complications; Quality of Life; Remission Induction; Stomach; Stomach Neoplasms; Survival Analysis; Tegafur | 2008 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2007 |
Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Survival Analysis; Tegafur | 2008 |
Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Patient Selection; Research Design; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur | 2008 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Infusions, Parenteral; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Injections, Intravenous; Japan; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Tegafur | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2008 |
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Proteins; Oxonic Acid; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Tegafur; Treatment Outcome | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2008 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Neoplasms; Oxonic Acid; Polymorphism, Genetic; Pyridines; Tegafur | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; Disease-Free Survival; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Patient Selection; Phenotype; Polymorphism, Genetic; Tegafur; Time Factors; Treatment Outcome | 2008 |
Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectal Neoplasms; Tegafur | 2008 |
Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2009 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pilot Projects; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2008 |
Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2008 |
Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspases; Chemotherapy, Adjuvant; Drug Combinations; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Oxonic Acid; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; T-Lymphocytes; Tegafur | 2008 |
A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Tegafur; Treatment Outcome | 2008 |
Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur | 2008 |
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2009 |
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Recurrence; Tegafur | 2008 |
Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Pyridines; Single-Blind Method; Stomach Neoplasms; Tegafur; Treatment Outcome | 2008 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
[Clinical trials of neo-adjuvant chemotherapy for advanced gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2008 |
[Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastric Lavage; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pilot Projects; Stomach Neoplasms; Tegafur | 2008 |
[Clinical trial of non-specific immunotherapy using Lentinan in advanced or recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Immunotherapy; Lentinan; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy; Irinotecan; Male; Oxonic Acid; Peptides; Tegafur; Tomography, X-Ray Computed | 2008 |
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Body Surface Area; Drug Combinations; Drug Dosage Calculations; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2009 |
Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome; Young Adult | 2009 |
Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gene Dosage; Hemoglobins; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
[Clinical phase I trial of S-1 in the combination with DOC using super-selective intra-arterial infusion with oral cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Taxoids; Tegafur | 2009 |
[The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tegafur | 2009 |
A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Cavity; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur | 2009 |
A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Feasibility Studies; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2010 |
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Safety; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2009 |
Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fever; Humans; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Pain; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Uracil | 2009 |
Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Liver; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Thrombocytopenia; Treatment Outcome; Vomiting | 2010 |
Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome; Young Adult | 2009 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Enzymes; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survival Rate; Tegafur | 2009 |
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2A6; Docetaxel; Drug Combinations; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Oxonic Acid; Pilot Projects; Polymorphism, Genetic; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome; Young Adult | 2009 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome; Young Adult | 2009 |
Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Preoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tegafur; Treatment Failure | 2010 |
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Tegafur; Thrombocytopenia | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Female; Humans; Leukopenia; Male; Metabolic Clearance Rate; Neutropenia; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Survival Analysis; Taxoids; Tegafur | 2010 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Male; Middle Aged; Oxonic Acid; Proportional Hazards Models; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome; Young Adult | 2009 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Korea; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2010 |
A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2010 |
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fatigue; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Oxonic Acid; Proportional Hazards Models; Prospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cytokines; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Interferons; Interleukin-2; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2010 |
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2010 |
Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Longitudinal Studies; Male; Middle Aged; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur; Time Factors; Treatment Outcome | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Research Personnel; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2011 |
A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Digestive System Surgical Procedures; Drug Combinations; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Stomach Neoplasms; Tegafur | 2010 |
Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: phase I trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Radiation; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Oxonic Acid; Preoperative Period; Tegafur; Treatment Outcome | 2010 |
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Oxonic Acid; Survival Rate; Tegafur | 2011 |
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Preoperative Care; Radiotherapy Dosage; Rectal Neoplasms; Tegafur; Thrombocytopenia; Vomiting | 2011 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2010 |
Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Glottis; Humans; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Radiotherapy; Tegafur; Treatment Outcome | 2010 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2011 |
Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Preoperative Care; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2011 |
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2010 |
Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2010 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2A6; Disease Progression; Drug Combinations; Female; Fluorouracil; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Oxonic Acid; Pharmacogenetics; Tegafur | 2010 |
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Japan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Tegafur | 2011 |
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Survival; Tegafur; Treatment Outcome | 2010 |
Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Oxonic Acid; Patient Selection; Sample Size; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gastroesophageal Reflux; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Tegafur | 2010 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2010 |
Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study.
Topics: Adult; Aged; Alanine Transaminase; Androgen Antagonists; Anorexia; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Body Surface Area; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Humans; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Oxonic Acid; Prostate-Specific Antigen; Prostatic Neoplasms; Safety; Tegafur; Treatment Outcome | 2010 |
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Republic of Korea; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2012 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur | 2010 |
A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taiwan; Tegafur | 2011 |
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxonic Acid; Polymorphism, Single Nucleotide; Prospective Studies; Pyridines; Tegafur | 2011 |
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Republic of Korea; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2012 |
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2011 |
Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Stomach Neoplasms; Tegafur | 2011 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2011 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Intervals; Disease Progression; Drug Combinations; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2011 |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Feasibility and efficacy of combination chemotherapy with S-1 and fractional Cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Outpatients; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Tegafur; Young Adult | 2010 |
Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2010 |
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Female; Gene Expression; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Orotate Phosphoribosyltransferase; Oxonic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Tegafur; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2010 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Japan; Leukopenia; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2010 |
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Survival Analysis; Tegafur | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Organoplatinum Compounds; Oxonic Acid; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Patient Compliance; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Fatigue; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capsules; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy; Suspensions; Tegafur | 2011 |
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Treatment Failure | 2012 |
Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Oxonic Acid; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Tegafur; Treatment Outcome | 2011 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Tegafur | 2011 |
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Biliary Tract Neoplasms; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Humans; Inactivation, Metabolic; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Single Nucleotide; Tegafur; Treatment Outcome; Young Adult | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Selection; Salvage Therapy; Serum Albumin; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Platinum Compounds; Recurrence; Tegafur; Treatment Outcome | 2011 |
Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Uterine Cervical Neoplasms | 2011 |
Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2011 |
Efficacy and safety of S-1 in patients with metastatic breast cancer: retrospective review in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2010 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Interactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2011 |
Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Mitomycin; Neoplasm Staging; Oxonic Acid; Patient Selection; Radiotherapy, Adjuvant; Tegafur; Treatment Outcome | 2011 |
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Osteonectin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Fibroblast Growth Factors; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Tegafur; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tegafur | 2012 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2012 |
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Infusions, Intravenous; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2011 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2012 |
Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Survival Analysis; Tegafur; Young Adult | 2012 |
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Area Under Curve; Asian People; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Hyponatremia; Japan; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Oxonic Acid; Quinazolines; Stomach Neoplasms; Tegafur; Treatment Outcome; Tumor Burden | 2012 |
Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Oxonic Acid; Tegafur; Trastuzumab | 2011 |
Phase I study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with resectable advanced gastric cancer (KOGC-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Humans; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Postoperative Period; Pyridines; Rectal Neoplasms; Remission Induction; Tegafur; Vomiting | 2011 |
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2012 |
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Proton Pump Inhibitors; Tegafur; Treatment Outcome | 2012 |
Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Laparotomy; Male; Multivariate Analysis; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2012 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Combinations; Esophagitis; Female; Fever; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized ph
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Premedication; Risk Assessment; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2012 |
Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Postoperative Complications; Radiotherapy Dosage; Rectal Neoplasms; Tegafur; Tumor Burden | 2011 |
Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2012 |
Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Infusions, Intravenous; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2012 |
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Proteoglycans; Recurrence; Stomach Neoplasms; Tegafur | 2011 |
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2012 |
Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2012 |
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Patient Compliance; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Japan; Male; Middle Aged; Oxonic Acid; Patient Selection; Prospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.
Topics: Aged; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Radiation Dosage; Rectal Neoplasms; Tegafur | 2013 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2012 |
Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Patient Compliance; Pyridines; Tegafur; Treatment Outcome | 2012 |
A Phase III trial to evaluate the effect of perioperative nutrition enriched with eicosapentaenoic acid on body weight loss after total gastrectomy for T2-T4a gastric cancer.
Topics: Adult; Aged; Anastomosis, Roux-en-Y; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dietary Supplements; Drug Combinations; Eicosapentaenoic Acid; Female; Gastrectomy; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Perioperative Period; Practice Guidelines as Topic; Quality of Life; Research Design; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome; Weight Loss | 2012 |
[The updated treatment strategy for gastric cancer with peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2012 |
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur; Uracil | 2012 |
A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Treatment Outcome | 2012 |
A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2012 |
Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Follow-Up Studies; Gastrectomy; Humans; Oxonic Acid; Peritoneal Cavity; Peritoneal Lavage; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Creatinine; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Treatment Outcome | 2012 |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Polymorphism, Genetic; Tegafur; Treatment Outcome | 2012 |
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome | 2012 |
Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2012 |
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Oxonic Acid; Tegafur | 2013 |
A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2013 |
Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Glomerular Filtration Rate; Humans; Inulin; Kidney Function Tests; Male; Middle Aged; Oxonic Acid; Pyridines; Reference Values; Tegafur | 2012 |
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Epirubicin; Female; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; HLA-A24 Antigen; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; T-Lymphocytes, Cytotoxic; Tegafur; Vaccines, Subunit; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2012 |
[Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Platinum; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2012 |
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Korea; Lymph Node Excision; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Phosphorylation; Pilot Projects; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2012 |
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Creatinine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Oxonic Acid; Tegafur; Treatment Outcome | 2012 |
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Salvage Therapy; Tegafur; Young Adult | 2013 |
Feasibility of concurrent chemoradiotherapy with S-1 administered on alternate days for elderly patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Oxonic Acid; Radiotherapy, Conformal; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2012 |
A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Prospective Studies; Tegafur; Young Adult | 2012 |
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Oxonic Acid; Taxoids; Tegafur | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2013 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Republic of Korea; Tegafur | 2012 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2013 |
Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
Topics: Aged; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Dehydration; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fatigue; Female; Humans; Hypoalbuminemia; Hypokalemia; Hyponatremia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2013 |
Prospective feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396).
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Protocols; Drug Combinations; Feasibility Studies; Humans; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2013 |
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Tegafur; Treatment Outcome; Young Adult | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prospective Studies; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Rhabdomyolysis; Tegafur; Treatment Outcome | 2013 |
Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Protocols; Colectomy; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Humans; Japan; Neoplasm Staging; Oxonic Acid; Research Design; Tegafur; Time Factors; Treatment Outcome | 2013 |
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Survival Analysis; Tegafur | 2013 |
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur | 2013 |
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Therapy; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Endonucleases; Endosonography; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Male; Neoplasm Staging; Oxonic Acid; Pneumonectomy; Postoperative Period; Randomized Controlled Trials as Topic; Tegafur | 2014 |
Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneum; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Tegafur | 2013 |
Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Survival Rate; Tegafur | 2013 |
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2013 |
Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Proportional Hazards Models; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cross-Over Studies; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur; Therapeutic Equivalency | 2013 |
Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Linitis Plastica; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Stomach Ulcer; Tegafur; Treatment Outcome | 2013 |
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2013 |
Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Young Adult | 2013 |
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oxonic Acid; Quality of Life; Survival Analysis; Taxoids; Tegafur | 2013 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2013 |
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Drug Combinations; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Radiotherapy, Conformal; Survival Rate; Tegafur | 2013 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | 2013 |
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pilot Projects; Tegafur; Treatment Outcome; Uterine Cervical Neoplasms | 2013 |
Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Drug Combinations; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pyrroles; Stomach Neoplasms; Sunitinib; Tegafur; Treatment Outcome | 2014 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Drug Combinations; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Radiotherapy Dosage; Survival Rate; Tegafur; Thrombocytopenia; Time Factors; Treatment Failure | 2013 |
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Time Factors | 2014 |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Count; Chemokine CCL2; Drug Combinations; Endothelial Cells; Female; Fluorouracil; Humans; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Tegafur; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HLA Antigens; Humans; Immunoglobulins; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Precision Medicine; Prognosis; Survival Rate; Tegafur; Vaccination; Young Adult | 2013 |
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Japan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Leukopenia; Male; Middle Aged; Multivariate Analysis; Nausea; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2013 |
Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; ROC Curve; Tegafur; Thrombocytopenia; Treatment Outcome | 2013 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2014 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
[Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Combinations; Humans; Japan; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2013 |
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2014 |
Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2013 |
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Irinotecan; Male; Oxonic Acid; Prognosis; RNA, Messenger; Stomach Neoplasms; Survival; Tegafur; Thymidylate Synthase; Vascular Endothelial Growth Factor A | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2013 |
Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2013 |
Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pharmacogenetics; Polymorphism, Genetic; Tegafur | 2013 |
A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Tegafur | 2013 |
Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Oxonic Acid; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2014 |
Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
[Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Tegafur | 2013 |
Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Quality-Adjusted Life Years; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Tegafur | 2013 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2013 |
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2014 |
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2013 |
Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2014 |
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Combinations; Female; Humans; Induction Chemotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Risk Factors; Taxoids; Tegafur; Treatment Outcome; Tumor Burden | 2013 |
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Treatment Outcome | 2014 |
Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Tegafur | 2013 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2014 |
Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiotherapy Dosage; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A phase I study of concurrent chemoradiotherapy using oral s-1 for head and neck cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur; Young Adult | 2014 |
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2014 |
Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Tegafur; Thrombocytopenia; Treatment Outcome | 2013 |
Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Photochemotherapy; Prospective Studies; Pyrimidines; Quality of Life; Retreatment; Survival Analysis; Tegafur; United States | 2014 |
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2014 |
Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2014 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Tegafur | 2014 |
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Interleukin-6; Interleukin-8; L-Lactate Dehydrogenase; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Proto-Oncogene Proteins c-sis; Pyrroles; Tegafur; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Radiographic Image Interpretation, Computer-Assisted; Stomach Neoplasms; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2014 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur | 2014 |
Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Preoperative Care; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2014 |
S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Stomach Neoplasms; Tegafur | 2014 |
Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Combinations; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Oxonic Acid; Postoperative Complications; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Postoperative Complications; Prognosis; Prospective Studies; Risk Factors; Stomach Neoplasms; Tegafur | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Combinations; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Oxonic Acid; Paclitaxel; Tegafur | 2014 |
Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2013 |
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Tegafur; Treatment Outcome | 2014 |
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Chemoradiotherapy, Adjuvant; Diarrhea; Dose Fractionation, Radiation; Drug Combinations; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pelvis; Preoperative Care; Rectal Neoplasms; Tegafur; Vomiting | 2015 |
Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Drug Therapy; ErbB Receptors; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Tegafur; Treatment Failure; Treatment Outcome; Vomiting | 2014 |
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Risk; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Uracil; Young Adult | 2014 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Uracil | 2014 |
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Receptor, ErbB-2; Tegafur; Trastuzumab | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2014 |
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Platinum; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Radiotherapy, Conformal; Rectal Neoplasms; Rectum; Tegafur | 2015 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2015 |
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Stomatitis; Survival Analysis; Tegafur; Treatment Outcome; Venous Thrombosis | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Drug Combinations; Female; Histone Deacetylases; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Treatment Outcome; Valproic Acid | 2014 |
Phase II study of concurrent chemoradiotherapy with S-1 in patients with stage II (T2N0M0) squamous cell carcinoma of the Pharynx or Larynx.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pharyngeal Neoplasms; Tegafur | 2014 |
S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Postoperative Complications; Rectal Neoplasms; Tegafur | 2015 |
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2015 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Survival Analysis; Tegafur | 2015 |
HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Oropharyngeal Neoplasms; Oxonic Acid; Papillomaviridae; Prodrugs; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur | 2014 |
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diarrhea; Drug Combinations; Female; Fluorouracil; Gastrectomy; Gastrointestinal Tract; Histamine H2 Antagonists; Humans; Lymph Node Excision; Male; Middle Aged; Nausea; Oxonic Acid; Piperidines; Prospective Studies; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2014 |
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Radiotherapy; Radiotherapy Dosage; Retreatment; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Phase I study of S-1 plus fractional cisplatin as adjuvant chemotherapy for advanced gastric cancer in an outpatient setting (KOGC-03).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Outpatients; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2014 |
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Prognosis; Radiotherapy Dosage; Survival Rate; Tegafur; Young Adult | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2015 |
A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pelvis; Prognosis; Rectal Neoplasms; Remission Induction; Tegafur; Young Adult | 2015 |
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Young Adult | 2015 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Tegafur; Treatment Outcome | 2015 |
The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Doxorubicin; Female; Heart Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2015 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Furans; Humans; Ketones; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur; Young Adult | 2015 |
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Safety; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome | 2015 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Tegafur | 2015 |
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Tegafur | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2015 |
Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome | 2015 |
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Tegafur | 2015 |
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tegafur; Young Adult | 2015 |
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Failure | 2015 |
Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Models, Biological; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2015 |
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2015 |
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2A6; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Perioperative Care; Pharmacogenetics; Postoperative Care; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2016 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyrimidines; Tegafur | 2015 |
Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Female; Glottis; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Prospective Studies; Radiotherapy Dosage; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Tegafur | 2015 |
Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
Topics: Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Quality of Life; Survival Rate; Taxoids; Tegafur | 2015 |
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Prospective Studies; Survival Analysis; Tegafur | 2015 |
S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer: a pilot randomized-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Tegafur | 2015 |
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2016 |
How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Time Factors; Treatment Outcome | 2015 |
A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2015 |
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2015 |
Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Postoperative Care; Stomach Neoplasms; Tegafur | 2015 |
Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Humans; Medication Adherence; Middle Aged; Oxonic Acid; Rectal Neoplasms; Research Design; Tegafur; Young Adult | 2015 |
A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Infusions, Intraventricular; Infusions, Parenteral; Injections, Intraperitoneal; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Serous Membrane; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Platinum; Retreatment; Taxoids; Tegafur; Treatment Outcome | 2015 |
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cisplatin; Docetaxel; Drug Combinations; ErbB Receptors; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Trastuzumab | 2015 |
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; ErbB Receptors; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur; Trastuzumab | 2015 |
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2015 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2015 |
A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2014 |
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2015 |
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Pyridines; Radiotherapy Dosage; Tegafur; Treatment Outcome; Young Adult | 2015 |
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur; Treatment Outcome; Young Adult | 2015 |
Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pilot Projects; Prognosis; Radiotherapy Dosage; Survival Rate; Tegafur; Uterine Cervical Neoplasms | 2016 |
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Salvage Therapy; Tegafur; Treatment Outcome | 2015 |
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Combinations; Follow-Up Studies; Humans; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Young Adult | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Patient Selection; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2015 |
Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Tegafur | 2015 |
Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Safety; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2016 |
BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; Biomarkers, Tumor; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Non-Randomized Controlled Trials as Topic; Oxonic Acid; Peptide Fragments; Prognosis; Proto-Oncogene Proteins; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2016 |
Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Retreatment; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2015 |
A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Tegafur | 2016 |
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting | 2016 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Topics: Adenocarcinoma; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Feeding and Eating Disorders; Female; Humans; Hyponatremia; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2016 |
Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2016 |
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Capsules; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase | 2016 |
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cognition Disorders; Docetaxel; Drug Combinations; Gastrointestinal Diseases; Humans; Lung Neoplasms; Oxonic Acid; Quality of Life; Taxoids; Tegafur | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Copy Number Variations; Drug Combinations; Female; Genome-Wide Association Study; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur; White People; Young Adult | 2016 |
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Prospective Studies; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Tegafur; Trastuzumab | 2016 |
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Oxonic Acid; Patient Selection; Tegafur; Treatment Outcome | 2016 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur; Uracil | 2016 |
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Klatskin Tumor; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Treatment Outcome | 2016 |
Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Oxonic Acid; Pyridines; Radiotherapy, Conformal; Tegafur; Treatment Outcome | 2016 |
Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Combinations; Female; Genes, ras; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Recurrence; Tegafur | 2016 |
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2016 |
Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dissection; Drug Combinations; Esophagogastric Junction; Feasibility Studies; Female; Gastrectomy; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Combinations; Fatigue; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2016 |
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxonic Acid; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Tegafur | 2016 |
Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric canc
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Tegafur | 2016 |
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur | 2016 |
Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cystine; Dietary Supplements; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Neoplasms; Glutamates; Glutathione; Humans; Male; Middle Aged; Oxonic Acid; Protective Agents; Tegafur; Treatment Outcome | 2016 |
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiotherapy Planning, Computer-Assisted; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Panitumumab; Proto-Oncogene Proteins p21(ras); Survival Rate; Tegafur | 2016 |
A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Platinum Compounds; Survival Rate; Tegafur; Treatment Failure; Treatment Outcome | 2016 |
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Tegafur; Treatment Failure; Treatment Outcome | 2016 |
Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Female; Humans; Lentinan; Male; Middle Aged; Monocytes; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2016 |
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
Topics: Adult; Aged; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Middle Aged; Oxonic Acid; Quality of Life; Quality-Adjusted Life Years; Surveys and Questionnaires; Taxoids; Tegafur | 2017 |
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Uterine Cervical Neoplasms | 2016 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; RNA, Messenger; Tegafur; Tetrahydrofolate Dehydrogenase; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2016 |
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Stomach Neoplasms; Tegafur | 2017 |
Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Drug Combinations; Humans; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiosurgery; Research Design; Survival Rate; Tegafur | 2016 |
Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2A6; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pharmacogenomic Testing; Stomach Neoplasms; Tegafur | 2017 |
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur | 2017 |
Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
Topics: Aged; Area Under Curve; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Kidney; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Renal Insufficiency; Tegafur | 2017 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Survival Analysis; Tegafur; White People | 2017 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Oxonic Acid; Tegafur | 2017 |
Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Paclitaxel; Remission Induction; Retrospective Studies; Tegafur; Vomiting | 2017 |
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Treatment Outcome | 2017 |
The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.
Topics: Aged; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Postoperative Care; Proportional Hazards Models; Risk Factors; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2017 |
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2018 |
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Drug Combinations; Fatigue; Feeding and Eating Disorders; Female; Humans; Hyperbilirubinemia; Hyperpigmentation; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur | 2017 |
Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Microarray Analysis; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2017 |
Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2017 |
A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Dose Hypofractionation; Survival Rate; Tegafur | 2017 |
Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Substitution; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retreatment; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Drugs, Chinese Herbal; Esophageal Neoplasms; Female; Humans; Karnofsky Performance Status; Leukopenia; Male; Nausea; Neutropenia; Oxonic Acid; Tegafur; Vomiting | 2017 |
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophagogastric Junction; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Ramucirumab; Stomach Neoplasms; Tegafur | 2018 |
Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2017 |
A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Quality of Life; Stomach Neoplasms; Tegafur | 2017 |
Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2017 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Stomatitis; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Patient Compliance; Prospective Studies; Tegafur; Treatment Outcome; Young Adult | 2017 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur | 2017 |
Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Oxonic Acid; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2018 |
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Japan; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Taxoids; Tegafur; Time Factors | 2018 |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Young Adult | 2017 |
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Wnt-5a Protein | 2018 |
Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
Topics: Adult; Aged; Chemoradiotherapy; Digestive System Surgical Procedures; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Tegafur; Young Adult | 2017 |
Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Fluorouracil; Health Status; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Patient Reported Outcome Measures; Quality of Life; Surveys and Questionnaires; Taxoids; Tegafur | 2018 |
A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cytochrome P-450 CYP2A6; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Oxonic Acid; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Random Allocation; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2018 |
Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Preoperative Care; Stomach Neoplasms; Tegafur; Treatment Outcome | 2018 |
S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Radiotherapy, Intensity-Modulated; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Young Adult | 2017 |
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Tegafur; Uracil | 2018 |
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2018 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Tegafur; Young Adult | 2018 |
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Creatinine; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Oxonic Acid; Precision Medicine; Survival Rate; Tegafur; Treatment Outcome | 2018 |
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administration Schedule; Drug Combinations; Exome Sequencing; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Oxonic Acid; Proto-Oncogene Proteins p21(ras); Tegafur; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Multivariate Analysis; Oxonic Acid; Propensity Score; Stomach Neoplasms; Tegafur; Treatment Outcome | 2018 |
Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Receptor, ErbB-2; Tegafur; Trastuzumab | 2018 |
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Republic of Korea; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2019 |
Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Postoperative Complications; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2017 |
A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Drug Combinations; Endpoint Determination; Female; Follow-Up Studies; Humans; Japan; Male; Medical Oncology; Middle Aged; Observation; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Tegafur | 2018 |
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tegafur; WT1 Proteins | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Metastasis; Oxonic Acid; Survival Rate; Tegafur | 2018 |
Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Tegafur; Treatment Outcome | 2018 |
Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retreatment; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Humans; Maximum Tolerated Dose; Oxonic Acid; Prospective Studies; Taxoids; Tegafur | 2018 |
A pilot study of oral S-1 for treating heavily pretreated patients with advanced or recurrent cervical cancer among Chinese population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; China; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Middle Aged; Oxonic Acid; Pilot Projects; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2018 |
Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome; Uracil | 2018 |
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Combinations; Female; Follow-Up Studies; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Sulfonamides; Tegafur; Tissue Distribution | 2019 |
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome; Vinorelbine | 2018 |
A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pneumonectomy; Postoperative Period; Tegafur | 2018 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Postoperative Care; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2019 |
Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retreatment; Tegafur; Treatment Outcome | 2019 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2019 |
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Survival Rate; Tegafur | 2018 |
Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2019 |
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Endostatins; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Recombinant Proteins; Stomach Neoplasms; Tegafur; Treatment Outcome | 2018 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Oxaliplatin; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2019 |
IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Young Adult | 2019 |
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Quinazolines; Tegafur; Thiophenes | 2019 |
Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Survival Rate; Tegafur | 2019 |
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Intention to Treat Analysis; Japan; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur | 2019 |
Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome; Young Adult | 2019 |
Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Capecitabine; Drug Combinations; Female; Follow-Up Studies; Humans; Lymphocytes; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Retreatment; Survival Rate; Tegafur | 2019 |
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Hand-Foot Syndrome; Humans; Incidence; Kaplan-Meier Estimate; Oxonic Acid; Progression-Free Survival; Tegafur | 2019 |
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Nanoparticles; Oxonic Acid; Paclitaxel; Prognosis; Survival Rate; Tegafur | 2019 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Survival Analysis; Tegafur; Tumor Burden | 2019 |
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2019 |
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Oxonic Acid; Quality of Life; Tegafur; Treatment Outcome | 2019 |
Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Receptor, ErbB-2; Tegafur; Trastuzumab; Treatment Outcome | 2019 |
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Female; Humans; Leukopenia; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Progression-Free Survival; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2019 |
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Survival Rate; Tegafur; Young Adult | 2019 |
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Care; Stomach Neoplasms; Tegafur | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Topoisomerase I Inhibitors | 2019 |
Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Propensity Score; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Topics: Adult; Aged; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Dendritic Cells; Double-Blind Method; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multicenter Studies as Topic; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Randomized Controlled Trials as Topic; Tegafur; Time Factors; Treatment Outcome; WT1 Proteins; Young Adult | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Outcome Assessment, Health Care; Oxonic Acid; Prospective Studies; Radiotherapy, Intensity-Modulated; Stomach Neoplasms; Tegafur | 2019 |
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Patient Compliance; Quality of Life; Survival Analysis; Tegafur | 2019 |
Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Oxonic Acid; Prognosis; Prospective Studies; Survival Rate; Tegafur | 2019 |
A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Topics: Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Stomach; Stomach Neoplasms; Tegafur; Treatment Outcome | 2019 |
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Tegafur; Trastuzumab; Treatment Outcome; Young Adult | 2019 |
A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studies; Diarrhea; Drug Combinations; Female; Follow-Up Studies; Food, Formulated; Humans; Incidence; Japan; Male; Middle Aged; Nutritional Support; Oxonic Acid; Pilot Projects; Prognosis; Prospective Studies; Stomach Neoplasms; Stomatitis; Tegafur; Young Adult | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; China; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2019 |
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Incidence; Male; Middle Aged; Nausea; Neutropenia; Oxaliplatin; Oxonic Acid; Sex Factors; Stomach Neoplasms; Stomatitis; Tegafur; Thrombocytopenia; Vomiting | 2019 |
An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2019 |
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2019 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chromatography, Liquid; Cross-Over Studies; Drug Compounding; Fluorouracil; Humans; Oxonic Acid; Pyridines; Republic of Korea; Stomach Neoplasms; Tandem Mass Spectrometry; Tegafur; Therapeutic Equivalency | 2019 |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Nausea; Oxonic Acid; Tegafur; Vomiting | 2019 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1).
Topics: Adult; Aged; Anemia; Chemoradiotherapy; Cisplatin; Deglutition Disorders; Drug Combinations; Female; Humans; Hypoalbuminemia; Male; Middle Aged; Nutritional Support; Oxonic Acid; Prognosis; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2019 |
Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study).
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Patient Compliance; Perioperative Care; Survival Analysis; Tegafur; Treatment Outcome | 2019 |
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Prospective Studies; Pyridines; Survival Rate; Tegafur; Thymoma; Thymus Neoplasms | 2020 |
Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Tegafur; Young Adult | 2019 |
A Phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Protocols; Docetaxel; Drug Combinations; Female; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Postoperative Care; Preoperative Care; Stomach Neoplasms; Tegafur | 2020 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Drug Combinations; Humans; Middle Aged; Multicenter Studies as Topic; Oxonic Acid; Prognosis; Research Design; Tegafur; Thymoma; Thymus Neoplasms; Young Adult | 2020 |
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Neutropenia; Oxonic Acid; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Receptor, ErbB-2; Remission Induction; Stomach Neoplasms; Tegafur | 2020 |
Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Disease-Free Survival; Drug Combinations; Gallbladder Neoplasms; Humans; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2020 |
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Survival Rate; Tegafur | 2020 |
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Clinical study of XiangShaLiuJunZi decoction combined with S-1 as maintenance therapy for stage III or IV gastric carcinoma and colorectal carcinoma.
Topics: Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Humans; Maintenance Chemotherapy; Neoplasm Staging; Oxonic Acid; Phytotherapy; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinoma; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Prospective Studies; Radiofrequency Ablation; Tegafur; Treatment Outcome | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Survival Rate; Tegafur; Young Adult | 2020 |
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Progression-Free Survival; Proportional Hazards Models; Tegafur; Treatment Outcome | 2020 |
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2020 |
Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
Response Shift-Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Combinations; Female; Humans; Latent Class Analysis; Middle Aged; Oxonic Acid; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Taxoids; Tegafur | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2020 |
The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Confidence Intervals; Disease-Free Survival; Drug Combinations; Female; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Oxonic Acid; Prognosis; ROC Curve; Sample Size; Stomach Neoplasms; Tegafur | 2020 |
Phase I dose-escalation trial of S-1 combined with carbon-ion radiotherapy for sinonasal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Heavy Ion Radiotherapy; Humans; Kaplan-Meier Estimate; Male; Maxillary Sinus Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2020 |
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Proportional Hazards Models; Pyrimidines; Pyrophosphatases; Response Evaluation Criteria in Solid Tumors; Stomach Neoplasms; Sulfonamides; Tegafur; Ubiquitin-Protein Ligases | 2021 |
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Palliative Care; Retreatment; Tegafur; Thymus Neoplasms; Treatment Outcome | 2020 |
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myocardial Infarction; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2021 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Nomograms; Oxonic Acid; Renal Insufficiency; Tegafur | 2021 |
Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Complications; Preoperative Care; Stomach Neoplasms; Tegafur; Time Factors | 2021 |
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Thoracic Neoplasms | 2021 |
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tegafur; Time Factors; Young Adult | 2021 |
The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Stomach Neoplasms; Tegafur; Young Adult | 2021 |
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Prognosis; Rectal Neoplasms; Survival Rate; Tegafur | 2021 |
Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Treatment Outcome | 2021 |
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Hydroxamic Acids; Japan; Male; Middle Aged; Oxonic Acid; Placebos; Platinum Compounds; Progression-Free Survival; Sulfonamides; Tegafur; Young Adult | 2021 |
Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Topics: Adult; Aged; Drug Combinations; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2021 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxonic Acid; Proto-Oncogene Proteins B-raf; Quality of Life; Tegafur | 2021 |
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate; Tegafur | 2021 |
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Receptor, ErbB-2; Survival Analysis; Taxoids; Tegafur; Treatment Outcome; Young Adult | 2021 |
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fatigue; Feasibility Studies; Female; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Compliance; Stomach Neoplasms; Tegafur | 2021 |
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2022 |
2129 other study(ies) available for tegafur and oxonic acid
| Article | Year |
|---|---|
Complete response of transverse colon carcinoma to S1, a new chemotherapy agent: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colon; Colonic Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Tegafur | 1995 |
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Transplantation; Oxonic Acid; Prodrugs; Pyridines; Rats; Rats, Nude; RNA; Tegafur; Transplantation, Heterologous | 1996 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Diarrhea; Dogs; Drug Combinations; Female; Lethal Dose 50; Lymph Nodes; Male; Mice; Motor Activity; Oxonic Acid; Pyridines; Rats; Salivation; Spleen; Survival Rate; Tegafur; Thymus Gland | 1996 |
[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Body Weight; Bone Marrow; Drug Combinations; Edema; Female; Hematologic Tests; Lymph Nodes; Male; No-Observed-Adverse-Effect Level; Organ Size; Oxonic Acid; Pyridines; Rats; Tegafur; Thymus Gland; Urine | 1996 |
[An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marrow; Cornea; Dogs; Drug Combinations; Epithelium; Eye; Female; Hematologic Tests; Lung; Male; Organ Size; Oxonic Acid; Pyridines; Tegafur; Thymus Gland | 1996 |
[A 26-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Body Weight; Drug Combinations; Epidermis; Female; Hematologic Tests; Hyperplasia; Inflammation; Kidney; Lymphoid Tissue; Male; No-Observed-Adverse-Effect Level; Organ Size; Oxonic Acid; Pyridines; Rats; Tegafur; Testis | 1996 |
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagulation; Body Weight; Dogs; Drug Combinations; Eye; Eye Diseases; Female; Hematologic Tests; Hyperpigmentation; Lymph Nodes; Male; Organ Size; Oxonic Acid; Pyridines; Skin; Skin Diseases; Tegafur; Urinalysis | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (I)--Fertility study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body Weight; Bone and Bones; Drug Combinations; Eating; Embryonic and Fetal Development; Female; Fertility; Male; No-Observed-Adverse-Effect Level; Organ Size; Osteogenesis; Oxonic Acid; Pregnancy; Pyridines; Rats; Tegafur | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)--Teratological study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Body Weight; Bone and Bones; Drug Combinations; Eating; Embryonic and Fetal Development; Female; Fertility; Male; No-Observed-Adverse-Effect Level; Oxonic Acid; Pregnancy; Pregnancy, Animal; Pyridines; Rats; Reproduction; Tegafur | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)--Teratological study in rabbits by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body Weight; Bone and Bones; Drug Combinations; Eating; Embryonic and Fetal Development; Female; Male; No-Observed-Adverse-Effect Level; Osteogenesis; Oxonic Acid; Pregnancy; Pregnancy, Animal; Pyridines; Rabbits; Reproduction; Tegafur; Time Factors | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Topics: Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Behavior, Animal; Body Weight; Drug Combinations; Eating; Estrus; Female; Kidney; Male; No-Observed-Adverse-Effect Level; Organ Size; Oxonic Acid; Pregnancy; Pyridines; Rats; Tegafur | 1996 |
[Antigenicity tests of a new antineoplastic agent S-1].
Topics: Administration, Oral; Animals; Antigens; Antimetabolites, Antineoplastic; Cricetinae; Drug Combinations; Female; Freund's Adjuvant; Guinea Pigs; Hemagglutination Tests; Immune System; Immunization; Male; Mice; Mice, Inbred BALB C; Oxonic Acid; Passive Cutaneous Anaphylaxis; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin; Tegafur | 1996 |
[Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Cells, Cultured; Chromosome Aberrations; Cricetinae; Drug Combinations; Escherichia coli; Mutagenicity Tests; Oxonic Acid; Pyridines; Salmonella typhimurium; Tegafur | 1996 |
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Fluorouracil; Immune System; Immune Tolerance; Immunologic Tests; Mice; Mice, Inbred BALB C; Organ Size; Oxonic Acid; Pyridines; Spleen; Tegafur; Thymus Gland; Uracil | 1996 |
Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass sp
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Oxonic Acid; Pyridines; Sensitivity and Specificity; Tegafur | 1997 |
Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Rats, Inbred F344; Rats, Nude; Species Specificity; Tegafur; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured | 1998 |
Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Digestive System; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Neoplasm Transplantation; Oxonic Acid; Pyridines; Rats; Rats, Inbred F344; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous | 1998 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Mitosis; Neoplasm Transplantation; Oxonic Acid; Prodrugs; Pyridines; Rats; Rats, Inbred F344; Tegafur; Thymidylate Synthase; Treatment Outcome | 1999 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Combinations; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oxonic Acid; Pyridines; Tegafur; Transplantation, Heterologous | 1999 |
Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 1999 |
New anti-cancer agent S-1: metabolism based drug combination.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Dogs; Drug Combinations; Oxonic Acid; Pyridines; Rats; Tegafur | 2000 |
[Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cisplatin; Colonic Neoplasms; Drug Combinations; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxonic Acid; Pyridines; Splenic Neoplasms; Tegafur | 2000 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fluorodeoxyuridylate; Fluorouracil; Ileum; Male; Oxonic Acid; Pyridines; Rats; Tegafur; Thymidylate Synthase | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Transplantation, Heterologous; Tumor Cells, Cultured; Uracil | 2000 |
Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Topics: Administration, Oral; Allopurinol; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biotransformation; Carbon Radioisotopes; Chlorpromazine; Drug Combinations; Drugs, Chinese Herbal; Fluorouracil; Glycyrrhiza; Intestine, Small; Male; Microsomes, Liver; Oxonic Acid; Paeonia; Pyridines; Rats; Rats, Inbred Strains; Sarcoma, Yoshida; Tegafur; Tissue Distribution; Triazines; Uracil; Xanthine Oxidase | 2000 |
Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Synergism; Enzyme Induction; Fluorouracil; Folic Acid; Male; Methionine; Mice; Neoplasm Transplantation; Oxonic Acid; Pyridines; Rats; Sarcoma, Yoshida; Tegafur | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Biotransformation; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Isoenzymes; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Organic Chemicals; Oxonic Acid; Probucol; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyridines; Tegafur; Telomerase; Xenograft Model Antitumor Assays | 2000 |
[A complete response persisting for seven months with the use of TS-1 in a patient with paraaortic lymph node metastasis of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Drug Administration Schedule; Drug Combinations; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2000 |
[A case report of TS-1 in a patient with advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Palliative Care; Pyridines; Stomach Neoplasms; Tegafur | 2000 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
[A case of stage IV gastric cancer with multiple liver metastases and carcinomatous ascites responding to TS-1 for six months before progression].
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Disease Progression; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A case of recurrent gastric cancer successfully treated with TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Muscle Neoplasms; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biotransformation; Calcium Channel Blockers; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Immunoblotting; Intestinal Mucosa; Intestine, Small; Male; Microsomes; NADPH-Ferrihemoprotein Reductase; Nifedipine; Oxonic Acid; Pentosyltransferases; Pyridines; Rats; Rats, Inbred Strains; Tegafur | 2001 |
[Three cases of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Humans; Keratoderma, Palmoplantar; Middle Aged; Oxonic Acid; Pyridines; Sigmoid Neoplasms; Tegafur | 2001 |
Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Half-Life; Humans; Oxonic Acid; Pyridines; Reference Values; Statistics as Topic; Tegafur | 2001 |
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Lung Diseases, Interstitial; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
[Two elderly patients with advanced gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by oral administration of S-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chronotherapy; Circadian Rhythm; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Leucovorin; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A case of advanced gastric cancer that was resectable after asctic fluid had disappeared following administration of TS-1].
Topics: Antimetabolites, Antineoplastic; Ascitic Fluid; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Postoperative Care; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A case of hepatic metastasis of gastric cancer responding to TS-1, administered for two consecutive weeks and one week rest].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[Complete response in a case of advanced gastric cancer with liver and intra-abdominal lymph node metastases treated by combined chemotherapy of TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2001 |
[Case report: a recurrent gastric cancer in the terminal stage, associated with obstructive jaundice which responded significantly to oral administration of TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Cholestasis; Drug Combinations; Humans; Lymphatic Diseases; Male; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2001 |
[A case of remnant gastric cancer responding to neoadjuvant TS-1 therapy].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Gastric Stump; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A case report of rectal cancer with liver and pulmonary metastases responding to TS-1].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Rectal Neoplasms; Tegafur | 2001 |
Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2001 |
Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
Topics: Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Dihydrouracil Dehydrogenase (NAD+); Drug Combinations; Fluorouracil; Half-Life; Humans; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Oxonic Acid; Prodrugs; Pyridines; Tegafur | 2001 |
[A case of postoperative gastric cancer responding to adjuvant chemotherapy with TS-1--a novel oral formation of 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Postoperative Care; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2001 |
[A remarkably improved multimetastatic gastric cancer with the use of TS-1 and CDDP].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2001 |
[A case of advanced gastric cancer producing alpha fetoprotein with multiple liver metastases responding to TS-1 after TAE].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2001 |
[A surgical case of recurrent gastric cancer successfully treated by TS-1 plus low-dose consecutive administration of CDDP following TS-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of advanced gastric cancer successfully treated with TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2002 |
[A patient with advanced gastric cancer in the gastric tube whose QOL was improved by TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagoplasty; Humans; Male; Mediastinum; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
Unusual survival for more than 2 years with peritoneal metastases of gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2002 |
[A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluorouracil; Humans; Neoplasm Metastasis; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of gastric cancer with multiple liver metastases responding to TS-1].
Topics: Adenocarcinoma, Papillary; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; DNA Primers; DNA, Neoplasm; Drug Combinations; Escherichia coli; Genotype; Humans; Kinetics; Middle Aged; Mixed Function Oxygenases; Mutagenesis, Site-Directed; Oxonic Acid; Polymerase Chain Reaction; Polymorphism, Genetic; Pyridines; Recombinant Proteins; Stomach Neoplasms; Tegafur; Transfection | 2002 |
[Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Drug Evaluation; Mice; Mice, Nude; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative].
Topics: Adenocarcinoma, Papillary; Administration, Oral; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Liver Diseases; Lymphatic Metastasis; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Successful treatment of gastric cancer accompanied by multiple liver metastases with TS-1 followed by curative gastrectomy affiliation].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cisplatin; Disease Models, Animal; Drug Combinations; Humans; Kidney Function Tests; Male; Middle Aged; Oxonic Acid; Pyridines; Rabbits; Renal Insufficiency; Stomach Neoplasms; Tegafur | 2002 |
An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Clinical study of individual TS-1 therapy for inoperable gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2002 |
[Complete response in an elderly patient with advanced gastric scirrhous cancer treated with combined chemotherapy of TS-1 and CDDP].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2002 |
[A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectomy; Gastric Stump; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of gastric carcinoma with metastasis in a paraaortic lymph node that responded to TS-1/CDDP combination therapy, in which the patient was able to undergo extirpation with grade B curability].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur | 2002 |
[A case of gastric cancer with paraaortic lymph node metastasis responding to TS-1/CDDP as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Preoperative Care; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2002 |
[Two cases of stage IV type 4 gastric cancer with good response to TS-1].
Topics: Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Preoperative Care; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Complete response in a case of recurrent gastric cancer treated with TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Oxonic Acid; Pyridines; Remission Induction; Tegafur | 2002 |
[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2002 |
[A case of advanced gastric cancer with invasion of pancreas effectively treated by combined chemotherapy of TS-1 and paclitaxel (TXL)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[Every-other-day TS-1 administration for recurrent or non-curative advanced gastric carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Cholestasis; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2002 |
Advanced gastric cancer with liver metastases successfully treated with S-1.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Complete response in a case of advanced scirrhous type 3 gastric cancer of with bulky N2 para-aorta lymph node metastases treated by combined chemotherapy of TS-1 and CDDP].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2002 |
[TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Oxonic Acid; Preoperative Care; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Effective use of TS-1 in a case of advanced gastric cancer, both in treating the tumor and in maintaining the patient's quality of life].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[A case of recurrent advanced gastric cancer suggesting the efficacy of TS-1 and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Survivors; Tegafur | 2002 |
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Pyridines; Tegafur | 2002 |
[A case of stomach cancer in which TS-1 neoadjuvant therapy was effective against multiple hepatic metastasis, allowing a radical cure A surgery].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[A case of stage IV gastric carcinoma with lymph nodes metastases of the paraaorta responding markedly to TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2002 |
[Three cases of advanced and recurrent gastric cancer treated with paclitaxel after TS-1 administration].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Outpatients; Oxonic Acid; Paclitaxel; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2002 |
[Pharmacoeconomic study of chemotherapy for gastric cancer: analysis of medical costs for oral fluoropyrimidine TS-1 and conventional i.v therapy].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Drug Administration Schedule; Drug Combinations; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced lateral wall oropharyngeal carcinoma showing complete response to chemotherapy with TS-1].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Oropharyngeal Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2003 |
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Combinations; Etoposide; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Remission Induction; Serpins; Stomach Neoplasms; Tegafur | 2003 |
[A surgically resected case of advanced gastric carcinoma with peritoneal dissemination after treatment with combined chemotherapy of TS-1 and CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer treated with paclitaxel and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
[Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured | 2003 |
[A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Krukenberg Tumor; Lentinan; Neoplasms, Multiple Primary; Ondansetron; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case report--TS-1/CDDP combined chemotherapy found effective for metastatic recurrence after operation for colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon, Sigmoid; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Leucovorin; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Sigmoid Neoplasms; Splenic Neoplasms; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Tegafur | 2003 |
Complete response of Sister Mary Joseph Nodule from gastric adenocarcinoma treated with combination chemotherapy of low-dose S-1 and cisplatin.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome | 2002 |
[A case report of adjuvant chemotherapy (TS-1) for far advanced gastric cancer in which the patient maintained a good quality of life].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2003 |
[A patient with gastric cancer complicated with severe DIC and multiple bone metastasis showing a high response to combination of TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clodronic Acid; Disseminated Intravascular Coagulation; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Pyridines; Tegafur | 2003 |
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma; Cell Count; Dose-Response Relationship, Drug; Drug Combinations; Genes, Reporter; Green Fluorescent Proteins; Humans; Injections, Intraperitoneal; Luminescent Proteins; Male; Mesentery; Mice; Mice, Nude; Omentum; Oxonic Acid; Peritoneal Neoplasms; Prodrugs; Pyridines; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
[Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Combination therapy of fluoropyrimidine (TS-1) administration and selective intra-arterial cisplatin infusion for tongue carcinoma--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nausea; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Tongue Neoplasms; Vomiting, Anticipatory | 2003 |
[A case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Eating; Female; Fluorouracil; Japan; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors | 2003 |
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Evaluation; Female; Humans; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Product Surveillance, Postmarketing; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2003 |
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Tegafur; Time; Treatment Outcome | 2003 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Forecasting; Humans; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2003 |
Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study.
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Digestive System Surgical Procedures; Drug Combinations; Humans; Japan; Laparoscopy; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pilot Projects; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Japan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Oxidoreductases; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Pyridines; Statistics as Topic; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2003 |
[A case report of tongue squamous cell carcinoma showing a complete response to TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Tongue Neoplasms; Uracil | 2003 |
[A case of gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[Sustained NC status for a long period after combined chemotherapy of TS-1 and CDDP for residual lesions following gastrectomy for gastric cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoplasm, Residual; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[Remnant gastric cancer in which prolonged no change status was maintained with low-dose TS-1--a case report].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Neoplasm, Residual; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Conjunctivitis; Drug Combinations; Foot Dermatoses; Hand Dermatoses; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Pyridines; Stomach Neoplasms; Stomatitis; Syndrome; Tegafur; Vitamin B 6 | 2003 |
[A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritonitis; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer with abdominal paraaortic lymph node swelling successfully resected following neoadjuvant chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphangitis; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer which became operable after chemotherapy with combination of TS-1/CDDP and in which complete disappearance of liver metastasis was histopathologically confirmed].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Remission Induction; Splenectomy; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer with bone metastases and DIC responding to oral administration of TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Signet Ring Cell; Disseminated Intravascular Coagulation; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Fluorouracil; Male; Mice; Oxonic Acid; Pyridines; Sarcoma 180; Tegafur; Tissue Distribution | 2003 |
[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Four cases of gastric cancer with multiple hepatic metastases successfully treated with TS-1 in combination with low-dose cisplatinum].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric carcinoma successfully treated with TS-1/CDDP as a neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gallbladder cancer with biliary tract stenosis which responded to TS-1 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Diseases; Cisplatin; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Gallbladder Neoplasms; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2003 |
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; beta-Alanine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Oxidoreductases; Oxonic Acid; Pyridines; Tegafur; Uracil | 2003 |
[A case of mandibular gingival cancer (T4) responding to concurrent chemoradiotherapy with TS-1].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Gingival Neoplasms; Humans; Male; Mandible; Oxonic Acid; Pyridines; Radiotherapy Dosage; Tegafur | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Diseases; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur; Umbilicus | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
[A case of advanced gastric cancer attaining histological CR of paraaortic lymph node after TS-1/CDDP neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Gastric Mucosa; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastroscopy; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Radiotherapy, Adjuvant; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[A case of hepatocellular carcinoma treated with TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Tegafur; Tomography, X-Ray Computed | 2003 |
Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Combinations; Fluorouracil; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Pyridines; RNA, Neoplasm; Stomach Neoplasms; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2003 |
[Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Tegafur | 2003 |
[A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer with multiple liver metastases responding to TS-1 and CDDP].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[Efficacy of TS-1 in patients with peritonitis carcinomatosa from gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Length of Stay; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Peritonitis; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2003 |
[A case of distant metastasis from advanced gastric cancer treated with TS-1, which maintained NC (no change) for 9 months].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2003 |
[A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Injections, Intraperitoneal; Male; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
[A case of advanced gastric cancer that had invaded the duodenum treated with combined chemotherapy using TS-1 and low-dose CDDP, which prevented the need for a pancreaticoduodenectomy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Duodenal Neoplasms; Female; Gastrectomy; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreaticoduodenectomy; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
[Pancytopenia and ARDS with high dose hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Oxonic Acid; Pancytopenia; Pyridines; Respiratory Distress Syndrome; Stomach Neoplasms; Tegafur | 2003 |
[TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer: a preliminary report].
Topics: Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Lentinan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of lymph node recurrence after curative operation of type 4 gastric cancer, successfully treated with TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chi-Square Distribution; Clinical Trials as Topic; Drug Combinations; Europe; Female; Humans; Male; Middle Aged; Models, Biological; Oxonic Acid; Pyridines; Statistics, Nonparametric; Tegafur; United States; Western World | 2003 |
[A case of lymph node metastasis after total laryngectomy successfully treated with chemoradiotherapy with TS-1].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Laryngeal Neoplasms; Laryngectomy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Radiotherapy Dosage; Skin Neoplasms; Tegafur | 2003 |
[A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Lymphatic Metastasis; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Radiotherapy Dosage; Remission Induction; Stomach; Stomach Neoplasms; Tegafur | 2003 |
[Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2003 |
[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Quality of Life; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2003 |
[Two resected cases of advanced gastric cancer with peritoneal dissemination after successful treatment with TS-1 plus low-dose CDDP].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
[A case of gastric cancer with multiple liver metastases and spleen metastasis that responded to low-dose CDDP/TS-1 combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Splenic Neoplasms; Stomach Neoplasms; Tegafur | 2004 |
[A case of malignant gastric outlet stenosis palliated with self-expandable metallic stent and responding to TS-1, an oral fluorouracil derivative].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Outlet Obstruction; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stents; Stomach Neoplasms; Tegafur | 2004 |
[A case of recurrent advanced gastric cancer with lung metastasis effectively treated by combined chemotherapy of TS-1 and weekly CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA; DNA, Complementary; Drug Combinations; Electrophoresis; Female; Genotype; Heterozygote; Homozygote; Humans; Loss of Heterozygosity; Male; Middle Aged; Oxonic Acid; Polymerase Chain Reaction; Polymorphism, Genetic; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tegafur; Thymidylate Synthase; Time Factors; Treatment Outcome | 2004 |
[A case of advanced maxillary carcinoma with cervical lymph node metastases showing a complete response to the combination therapy of CDDP, TS-1 and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Maxillary Neoplasms; Neck; Neutropenia; Oxonic Acid; Pyridines; Radiotherapy, Adjuvant; Stomatitis; Tegafur; Thrombocytopenia | 2004 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Tegafur | 2004 |
[A case of carcinomatous lymphangitis of the lungs due to stomach cancer responding to TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Peritoneal Neoplasms; Pleural Effusion, Malignant; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2004 |
[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Umbilicus | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2004 |
[A case of advanced colon cancer with peritoneal dissemination completely responding to TS-1].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Tegafur | 2004 |
Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Mitomycin; Oxonic Acid; Pyridines; Radiography; Stomach Neoplasms; Tegafur; Treatment Failure | 2004 |
[A case of advanced gastric cancer with simultaneous multiple bone metastases and double occurrence of disseminated intravascular coagulation successfully controlled with combined chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Disseminated Intravascular Coagulation; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of postoperative chestwall recurrence of gastric cancer responding to a combination of radiation, hyperthermia and oral administration of TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Hyperthermia, Induced; Leukopenia; Male; Oxonic Acid; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur; Thoracic Neoplasms | 2004 |
[Two cases of advanced and recurrent gastric cancer responding markedly to TS-1/CDDP therapy].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of recurrent pleural effusion and positive cytology of advanced gastric cancer treated by TS-1 plus weekly taxane as second-line chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-19-9 Antigen; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Pleural Effusion, Malignant; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Pyridines; Remission Induction; Tegafur | 2004 |
[A case report of advanced cardiac cancer showing a complete response to TS-1 as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cardia; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of gastric cancer with multiple liver metastases responding completely to TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of complete response in a primary lesion treated by combined chemotherapy of TS-1 and CDDP for small cell carcinoma of the stomach with liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Gastrectomy; Humans; Leukopenia; Male; Middle Aged; Oxonic Acid; Postoperative Period; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Edema; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of neck metastasis from hypopharyngeal carcinoma successfully treated with TS-1].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Humans; Hypopharyngeal Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Oxonic Acid; Pyridines; Tegafur | 2004 |
[An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Gingival Neoplasms; Humans; Leukopenia; Maxillary Sinus Neoplasms; Mouth Mucosa; Mouth Neoplasms; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Thrombocytopenia; Vomiting, Anticipatory | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neck; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[Two cases of recurrent gastric cancer treated by combined chemotherapy of TS-1 and low-dose cis-platinum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[Two cases of recurrent gastric cancer at anastomosis medicated by TS-1].
Topics: Aged; Anastomosis, Roux-en-Y; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2004 |
[A case of hepatocellular carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Protein Precursors; Prothrombin; Pyridines; Tegafur | 2004 |
Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Combinations; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Oxonic Acid; Pyridines; Tegafur; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2004 |
A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy.
Topics: Adenocarcinoma; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Jejunum; Middle Aged; Oxonic Acid; Palliative Care; Pyridines; Stomach; Stomach Neoplasms; Tegafur | 2004 |
[A case of heterochronous liver metastasis of gastric cancer favorably responding to TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Postoperative Period; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of advanced gastric cancer with bulky N2 lymph node metastases resected after successful treatment with TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Preoperative Care; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin.
Topics: Ascites; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Esophagectomy; Female; Floxuridine; Fluorouracil; Gastrectomy; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Pyridines; Radiography, Thoracic; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2004 |
[Examination of second-line therapies following administration of low-dose TS-1+CDDP for highly-advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Radiotherapy Dosage; Remission Induction; Tegafur | 2004 |
[A case of advanced gastric cancer with a tumor embolus in the portal vein successfully treated with TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Neoplastic Cells, Circulating; Oxonic Acid; Portal Vein; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of effective treatment of oral TS-1 and intravenous MMC administration for multiple metastases of gastric cancer].
Topics: Adenocarcinoma, Papillary; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of inoperable scirrhous gastric cancer that responded remarkably to a combination of TS-1+paclitaxel and showed complete loss of ascites].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2004 |
[Successful treatment of multiple pulmonary metastases of adenoid cystic carcinoma of the external auditory meatus with TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenoid Cystic; Drug Administration Schedule; Drug Combinations; Ear Canal; Ear Neoplasms; Humans; Lung Neoplasms; Male; Oxonic Acid; Pyridines; Tegafur | 2004 |
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Renal Dialysis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2004 |
[TS-1 was prescribed for a patient with stomach cancer with peritoneal dissemination who survived for 3 years and 2 months].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2004 |
[A case of paraaortic lymph nodes metastases responding to TS-1 following surgery for gastric cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of gastric cancer complicated with multiple lung metastases responding to TS-1].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Cardiomyopathy, Dilated; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Drug Combinations; Humans; Oxonic Acid; Pyridines; Reactive Nitrogen Species; Reactive Oxygen Species; Salivary Gland Neoplasms; Tegafur | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Tumor Cells, Cultured | 2004 |
[A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Drug Combinations; Gallbladder Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreaticoduodenectomy; Pancreaticojejunostomy; Pyridines; Tegafur | 2004 |
[A complete response using TS-1 in a patient with paramesenteric lymph node recurrence of gastric cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Arteries; Oxonic Acid; Postoperative Period; Pyridines; Recurrence; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pyridines; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[A case of gastric cancer with abdominal paraaortic lymph node metastases responding to TS-1 plus CDDP neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of multiple pulmonary metastases from rectal cancer effectively treated by TS-1 and low-dose CDDP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Rectal Neoplasms; Remission Induction; Tegafur | 2004 |
The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Fatal Outcome; Female; Humans; Hyponatremia; Hypopharyngeal Neoplasms; Inappropriate ADH Syndrome; Osmolar Concentration; Oxonic Acid; Pyridines; Radiotherapy, Adjuvant; Tegafur; Vasopressins | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Drug Combinations; Female; Mice; Mice, SCID; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Pyridines; Tegafur; Transplantation, Heterologous | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2004 |
[Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dendritic Cells; Drug Combinations; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasms, Experimental; Oxonic Acid; Picibanil; Pyridines; Receptors, Cell Surface; Sarcoma, Experimental; Tegafur; Toll-Like Receptor 4; Toll-Like Receptors | 2004 |
[Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion].
Topics: Administration, Oral; Adult; Aged; Agmatine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Oxonic Acid; Proteoglycans; Pyridines; Stomach Neoplasms; Succinates; Tegafur; Treatment Outcome | 2004 |
[A case report of the 8 year survivor--unresectable liver metastases from advanced gastric cancer (Stage IV) were completely responsive, after 4 years from a total sequential gastrectomy, combining docetaxel treatment to regress the recurrence].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[Three successful case reports of advanced gastric cancer with chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case responding to weekly paclitaxel therapy as second-line chemotherapy for gastric cancer previously treated with TS-1].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Humans; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Tegafur | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Hydronephrosis; Lymph Node Excision; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Stents; Stomach Neoplasms; Tegafur | 2004 |
[Two cases of advanced and recurrent gastric cancer treated with the combination of chemotherapy and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinations; Fluorouracil; Hepatectomy; Humans; Interferon-alpha; Interferon-beta; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Tegafur; Time Factors; Uracil | 2004 |
[TS-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lentinan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of gastric cancer with paraaortic lymph node metastasis responding to TS-1/CDDP combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
[A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1 and CDDP].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dendritic Cells; Drug Combinations; Fibrosarcoma; Immunotherapy, Adoptive; Lentinan; Lung Neoplasms; Lymphoma; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Rats, Inbred Strains; Spleen; Survival Rate; T-Lymphocytes, Cytotoxic; Tegafur | 2005 |
Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Hemoglobins; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Preoperative Care; Pyridines; Tegafur | 2004 |
[Complete response in an elderly patient with advanced gastric cancer treated with TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Gastroscopy; Humans; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2004 |
[A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Radiography, Abdominal; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2004 |
[Clinical efficacy of TS-1 combined with cisplatin for advanced cardiac gastric cancer with multiple liver metastases--two case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Radiography, Abdominal; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2004 |
[Low-dose paclitaxel therapy as second-line chemotherapy for patients who previously received TS-1 therapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2004 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Pancreatic Neoplasms; Polysaccharides; Prognosis; Pyridines; Survival Analysis; Survival Rate; Tegafur; Ultrasonography | 2005 |
[Two cases of gastric cancer with multiple liver metastases responding to TS-1 with hepatic arterial infusion of CDDP following low-dose 5-FU and CDDP chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Creatinine; Drug Combinations; Female; Health Surveys; Humans; Japan; Male; Middle Aged; Oxonic Acid; Product Surveillance, Postmarketing; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Neoadjuvant chemotherapy with S-1 and surgical resection for a mucinous gastric cancer with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2005 |
[A case of hepatocellular carcinoma with bone metastasis treated by TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
[Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2005 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Organoplatinum Compounds; Oxonic Acid; Pilot Projects; Pyridines; Quality of Life; Survival Rate; Tegafur | 2005 |
[A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[A case of CA19-9 producing gastric cancer treated by low-dose administration of TS-1 for adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[A patient with multiple bone metastases from gastric cancer after an 8-year disease-free interval following gastrectomy].
Topics: Adenocarcinoma; Anastomosis, Roux-en-Y; Antimetabolites, Antineoplastic; Bone and Bones; Bone Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Pyridines; Radionuclide Imaging; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangiosis responding remarkably to combination chemotherapy of docetaxel (TXT) and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[Preoperative chemotherapy with TS-1 and low dose cisplatin for oral squamous cell carcinoma patients--a preliminary study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neutropenia; Oxonic Acid; Pyridines; Tegafur | 2005 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Floxuridine; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Tegafur; Thymidine Phosphorylase; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2005 |
[A case of advanced gastric cancer effectively treated by TS-1 for 4 years].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2005 |
[Successfully resected advanced gastric carcinoma after combined chemotherapy of TS-1 plus CDDP--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Fluorouracil; Gastrectomy; Humans; Kidney Failure, Chronic; Male; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Renal Dialysis; Stomach Neoplasms; Tegafur | 2005 |
[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of curatively resected AFP producing gastric cancer that responded remarkably to 1 course of TS-1 and showed complete loss of multiple liver metastatic tumors].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Oxonic Acid; Preoperative Care; Prognosis; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
Topics: Deglutition Disorders; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gas Chromatography-Mass Spectrometry; Gastrostomy; Humans; Informed Consent; Intubation, Gastrointestinal; Male; Middle Aged; Oropharyngeal Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2005 |
[Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Pyridines; Tegafur | 2005 |
Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Rats; Rats, Inbred F344; Rats, Nude; Stomach Neoplasms; Taxoids; Tegafur; Transplantation, Heterologous | 2005 |
[TS-1 therapy via intestinal catheter used for tube feeding in a patient with gastric cancer after total gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Catheterization; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Enteral Nutrition; Gastrectomy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
[A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[A case of gastric cancer with peritoneal recurrence which developed during adjuvant administration of TS-1 showing complete response by weekly docetaxel regimen].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2005 |
Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Dacryocystorhinostomy; Drug Combinations; Female; Gastrointestinal Neoplasms; Humans; Intubation; Lacrimal Duct Obstruction; Male; Middle Aged; Nasolacrimal Duct; Oxonic Acid; Pyridines; Tegafur; Therapeutic Irrigation | 2005 |
[Clinical study of TS-1 for inoperative and recurrent gastric cancer and evaluation of long survival cases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Signet Ring Cell; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Peritonitis; Pyridines; Rectal Diseases; Stomach Neoplasms; Tegafur | 2005 |
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Methotrexate; Oxonic Acid; Palliative Care; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Krukenberg Tumor; Lymphangitis; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of gastric cancer with abdominal para-aortic lymph node metastases responding to TS-1 + CDDP neoadjuvant chemotherapy].
Topics: Aorta, Abdominal; Cisplatin; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of peritoneal dissemination of postoperative primary duodenal cancer successfully treated by TS-1 therapy].
Topics: Antimetabolites, Antineoplastic; Colectomy; Drug Combinations; Duodenal Neoplasms; Humans; Liver; Male; Middle Aged; Neoplasm Seeding; Omentum; Oxonic Acid; Pancreaticoduodenectomy; Pyridines; Tegafur | 2005 |
[A case of transverse colon cancer with left supraclavicular lymph node metastasis and paraaortic lymph node metastases responding to TS-1].
Topics: Antimetabolites, Antineoplastic; Aorta; Biomarkers, Tumor; CA-19-9 Antigen; Clavicle; Colectomy; Colon, Transverse; Colonic Neoplasms; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Tegafur; Treatment Outcome | 2005 |
S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Drug Combinations; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; In Situ Nick-End Labeling; In Vitro Techniques; Male; Mice; Mice, Nude; Mouth Neoplasms; Oxonic Acid; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Radiation-Sensitizing Agents; Tegafur | 2005 |
Just when you thought the fluorouracil debate was over: S-1 and gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pilot Projects; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
[Preoperative combination chemotherapy with TS-1 is effective in a case gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Preoperative Care; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Infusions, Intravenous; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with paraaortic lymph node metastasis reaching long-term survival by TS-1 treatment].
Topics: Antimetabolites, Antineoplastic; Aorta; Colectomy; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2005 |
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Drug Combinations; Fluorouracil; Male; Mice; Mice, Inbred Strains; Oxonic Acid; Pyridines; RNA, Neoplasm; Sarcoma 180; Tegafur; Thymidine Kinase; Uridine Triphosphate | 2005 |
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Etoposide; Female; Gastrectomy; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[Prediction and treatment of peritoneal dissemination in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Humans; Ileus; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Lavage; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[A case of advanced gastric cancer effectively treated by combined chemotherapy of TS-1 and paclitaxel].
Topics: Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Splenic Neoplasms; Stomach Neoplasms; Tegafur | 2005 |
[A Case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Radiography, Abdominal; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2005 |
[Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
[A case of gastric cancer with liver invasion responding to TS-1/low-dose CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Quality of Life; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with obstructive jaundice that responded to TS-1/CPT-11 combination therapy after percutaneous transhepatic cholangio drainage].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Camptothecin; Combined Modality Therapy; Drainage; Drug Administration Schedule; Drug Combinations; Gastroscopy; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Stents; Tegafur | 2005 |
Level of 5-fluorodeoxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Combinations; Female; Floxuridine; Humans; Male; Middle Aged; Oxonic Acid; Preoperative Care; Pyridines; Stomach Neoplasms; Tegafur; Thymidylate Synthase | 2005 |
Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Topics: Administration, Oral; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Body Weight; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Intestinal Mucosa; Jejunal Diseases; Male; Orotate Phosphoribosyltransferase; Oxonic Acid; Pyridines; Rats; Rats, Sprague-Dawley; Tegafur | 2006 |
[A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Intestinal Neoplasms; Intestine, Small; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Remission Induction; Tegafur | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; Drug Combinations; Drug Screening Assays, Antitumor; Fluorouracil; Infusions, Parenteral; Mice; Mice, Nude; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Kidney Diseases; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with liver and lung metastases markedly responded to TS-1-based sequential chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Paclitaxel; Pyridines; Remission Induction; Taxoids; Tegafur | 2005 |
[A case of gastric cancer with liver metastasis resected after the combination chemotherapy with CDDP and TS-1].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Microwaves; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Constriction, Pathologic; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pancreatectomy; Pyridines; Rectal Diseases; Rectal Neoplasms; Splenectomy; Stomach Neoplasms; Tegafur | 2005 |
[A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Tegafur | 2005 |
[A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Preoperative Care; Pyridines; Rectal Neoplasms; Tegafur | 2005 |
[A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Hepatectomy; Humans; Infusions, Intra-Arterial; Injections, Subcutaneous; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Pneumonectomy; Pyridines; Tegafur; Thrombectomy; Vena Cava, Inferior | 2005 |
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil.
Topics: Animals; Drug Combinations; Enzyme Inhibitors; Fluorouracil; Immunophenotyping; Interleukin-2; Killer Cells, Natural; Male; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Tegafur | 2006 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2005 |
[Neoadjuvant chemotherapy using TS-1 and CDDP against large type 3/Type 4/Bulky N 2 advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur | 2005 |
[Radiation therapy leading to complete response of residual lymph node metastasis in advanced gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of gastric cancer with multiple liver metastases effectively treated by hepatic arterial infusion of MMC, TS-1/CDDP therapy, and thermotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Hepatic Artery; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Kidney Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of synchronous gastric and hepatocellular carcinoma successfully treated by TS-1 and hepatic arterial infusion chemotherapy (HAI) of low-dose CDDP].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Gastrectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Salvage Therapy; Taxoids; Tegafur | 2005 |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Topics: Aged; Antimetabolites, Antineoplastic; beta-Alanine; Cardiovascular Diseases; Colonic Neoplasms; Drug Combinations; Electrocardiography; Fluorouracil; Heart; Humans; Liver Neoplasms; Lung Neoplasms; Male; Oxonic Acid; Tegafur | 2005 |
[A case of AFP-producing gastric cancer with multiple liver metastasis responding to TS-1 and cisplatin combination chemotherapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Leukopenia; Neutropenia; Oxonic Acid; Product Surveillance, Postmarketing; Pyridines; Registries; Stomach Neoplasms; Tegafur; Thrombocytopenia | 2006 |
[Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1].
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[Three advanced gastric cancer cases with liver metastases successfully treated by TS-1/CDDP combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[A case of gastric adenosquamous carcinoma with abdominal paraaortic lymph node metastases successfully treated by TS-1 plus CDDP neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Preoperative Care; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Oxonic Acid; Pyridines; Sigmoid Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
[Liver metastasis from sigmoid colon cancer with peritoneal dissemination showed a complete response to TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Remission Induction; Sigmoid Neoplasms; Tegafur | 2006 |
[A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mastectomy, Segmental; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
[Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
[Successful monotherapy with S-1 in three cases of recurrent/advanced breast cancer non-responsive to anthracycline and taxane anticancer drugs].
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy, Segmental; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Topics: Adenocarcinoma, Scirrhous; Animals; Antimetabolites, Antineoplastic; Benzenesulfonates; Cyclooxygenase 2 Inhibitors; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Tumor Cells, Cultured | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[Two cases of gastric cancer with peritoneal dissemination that responded to TS-1 without progression or recurrence for over 3 years].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2006 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[DLST as a method for detecting TS-1-induced allergy].
Topics: Adult; Antimetabolites, Antineoplastic; Drug Combinations; Drug Hypersensitivity; False Positive Reactions; Humans; Immunologic Tests; Lymphocyte Activation; Male; Oxonic Acid; Pyridines; Tegafur; Thymidine | 2006 |
[A case report of cancer of the lip--complete response by a neo-adjuvant chemotherapy using a novel method of TS-1 administration].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Lip; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Oxonic Acid; Pyridines; Remission Induction; Tegafur | 2006 |
[Case study--an elderly patient with Stage IV advanced gastric cancer achieved good performance status (PS) without subjective symptoms for more than two years by chemotherapy].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Time Factors | 2006 |
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehydrogenase (NADP); Docetaxel; Drug Combinations; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Multienzyme Complexes; Orotate Phosphoribosyltransferase; Orotidine-5'-Phosphate Decarboxylase; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oxonic Acid; Pyridines; Succinate Dehydrogenase; Taxoids; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured | 2006 |
[A case of scirrhous gastric cancer responding to TS-1/CDDP neoadjuvant chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[A case of advanced colon cancer with metastases to both para-aortic lymph nodes and cervical vertebrae effectively treated by TS-1 therapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Aorta; Cecal Neoplasms; Cervical Vertebrae; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Oxonic Acid; Pyridines; Remission Induction; Spinal Neoplasms; Tegafur | 2006 |
[Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur | 2006 |
[The present state and future of home care for gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Forecasting; Home Care Services, Hospital-Based; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Parenteral Nutrition, Home; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[A case of unresectable non-small cell lung cancer with pleural dissemination successfully treated with DIF].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Pleural Effusion, Malignant; Pyridines; Quality of Life; Tegafur; Uracil | 2006 |
[A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms, Second Primary; Oxonic Acid; Pneumonectomy; Pyridines; Tegafur | 2006 |
[A case of gastric cancer with DIC caused by multiple bone metastases treated with TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Combined Modality Therapy; Disseminated Intravascular Coagulation; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Multienzyme Complexes; Orotate Phosphoribosyltransferase; Orotidine-5'-Phosphate Decarboxylase; Oxonic Acid; RNA, Messenger; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dihydrouracil Dehydrogenase (NAD+); Docetaxel; Drug Combinations; Drug Synergism; Female; Humans; Mice; Mice, SCID; Oxonic Acid; Taxoids; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2006 |
TS-1 as first-line therapy for gastric linitis plastica: historical control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Linitis Plastica; Male; Methotrexate; Middle Aged; Mitomycin; Oxonic Acid; Pyridines; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur | 2006 |
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Topics: Adult; Aged; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Neoadjuvant S-1 and cisplatin for gastric carcinoma: there will be more to come.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black or African American; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Time | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
[Advanced gastric cancer responding to pathological CR after neoadjuvant TS-1 combined with CDDP therapy--report of a case].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of advanced gastric cancer successfully treated by TS-1 and CDDP after jejunostomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Parenteral; Jejunostomy; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Remission Induction; Splenectomy; Stomach Neoplasms; Tegafur | 2006 |
[A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Quality of Life; Tegafur | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fluorouracil; Humans; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Peritoneum; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Quality of Life; Remission Induction; Taxoids; Tegafur | 2006 |
[A case of advanced double cancer of the lung and stomach responding to combination chemotherapy of cisplatin and TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimidine Dehydrogenase Deficiency; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Male; Nausea; Oxonic Acid; Stomach Neoplasms; Tegafur; Uracil | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Sigmoid Diseases; Stomach Neoplasms; Tegafur | 2006 |
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Radiation-Sensitizing Agents; Tegafur; Xenograft Model Antitumor Assays | 2006 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Mice; Neoplasm Transplantation; Neoplasms; Oxonic Acid; Pharmaceutical Preparations; Rats; Sarcoma, Yoshida; Tegafur; Uracil | 2006 |
[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Topics: beta-Alanine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Kidney; Oxonic Acid; Stomach Neoplasms; Tegafur; Uracil | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Product Surveillance, Postmarketing; Registries; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[A combination study of S-1 and docetaxel in patients with head and neck cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Oxonic Acid; Taxoids; Tegafur | 2006 |
[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tegafur | 2006 |
[S-1 treatment against advanced HCC].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Humans; Interferon-alpha; Liver Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Remission Induction; Tegafur | 2006 |
Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Hematuria; Humans; Iliac Artery; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur; Urachus; Urinary Bladder Neoplasms | 2006 |
[TS-1 and irradiation combination therapy for head and neck cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Quality of Life; Radiotherapy Dosage; Remission Induction; Tegafur | 2006 |
[Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[Clinical efficacy of TS-1 in refractory bone recurrence of a postoperative squamous lung cancer patient].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pneumonectomy; Postoperative Period; Quality of Life; Ribs; Tegafur | 2006 |
[A case of unknown primary cancer responding to TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Unknown Primary; Oxonic Acid; Tegafur | 2006 |
[A case of partial response in liver metastatic lesion from gastric endocrine cell carcinoma treated with TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of advanced gastric cancer treated by TS-1 for 3 years and 7 months].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Oxonic Acid; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2006 |
[A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Oxonic Acid; Remission Induction; Tegafur | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Taxoids; Tegafur | 2006 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
[A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Oxonic Acid; Receptor, ErbB-2; Tegafur; Trastuzumab | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of N3 gastric cancer successfully treated by TS-1 followed by curative resection].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur | 2006 |
[A resected case of effective treatment with TS-1 and CDDP for advanced gastric cancer with carcinomatous ascites].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cholecystectomy; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Hysterectomy; Ileum; Ovarian Neoplasms; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of non-curatively resected colon cancer with liver and lymph node metastases treated by TS-1/CPT-11 combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur | 2006 |
[A case of rectal cancer with multiple liver metastases responding to TS-1].
Topics: Adenocarcinoma; Ambulatory Care; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Rectal Neoplasms; Tegafur | 2006 |
[Case of leptomeningeal carcinomatosis effectively treated with intrathecal chemotherapy using ventriculoperitoneal shunt].
Topics: Adenocarcinoma, Papillary; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Injections, Spinal; Intracranial Hypertension; Male; Meningeal Neoplasms; Methotrexate; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Ventriculoperitoneal Shunt | 2006 |
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Gastrectomy; Humans; Intestinal Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Patient Compliance; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase; Time Factors; Treatment Outcome | 2006 |
Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Middle Aged; Oxonic Acid; Tegafur; Time Factors | 2006 |
[A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A resected case of advanced gastric cancer with multiple liver metastasis responding to preoperative TS-1/CDDP chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Anemia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Stomatitis; Tegafur; Vomiting, Anticipatory | 2006 |
[Resolution of liver metastases in response to S-1 monotherapy in advanced pancreatic cancer--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2006 |
[Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Female; Hemoglobins; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
Acute cerebral infarction during combination chemotherapy with s-1 and cisplatin for a young patient with a mucin-producing adenocarcinoma of the stomach.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cerebral Infarction; Cisplatin; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Thromboembolism | 2006 |
Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2006 |
Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neutropenia; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
[An advanced pulmonary adenocarcinoma case in which TS-1 proved effective].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2006 |
[An elderly patient with non-resectable lung cancer responding to TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Quality of Life; Tegafur | 2006 |
[Three cases of successfully resectable advanced gastric cancer responding to TS-1 plus CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[A case of perforated gastric cancer in which complete response was confirmed with resection following TS-1/CDDP combined chemotherapy after omentopexy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Intestinal Perforation; Male; Middle Aged; Omentum; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survivors; Tegafur; Uracil | 2006 |
[A case of duodenal carcinoma with massive peritoneal carcinomatosis complicating a pulmonary embolism].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Therapy, Combination; Duodenal Neoplasms; Female; Heparin; Humans; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Pulmonary Embolism; Quality of Life; Taxoids; Tegafur; Warfarin | 2006 |
[Partial response of liver metastasis from colon cancer following intermittent oral administration of TS-1 after intra-hepatic arterial single injection of CDDP, doxorubicin and 5-FU].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colectomy; Colonic Neoplasms; Doxorubicin; Drug Administration Routes; Drug Combinations; Fluorouracil; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Oxonic Acid; Quality of Life; Remission Induction; Tegafur | 2006 |
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Safety; Stomach Neoplasms; Tegafur | 2007 |
[Three cases of corneal disorders associated with an oral anticancer drug S-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Female; Humans; Lacrimal Duct Obstruction; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur | 2006 |
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Hepatectomy; Humans; Immunologic Factors; Injections, Subcutaneous; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Splenic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
[A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fusion Proteins, bcr-abl; Gastrectomy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur | 2006 |
[A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pylorus; Stomach Neoplasms; Tegafur | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Combinations; Endothelium, Vascular; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Oxonic Acid; Phosphorylation; Proto-Oncogene Proteins c-akt; Tegafur; Vascular Endothelial Growth Factor A | 2007 |
Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2007 |
[Two cases of primary peritoneal cystadenocarcinoma--diagnosis, treatment, and clinical feature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma; Drug Combinations; Female; Humans; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[A case of stage IV gastric cancer treated sequentially for over two years by TS-1, paclitaxel, and CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case of stage IV advanced gastric cancer responding to TS-1/CDDP neoadjuvant chemotherapy which leads to a pathological complete response].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report].
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Remission Induction; Tegafur | 2007 |
Remission of primary duodenal adenocarcinoma with liver metastases with S-1 chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Duodenal Neoplasms; Female; Humans; Liver Neoplasms; Oxonic Acid; Tegafur | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
[A case of multidrug-resistant non-small cell lung cancer responding to TS-1].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Tegafur | 2007 |
[Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2007 |
[A case of advanced gastric cancer with liver metastases successfully treated by combination therapy of TS-1 and docetaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Postoperative Period; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A resected case of advanced gastric cancer after treatment with low-dosage TS-1].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Stomatitis; Tegafur | 2007 |
Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
[Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Models, Animal; Drug Combinations; Drug Evaluation; Folic Acid; Humans; Leucovorin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxonic Acid; Tegafur | 2007 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Quality of Life; Remission Induction; Tegafur | 2007 |
[A case of adenosquamous gastric carcinoma successfully treated with TS-1, low-dose CDDP and docetaxel as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Complete response in an elderly patient with advanced gastric cancer treated with TS-1].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Diabetes Complications; Drug Administration Schedule; Drug Combinations; Humans; Hypertension; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Mastectomy; Neoplasm Invasiveness; Oxonic Acid; Skin Neoplasms; Tegafur; Uracil | 2007 |
Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
[Clinical efficacy of biweekly paclitaxel and S-1 regimen for 14 gastric cancer patients with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Routes; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Oxonic Acid; Pancreas; Splenectomy; Stomach Neoplasms; Tegafur | 2007 |
A case of suspected S-1 induced interstitial pneumonia.
Topics: Adult; Antimetabolites, Antineoplastic; Diagnosis, Differential; Drug Combinations; Dyspnea; Female; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymph Nodes; Lymphatic Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2007 |
[Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Tegafur | 2007 |
[Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2007 |
[An inadvertent contraindicated combined use of newly prescribed TS-1 and unused doxifluridine].
Topics: Aged; Contraindications; Drug Combinations; Floxuridine; Humans; Male; Medication Errors; Oxonic Acid; Rectal Neoplasms; Self Medication; Tegafur | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug Combinations; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Mucous Membrane; Oxonic Acid; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2007 |
Combination therapy of S-1 and CDDP for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2007 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mouth Neoplasms; Nausea; Organoplatinum Compounds; Oxonic Acid; Tegafur; Thrombocytopenia; Vomiting, Anticipatory | 2007 |
[Clinical evaluation of palliative chemotherapy with S-1 for oral cancer patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Palliative Care; Tegafur | 2007 |
[A case of advanced oral squamous cell carcinoma responding to concurrent radiotherapy with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mouth Neoplasms; Oxonic Acid; Radiotherapy Dosage; Remission Induction; Tegafur | 2007 |
[A case of maxillary sinus carcinoma showing long time survival after lung metastasis with administration of S-1 as tumor dormancy therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Maxillary Sinus Neoplasms; Oxonic Acid; Survivors; Tegafur | 2007 |
[An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of postoperative multiple pulmonary metastases of non-small-cell lung cancer successfully treated with S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neoplasm Staging; Oxonic Acid; Pneumonectomy; Postoperative Period; Quality of Life; Tegafur; Thoracic Surgery, Video-Assisted | 2007 |
[A case of liver metastasis of gastric cancer undergoing non-curative operation responding completely to combination therapy of S-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2007 |
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
[Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2007 |
[A case of complete response (CR) persisting for 2 years from S-1 administered five days a week in a patient with gastric cancer].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated with fourth-line chemotherapy of S-1 alone].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
[A case of advanced gastric cancer with lung metastasis effectively treated by combination chemotherapy using S-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Postoperative Period; Stomach Neoplasms; Tegafur | 2007 |
[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Camptothecin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Tegafur | 2007 |
[Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Sigmoid Neoplasms; Survivors; Tegafur | 2007 |
Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Creatinine; Drug Combinations; Female; Health Surveys; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutrophils; Oxonic Acid; Platelet Count; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Dose-Response Relationship, Drug; Drug Combinations; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Pancreatic Neoplasms; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Trastuzumab; Xenograft Model Antitumor Assays | 2007 |
Combination chemotherapy using TS-1, Paclitaxel and cisplatin for multiple lung metastases from AFP-producing gastric cancer: a case report.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur | 2007 |
[Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Clinical study of S-1 for advanced gastric cancer after reduction surgery].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Complete remission of hepatic metastasis of gastric cancer with CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Leukopenia; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peripheral Nervous System Diseases; Stomach Neoplasms; Tegafur | 2007 |
[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
[A case of long survival of unresected gastric cancer with excellent QOL administered by S-1 alone].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case of breast metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[A case of unresectable advanced gallbladder cancer treated by systemic chemotherapy combined with hepatic arterial infusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Epirubicin; Female; Gallbladder Neoplasms; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Mitomycin; Oxonic Acid; Remission Induction; Tegafur | 2007 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2007 |
[A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1].
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Mucin-1; Oxonic Acid; Quality of Life; Tegafur | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Skin Neoplasms; Tegafur; Toremifene | 2007 |
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Radiography, Thoracic; Survival Rate; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Pulmonary toxicity by a cytotoxic agent, S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Humans; Lung; Male; Oxonic Acid; Respiratory Distress Syndrome; Tegafur; Tongue Neoplasms | 2007 |
Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; beta-Alanine; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2007 |
[Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Risk Factors; Survival Rate; Tegafur | 2007 |
[A case of curatively resected AFP producing gastric cancer with massive lymph node metastasis effectively treated by neoadjuvant-chemotherapy of S-1 and CDDP].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Preoperative Care; Stomach Neoplasms; Tegafur | 2007 |
[Complete resection of advanced gastric cancer with multiple liver metastases following a bypass operation and one year of chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Routes; Drug Combinations; Gastrectomy; Gastric Bypass; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Drug Administration Schedule; Drug Combinations; Glycine; Humans; Male; Neutropenia; Oxonic Acid; Paclitaxel; Respiratory Distress Syndrome; Serine Proteinase Inhibitors; Sulfonamides; Tegafur | 2007 |
[A case report of S-1 monotherapy as first-line treatment for metastatic gallbladder cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Oxonic Acid; Quality of Life; Tegafur | 2007 |
[Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2007 |
A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
Successful preoperative chemotherapy with S-1 plus low-dose cisplatin for advanced gastric cancer with synchronous liver metastases: report of 2 cases.
Topics: Cisplatin; Drug Combinations; Drug Therapy, Combination; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Preoperative Care; Stomach Neoplasms; Tegafur; Tomography Scanners, X-Ray Computed | 2007 |
[A case of oral squamous cell carcinoma responding to S-1].
Topics: Administration, Oral; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Drug Combinations; Female; Humans; Mouth Neoplasms; Oxonic Acid; Serpins; Tegafur; Treatment Outcome | 2007 |
[Two cases of stage IV gastric cancer responding to chemotherapy with S-1 or UFT].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case report of successful control of liver metastasis from duodenal cancer with combined S-1 and docetaxel chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Duodenal Neoplasms; Humans; Liver Neoplasms; Male; Oxonic Acid; Taxoids; Tegafur | 2007 |
[A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2007 |
[A case of unresectable advanced pancreatic cancer with peritoneal dissemination responding to continuous dose S-1 monotherapy after chemo-radiation therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Cavity; Peritonitis; Quality of Life; Tegafur | 2007 |
Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; In Situ Nick-End Labeling; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Mouth Neoplasms; Oxonic Acid; Radiotherapy Dosage; Tegafur; Tumor Cells, Cultured | 2007 |
Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cohort Studies; Drug Combinations; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Kidney Diseases; Liver Function Tests; Male; Middle Aged; Oxonic Acid; Prospective Studies; Registries; Stomach Neoplasms; Tegafur | 2008 |
[A case of gastric cancer with severe lymph node metastasis effectively treated with docetaxel / S-1 as neoadjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cardia; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stents; Stomach Neoplasms; Tegafur | 2007 |
[A case of unresectable gastric cancer complicated by serious pyloric stenosis in which S-1 administration after gastrojejunostomy proved effective].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastric Bypass; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyloric Antrum; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2007 |
[Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
[Neoadjuvant chemotherapy with combination of S-1 and CPT-11 in advanced rectal cancer - a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Rectal Neoplasms; Tegafur | 2007 |
A case of suspected vasospastic angina related to S-1 administration.
Topics: Angina Pectoris, Variant; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Coronary Vasospasm; Drug Combinations; Fatty Acids; Humans; Iodobenzenes; Male; Middle Aged; Oxonic Acid; Radionuclide Imaging; Stomach Neoplasms; Tegafur | 2007 |
Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tegafur; Thymidylate Synthase | 2007 |
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur | 2007 |
Gastric small cell carcinoma successfully treated by surgery and postoperative chemotherapy consisting of cisplatin and S-1: report of a case.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Diagnosis, Differential; Drug Combinations; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Period; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
East meets west in the treatment of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2007 |
The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Interactions; Humans; Male; Oxonic Acid; Phenytoin; Pyridines; Tegafur | 2008 |
[Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Tegafur | 2007 |
[Severe advanced lower gingival carcinoma effectively reduced by chemoradiation with S-1--report of a case].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gingival Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Quality of Life; Radiotherapy Dosage; Tegafur | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination responding to S-1/CDDP neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[Marked response to S-1 chemotherapy for para-aortic lymph node metastasis arising from gastric cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Aorta; Drug Administration Schedule; Drug Combinations; Gastrectomy; Gastric Stump; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of cytology-positive, stage IV gastric cancer, alive with no recurrence for 4 years, curatively treated with combination chemotherapy using S-1, CPT-11 and subsequent total gastrectomy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
[A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Constriction, Pathologic; Drug Administration Routes; Drug Combinations; Gastric Bypass; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pylorus; Stomach Neoplasms; Tegafur | 2007 |
Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Tegafur; Treatment Outcome | 2008 |
Complete response of a patient with advanced gastric cancer, showing Epstein-Barr virus infection, to preoperative chemotherapy with S-1 and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Epstein-Barr Virus Infections; Female; Gastrectomy; Herpesviridae; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; RNA, Viral; Stomach Neoplasms; Tegafur | 2007 |
[Evaluation of combination chemotherapy with S-1 and docetaxel for patients with oral squamous cell carcinomas].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Taxoids; Tegafur | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagoplasty; Humans; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Immunosuppressive Agents; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
[Complete histological response in gastric cancer stage IV after neoadjuvant chemotherapy including S-1 combined with CDDP--report of a case].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2007 |
[Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2007 |
Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hydronephrosis; Infusions, Parenteral; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
[A case of advanced gastric cancer with pyloric stenosis and obstructive jaundice responding to s-1/paclitaxel combination therapy after endoscopic balloon dilatation and endoscopic biliary drainage].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Diseases; Catheterization; Drug Combinations; Endoscopes; Female; Humans; Jaundice, Obstructive; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pyloric Stenosis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of gastric cancer with multiple bone metastasis that responded to S-1 with low-dose cis-platinum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Failure | 2008 |
[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Fluorouracil; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mixed Function Oxygenases; Oxonic Acid; Smoking; Tegafur | 2008 |
[A long-term surviving patient with unresectable lung metastasis from colon cancer treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy--a case report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Immunotherapy; Injections, Intravenous; Irinotecan; Lung Neoplasms; Lymphocyte Activation; Lymphocyte Transfusion; Lymphocytes; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Uracil | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Follow-Up Studies; Humans; Lung Neoplasms; Male; Oxonic Acid; Prognosis; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
[A case report-the marked response to S-1 + CDDP chemotherapy for post-operative local recurrence of advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Gastroscopes; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[Primary lung cancer that I was preoperative and needed discrimination for and one example of the repetition cancer of the colon].
Topics: Colonic Neoplasms; Colonoscopy; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2007 |
[An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of advanced breast cancer successfully treated with multi-disciplinary therapy and S-1 administration].
Topics: Biopsy, Needle; Breast Neoplasms; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2007 |
[Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of unresectable gastric cancer successfully treated with combination chemotherapy of S-1 + CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of S-1 resistant multiple lung metastases after curative total gastrectomy for gastric cancer successfully treated by S-1 combined with CPT-11 as the third-line chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Drug Resistance, Neoplasm; Female; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2007 |
[Progression of gastric cancer observed for three and a half years under S-1 administration].
Topics: Disease Progression; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2007 |
[A successful case of liver metastasis from gastric cancer treated with S-1 + induced hypertensive hepatic arterial infusion chemotherapy--a case report].
Topics: Drug Combinations; Gastrectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pressure; Stomach Neoplasms; Tegafur; Treatment Outcome | 2007 |
[Two patients of progressive gastric cancer accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC successfully controlled by combination of S-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Progression; Drug Combinations; Female; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiography; Stomach Neoplasms; Tegafur; Treatment Failure | 2007 |
[Three cases of unresectable advanced gastric cancer treated with S-1 based chemotherapy after surgical bypass].
Topics: Aged; Drug Combinations; Female; Gastric Bypass; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Tomography, X-Ray Computed | 2007 |
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA Primers; DNA-Binding Proteins; Drug Combinations; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxonic Acid; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Pulmonary toxicity by an oral anti-neoplatic agent, S-1.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Lung Diseases; Oxonic Acid; Tegafur | 2008 |
S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur; Tomography, X-Ray Computed | 2007 |
The successfully curative treatment of advanced gastric adenocarcinoma with multiple liver metastases and paraaortic lymph node metastases by salvage operation following the biweekly paclitaxel and S-1 combination chemotherapy: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Remission Induction; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tomography Scanners, X-Ray Computed | 2008 |
[A case of advanced gastric cancer successfully treated by combination therapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Combinations; Female; Gastroscopy; Humans; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2008 |
[Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A patient with gastric cancer complicated with multiple spinal bone metastases showing a complete remission to combination of S-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Oxonic Acid; Remission Induction; Spine; Stomach Neoplasms; Tegafur | 2008 |
[A case of sigmoid colon cancer with multiple liver metastases responding to S-1].
Topics: Aged; Biomarkers, Tumor; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2008 |
[Remarkably reduced tumor marker SCC levels by combined chemotherapy of paclitaxel and S-1 in two cases of advanced cervical cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Oxonic Acid; Paclitaxel; Serpins; Tegafur; Treatment Failure; Uterine Cervical Neoplasms | 2008 |
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Nausea; Oxonic Acid; Retrospective Studies; Tegafur | 2008 |
Oral treatment for gastric cancer: new choices, better choices?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Japan; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur | 2008 |
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections, Subcutaneous; Interferon-alpha; Leukopenia; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pilot Projects; Remission Induction; Survival Rate; Tegafur; Thrombocytopenia | 2008 |
[Adjuvant chemotherapy with S-1 for head and neck carcinoma].
Topics: Chemotherapy, Adjuvant; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Time Factors | 2008 |
[Therapeutic experience of S-1 plus other drug combination therapy for synchronia multiple liver metastases of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Keratin-19; Keratins; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[Squamous cell carcinoma of the lower lip, completely responding to concurrent chemoradiotherapy with S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; Lip Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2008 |
[A case of advanced gastric cancer responding to neoadjuvant S-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of complete response treated by gastrectomy with lymphadenectomy and combined chemotherapy of peroral S-1 and CDDP by arterial infusion for gastric cancer with multiple liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Oxonic Acid; Positron-Emission Tomography; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pleurisy; Positron-Emission Tomography; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of advanced rectal cancer responding to radiation therapy and chemotherapy with S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Combined Modality Therapy; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2008 |
[A case report of pseudomyxoma peritonei demonstrating complete response after intensive therapy consisting of cytoreductive surgery and adjuvant chemotherapy with paclitaxel and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Pseudomyxoma Peritonei; Tegafur; Tomography, X-Ray Computed | 2008 |
[Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Bone Marrow Neoplasms; Bone Neoplasms; Female; Gallbladder Neoplasms; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Radionuclide Imaging; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure | 2008 |
Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2008 |
S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Tegafur | 2008 |
The unanswered question: what is the determinant of S-1 pharmacokinetics?
Topics: Alleles; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asian People; Body Size; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2A6; Drug Combinations; Fluorouracil; Humans; Lung Neoplasms; Oxonic Acid; Tegafur | 2008 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Gastroscopy; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer treated with S-1/CDDP combination chemotherapy through jejunostomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Gastroscopy; Humans; Jejunostomy; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of unresectable advanced gallbladder cancer successfully treated by oral S-1 and hepatic arterial infusion (HAI) of low-dose CDDP therapy].
Topics: Administration, Oral; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Female; Gallbladder Neoplasms; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of drug-induced interstitial pneumonia caused by TS-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Diseases, Interstitial; Male; Oxonic Acid; Pyridines; Tegafur | 2008 |
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Tegafur; Thrombospondin 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; Leukocyte Count; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Determining S-1 dosage at hospitals prioritizing cancer chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Female; Hospitals; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Tegafur | 2008 |
[Utility-based evaluation of the quality of life of patient's with gastric cancer who receive chemotherapy--comparison of patients' quality of life between oral TS-1 and conventional injectable combination therapy].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Outcome Assessment, Health Care; Oxonic Acid; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Tegafur | 2008 |
[Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Radiotherapy; Radiotherapy Dosage; Tegafur | 2008 |
[A case of metastatic gastric endocrine cell carcinoma which could be curably resected after chemotherapy with S-1/CDDP].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[A case of advanced gastric cancer with Schnitzler's metastases effectively treated by the combination of paclitaxel and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiography; Tegafur | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
[A case of unresectable sigmoid colon cancer in an elderly patient responding to S-1].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2008 |
Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cardiac Tamponade; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Humans; Male; Mice; Mice, Inbred BALB C; Orotate Phosphoribosyltransferase; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase; Uridine Phosphorylase; Xenograft Model Antitumor Assays | 2008 |
Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Salvage Therapy; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2008 |
Chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Japan; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
Advanced gastric carcinoma combined with extra-adrenal pheochromocytoma resected after three courses of S-1 and cisplatin as neoadjuvant chemotherapy: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pheochromocytoma; Stomach Neoplasms; Tegafur | 2008 |
Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Male; Mice; Mice, Nude; Oxonic Acid; Tegafur; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
[Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer].
Topics: Aged; Drug Combinations; Female; Health; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors; Uracil | 2008 |
[A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lung Diseases, Interstitial; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Case of gastric cancer with recurrence of carcinomatous lymphangiosis of the lung 7.6 years after surgery and successfully treated with S-1/low-dose CDDP/Lentinan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Lentinan; Lung Neoplasms; Lymphatic Metastasis; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of gastric cancer with peritoneal dissemination responding to combination chemotherapy with oral fluoropyrimidine and weekly paclitaxel].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Male; Neoadjuvant Therapy; Orotate Phosphoribosyltransferase; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
[A case report of S-1 single effective use as third-line chemotherapy and re-challenge in a recurrent squamous cell lung cancer patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Drug Combinations; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[Pathological complete response in an elderly patient with locally advanced gastric cancer treated with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Female; Gastrectomy; Gastroscopy; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer with multiple liver metastases completely responding to combination of paclitaxel and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of disseminated bone marrow carcinosis with disseminated intravascular coagulation successfully controlled with S-1 after total gastrectomy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bone Marrow Neoplasms; Disseminated Intravascular Coagulation; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Radionuclide Imaging; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of peritoneal disseminated sigmoid colon cancer with liver metastasis responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Peritoneal Neoplasms; Sigmoid Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Combinations; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
[Case of gastric cancer with isolated brain metastasis successfully managed by gamma knife radiotherapy and chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Radiosurgery; Stomach Neoplasms; Tegafur; Treatment Outcome | 2008 |
[Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Critical Pathways; Drug Combinations; Gastrectomy; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
[A case of bleeding tendency due to warfarin in a patient treated with chemotherapy by S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Duodenal Neoplasms; Hemorrhage; Humans; Male; Oxonic Acid; Stereoisomerism; Tegafur; Thrombosis; Treatment Failure; Warfarin | 2008 |
[A case of advanced gastric cancer successfully treated with S-1 and paclitaxel followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cholecystectomy; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of complete response to combination therapy of S-1 and CDDP for Stage IV gastric cancer with Virchow's lymph node and para-aorta lymph node metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Biopsy; Carcinoembryonic Antigen; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastroscopy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of synchronous triple cancer involving lung, stomach and bladder, responding to combination chemotherapy of S-1 and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastroscopy; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
[A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[Successful control of pancreatic cancer pain using S-1 chemotherapy--a case report].
Topics: Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Male; Middle Aged; Oxonic Acid; Pain; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tegafur; Treatment Outcome | 2009 |
Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur | 2008 |
Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Combinations; Female; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Retrospective Studies; Tegafur; Treatment Outcome | 2008 |
S-1 treatment for chemorefractory thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Male; Oxonic Acid; Radiography, Thoracic; Salvage Therapy; Tegafur; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone.
Topics: Adenocarcinoma; Aged, 80 and over; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer successfully treated by surgery after chemotherapy with S-1/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of advanced gastric cancer with long-term survival treated by S-1/paclitaxel as neo-adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastroscopy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer with giant lymph node metastasis responding to S-1/CDDP neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Gastroscopy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Case report of gastric cancer patient who suffered life-threatening adverse events including severe myelosuppression during neoadjuvant chemotherapy with S-1 and CDDP combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug Combinations; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2008 |
[Marked efficacy of S-1 against hepatic metastasis of multiple drug-resistant breast cancer--a report of 2 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2009 |
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Drug Combinations; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred BALB C; Oxonic Acid; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
[Two cases of giant metastatic cervical lymphnode from oral cancer responding to concurrent chemoradiotherapy with S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neck; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Mice; Oxonic Acid; Tegafur; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2008 |
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retreatment; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2008 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of early recurrence with multiple liver metastases after curative operation of gastric cancer successfully treated by S-1/CDDP combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Marked response to combination chemotherapy using S-1, CPT-11 for lymph node metastasis of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of interstitial pneumonia after S-1 administration for gastric cancer].
Topics: Aged, 80 and over; Drug Combinations; Humans; Lung Diseases, Interstitial; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of unresectable advanced thymic carcinoma in an elderly woman responding to S-1 with good QOL maintained].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Female; Humans; Neoplasm Staging; Oxonic Acid; Quality of Life; Tegafur; Thymoma; Tomography, X-Ray Computed | 2008 |
[A case of primary unknown cancer responding to CDGP/S-1].
Topics: Aged; Biopsy; Drug Combinations; Female; Humans; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxonic Acid; Positron-Emission Tomography; Tegafur; Ultrasonography | 2008 |
Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Loss, Surgical; Combined Modality Therapy; Drug Combinations; Female; Gastric Bypass; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Quality of Life; Retrospective Studies; Stomach Neoplasms; Tegafur | 2008 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Neoplasms; Oxonic Acid; Tegafur | 2009 |
S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2009 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2008 |
Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Tegafur; Treatment Outcome | 2008 |
Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Diseases; Cell Proliferation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Gastrointestinal Tract; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tetrazolium Salts; Tumor Cells, Cultured | 2008 |
Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[A successful case of advanced nasal adenocarcinoma treated with tumor dormancy therapy with S -1 alone].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Drug Combinations; Female; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Nose Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis responding remarkably to combination chemotherapy of docetaxel, CDDP and S-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Gastroscopy; Humans; Lung Neoplasms; Lymphangitis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of advanced gastric cancer successfully treated by S-1 based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced gastric cancer showing high serum CYFRA21-1 level responding to chemotherapy with S-1].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Gastroscopy; Humans; Keratin-19; Keratins; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Colonic Neoplasms; Colonoscopy; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritonitis; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[The future of loco-regional treatment for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
[Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer].
Topics: Antineoplastic Agents; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2008 |
[A case of advanced gastric cancer responding to S-1/paclitaxel was pathologically complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of liver and lung metastases in gastric cancer successfully treated with S-1 and paclitaxel mono-therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Oxonic Acid; Paclitaxel; Radiography; Stomach Neoplasms; Tegafur | 2008 |
[A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Camptothecin; Cell Proliferation; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
[Two cases of long-term survival with CY1, stage IV gastric cancer due to surgery and postoperative chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2008 |
[Successful treatment of embolization and chemoradiationtherapy with S-1 for the advanced gastric cancer which was actively bleeding].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Embolization, Therapeutic; Gastroscopy; Hemorrhage; Humans; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
[A partial response to combined S-1 and CDDP chemotherapy enabling a curative resection in a patient with locally advanced duodenal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Duodenal Neoplasms; Duodenoscopy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2008 |
[S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Prohibitins; Tegafur; Tomography, X-Ray Computed | 2008 |
[Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Sigmoid Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proctoscopy; Rectal Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan | 2008 |
[A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Neoplasm Metastasis; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
[Advanced gastric cancer showing complete response to neoadjuvant chemotherapy with CPT-11 and S-1-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of perforated gastric cancer in which resection for elimination was possible S-1/CDDP combined chemotherapy for peritonitis carcinomatosa].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastroscopy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Adenosquamous carcinoma of maxillary sinus: case showing complete response to S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Drug Combinations; Humans; Lymphatic Metastasis; Male; Maxillary Sinus Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cohort Studies; Drug Combinations; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur | 2009 |
Advanced gastric cancer patient with peritonitis carcinomatosa successfully treated with a combination therapy of paclitaxel and TS-1, but relapsed with multiple bone metastasis and died from rapidly progressive meningitis carcinomatosa--advanced gastric
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Combinations; Fatal Outcome; Humans; Male; Meningitis; Middle Aged; Oxonic Acid; Paclitaxel; Peritonitis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Oxonic Acid; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Tegafur; Thymidylate Synthase | 2009 |
Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastrectomy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
Pharmacokinetic study of S-1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fasting; Fluorouracil; Food; Gastric Acidity Determination; Half-Life; Humans; Hydrogen-Ion Concentration; Oxonic Acid; Pantoprazole; Pyridines; Tegafur; Triazines; Uracil | 2009 |
Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2009 |
[Treatment results of chemotherapy with S-1 for head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Cisplatin and S-1 combination therapy after reduction surgery for stage IV gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2009 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Positron-Emission Tomography; Tegafur | 2009 |
Assessing potential synergistic effects of S-1 plus paclitaxel chemotherapy in gastric cancer.
Topics: Antineoplastic Agents; Drug Combinations; Drug Synergism; Humans; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Digestive System Diseases; Drug Combinations; Humans; Medical Records; Neoplasms; Oxonic Acid; Patient Care; Retrospective Studies; Tegafur | 2009 |
[A case of an older adult patient with recurrent gastric cancer successfully treated by low-dose S-1 for a long time].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Cisplatin; Drug Combinations; Hematopoiesis; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Risk Factors; Stomach Neoplasms; Tegafur | 2009 |
[Administration of S-1 after gastrojejunostomy for unresectable gastric cancer with pyloric stenosis].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Drug Combinations; Female; Gastric Bypass; Hospitalization; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Pyloric Stenosis; Stomach Neoplasms; Survival Rate; Tegafur | 2009 |
[Gastrojejunostomy for irresectable gastric cancer with pyloric stenosis-new role of surgery in the era of S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Fatal Outcome; Gastric Bypass; Gastroscopy; Humans; Male; Middle Aged; Oxonic Acid; Pyloric Stenosis; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced gastric cancer effectively treated with paclitaxel/S-1 as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oxonic Acid; Quinazolines; Tegafur; Tomography, X-Ray Computed | 2009 |
[A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Immunotherapy; Middle Aged; Oxonic Acid; Skin Neoplasms; Tegafur; Tomography, X-Ray Computed; Trastuzumab | 2009 |
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyrimidines; Retrospective Studies; Tegafur | 2009 |
Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylisoquinolines; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Mouth Neoplasms; Orotate Phosphoribosyltransferase; Oxonic Acid; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prodrugs; Tegafur | 2009 |
Treatment of patients with unresectable advanced carcinoma of biliary tract - chemotherapy and surgical resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur | 2009 |
[S-1 activity in non-small cell lung cancer in clinical practice].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2009 |
[Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Radiography; Recurrence; Salvage Therapy; Tegafur; Treatment Outcome | 2009 |
[A case of complete response (CR) persisting for 3 years and 3 months from combination therapy of S-1 and CDDP in a patient with advanced gastric cancer with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2009 |
[Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Drug Combinations; Floxuridine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; Esophageal Neoplasms; Female; Gastroscopy; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of synchronous hepatocellular carcinoma successfully treated by S-1 and cisplatin (CDDP) as neoadjuvant chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced adenocarcinoma of the ethmoid sinus treated by chemoradiation with S-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Ethmoid Sinus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nose Neoplasms; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of hypopigmentation triggered by S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hypopigmentation; Male; Oxonic Acid; Remission Induction; Tegafur; Tongue Neoplasms | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Uracil; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2009 |
[Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prospective Studies; Survival Rate; Tegafur | 2009 |
[Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur | 2009 |
[A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Gemcitabine; Humans; Jaundice, Obstructive; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
[A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Female; Humans; Oxonic Acid; Tegafur; Thyroid Neoplasms; Uracil | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiography; Esophageal Neoplasms; Humans; Hypopharyngeal Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pacemaker, Artificial; Sick Sinus Syndrome; Stomach Neoplasms; Tegafur | 2009 |
The usefulness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2009 |
S-1 monotherapy in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Prognosis; Retrospective Studies; Statistics, Nonparametric; Tegafur; Thymidylate Synthase | 2010 |
Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur | 2009 |
[Prognostic factors and usefulness of chemotherapy with S-1 in patients received gastrectomy for stage IV gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Male; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Oxonic Acid; Quality of Life; Tegafur | 2009 |
[A case of nonresected gastric cancer with peritoneal dissemination effectively treated by S-1/DOC and PTX/ CDDP combination chemotherapy with good QOL].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneum; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
[A case of double cancer of sigmoid colon cancer with lung metastases, peritoneal dissemination and early gastric cancer responding to S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Peritoneum; Sigmoid Neoplasms; Stomach Neoplasms; Tegafur | 2009 |
[Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report].
Topics: Adenocarcinoma; Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Peritoneum; Peritonitis; Quality of Life; Tegafur | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
Successful treatment of refractory bronchioloalveolar carcinoma with S-1 (oral fluoropyrimidine).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2009 |
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Gastrointestinal Agents; Humans; Intestinal Obstruction; Neoplasm Staging; Octreotide; Oxonic Acid; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
S-1 mediates the inhibition of lymph node metastasis in oral cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Combinations; Gene Expression; Green Fluorescent Proteins; Humans; Integrins; Lymphatic Metastasis; Mice; Mice, Nude; Mouth Neoplasms; Oxonic Acid; Signal Transduction; Tegafur; Xenograft Model Antitumor Assays | 2009 |
[Effectiveness of S-1 therapy for unresectable/advanced pancreas cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Female; Hospitalization; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
[Analysis of patients with locally advanced gastric cancer undergoing gastrectomy after pre-operative chemotherapy including S-1].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Inflammation; Middle Aged; Oxonic Acid; Skin Neoplasms; Taxoids; Tegafur; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
[A case of advanced non-small-cell lung cancer successfully treated with S-1 plus CBDCA after multiple chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoembryonic Antigen; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced gastric cancer successfully treated by combination therapy of S-1 and docetaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of advanced cancer of the gastric remnant with complete response to S-1 plus docetaxel chemotherapy as confirmed histopathologically].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2009 |
[A case of gastric cancer with posterior mediastinal lymph node metastasis responding to combination therapy of Paclitaxel and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[A case of cardiac tamponade induced by gastric cancer responding to S-1].
Topics: Antimetabolites, Antineoplastic; Cardiac Tamponade; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[Difficult management of warfarin anticoagulant therapy due to S-1 administration for gastric cancer--report of a case].
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Cerebral Infarction; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Warfarin | 2009 |
[A case report of primary duodenal adenocarcinoma with marked lymph node metastases responding to chemotherapy with S-1 plus CDDP combination].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Duodenal Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Tegafur | 2009 |
[Long survival of a case of unresected duodenal cancer treated by S-1 before and after duodenojejunostomy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Duodenal Neoplasms; Duodenostomy; Female; Humans; Jejunostomy; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Prospective Studies; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Pyridines; Radiosurgery; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Tumor Burden | 2009 |
[Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Drug Combinations; Fibroblast Growth Factor 2; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oxonic Acid; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Vascular Endothelial Growth Factors | 2009 |
[Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Uracil | 2009 |
[Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Prognosis; Recurrence; Salvage Therapy; Survival Rate; Tegafur | 2009 |
[Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Combinations; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Oxonic Acid; Quality of Life; Recurrence; Salvage Therapy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Recurrence; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced gastric cancer effectively treated on an outpatient basis by biweekly S-1 and docetaxel combination chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Combinations; Gastroscopy; Humans; Male; Neoplasm Staging; Outpatients; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN].
Topics: Angiography; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Drug Combinations; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Polyethylene Glycols; Recombinant Proteins; Tegafur; Tomography, X-Ray Computed | 2009 |
Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Drug Combinations; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Palliative Care; Retrospective Studies; Tegafur; Treatment Outcome | 2009 |
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Transformed; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Disease Models, Animal; Drug Combinations; Humans; Immunoenzyme Techniques; Luciferases; Male; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Proteins; Oxonic Acid; Photons; Pleural Neoplasms; Tegafur; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2010 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Oxonic Acid; Patient Selection; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2009 |
A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Drug Therapy; Female; Gemcitabine; Humans; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
Topics: Aged; Biomarkers, Pharmacological; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Pilot Projects; Retrospective Studies; Stomach Neoplasms; Tegafur; Thymidylate Synthase | 2009 |
[Feasibility of S-1/CDDP therapy for outpatients with advanced gastric cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[Response to S-1+paclitaxel in far-advanced gastric cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Etoposide; Fluorouracil; Gastrectomy; Humans; Immunohistochemistry; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
[Huge ascending colon carcinoma, treated successfully with S-1 plus CPT-11, followed by significant tumor reduction and curative resection--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of advanced rectal cancer that responded to S-1 with an extended complete response].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
[A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
Topics: Administration, Oral; Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Inguinal Canal; Injections, Intravenous; Lymphatic Metastasis; Oxonic Acid; Radiotherapy Dosage; Tegafur | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Breath Tests; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Gas Chromatography-Mass Spectrometry; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tegafur; Uracil | 2010 |
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Tegafur | 2009 |
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Tegafur; Xenograft Model Antitumor Assays | 2010 |
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Immunosuppressive Agents; Japan; Male; Oxonic Acid; Pancreaticoduodenectomy; Postoperative Care; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2009 |
CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Drug Combinations; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Silencing; Humans; Irinotecan; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Proto-Oncogene Proteins; Tegafur | 2010 |
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Chemical and Drug Induced Liver Injury; Dihydrouracil Dehydrogenase (NADP); Dimethylnitrosamine; Drug Combinations; Fluorouracil; Kidney; Liver; Liver Diseases; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Tegafur | 2009 |
Cholangiocarcinoma producing parathyroid hormone-related peptide treated with chemoradiation using gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Drug Combinations; Humans; Male; Oxonic Acid; Parathyroid Hormone-Related Protein; Radiotherapy, Adjuvant; Tegafur | 2009 |
[The effectiveness of concomitant radiotherapy with S-1 and nedaplatin for tongue cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Survival Rate; Tegafur; Tongue Neoplasms | 2009 |
[Complete response by S-1 with multiple pulmonary metastases 4 years after lung resection-a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pneumonectomy; Remission Induction; Tegafur | 2009 |
[A case report of complete response by S-1/docetaxel combination chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of advanced gastric cancer with disseminated carcinomatosis of bone marrow treated by S-1 and CDDP].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Drug Combinations; Humans; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2009 |
[A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2009 |
[Effect on neoadjuvant chemotherapy using s-1 for unresectable liver metastasis from rectal cancer-a case report].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Drug Combinations; Female; Hepatectomy; Humans; Liver Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2009 |
[Current trends and problems in chemotherapy for elderly patients with advanced gastric cancer].
Topics: Adult; Age Factors; Aged; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
[Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Laparoscopy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Oxonic Acid; Taxoids; Tegafur | 2009 |
[Intra-peritoneal chemotherapy for scirrhous gastric cancer].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Infusions, Parenteral; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[Assessment of chemoradiation therapy for advanced rectal cancer invaded the pelvic organ].
Topics: Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Male; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur | 2009 |
[A resected case of pathologically complete response of a pelvic recurrence from rectal cancer after chemoradiotherapy with S-1].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur | 2009 |
[A case of locally recurrent rectal cancer responding to radiation and chemotherapy with S-1].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Postoperative Period; Tegafur | 2009 |
[A case of unresectable type 4 gastric cancer which has kept a long-term partial response with adjuvant systemic chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Aorta, Abdominal; Chemotherapy, Adjuvant; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Infusions, Parenteral; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2009 |
[A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Male; Oxonic Acid; Quality of Life; Stents; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cardia; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[A case of advanced gastric cancer with histological complete response after S-1 chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Immunohistochemistry; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[Three scirrhous gastric cancer cases with CY negativity in second-look staging laparoscopy after chemotherapy to whom curative surgery was carried out].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Humans; Laparoscopy; Male; Middle Aged; Oxonic Acid; Second-Look Surgery; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of the local advanced gastric cancer which became a resection possible in S-1/CDDP/lentinan neoadjuvant chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lentinan; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur | 2009 |
[A case of bilateral pulmonary metastasis from gastric cancer performed radical thoracoscopic lobectomy after neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Oxonic Acid; Pneumonectomy; Stomach Neoplasms; Tegafur; Thoracoscopy | 2009 |
[A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
Topics: Antimetabolites, Antineoplastic; Carnitine O-Palmitoyltransferase; Drug Combinations; Duodenal Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Tegafur | 2009 |
[A long-term survival case of liver metastasis of gastric cancer under interdisciplinary therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Combinations; Embolization, Therapeutic; Female; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasms, Second Primary; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of advanced gastric cancer with liver metastases resected successfully after S-1 monotherapy and S-1/CDDP combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2009 |
[A case of far-advanced gastric cancer with peritoneal dissemination and obstructive jaundice effectively treated with combination chemotherapy and interventional radiology].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Jaundice, Obstructive; Male; Neoplasm Seeding; Oxonic Acid; Peritoneal Neoplasms; Radiography, Interventional; Stomach Neoplasms; Tegafur | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Combined Modality Therapy; Drug Combinations; Fluorouracil; Hepatectomy; Humans; Interferons; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Oxonic Acid; Tegafur | 2009 |
[A case of complete response to S-1 therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Tegafur | 2009 |
[A case report of S-1 monotherapy responding to unresectable gallbladder cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gallbladder Neoplasms; Humans; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2009 |
[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
[A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Tegafur | 2009 |
[A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritonitis; Stomach Neoplasms; Tegafur | 2009 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Drug Combinations; Epirubicin; Female; Fluorouracil; Humans; Oxonic Acid; Paclitaxel; Pentoxifylline; Quality of Life; Tegafur; Treatment Outcome | 2009 |
Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Renal Dialysis; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1.
Topics: Aged; Antineoplastic Agents; Drug Combinations; Eye Diseases; Female; Humans; Inflammation; Male; Microscopy, Confocal; Middle Aged; Mucositis; Oxonic Acid; Tegafur | 2009 |
Effect of a matrix metalloproteinase-12 inhibitor, S-1, on allergic airway disease phenotypes in mice.
Topics: Animals; Blotting, Western; Bronchoalveolar Lavage Fluid; Drug Combinations; Elastin; Eosinophils; Glyceraldehyde-3-Phosphate Dehydrogenases; Immunohistochemistry; Leukocyte Count; Lung; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Oxonic Acid; Protease Inhibitors; Respiratory Hypersensitivity; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tegafur; Up-Regulation | 2010 |
[Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
[Treatment with S-1 and radiation therapy for advanced lung cancer invading chest wall].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Quality of Life; Tegafur; Thoracic Neoplasms; Thoracic Wall | 2010 |
[A case of acinar cell carcinoma of pancreas with liver metastases treated effectively by S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2010 |
[Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chemotherapy, Adjuvant; Dihydropyrimidine Dehydrogenase Deficiency; Drug Combinations; Female; Gastrectomy; Humans; Liver; Lymph Node Excision; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur | 2010 |
[A case of type 4 advanced gastric cancer treated by S-1 simple suspension method with CDDP].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Constriction, Pathologic; Drug Combinations; Female; Humans; Oxonic Acid; Quality of Life; Stomach Neoplasms; Suspensions; Tegafur | 2010 |
[A case of advanced gastric cancer with a complete response to S-1 plus CPT-11 chemotherapy for eight years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Oxonic Acid; Pyloric Antrum; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
[A case of advanced gastric cancer with multiple liver metastases completely responding long term to paclitaxel plus S-1 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
[Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
[Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[S-1 + CPT-11 combination therapy with continuing 30-month CR in a recurrent gastric cancer with para-aortic lymph node metastasis in adjuvant chemotherapy with S-1--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
Efficacy and feasibility of combination chemotherapy with S-1 and cisplatin (2 weeks regimen) for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Fluorouracil; Humans; Oxonic Acid; Pyridines; Reproducibility of Results; Tandem Mass Spectrometry; Tegafur | 2010 |
[Effectiveness of concomitant therapy with S-1, nedaplatin, and radiation for laryngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Survival Rate; Tegafur; Voice Quality | 2010 |
[Combination therapy of S-1 and 24-h infusion of cisplatin after palliative gastrectomy for stage IV gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
[Problems of adjuvant chemotherapy with S-1 for gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2010 |
[Adjuvant surgery for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2010 |
[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Quinazolines; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Female; Humans; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of type 4 gastric cancer with peritoneal dissemination complicating venous thromboembolism treated effectively by combination of S-1 and warfarin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Drug Combinations; Female; Gastroscopy; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Venous Thromboembolism; Warfarin | 2010 |
[A case of advanced gastric cancer responding to S-1 chemotherapy for three weeks].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of early poorly-differentiated neuroendocrine carcinoma of stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
[A case of multiple pulmonary and remnant liver metastases of hepatocellular carcinoma (HCC) after partial hepatic resection remarkably responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2010 |
Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Oxonic Acid; Palliative Care; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2010 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed | 2010 |
Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Salvage Therapy; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2010 |
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Delivery Systems; Drug Synergism; Female; Humans; Intestinal Mucosa; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxonic Acid; RNA, Messenger; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Effective management of an advanced gastric cancer patient by TS-1 combined chemotherapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG): a case report.
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Female; Gastrostomy; Humans; Intubation, Gastrointestinal; Jejunum; Oxonic Acid; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2010 |
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Oxonic Acid; Tegafur | 2011 |
[Strategy of treatment for gastric cancer with peritoneal metastasis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
[Therapeutic outcome and prognosis in S-1+CDDP chemotherapy for advanced gastric cancer--postoperative histopathological assessment].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
[Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Digestive System Neoplasms; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lentinan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
[A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Time Factors | 2010 |
[A case of gastric cancer with Virchow and para-aortic node metastases treated successfully using S-1].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Radiography; Stomach Neoplasms; Tegafur | 2010 |
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Radiotherapy Dosage; Salvage Therapy; Tegafur; Thymectomy; Thymus Neoplasms | 2010 |
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.
Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Radiation; Drug Combinations; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Tegafur | 2010 |
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Combinations; E2F1 Transcription Factor; Fluorouracil; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Oxonic Acid; Retinoblastoma Protein; RNA, Messenger; Tegafur; Thymidylate Synthase; Vorinostat | 2010 |
[Feasibility study of adjuvant chemotherapy with S-1 for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancytopenia; Survival Rate; Tegafur | 2010 |
[Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2010 |
[Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[Successful management with S-1 of recurrent gastric cancer after adjuvant chemotherapy with paclitaxel/UFT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
[A case of advanced gastric cancer with distant lymph node metastases in cervical, supraclavicular and superior mediastinum successfully treated with S-1/Cisplatin (CDDP)/Lentinan combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastroscopy; Head; Humans; Lentinan; Lymphatic Metastasis; Neck; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of metachronous multiple lung metastases and intraabdominal lymph node metastases of rectal cancer responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Drug Delivery Systems; Drug Synergism; Fluorouracil; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diabetes Mellitus; Drug Combinations; Esophageal Neoplasms; Humans; Hypertension; Male; Neoplasm Staging; Oxonic Acid; Radiotherapy; Remission Induction; Tegafur | 2010 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagoscopy; Fatal Outcome; Gastroscopy; Home Care Services; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Terminal Care; Time Factors; Tomography, X-Ray Computed | 2008 |
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2010 |
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
[Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[Effectiveness of simultaneous combination therapy using S-1 and nedaplatin/radiation (SN therapy) for 4 cases of maxillary cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Humans; Male; Maxillary Neoplasms; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of advanced gastric cancer responding to neoadjuvant chemotherapy with S-1 and CDDP combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastroscopy; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[Three cases of metastatic breast cancer effectively treated with S-1 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
[A patient with small intestinal cancer and extensive lymph node metastasis who responded to S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Intestinal Neoplasms; Intestine, Small; Lymphatic Metastasis; Male; Oxonic Acid; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2010 |
[Long survival of a colon cancer case with synchronous multiple liver metastases responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Quality of Life; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
[A case of metastatic bladder cancer occurring after surgery for differentiated gastric cancer controlled by combination therapy of paclitaxel/S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2010 |
Advanced ampullary carcinoma showing complete response to S-1: report of a case.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Cholecystectomy; Choledochostomy; Common Bile Duct Neoplasms; Drug Combinations; Humans; Oxonic Acid; Tegafur; Treatment Outcome | 2010 |
Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Mice; Middle Aged; Oxonic Acid; Tegafur; Uracil; Xenograft Model Antitumor Assays | 2010 |
Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Topics: Activin Receptors, Type I; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Oxonic Acid; Phosphorylation; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Stomach Neoplasms; Tegafur; Transforming Growth Factor beta1 | 2010 |
S-1 induces meibomian gland dysfunction.
Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Dry Eye Syndromes; Eyelid Diseases; Female; Humans; Male; Meibomian Glands; Microscopy, Confocal; Middle Aged; Neoplasms; Oxonic Acid; Tegafur | 2010 |
Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.
Topics: Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Palliative Care; Prognosis; Survival Rate; Tegafur; Tumor Burden; Young Adult | 2011 |
[A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Tegafur; Tomography, X-Ray Computed | 2010 |
[Three cases of gastric cancer with para-aortic lymph node metastases succesfully treated by S-1/CDDP combination therapy followed by curative resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of recurrence with liver metastasis after total gastrectomy for StageIA gastric carcinoma successfully treated with S-1/CDDP combination followed by S-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Gastroenterostomy; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Oxonic Acid; Remission Induction; Splenectomy; Splenic Neoplasms; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
[A case of gastric cancer with para-aortic lymph node metastasis successfully treated with S-1/paclitaxel/lentinan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biopsy; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lentinan; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of primary gastric choriocarcinoma treated by curative operation after neoadjuvant chemotherapy with S-1/CDDP].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Drug Combinations; Fatal Outcome; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Remission Induction; Tegafur | 2010 |
[A case of abdominal wall metastasis from pancreatic cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy; Carcinoma; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Patient Selection; Predictive Value of Tests; Prognosis; Retrospective Studies; Specimen Handling; Stomach Neoplasms; Tegafur | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cimetidine; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Hypertension; Interferon-alpha; Life Style; Neoplasms; Oxonic Acid; Renin-Angiotensin System; Tegafur; Tetrazoles | 2010 |
Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Glottis; Humans; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Pyridines; Radiation-Sensitizing Agents; Tegafur | 2010 |
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
Timing of expression of blood coagulation abnormality in patients treated with warfarin and s-1 concomitantly.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; International Normalized Ratio; Male; Middle Aged; Monitoring, Physiologic; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Warfarin | 2010 |
Metastatic cutaneous squamous cell carcinoma treated successfully with surgery, radiotherapy and S-1/cisplatin chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Skin Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
[Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Humans; Imidazoles; Oxonic Acid; Pleural Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
[A case of luminal B recurrent breast cancer with liver and lymph node metastases successfully treated with combination therapy of S-1 plus trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Recurrence; Salvage Therapy; Tegafur; Tomography, X-Ray Computed; Trastuzumab | 2010 |
[A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Recurrence; Salvage Therapy; Taxoids; Tegafur | 2010 |
[A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
[Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neuroendocrine Tumors; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Fatal Outcome; Head and Neck Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Tegafur | 2010 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagoscopy; Gastroscopy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
[S-1-based chemotherapy for recurrent gastric cancer with peritoneal dissemination resulting in long-term survival--report of a case].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
[A case of advanced gastric cancer responding to S-1/paclitaxel/lentinan as neoadjuvant chemoimmunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lentinan; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoplasm Staging; Oxonic Acid; Positron-Emission Tomography; Recurrence; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
A case of pathological complete response of advanced rectal cancer to preoperative chemoradiotherapy using S-1.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colostomy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Rectal Neoplasms; Tegafur | 2010 |
Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Combinations; Female; Fluorouracil; Humans; Lentinan; Mice; Mice, Nude; Mouth Neoplasms; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2010 |
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Oxonic Acid; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome | 2011 |
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Female; Genes, p53; Glycoproteins; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Peptides; Polyethylene Glycols; Predictive Value of Tests; Receptors, Interferon; Recombinant Proteins; Survival Rate; Tegafur; Thymidylate Synthase; Treatment Outcome | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Pyridines; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2011 |
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur | 2010 |
[A comparative study of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or laryngeal cancer].
Topics: Aged; Aged, 80 and over; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Pharyngeal Neoplasms; Survival Rate; Tegafur | 2010 |
[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2010 |
[Effectiveness of simultaneous combination therapy using S-1, nedaplatin and radiotherapy for 7 cases of oropharynx cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle Aged; Organoplatinum Compounds; Oropharyngeal Neoplasms; Oxonic Acid; Tegafur | 2010 |
[A case of anastomotic recurrence of gastric cancer who underwent esophagojejunostomy, treated with S-1 monotherapy leading to complete response (CR)].
Topics: Aged; Combined Modality Therapy; Drug Combinations; Gastroenterostomy; Gastroscopy; Humans; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A very elderly case of recurrent gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of docetaxel (DOC) and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of recurrent gallbladder cancer with a remarkable tumor response to S-1].
Topics: Aged; Drug Combinations; Fatal Outcome; Gallbladder Neoplasms; Humans; Male; Oxonic Acid; Radiography; Recurrence; Tegafur; Tomography Scanners, X-Ray Computed | 2010 |
[A case of interstitial pneumonitis induced by S-1].
Topics: Aged, 80 and over; Breast Neoplasms; Drug Combinations; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polyethylene Glycols; Tegafur; Treatment Outcome; Tumor Burden | 2010 |
[A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystectomy; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Tegafur; Urachus; Urinary Bladder Neoplasms | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Combinations; Estrogen Receptor alpha; Estrogens; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oxonic Acid; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Uracil | 2011 |
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Colonic Neoplasms; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Gastrectomy and chemotherapy with S-1 for gastric cancer in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antimetabolites, Antineoplastic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Pneumocystis carinii; Pneumocystis Infections; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Randomized Controlled Trials as Topic; Tegafur | 2010 |
Gastrojejunostomy followed by induction chemotherapy for incurable gastric cancer with outlet obstruction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastric Bypass; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Disease Progression; Drug Combinations; Female; Health Status Indicators; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure | 2010 |
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Postoperative Care; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2010 |
[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Drug Combinations; Male; Mice; Neoplasm Transplantation; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2010 |
[Optic lesions in patients with epiphora during S-1 therapy].
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Eye Diseases; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasms; Oxonic Acid; Tegafur | 2010 |
[A case with parotid carcinoma showing a pathologically complete response after treatment with S-1 alone].
Topics: Biopsy; Combined Modality Therapy; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Parotid Neoplasms; Positron-Emission Tomography; Remission Induction; Tegafur | 2010 |
[Combination chemotherapy of S-1, docetaxel and CDDP produces a remarkable response in a patient with metastases of supraclavicular lymph nodes and gingival carcinoma of the mandible].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clavicle; Docetaxel; Drug Combinations; Female; Gingival Neoplasms; Humans; Lymphatic Metastasis; Mandibular Neoplasms; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
[S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Ultrasonography | 2010 |
[A case report of advanced gallbladder cancer with multiple liver metastases effectively treated by concentrated therapy with S-1].
Topics: Aged; Drug Combinations; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur | 2011 |
Adjuvant S-1 chemotherapy for gastric cancer and peritoneal wash.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Humans; Oxonic Acid; Peritoneal Lavage; Stomach Neoplasms; Tegafur | 2011 |
A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Stomach Neoplasms; Tegafur; Thymidylate Synthase | 2010 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxonic Acid; Pyridines; Radiation-Sensitizing Agents; Tegafur; Whole-Body Irradiation; Xenograft Model Antitumor Assays | 2010 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2010 |
[Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Survival Rate; Tegafur | 2010 |
[The role of adjuvant chemotherapy with S-1 for gastric cancer patients].
Topics: Chemotherapy, Adjuvant; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
[A case of submandibular gland cancer in elderly patients showed significant effect by S-1 and intravenous docetaxel chemotherapy concurrent with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Infusions, Intravenous; Male; Oxonic Acid; Positron-Emission Tomography; Submandibular Gland Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
[A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
[A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy].
Topics: Aged; Combined Modality Therapy; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2010 |
S-1 is an active anticancer agent for advanced thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Tegafur; Thymus Neoplasms | 2010 |
Another step toward the cure of metastatic renal cell carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Combinations; Humans; Kidney Neoplasms; Oxonic Acid; Tegafur | 2010 |
[A case of AFP-producing gastric cancer with hepatic metastases that accompanied early gastric cancer treated effectively by chemotherapy].
Topics: Aged; alpha-Fetoproteins; Drug Combinations; Humans; Liver Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Humans; Male; Mesothelioma; Mice; Mice, SCID; Neoplasm Proteins; Oxonic Acid; Pentosyltransferases; Pleural Neoplasms; Pyridines; Random Allocation; Survival Analysis; Tegafur; Thymidine Phosphorylase; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
[Clinical characteristics of cases showing complete regression of the primary tumor after S-1 combined with cisplatin administered as neoadjuvant chemotherapy in advanced gastric carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxonic Acid; Quality of Life; Tegafur; Treatment Outcome | 2010 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Hematologic Diseases; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Risk Factors; Tegafur | 2010 |
[A case of non-small cell lung cancer responding to S-1 over a year].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Radiography; Tegafur | 2010 |
[Complete histological response in advanced gastric cancer with Virchow's node metastasis after chemotherapy including S-1/CDDP--report of a case].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel, cisplatin and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neutropenia; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[A case with local recurrence of rectal cancer that responded to S-1 and PSK with long-term complete response].
Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Proteoglycans; Rectal Neoplasms; Tegafur; Treatment Outcome | 2010 |
Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Radiotherapy; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Orotate Phosphoribosyltransferase; Oxonic Acid; Paclitaxel; ROC Curve; Tegafur; Thymidylate Synthase; Treatment Outcome | 2011 |
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Camptothecin; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Failure | 2011 |
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Postoperative Care; Predictive Value of Tests; Pyridines; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bile; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asia, Eastern; Asian People; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Genotype; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Phenotype; Tegafur; White People | 2011 |
Laparoscopy-assisted total gastrectomy for advanced gastric cancer with carcinomatous ascites after S1 plus cisplatin chemotherapy: a case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Drug Combinations; Endoscopy, Gastrointestinal; Gastrectomy; Humans; Laparoscopy; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Tegafur | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2010 |
[A case of advanced colon cancer with metastases to both supraclavicular and para-aortic lymph nodes effectively treated by radiation and S-1 therapy].
Topics: Administration, Oral; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Tegafur | 2010 |
Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer".
Topics: Aged; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Combinations; Frail Elderly; Health Status Indicators; Humans; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Oxonic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cisplatin; Drug Combinations; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Tegafur | 2010 |
[The effects of gastrojejunostomy for patients with advanced gastric cancer accompanied by peritoneal dissemination].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastric Bypass; Gastric Outlet Obstruction; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A case of type 4 advanced gastric cancer with aplastic anemia successfully treated with neoadjuvant chemotherapy and surgical resection].
Topics: Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Parenteral; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[Long-term survival of patient with gastric cancer treated by S-1 + paclitaxel combination chemotherapy against multiple liver metastases after gastrectomy and adrenalectomy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
[Long-term control of sacral metastasis from rectal cancer with S-1 + radiation treatment (RT) and mFOLFOX6 combination therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxonic Acid; Radiotherapy Dosage; Rectal Neoplasms; Sacrum; Tegafur | 2010 |
[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
Topics: Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Tegafur | 2010 |
[A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Duodenal Neoplasms; Humans; Male; Mesenteric Artery, Superior; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Taxoids; Tegafur | 2010 |
[A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2010 |
[A case of pneumocystis pneumonia during chemotherapy for gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dexamethasone; Drug Combinations; Fatal Outcome; Glucocorticoids; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pneumonia, Pneumocystis; Stomach Neoplasms; Tegafur; Trimethoprim, Sulfamethoxazole Drug Combination | 2010 |
[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[Long-term disease-free survival following multimodal treatment in a patient with curatively unresectable advanced gastric cancer with metachronous liver metastasis].
Topics: Antimetabolites, Antineoplastic; Catheter Ablation; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasms, Second Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[An elderly patient with advanced gastric cancer maintaining complete response for over 3 years by oral administration of UFT following short span of S-1].
Topics: Adenocarcinoma; Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Uracil | 2010 |
[A case of AGC with pCR after preoperative chemotherapy including S-1 plus cisplatin].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Lavage; Splenectomy; Stomach Neoplasms; Tegafur; Time Factors | 2010 |
[A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
[An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Infusions, Parenteral; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
[Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Preoperative Period; Stomach Neoplasms; Tegafur | 2010 |
[Three cases of gastric cancer treated by S-1 combined with docetaxel in place of cisplatin].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[A case of advanced gastric cancer patient who died from meningitis carcinomatosa after S-1 + CDDP therapy with good response].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Male; Meningitis; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A successfully treated case of type 4 gastric cancer with intraperitoneal free cancer cells undergoing a curative resection followed by neoadjuvant chemotherapy with S-1 plus cisplatin].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Oxonic Acid; Peritoneal Cavity; Stomach Neoplasms; Tegafur | 2010 |
[Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[A case of elderly advanced gastric cancer patient with multiple liver metastases effectively treated by hepatic arterial infusion chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Combined Modality Therapy; Drug Combinations; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2010 |
[A case of unresectable advanced gastric cancer successfully treated with chemotherapy after gastrojejunostomy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Gastric Bypass; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Krukenberg Tumor; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of advanced gastric cancer successfully treated with chemoradiotherapy targeting for recurrent lymph node metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[Report of two cases successfully treated by chemo-radiation against lymph node metastasis after gastric cancer surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[The assessment of chemoradiation therapy with CDDP/S-1 for advanced gastric cancer that was actively bleeding].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Two cases of gastric endocrine cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Adrenalectomy for solitary adrenal metastasis from colorectal cancer].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
[A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Humans; Hysterectomy; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxonic Acid; Tegafur; Tumor Burden | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur; Vitamin B Complex | 2010 |
[A case report of locally advanced rectal carcinoma effectively treated with preoperative chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymph Node Excision; Oxonic Acid; Radiotherapy Dosage; Rectal Neoplasms; Rectum; Tegafur | 2010 |
[A case of local relapsed rectal cancer responding to low-dose S-1].
Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Rectal Neoplasms; Tegafur; Uracil | 2010 |
[A long-term survival case of hepatocellular carcinoma with bone metastasis and inferior vena cava tumor thrombus successfully treated with multidisciplinary therapy].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Combinations; Humans; Immunologic Factors; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Tegafur; Vena Cava, Inferior; Venous Thrombosis | 2010 |
[Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2010 |
[A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Drug Combinations; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2010 |
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Tegafur; Treatment Outcome | 2010 |
[A case report of primary adenocarcinoma of small intestine].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Ileal Neoplasms; Intestinal Neoplasms; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxonic Acid; Tegafur | 2010 |
[A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
Successful S-1 monotherapy for chemorefractory thymic carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Salvage Therapy; Tegafur; Thymus Neoplasms; Treatment Outcome | 2011 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |
[A case of sclerosing cholangitis caused by oral chemotherapy with S-1].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Cholangitis, Sclerosing; Drug Combinations; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2011 |
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Palliative Care; Proportional Hazards Models; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur | 2011 |
Synchronous double primary lung cancers with different response to pemetrexed.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Combinations; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Pemetrexed; Tegafur | 2011 |
Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Ki-67 Antigen; Male; Mice; Mice, SCID; Oxonic Acid; Prostatectomy; Prostatic Neoplasms; Taxoids; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Gastric cancer with choriocarcinoma and yolk sac tumor components: case report.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Disease-Free Survival; Drug Combinations; Endodermal Sinus Tumor; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Radiotherapy, Adjuvant; Stomach Neoplasms; Tegafur | 2011 |
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cisplatin; Cytochrome P-450 CYP2A6; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Tegafur; X-ray Repair Cross Complementing Protein 1 | 2011 |
[A case of advanced upper gingival carcinoma responding completely to concurrent chemoradiotherapy with S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Drug Combinations; Gingival Neoplasms; Humans; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
[Histological complete response in a case of advanced gastric cancer treated by neoadjuvant TS-1 combined with CDDP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Efficacy of concurrent chemoradiotherapy with S-1 plus nedaplatin for hypopharyngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Tegafur | 2011 |
[Investigation of epiphora following S-1 therapy].
Topics: Aged; Drug Combinations; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasms; Oxonic Acid; Tegafur | 2011 |
[A case of multiple para-aortic lymph node metastases from squamous cell carcinoma of an unknown primary responding completely to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Oxonic Acid; Positron-Emission Tomography; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of recurrent gastric cancer successfully treated with S-1 plus CDDP (divided into small dosages)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Male; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2011 |
[Combination chemotherapy of S-1/low-dose CDDP/lentinan for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Lentinan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
[Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography Scanners, X-Ray Computed | 2011 |
[A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Acinar Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Piperidines; Quinazolines; Tegafur; Tumor Cells, Cultured | 2011 |
A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Conjunctival Diseases; Corneal Diseases; Drug Combinations; Epithelium, Corneal; Humans; Lung Neoplasms; Male; Oxonic Acid; Pigmentation Disorders; Tegafur | 2011 |
[Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Tegafur; Tomography Scanners, X-Ray Computed | 2011 |
[A case of possible retroperitoneal metastasis of breast cancer successfully treated with oral S-1 and cyclophosphamide therapy after TC therapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Retroperitoneal Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[Retroperitoneal metastasis of hepatocellular carcinoma - a case report].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Hepatitis B virus; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Recurrence; Retroperitoneal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Fatal Outcome; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of rectal cancer with sacrum metastasis treated with S-1 leading to a complete response].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Oxonic Acid; Rectal Neoplasms; Remission Induction; Sacrum; Tegafur | 2011 |
Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Combinations; Female; Gastrectomy; Humans; Immunoglobulins, Intravenous; Middle Aged; Oxonic Acid; Palliative Care; Stevens-Johnson Syndrome; Stomach Neoplasms; Stomatitis; Tegafur | 2011 |
Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2011 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with carcinomatous lymphangitis of the lung].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Lung Neoplasms; Lymphangitis; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Fingers; Gangrene; Gemcitabine; Humans; Ischemia; Male; Necrosis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Raynaud Disease; Scleroderma, Systemic; Tegafur; Toes | 2011 |
Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Watchful Waiting | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Humans; Male; Mucous Membrane; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[Efficacy of concurrent chemoradiotherapy in cases with cervical lymph node metastasis from oropharyngeal or hypopharyngeal cancer].
Topics: Adult; Aged; Aminohydrolases; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Humans; Hypopharyngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck; Oropharyngeal Neoplasms; Oxonic Acid; Tegafur | 2011 |
[S-1 treatment for elderly patients over 75 years with gastric cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of hypopharyngeal cancer successfully treated with concurrent S-1, nedaplatin and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Humans; Hypopharyngeal Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
[A patient with of metastatic breast cancer with a well-controlled quality of life using S-1 therapy as first-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of advanced small intestinal cancer treated with S-1 plus cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Fatal Outcome; Female; Humans; Jejunal Neoplasms; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of advanced mullerian cancer successfully treated with S-1 chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Drug Combinations; Female; Humans; Ovarian Neoplasms; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2011 |
Alternating treatment with S-1 plus low-dose cisplatin and S-1 alone for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Young Adult | 2011 |
Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Thymidylate Synthase | 2011 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase | 2011 |
Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Female; Humans; Middle Aged; Muscle Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Retroperitoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cerebral Infarction; Docetaxel; Drug Combinations; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Neutropenia; Oxonic Acid; Taxoids; Tegafur | 2011 |
[Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Patient Care Team; Stomach Neoplasms; Tegafur | 2011 |
[A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Middle Aged; Oxonic Acid; Quality of Life; Tegafur; Zoledronic Acid | 2011 |
[A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A resected case of advanced gastric cancer with multiple liver metastasis successfully treated by preoperative and postoperative S-1/CPT-11 combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of stage III B advanced gastric cancer with psoriasis vulgaris responding to S-1/CDDP neoadjuvant chemotherapy leading to a pathologically complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Psoriasis; Remission Induction; Stomach Neoplasms; Tegafur | 2011 |
[A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Salvage Therapy; Tegafur | 2011 |
Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Polymerase Chain Reaction; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome; Young Adult | 2011 |
Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2011 |
Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Efficacy and toxicity of S-1 plus cisplatin combination neoadjuvant chemotherapy in patients with oral cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Immunohistochemistry; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Orotate Phosphoribosyltransferase; Oxonic Acid; Tegafur; Thymidylate Synthase | 2011 |
[Side effects analyses in consideration of renal function for S-1-administered patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Creatine; Drug Combinations; Female; Humans; Kidney Diseases; Male; Middle Aged; Oxonic Acid; Tegafur; Young Adult | 2011 |
[Effect of S-1 in a patient with metastatic eyelid sebaceous carcinoma].
Topics: Aged; Drug Combinations; Eyelid Neoplasms; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Positron-Emission Tomography; Sebaceous Gland Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
Phenytoin toxicity in a patient receiving concomitant use of phenytoin and S-1 plus cisplatin chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Phenytoin; Stomach Neoplasms; Tegafur | 2011 |
[Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Duodenal Neoplasms; Fatal Outcome; Female; Humans; Irinotecan; Jejunal Neoplasms; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of multiple bone metastasis of gastric carcinoma accompanying DIC successfully controlled with combination of S-1 and low-dose CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2011 |
Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
A case of gastric cancer accompanied with massive splenic invasion by metastatic lymph nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Endoscopy, Digestive System; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Splenectomy; Splenic Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Fluorouracil; Humans; Mass Spectrometry; Neoplasm Proteins; Oxonic Acid; Pancreatic Neoplasms; Proteomics; Pyridines; Tegafur | 2011 |
[Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease Progression; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Patient Care Planning; Positron-Emission Tomography; Radiosurgery; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Analysis of patients with advanced gastric cancer undergoing S-1/CDDP combined neoadjuvant chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur | 2011 |
[A case of multiple metastases breast cancer controlled using S-1 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; Humans; Oxonic Acid; Pleural Neoplasms; Positron-Emission Tomography; Recurrence; Salvage Therapy; Tegafur | 2011 |
[A case of advanced gastric cancer with tumor embolus in the portal vein successfully treated with S-1 and CDDP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Embolism; Humans; Male; Neoplasm Staging; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of unresectable advanced gastric cancer treated with S-1/low-dose CDDP combination chemotherapy through jejunostomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Humans; Jejunostomy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2011 |
[An elderly gastric cancer patient with multiple-node metastases treated successfully using S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2011 |
[A patient with advanced remnant gastric cancer responding completely to S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Gastric Stump; Humans; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Complete response to S-1/CDDP combination in a patient with obstructive jaundice secondary to lymph node metastasis by gastric cancer - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Jaundice, Obstructive; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Response in a case of advanced rectal cancer treated by chemoradiation with S-1/oxaliplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Japan; Logistic Models; Middle Aged; Oxonic Acid; Product Surveillance, Postmarketing; Prospective Studies; Severity of Illness Index; Tegafur; Trastuzumab | 2011 |
[Laryngeal cancer treatment outcomes in our department].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2011 |
[A case of advanced gastric cancer showing a complete histological response after S-1/CDDP neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of carcinoma associated with anal fistula resected after preoperative chemoradiotherapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Oxonic Acid; Rectal Fistula; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of breast cancer with postoperative metastasis to the supraclavicular lymph nodes-recurrence-free survival achieved by surgical excision following chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Breast Neoplasms; Clavicle; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Recurrence; Remission Induction; Tegafur | 2011 |
[A case of long-term survival after resection of aortic arch for locally advanced non-small cell lung cancer with induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Oxonic Acid; Tegafur; Time Factors | 2011 |
Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Floxuridine; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Tegafur | 2011 |
Feasibility study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2011 |
Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Floxuridine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Combinations; Gene Knockdown Techniques; Gene Silencing; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxonic Acid; RNA, Small Interfering; Tegafur; Xenograft Model Antitumor Assays | 2011 |
Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2012 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
[Present state and prospects of adjuvant chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Combinations; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
[Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Quality of Life; Tegafur; Time Factors | 2011 |
[A case of liver metastasis from gastric cancer responding to S-1/CDDP chemotherapy, allowing partial gastrectomy and left hepatectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Pancreatoduodenectomy for locally advanced ascending colon cancer after neoadjuvant chemotherapy (mFOLFOX6)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxonic Acid; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed | 2011 |
Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Tegafur | 2011 |
Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: a single-center feasibility study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Patient Selection; Pneumonectomy; Prognosis; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Paget Disease, Extramammary; Skin Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2011 |
Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Breast Neoplasms; Drug Combinations; ErbB Receptors; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Neoplasm Staging; Oxonic Acid; Receptor, ErbB-2; Receptors, Estrogen; Tegafur; Trastuzumab | 2011 |
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Head and Neck Neoplasms; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Platinum Compounds; Retrospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
[Evaluation of S-1 for stage IV gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2011 |
[Evaluation of pre-operative chemotherapy with S-1 plus CDDP against advanced gastric cancer with paraaortic lymph node metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of advanced gastric cancer showing pathological CR after neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
[A case of gastric cancer with liver metastasis had a good reaction to S-1/CDDP chemotherapy after S-1 chemotherapy was ineffective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Synergism; Female; Humans; Liver Neoplasms; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Oxonic Acid; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur | 2012 |
Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 case reports.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Drug Combinations; Drug Interactions; Female; Humans; International Normalized Ratio; Male; Middle Aged; Oxonic Acid; Prothrombin Time; Tegafur; Warfarin | 2011 |
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
[S-1-based chemotherapy for unresectable advanced gastric cancer of the elderly or patients with renal dysfunction].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Kidney Diseases; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2011 |
[The feasibility of oral fluoropyrimidines as adjuvant chemotherapy after resection and local coagulation therapy of colorectal liver metastases].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Combinations; Electrocoagulation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Uracil | 2011 |
[Clinical analyses of oral squamous cell carcinoma patients showing a complete response to chemotherapy with S-1 alone].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Recurrence; Survival Rate; Tegafur | 2011 |
[Synchronous double cancer of the gallbladder and rectum successfully treated with S-1 as second-line chemotherapy- a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Gallbladder Neoplasms; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Remission Induction; Tegafur | 2011 |
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Proportional Hazards Models; Tegafur | 2012 |
Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cetuximab; Drug Combinations; Drug Synergism; ErbB Receptors; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Gamma Rays; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2011 |
Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cetuximab; Combined Modality Therapy; Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gene Amplification; Humans; Male; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Stomach Neoplasms; Tegafur; Xenograft Model Antitumor Assays | 2012 |
[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2011 |
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13).
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Inversion; Drug Combinations; Humans; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Second Primary; Oxonic Acid; Tegafur | 2011 |
Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Statistics, Nonparametric; Tegafur | 2012 |
[The clinical effect of combination therapy for oral cancer with S-1, superselective intra-arterial chemotherapy, and radiation therapy].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Drug Combinations; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
[A long-term survivor who received S-1-based multidisciplinary therapy for unresectable advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
[S-1/krestin immunochemotherapy for patients with advanced gastric cancer].
Topics: Adult; Drug Combinations; Female; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Proteoglycans; Stomach Neoplasms; Tegafur | 2011 |
[A case of S-1/CDDP chemotherapy for inoperable advanced gastric cancer which led to gastrectomy with histological complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[A case of advanced gastric cancer with splenic vein thrombus successfully treated with S-1 plus CPT-11 neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Splenic Vein; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Venous Thrombosis | 2011 |
[A case report of the combination therapy with S-1 plus CDDP intraperitoneal chemotherapy for CY positive cancer patient].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2011 |
[Preoperative chemoradiotherapy with S-1 for advanced low rectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
[A case report of scirrhous gastric carcinoma diagnosed by staging laparoscopy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Laparoscopy; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case report of pathologically complete response of rectal cancer after preoperative treatment of CPT-11, S-1, and radiation therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
[A case of long-term survival after curative resection of advanced rectal cancer treated by pre-operative chemoradiotherapy].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Rectal Neoplasms; Remission Induction; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
[A case report of chemoradiotherapy combined with S-1 responding to squamous cell carcinoma of the anal canal].
Topics: Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2011 |
[Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Aorta; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2011 |
[A case of locally advanced gastric cancer responding to preoperative S-1/CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Two cases of advanced gastric cancer completely responding to S-1 neoadjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
[A case report of stage IV inoperable gastric cancer demonstrating a cCR treated with S-1/Paclitaxe (l PTX) therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Female; Humans; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[A case report-highly advanced gastric cancer leading to perforation during neoadjuvant chemotherapy with docetaxel, cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Stomach Rupture; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[Peritoneal lavage cytology under local anesthesia for detection of peritoneal recurrence after surgery].
Topics: Aged; Anesthesia, Local; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
[Curative resection of gallbladder cancer with simultaneous liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
[A case of long-term survival of a patient with intrahepatic bile duct cancer and early nodal recurrence who responded to S-1 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of complete response to interferon-α and S-1 combination therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Embolization, Therapeutic; Hepatectomy; Humans; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Oxonic Acid; Recurrence; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of successful surgical resection followed by S-1 administration for hepatocellular carcinoma with lung metastases and a tumor thrombus into right atrium].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Combinations; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[Oral antineoplastic agents for prostate cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Estramustine; Humans; Male; Oxonic Acid; Prostatic Neoplasms; Tegafur; Uracil | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
Acinar cell carcinoma of the pancreas: a possible role of S-1 as chemotherapy for acinar cell carcinoma. A case report.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2012 |
[Evaluation of the S-1 granule forms in gastric cancer patients who received treatment with S-1 capsule-questionnaire survey about drug dosage forms].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capsules; Deglutition; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Powders; Stomach Neoplasms; Surveys and Questionnaires; Tegafur | 2012 |
[A case of advanced gastric cancer with multiple bone metastases and distant lymph node metastases successfully treated by S-1/CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced gastric cancer with peritoneal dissemination successfully treated with S-1 and intraperitoneal docetaxel administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of bile duct cancer with positive surgical margin obtaining long-term survival after S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Combined Modality Therapy; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed | 2012 |
[A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Topics: Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Histamine H1 Antagonists; Humans; Male; Mianserin; Mirtazapine; Nausea; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur | 2012 |
Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2012 |
To resect or not resect in metastatic gastric cancer: that is the question!
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Anaplastic Lymphoma Kinase; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins; Drug Combinations; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Microtubule-Associated Proteins; Oxonic Acid; Pemetrexed; Positron-Emission Tomography; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Tegafur; Treatment Outcome | 2012 |
High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
C-reactive protein is a potential prognostic factor for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Antagonism; Drug Combinations; Drug Compounding; Drug Synergism; Injections, Intravenous; Liposomes; Male; Mice; Mice, Inbred BALB C; Nanotechnology; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Particle Size; Polyethylene Glycols; Technology, Pharmaceutical; Tegafur; Tissue Distribution | 2012 |
Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Base Sequence; Cytochrome P-450 CYP2A6; Digestive System Neoplasms; Drug Combinations; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Molecular Sequence Data; Oxonic Acid; Polymorphism, Genetic; Tegafur; Treatment Outcome; Young Adult | 2012 |
Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Telomerase; Young Adult | 2012 |
Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Panitumumab; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Tegafur; Time Factors; Treatment Outcome | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Taxoids; Tegafur | 2012 |
[A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of hepatoid adenocarcinoma of the stomach].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[A case of advanced gastric cancer with liver metastases successively treated with S-1/CDDP combination therapy followed by curative resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of stage IV gastric cancer with multiple liver metastases responding to chemotherapy with weekly PTX after failure of chemotherapy with S-1 and CDDP combination].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of cecal cancer with abdominal wall abscess].
Topics: Abdominal Wall; Abscess; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Cecal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2012 |
Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; S Phase; Tegafur | 2012 |
[The value of transbronchial lung biopsy findings in the diagnosis of a case of TS-1-induced pulmonary toxicity].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Humans; Lung; Lung Diseases; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Pilot Projects; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2012 |
Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Combinations; Endoscopy; Female; Humans; Incidence; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Tegafur | 2012 |
[Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced gastric cancer responding to S-1 therapy, leading to pathologically complete response].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2012 |
[A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Gastric Stump; Gastroscopy; Humans; Male; Neoplasm Staging; Neoplasms, Second Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Tegafur | 2012 |
Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Prognostic significance of aquaporins in human biliary tract carcinoma.
Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur | 2012 |
Histopathological changes in parotid and submandibular glands of patients treated with preoperative chemoradiation therapy for oral cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Parotid Gland; Preoperative Period; Retrospective Studies; Salivation; Submandibular Gland; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of lung metastases of carcinoma of the ampulla of vater effectively treated with S-1].
Topics: Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Drug Combinations; Duodenal Neoplasms; Female; Humans; Lung Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A successful resected case of far-advanced CA19-9-producing gastric cancer by neoadjuvant chemotherapy with S-1 and Cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[Two cases of stage IV gastric cancer undergoing adjuvant surgery after down staging by chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of advanced gastric cancer successfully treated with docetaxel and S-1 combined therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Positron-Emission Tomography; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Quality of Life; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of pulmonary pleomorphic carcinoma treated with S-1 following radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Chemoradiotherapy; Drug Combinations; Fatal Outcome; Humans; Lung Neoplasms; Male; Oxonic Acid; Salvage Therapy; Tegafur | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
[Laryngeal preservation for hypopharyngeal cancer by radiotherapy with S-1 and vitamin A(TAR therapy)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Humans; Hypopharyngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur; Vitamin A | 2012 |
[A case of disseminated carcinomatosis of bone marrow treated by S-1 and cisplatin after distal gastrectomy for early gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case study of advanced gastric cancer patient treated with S-1+paclitaxel/lentinan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Lentinan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced gastric cancer found to be remaining by gastrectomy after a clinically complete response to chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Recurrence; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2012 |
Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Lacrimal Duct Obstruction; Male; Middle Aged; Nasolacrimal Duct; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; ROC Curve; Stomach Neoplasms; Tegafur | 2012 |
The effect of lentinan combination therapy for unresectable advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lentinan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Tegafur | 2012 |
[Gastrojejunostomy followed by chemotherapy with S-1 in unresectable gastric cancer with pyloric stenosis].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastric Bypass; Humans; Male; Middle Aged; Oxonic Acid; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2012 |
[A case of drug-induced pulmonary injury showing organizing pneumonia pattern due to S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Humans; Lung Injury; Male; Oxonic Acid; Pneumonia; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case report of advanced gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of advanced gastric cancer with multiple liver metastases that achieved long-term survival on monotherapy of S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Bronchiectasis; Drug Combinations; Fatal Outcome; Female; Humans; Liver Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinations; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2012 |
Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nose Neoplasms; Oxonic Acid; Paranasal Sinus Neoplasms; Proton Therapy; Taxoids; Tegafur | 2012 |
Programmed chemotherapy for patients with metastatic unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
[Successful outcome from treatment modality with low-dose S-1 for three oldest old patients with advanced oral cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Mouth Neoplasms; Oxonic Acid; Tegafur | 2012 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Male; Oxonic Acid; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
[A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
[A case of multiple liver metastases of gastric cancer successfully treated by combination chemotherapy of S-1 and paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
A case of pancreatic cancer after heart transplantation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholestasis, Extrahepatic; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Duodenal Obstruction; Everolimus; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Postoperative Complications; Sirolimus; Stents; Tegafur | 2012 |
A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Immunohistochemistry; Leiomyosarcoma; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Drainage; Drug Combinations; Endoscopy, Digestive System; Female; Humans; Intestinal Obstruction; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stents; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced hepatocellular carcinoma with lung, brain and lymph node metastases recurred 8 years after hepatectomy successfully treated by operation, radiation and systemic chemotherapy using S-1/CDDP].
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur | 2012 |
Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Logistic Models; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2012 |
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2012 |
Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Clinical Trials, Phase II as Topic; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2012 |
[Examination of factors influencing continuity of S-1 adjuvant chemotherapy for gastric cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2012 |
[Tolerable evaluation for chemotherapy with S-1 plus cisplatin in elderly patients with advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatine; Drug Combinations; Drug Tolerance; Female; Humans; Kidney Function Tests; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Retrospective Studies; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced gastric cancer with recurrence-free long survival showing disappearance of distant lymph node metastases by S-1/docetaxel therapy followed by curative resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur; Time Factors; Tomography, X-Ray Computed | 2012 |
[A case of gastric cancer with peritoneal dissemination and massive ascites successfully treated with S-1/docetaxel therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Stents; Tegafur | 2012 |
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Laryngeal Neoplasms; Larynx; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Tegafur | 2012 |
Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Drugs, Chinese Herbal; Female; Gastrectomy; Humans; Immunotherapy; Krukenberg Tumor; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Phytotherapy; Postoperative Care; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
[A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur | 2012 |
[S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Staging; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2012 |
[A case of pathological complete response after chemotherapy for liver metastasis with subcapsular hemorrhage from gastric cancer:].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Gastrectomy; Hemorrhage; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Fatal Outcome; Hepatitis C; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur | 2012 |
Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Comorbidity; Deoxycytidine; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2013 |
Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Hypertension, Pulmonary; Lung Neoplasms; Male; Neoplasms, Unknown Primary; Oxonic Acid; Pulmonary Artery; Tegafur; Thoracic Surgery, Video-Assisted; Thrombotic Microangiopathies; Tomography, X-Ray Computed | 2012 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2012 |
A case of advanced cutaneous squamous cell carcinoma of the lower eyelid that was successfully treated with tegafur-gimeracil-oteracil potassium monotherapy.
Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Eyelid Neoplasms; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Oxonic Acid; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Tegafur | 2012 |
[Two cases of long-term response treated by S-1 with concurrent radiotherapy followed by S-1 treatment for non-small cell lung cancer patients].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed | 2012 |
[A case of recurrent gastric cancer showing partial response to capecitabine/CDDP after treatment with S-1/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2013 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Prognosis; Tegafur | 2012 |
[A case of advanced gastric cancer with multiple bone metastases and disseminated intravascular coagulation successfully treated by combination chemotherapy of S-1 plus docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intravascular Coagulation; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
[Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2012 |
A patient with gastric adenosquamous carcinoma with intraperitoneal free cancer cells who remained recurrence-free with postoperative S-1 chemotherapy.
Topics: Aged; Antineoplastic Agents; Ascitic Fluid; Carcinoma, Adenosquamous; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Tegafur | 2012 |
An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Chemotherapy, Adjuvant; Drug Combinations; Female; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Cyclin-Dependent Kinase Inhibitor p21; Drug Combinations; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Rectum; Tegafur; Time Factors; Treatment Outcome; Tumor Burden; Tumor Suppressor Protein p53 | 2013 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; National Cancer Institute (U.S.); Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Real-Time Polymerase Chain Reaction; Retrospective Studies; RNA, Messenger; Tegafur; United States; Up-Regulation | 2012 |
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Drug Delivery Systems; Liposomes; Liver; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polyethylene Glycols; Tegafur; Tissue Distribution | 2013 |
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Time Factors | 2013 |
Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Validation Studies as Topic | 2013 |
[Recent advance of chemotherapy in gastric cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Humans; Oxonic Acid; Peptide Fragments; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Intestinal Absorption; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[Clinicopathological characteristics of ten cases of advanced gastric carcinoma after S-1 combined with cisplatin administered as neoadjuvant chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of HER2-positive and AFP-producing gastric cancer successfully treated by trastuzumab/docetaxel/S-1 combination therapy].
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Taxoids; Tegafur; Trastuzumab | 2012 |
[Distal gastrectomy for initially unresectable gastric cancer with pyloric stenosis following gastrojejunostomy and S-1 plus CDDP chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Gastrectomy; Gastric Bypass; Humans; Middle Aged; Oxonic Acid; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2012 |
[A case report of complete response to low-dose S-1 monotherapy for pancreatic cancer in elderly patient].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Drug Combinations; Female; Humans; Oxonic Acid; Pancreatic Neoplasms; Stomach Neoplasms; Tegafur | 2012 |
Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Oxonic Acid; Risk Factors; Stomach Neoplasms; Tegafur; Weight Loss | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
[A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Proteoglycans; Stomach Neoplasms; Tegafur | 2012 |
[Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Weight Loss | 2012 |
[A case of postoperative liver metastasis from pancreatic carcinoma treated with percutaneous isolated hepatic perfusion(PIHP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Doxorubicin; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
[Case of stage IIB gastric cancer with positive margin treated with sequential therapy consisting of S-1, chemoradiation therapy with paclitaxel and CDDP, and S-1 after surgery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2012 |
[A case of advanced breast carcinoma treated with topical S-1 plus letrozole].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Oxonic Acid; Tegafur; Treatment Outcome; Triazoles | 2012 |
[A case of a geriatric patient with stage IV anal canal cancer showing complete response to chemoradiation therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Neoplasm Staging; Oxonic Acid; Tegafur | 2012 |
[Neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur | 2012 |
[A case of diffuse hepatocellular carcinoma(Vp4) treated by right hepatic trisegmentectomy and multidisciplinary therapy regimens].
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Hepatectomy; Humans; Interferon-alpha; Liver Neoplasms; Middle Aged; Oxonic Acid; Recurrence; Tegafur | 2012 |
[A patient with multiple liver metastases of gastric and rectal cancers after laparoscopic sigmoidectomy who responded completely to S-1 therapy followed by open gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Colectomy; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Laparoscopy; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur | 2012 |
[The feasibility of CDDP administration for gastric cancer outpatients undergoing S-1/cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Outpatients; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A comparative study of S-1 plus cisplatin and S-1 plus weekly cisplatin for unresectable gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
[Evaluation of outpatient clinical pathway, including the supportive therapy of S-1+cisplatin combination therapy for gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Critical Pathways; Drug Combinations; Female; Humans; Male; Middle Aged; Outpatients; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of paraaortic lymph node metastasis of gastric cancer resistant to chemotherapy successfully treated with chemoradiation therapy].
Topics: Antimetabolites, Antineoplastic; Aorta; Chemoradiotherapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
[A case of early gastric cancer with cervical lymph nodes recurrence 5 years after a curative resection].
Topics: Biopsy; Combined Modality Therapy; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case report of advanced gastric cancer with increased C-reactive protein(CRP) and decreased albumin levels: chemotherapy with nutritional supportive care using eicosapentaenoic acid (EPA)-enriched enteral nutrition agent].
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cisplatin; Drug Combinations; Eicosapentaenoic Acid; Enteral Nutrition; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Serum Albumin; Stomach Neoplasms; Tegafur | 2012 |
[A clinical case of lymph node recurrence after the resection of esophagogastric junction cancer treated by chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophagogastric Junction; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2012 |
[Chemotherapy-mediated tumor regression in a patient with stage IV stomach small cell cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capsules; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2012 |
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2012 |
[A case of gastric neuroendocrine carcinoma with liver metastasis and portal vein invasion successfully treated by S-1 and cisplatin chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur | 2013 |
[Questions on "gemcitabine plus S-1 combination therapy (G-S therapy) for pancreatic cancer with accentuated hepatic metastasis" (by Matsumoto, T. et al) published on Japanese Journal of Gastro-enterology Vol. 108, N0. 12].
Topics: Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A patient with advanced gastroesophageal junction cancer responding completely to S-1 monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Esophagogastric Junction; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of advanced gastric cancer with carcinomatous pericarditis effectively treated by S-1/CDDP combined therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Female; Humans; Middle Aged; Oxonic Acid; Pericarditis; Stomach Neoplasms; Tegafur | 2013 |
[Pathological complete remission using low-dose cisplatin plus S-1 for gastric cancer patient with liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Liver Neoplasms; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2013 |
[A case experienced long-term survival after repeat hepatectomy for liver metastases from gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lithostathine; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasm Staging; Oxonic Acid; Prospective Studies; Psychometrics; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome; Vomiting | 2013 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Frail Elderly; Humans; Leucovorin; Male; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Failure; Vascular Endothelial Growth Factor A | 2013 |
[Oral chemotherapy for advanced breast cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Molecular Targeted Therapy; Oxonic Acid; Tegafur | 2012 |
Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharmacy Service, Hospital; Stomach Neoplasms; Tegafur | 2013 |
S-1-induced lung injury combined with pneumocystis pneumonia.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Lung Injury; Lung Neoplasms; Male; Oxonic Acid; Pneumonia, Pneumocystis; Tegafur | 2013 |
A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Oxonic Acid; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
[A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Oxonic Acid; Recurrence; Tegafur; Zoledronic Acid | 2013 |
[Two cases of unresectable advanced gastric cancer treated with S-1, CDDP and trastuzumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Trastuzumab | 2013 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Disease Progression; Disseminated Intravascular Coagulation; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
Intramucosal gastric cancer with fifteen metastatic lymph nodes: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Gastric Mucosa; Gastroscopy; Humans; Immunohistochemistry; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase | 2013 |
The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Lymphocyte Count; Male; Middle Aged; Nutritional Status; Oxonic Acid; Predictive Value of Tests; Retrospective Studies; Serum Albumin; Stomach Neoplasms; Tegafur; Time Factors; Uracil; Young Adult | 2013 |
Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Spinal infarction related to the adjuvant chemotherapy for surgically resected non-small cell lung cancer: report of a case.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Infarction; Lung Neoplasms; Oxonic Acid; Pneumonectomy; Pyridines; Spinal Cord; Tegafur; Treatment Outcome | 2013 |
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pilot Projects; Quality of Life; Tegafur; Uterine Cervical Neoplasms | 2014 |
[Effectiveness of postoperative adjuvant chemotherapy using S-1 plus CDDP for type 4 gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2013 |
[A case of a septic pulmonary embolism-related implanted central venous port].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Catheters, Indwelling; Cisplatin; Drug Combinations; Female; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pulmonary Embolism; Sepsis; Stomach Neoplasms; Tegafur | 2013 |
Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Prognosis; Receptor, ErbB-2; Stomach Neoplasms; Tegafur | 2013 |
Choroidal and cutaneous metastasis from gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Choroid Neoplasms; Cisplatin; Drug Combinations; Endoscopy, Gastrointestinal; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging; Oxonic Acid; Positron-Emission Tomography; Predictive Value of Tests; Scalp; Skin Neoplasms; Stomach Neoplasms; Tegafur; Tomography, Emission-Computed, Single-Photon; Tomography, Optical Coherence; Treatment Outcome | 2013 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcoma; Chemoradiotherapy; Cisplatin; Cohort Studies; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxonic Acid; Pyridines; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2014 |
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Receptor, ErbB-2; Tegafur; Trastuzumab | 2014 |
Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Panitumumab; Prognosis; Prospective Studies; Survival Rate; Tegafur | 2013 |
New advances in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Etoposide; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Methotrexate; Organoplatinum Compounds; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2013 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Fluorouracil; Glycosylation; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2013 |
Acute aortic thrombosis during cisplatin based chemotherapy for gastric cancer.
Topics: Acute Disease; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aortic Diseases; Aortography; Arterial Occlusive Diseases; Carcinoma, Signet Ring Cell; Cisplatin; Dexamethasone; Drug Combinations; Heparin; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur; Thrombosis; Tomography, X-Ray Computed; Warfarin | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
S-1 induced a durable response in metastatic extramammary Paget's disease.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Genital Neoplasms, Male; Humans; Male; Oxonic Acid; Paget Disease, Extramammary; Tegafur | 2013 |
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Early Growth Response Protein 1; Humans; Mice; Mouth Neoplasms; Neovascularization, Pathologic; Oxonic Acid; Tegafur; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Follow-Up Studies; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Possible peripheral mechanism for taste disorder in rats administered S-1.
Topics: Animals; Drug Combinations; Ganglia; Male; Nerve Degeneration; Nerve Endings; Oxonic Acid; Quinine; Rats, Wistar; Taste Buds; Taste Disorders; Tegafur; Tongue | 2014 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2013 |
Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Feasibility and outcome of S-1 adjuvant chemotherapy for patients with gastric cancer treated based on the liaison-clinical pathway].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Critical Pathways; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
[An 84-year-old man with highly advanced gastric cancer showing good response after chemotherapy with docetaxel, cisplatin and S-1 combination therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab].
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Trastuzumab | 2013 |
[A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of advanced gastric cancer diagnosed as stage IV responding to combined modality therapy and surviving for a long duration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Time Factors | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
[A case of synchronous liver metastasis originating from advanced gastric cancer treated with combination chemotherapy involving S-1 and surgical intervention].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[Two cases of multiple liver metastases breast cancer successfully treated with combination chemotherapy by S-1, vinorelbine and medroxyprogesterone].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Gonadotropin-Releasing Hormone; Humans; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Oxonic Acid; Tamoxifen; Tegafur; Vinblastine; Vinorelbine | 2013 |
[A case of lung cancer resistant to pemetrexed responding to S-1 monotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of advanced gastric cancer with bulky lymph node metastases responding to S-1/CDDP neoadjuvant chemotherapy and leading to less invasive surgery and a pathologically complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Splenectomy; Stomach Neoplasms; Tegafur | 2013 |
[A case of metastatic colon cancer effectively treated by XELOX and IRIS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Oxaloacetates; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of advanced gastric cancer with esophageal invasion treated by neoadjuvant S-1/CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophagus; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur | 2013 |
[A case of metastatic acsending colon cancer showing sustained complete response to chemotherapy with SOX and followed UFT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Tomography, X-Ray Computed; Uracil | 2013 |
Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Drug Therapy; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outpatients; Oxonic Acid; Tegafur | 2013 |
Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Radiotherapy Dosage; Retrospective Studies; Tegafur; Tongue Neoplasms; Treatment Outcome | 2013 |
The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Forkhead Transcription Factors; Humans; Killer Cells, Natural; Male; Middle Aged; Oxonic Acid; Proteoglycans; Stomach Neoplasms; Tegafur | 2013 |
Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; E2F1 Transcription Factor; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Oxonic Acid; Simvastatin; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2013 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Tegafur; Tokyo | 2013 |
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Preoperative Care; Retrospective Studies; Tegafur | 2013 |
Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cohort Studies; Digestive System Surgical Procedures; Drug Combinations; Female; Humans; Immunohistochemistry; Lymph Node Excision; Male; Middle Aged; Oxonic Acid; Pilot Projects; Prognosis; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Tetraspanin 24; Young Adult | 2013 |
Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cecal Neoplasms; Drug Combinations; Edema; Humans; Hypoproteinemia; Keratin-20; Keratin-7; Male; Mutation; Neoplasms, Multiple Primary; Oxonic Acid; Pancreatic Neoplasms; Pancrelipase; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Panitumumab; Tegafur; Tomography, X-Ray Computed | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2013 |
[A case of recurrent non-small cell lung cancer successfully treated with multiple modality therapies including S-1 monotherapy as fifth-line chemotherapy hospital)].
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Recurrence; Tegafur | 2013 |
[A case of advanced gastric cancer with tumor embolus in portal vein successfully treated by neoadjuvant chemotherapy, operation and chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Embolism; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur | 2013 |
[Neoadjuvant chemotherapy with combined S-1 plus weekly low-dose cisplatin followed by surgical resection for advanced gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2013 |
[Assessment of the vulnerable elders survey as a predictive test for elderly patients with advanced or metastatic gastric cancer treated with combined S-1 and docetaxel therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Docetaxel; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Oxonic Acid; RNA Interference; RNA, Small Interfering; Tegafur; Thymidylate Synthase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrectomy; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
[A case of advanced signet ring cell carcinoma of the appendix that responded to S-1 and docetaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma, Signet Ring Cell; Docetaxel; Drug Combinations; Humans; Male; Oxonic Acid; Taxoids; Tegafur | 2013 |
[A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1 plus trastuzumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Humans; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Trastuzumab | 2013 |
[A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Oxonic Acid; Pancreatic Neoplasms; Proteoglycans; Recurrence; Salvage Therapy; Tegafur | 2013 |
Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; In Situ Hybridization, Fluorescence; Japan; Male; Middle Aged; Oxonic Acid; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Tegafur; Trastuzumab | 2014 |
[A case of unresectable gastric cancer with poor ingestion].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Patient Discharge; Quality of Life; Stomach Neoplasms; Tegafur | 2013 |
[A case of locally advanced gastric cancer in which the patient underwent curative gastrectomy after treatment with systemic chemotherapy with bi-weekly s-1/docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of advanced gastric cancer with regional lymph node metastasis showing pathological complete response after preoperative chemotherapy with docetaxel, cisplatin, and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival; Tegafur | 2014 |
[Postoperative adjuvant chemotherapy for gastric cancer after the adjuvant chemotherapy trial of S-1 for gastric cancer in Hiroshima prefecture: results from a questionnaire survey and future challenges].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans; Japan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Surveys and Questionnaires; Tegafur | 2013 |
[A case report of recurrent small bowel adenocarcinoma successfully treated with monoclonal antibody against EGFR and S-1].
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Jejunal Neoplasms; Male; Oxonic Acid; Panitumumab; Recurrence; Tegafur | 2013 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Middle Aged; Models, Statistical; Oxaloacetates; Oxonic Acid; Probability; Quality-Adjusted Life Years; Stomach Neoplasms; Tegafur | 2013 |
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2014 |
Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Administration Schedule; Drug Carriers; Drug Combinations; Drug Therapy, Combination; Liposomes; Liver; Male; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polyethylene Glycols; Tegafur; Tissue Distribution | 2014 |
[Strategy for the treatment of Stage IV gastric cancer with preoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[An appropriate distal resection margin for lower rectal cancer after preoperative chemoradiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Postoperative Complications; Rectal Neoplasms; Tegafur | 2013 |
[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
[Efficacy of combined local therapy especially with hepatic arterial infusion for liver metastasis from gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Catheter Ablation; Combined Modality Therapy; Drug Combinations; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2013 |
[Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Receptor, ErbB-2; Recurrence; Stomach Neoplasms; Tegafur | 2013 |
[A case of effective multidisciplinary treatment for advanced gallbladder carcinoma with distant lymph node metastases].
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2013 |
[Resection of a synchronous liver metastasis from gastric cancer associated with portal vein tumor thrombosis - a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Fatal Outcome; Female; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Thrombosis | 2013 |
[A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2013 |
[A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2013 |
[Ten cases of locally advanced rectal cancer that were treated with preoperative chemotherapy with S-1 plus oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur | 2013 |
[Multiple hepatic metastases from colon cancer successfully treated with irinotecan and S-1 plus panitumumab as second-line therapy-a case report].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Panitumumab; Salvage Therapy; Sigmoid Neoplasms; Tegafur | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Funnel Chest; Humans; Male; Oxonic Acid; Prognosis; Tegafur; Thoracoscopy; Time Factors | 2013 |
[A case of combined resection of multiple adjacent organs in a patient with locally advanced residual gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lentinan; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of gastric cancer with intensive peritoneal dissemination treated with long-term chemotherapy and surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of advanced gastric cancer with para-aortic lymph node metastasis successfully treated with preoperative S-1/Lentinan chemotherapy followed by curative gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biopsy; Drug Combinations; Gastrectomy; Humans; Lentinan; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2013 |
[A patient with advanced gastric cancer who responded to neoadjuvant S-1 plus cisplatin chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[The efficacy of neoadjuvant chemotherapy with S-1/CDDP (SP) to the patients with large type 3 and type 4 gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2013 |
[Preoperative chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Tegafur | 2013 |
[A case of locally advanced residual gastric cancer treated with combined resection of multiple adjacent organs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Pathological complete response in advanced gastric carcinoma with lymph node metastasis treated with combination neoadjuvant chemotherapy comprising S-1 and cisplatin-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of advanced gastric cancer responding to combined systemic and intraperitoneal chemotherapy with docetaxel, cisplatin, and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[An effective treatment by chemotherapy with CDDP+CPT-11 for recurrent gastric cancer which S-1 cannot be used owing to adverse effects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Contraindications; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2013 |
[A case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow successfully controlled by S-1 and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of advanced gastric cancer with peritoneal dissemination recurrence after gastrectomy effectively treated with combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive gastric cancer accompanied by distant lymph node metastasis].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2013 |
[A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of delayed subcutaneous metastases of gastric carcinoma effectively treated with S-1 plus cisplatin chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Skin Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Constriction, Pathologic; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Stomach Neoplasms; Tegafur | 2013 |
[Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
Topics: Chemotherapy, Adjuvant; Drug Combinations; Eicosapentaenoic Acid; Enteral Nutrition; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Weight Loss | 2013 |
[A case of advanced gastric cancer exhibiting pathological complete response after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[A case of lethal interstitial pneumonia after neoadjuvant chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Lung Diseases, Interstitial; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Cases of three patients undergoing chemotherapy for gastric cancer who developed Trousseau's syndrome].
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Stroke; Tegafur | 2013 |
[A case of emphysematous cholecystitis during the course of chemotherapy for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Emphysematous Cholecystitis; Female; Humans; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Vascular Access Devices | 2013 |
[Long-term survival after surgical resection of a cancer of unknown primary site-a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Neoplasms, Unknown Primary; Oxonic Acid; Tegafur; Time Factors | 2013 |
[Tegafur gimeracil oteracil potassium capsule induced acute interstitial lung disease: a case report].
Topics: Acute Disease; Adult; Antineoplastic Agents; Capsules; Drug Combinations; Humans; Lung Diseases, Interstitial; Male; Oxonic Acid; Pyridines; Tegafur; Tomography, X-Ray Computed | 2014 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2014 |
A case of gastric cancer with perforation caused by chemotherapy with docetaxel and S-1.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Intestinal Perforation; Male; Oxonic Acid; Radiography, Abdominal; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of appearance of a prominent rash in response to alternate-day S-1 administration as adjuvant chemotherapy for lower gingival cancer].
Topics: Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Drug Combinations; Exanthema; Female; Gingival Neoplasms; Histamine Antagonists; Humans; Oxonic Acid; Steroids; Tegafur | 2014 |
[Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Drug Interactions; Humans; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2013 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Liposomes; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Prospective cohort study: whether or not patients benefit from participation itself in randomized-controlled trials (SELECT BC ECO).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Oxonic Acid; Patient Participation; Patient Selection; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Research Subjects; Selection Bias; Taxoids; Tegafur | 2014 |
Chemoradiation using cisplatin and S-1 in locally advanced giant squamous cell carcinoma of the buttock.
Topics: Aged; Antineoplastic Agents; Buttocks; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Drug Combinations; Humans; Male; Oxonic Acid; Skin Neoplasms; Tegafur | 2014 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Common Bile Duct Neoplasms; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Pyridines; Retrospective Studies; Tegafur; Treatment Outcome | 2014 |
Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine.
Topics: Adult; Antineoplastic Agents; Axilla; Carcinoma; Cyclophosphamide; Drug Combinations; Epirubicin; Humans; Male; Oxonic Acid; Sweat Gland Neoplasms; Tegafur | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pain Measurement; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Tegafur | 2014 |
Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Radiotherapy, Conformal; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2014 |
Prominent hypereosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Eosinophilia; Female; Humans; Oxonic Acid; Purpura; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Drug Combinations; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Tegafur; Withholding Treatment | 2014 |
Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2013 |
A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
[A case of complete response(CR)to S-1 and paclitaxel(PTX)combination therapy in a patient with unresectable gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced gastric cancer treated with curative resection after preoperative combined chemotherapy with docetaxel, cisplatin, and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2014 |
[A case of large cell neuroendocrine carcinoma of the stomach with liver metastasis effectively treated with S-1 and CDDP combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors | 2014 |
[Induction chemotherapy with S-1/oxaliplatin prevented colostomy in a patient with advanced rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colostomy; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Safety; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
[A case of urachal carcinoma with multiple lung metastases treated by TS-1/CDDP chemotherapy].
Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Tegafur; Urinary Bladder Neoplasms | 2014 |
Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Amino Acid Transport System y+; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fusion Regulatory Protein 1, Heavy Chain; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Middle Aged; Minor Histocompatibility Antigens; Neoplasm Proteins; Neoplasm Staging; Oxonic Acid; Prognosis; Taxoids; Tegafur; Tongue Neoplasms; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2014 |
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heterografts; HT29 Cells; Humans; Leucovorin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Tegafur | 2015 |
Oral S-1 in advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Skin Neoplasms; Tegafur | 2014 |
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Care; Prognosis; Stomach Neoplasms; Tegafur; Young Adult | 2015 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Humans; Immunohistochemistry; Oxonic Acid; Prognosis; Receptor Protein-Tyrosine Kinases; Receptor, EphA2; Receptor, EphA3; Receptor, EphA5; Receptor, EphB2; Retrospective Studies; Stomach Neoplasms; Stromal Cells; Tegafur; Tumor Microenvironment | 2015 |
[A case of advanced gastric cancer with para-aortic lymph node metastases responding to S-1/CDDP chemotherapy that leads to a pathological complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
[Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[Case report of a patient with advanced and disseminated gastric carcinoma treated by s-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Czech Republic; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Letter regarding Wu JR et al.: S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Nausea; Oxonic Acid; Proton Pump Inhibitors; Retrospective Studies; Stomach Neoplasms; Tegafur; Vomiting | 2014 |
Inhibition of JNK3 promotes apoptosis induced by BH3 mimetic S1 in chemoresistant human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Biomimetic Materials; Cell Line, Tumor; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Mitogen-Activated Protein Kinase 10; Molecular Mimicry; Ovarian Neoplasms; Oxonic Acid; Proto-Oncogene Proteins c-bcl-2; Tegafur | 2015 |
Clinicopathological features and outcomes of gastric cancer patients with pulmonary lymphangitis carcinomatosa.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Diseases; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2014 |
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxonic Acid; Palliative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
[A case of a patient with gastric cancer and peritoneal dissemination who survived for more than 10 years after successful treatment with S-1].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Chemoradiotherapy; Disease-Free Survival; Drug Combinations; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Tegafur; Treatment Outcome | 2014 |
[A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
[A case of squamous cell carcinoma of the nipple skin successfully treated with S-1 alone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Nipples; Oxonic Acid; Tegafur | 2014 |
[Current status of adjuvant chemotherapy in patients with p-Stage II and p-Stage III gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2014 |
[A case of gastric cancer with N2 lymph node metastasis and pancreatic invasion effectively treated with docetax-el/S-1 as a neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreas; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
[A case of advanced gastric cancer with multiple liver metastases treated with preoperative TS-1/CDDP chemotherapy and resection, with a complete response and survival for 7 years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasms, Squamous Cell; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
[A case of a patient with advanced rectal cancer and urinary bladder fistula surviving for 6 years after chemoradiotherapy without surgery].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Remission Induction; Tegafur; Time Factors; Urinary Bladder Fistula | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Platinum Compounds; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2014 |
The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Complications; Rectal Neoplasms; Retrospective Studies; Tegafur; Time Factors | 2014 |
S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.
Topics: Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Care; Preoperative Care; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Oxonic Acid; Panitumumab; Practice Guidelines as Topic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytodiagnosis; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
[Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[A case of gastric cancer that responded to a preoperative combination therapy of S-1/CDDP plus trastuzumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Trastuzumab | 2014 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
[A case of advanced gastric cancer with multiple liver, lung, and lymph node metastases treated with S-1, CDDP, and trastuzumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Trastuzumab | 2014 |
[Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pelvic Neoplasms; Retrospective Studies; Tegafur; Thrombocytopenia; Treatment Outcome; Ultrasonography | 2014 |
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Platinum; Tegafur; Thymoma; Thymus Neoplasms; Treatment Outcome | 2014 |
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Creatinine; Drug Combinations; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tegafur; Time Factors | 2014 |
Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Severity of Illness Index; Survival Rate; Tegafur | 2015 |
Reply to the letter to the editor 'Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?' by Abali et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans; Leucovorin; Male; Oxonic Acid; Tegafur; Uracil | 2015 |
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Combinations; Female; Humans; Leucovorin; Male; Oxonic Acid; Tegafur; Uracil | 2015 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Radiotherapy, Conformal; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur | 2014 |
[Evaluation of immunity in elderly patients with unresectable gastric cancer receiving S-1/Lentinan combination chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Complement C3; Dinoprostone; Drug Combinations; Female; Humans; Lentinan; Male; Oxonic Acid; Prognosis; Stomach Neoplasms; T-Lymphocytes, Regulatory; Tegafur | 2014 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinations; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Protein Kinase Inhibitors; Pyrimidines; Tegafur; Thiazoles | 2014 |
Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proton Therapy; Radiotherapy Dosage; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2015 |
Hepatobiliary and pancreatic: sigmoidal mesenterial lymph node metastasis from pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon, Sigmoid; Diagnostic Imaging; Drug Combinations; Humans; Laparoscopy; Lymphatic Metastasis; Male; Mesentery; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2014 |
Comprehensive evaluation of the response of genes to the administration of the antitumor drug S-1 using a low density array.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Combinations; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Microarray Analysis; Neoplasm Proteins; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2015 |
[Long-term disease-free survival by S-1 therapy in a case of gastric cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome | 2015 |
Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Oxonic Acid; Retrospective Studies; Tegafur; Vascular Endothelial Growth Factor A | 2014 |
Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Weight; Drug Combinations; Electric Impedance; Female; Gastrectomy; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stomach Neoplasms; Tegafur | 2015 |
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Markov Chains; Models, Economic; Oxaloacetates; Oxonic Acid; Quality-Adjusted Life Years; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Inflammation; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Decorin in human oral cancer: a promising predictive biomarker of S-1 neoadjuvant chemosensitivity.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Decorin; Drug Combinations; Female; Gene Knockdown Techniques; Humans; Immunoblotting; Immunohistochemistry; Male; Mice, Nude; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2015 |
Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Salvage surgery after chemotherapy with S-1 plus cisplatin for α-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report.
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Portal Vein; Salvage Therapy; Stomach Neoplasms; Tegafur; Thrombosis | 2015 |
Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Sample Size; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Oxonic Acid; Retrospective Studies; Stomatitis; Tegafur; Time Factors | 2014 |
Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pyridines; Retrospective Studies; Tegafur | 2014 |
[Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2014 |
[A case of recurrent gastric cancer successfully treated with S-1 oral administration].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Quality of Life; Recurrence; Stomach Neoplasms; Tegafur | 2015 |
[A case of liver and para-aortic lymph node metastasis of colorectal cancer responding to S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Aorta; Colonic Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
[Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT -11 combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2015 |
Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Postoperative Complications; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2015 |
Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Tract; Male; Mice; Mice, Inbred BALB C; Oxonic Acid; T-Lymphocytes, Regulatory; Tegafur | 2015 |
Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Feasibility study of alternate-day S-1 as adjuvant chemotherapy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Tegafur | 2015 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combinations; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Tegafur | 2016 |
[Relationship between BH3 mimetic S1 and expression of BCL-2 family members in acute myeloid leukemia].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Molecular Mimicry; Oxonic Acid; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tegafur | 2015 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Etoposide; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Radiotherapy, Adjuvant; Survival Rate; Tegafur | 2015 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Patient Selection; Postoperative Period; Prodrugs; Proportional Hazards Models; Tegafur; Uracil | 2015 |
[A long term survival case of hilar cholangiocarcinoma with multiple metastases treated with chemotherapy and operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Catheter Ablation; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Oxonic Acid; Tegafur | 2014 |
[A case of pathological complete response to lt. Lateral lymph node metastasis from lower rectal cancer by S-1 combined neoadjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2014 |
[A case of hepatic metastases from colorectal cancer in a long-term survivor undergoing local combined modality therapy for repeated local recurrences].
Topics: Aged, 80 and over; Catheter Ablation; Combined Modality Therapy; Drug Combinations; Embolization, Therapeutic; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Time Factors | 2014 |
[Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Rectal Neoplasms; Remission Induction; Tegafur | 2014 |
[Squamous cell carcinoma of the anal canal showing complete response after concurrent chemoradiotherapy and S-1 plus mitomycin C - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Humans; Male; Mitomycin; Oxonic Acid; Tegafur | 2014 |
[A case of adenocarcinoma of the anal canal in which palliation was achieved by chemoradiotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Anus Neoplasms; Chemoradiotherapy; Drug Combinations; Humans; Male; Oxonic Acid; Palliative Care; Tegafur | 2014 |
[Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Lymph Node Excision; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2014 |
[Treatment of repeat TACE plus S-1 for multiple intrahepatic recurrence of hepatoma and gastric cancer].
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Hepatectomy; Humans; Liver Neoplasms; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2014 |
[A case of adjuvant surgery for a patient with initially unresectable locally advanced pancreatic cancer (LAPC) with a favorable response to S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Treatment Outcome | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2014 |
[A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2014 |
[A case of resection for a huge pancreatic acinar cell carcinoma with tumor thrombus in the portal vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Prognosis; Tegafur; Thrombosis | 2014 |
[A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Laser Therapy; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[Treatment strategy for patients with CY1 gastric cancer using subgroup analyses].
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2014 |
[Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2014 |
[Treatment of type four gastric cancer in our institution].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
[A case report of advanced gastric cancer with bulky lymph node metastases successfully treated with induction chemotherapy followed by curative resection].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Induction Chemotherapy; Lymphatic Metastasis; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[Two cases of advanced gastric cancer achieved pathological complete response by preoperative chemotherapy with S-1 plus weekly low-dose CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2014 |
[Pathological complete response in a case of advanced gastric cancer after neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 2014 |
[A case of surgery for stenosis of the colon from recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Combinations; Gastrectomy; Humans; Intestinal Obstruction; Male; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2014 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Esophageal Neoplasms; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2014 |
[A case of Stage IV gastric cancer was successfully treated with multi combination chemotherapy with S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Lung Neoplasms; Neoplasm Staging; Ovarian Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of advanced HER2- positive gastric cancer with a partial response to molecular targeted chemotherapy (S-1+CDDP+Trastuzumab)].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Molecular Targeted Therapy; Oxonic Acid; Pyloric Stenosis; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Lymphatic Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur | 2014 |
[A case of successful treatment of peritoneal dissemination from gastric cancer with S-1/DOC chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2014 |
[A case of resection margin involvement gastric carcinoma that relapsed late after additional gastrectomy].
Topics: Abdominal Abscess; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drainage; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2014 |
[A case of gastric cancer with multiple liver metastases that was successfully treated by chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2014 |
[A case of metastatic colon carcinoma following curative resection for advanced gastric cancer associated with metastases to the liver and gallbladder].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2014 |
[A case of recurrent gastric cancer successfully treated with TS-1+CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Oxonic Acid; Recurrence; Remission Induction; Silicates; Stomach Neoplasms; Tegafur; Titanium | 2014 |
[A case of advanced pancreas cancer successfully treated by using combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2015 |
Corneal limbal stem cell deficiency associated with the anticancer drug S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Epithelium, Corneal; Female; Gastrectomy; Humans; Limbus Corneae; Oxonic Acid; Stem Cells; Stomach Neoplasms; Tegafur; Visual Acuity | 2015 |
Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Eccrine Glands; Epithelium; Female; Humans; Metaplasia; Oxonic Acid; Pyridines; Sweat Gland Neoplasms; Syringoma; Tegafur | 2015 |
Combination chemotherapy with S-1 and docetaxel for cutaneous angiosarcoma resistant to paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Hemangiosarcoma; Humans; Oxonic Acid; Paclitaxel; Skin Neoplasms; Taxoids; Tegafur | 2015 |
A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tegafur; Treatment Outcome | 2015 |
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gene Expression Regulation, Enzymologic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome; Vomiting | 2015 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[Three cases of long-term control of non-small-cell lung cancer via S-1 monotherapy in elderly patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2015 |
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2015 |
[Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].
Topics: Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Epithelial Cells; Humans; Lacrimal Duct Obstruction; Neoplasms; Oxonic Acid; Tegafur | 2015 |
[S-1 plus cisplatin(SP) for advanced gastric cancer].
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Drug Combinations; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Chemoradiotherapy; Databases, Factual; Dose Fractionation, Radiation; Drug Combinations; Feasibility Studies; Fecal Incontinence; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Postoperative Complications; Radiation-Sensitizing Agents; Rectal Neoplasms; Rectum; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Topics: Adult; Aged; Cisplatin; Docetaxel; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Tegafur | 2015 |
Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fungal Proteins; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Oxonic Acid; Polysaccharides; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Creatinine; Cross-Sectional Studies; Cystatin C; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Inulin; Kidney Function Tests; Male; Middle Aged; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
A Successful Case of a Patient Undergoing Warfarin and S-1 Therapy Using Internet-based Control of Home-measured PT-INR.
Topics: Cholangiocarcinoma; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; International Normalized Ratio; Internet; Male; Middle Aged; Monitoring, Physiologic; Oxonic Acid; Prothrombin Time; Tegafur; Warfarin | 2015 |
Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Docetaxel; Drug Combinations; Duodenum; Female; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Male; Malnutrition; Middle Aged; Oxonic Acid; Prospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Fatigue; Feasibility Studies; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur; Vomiting | 2015 |
Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Epstein-Barr Virus Infections; Female; Fluorouracil; Follow-Up Studies; Herpesvirus 4, Human; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors | 2016 |
[Indication of alternate-day treatment with S-1 in patients with oral cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Oxonic Acid; Risk Factors; Tegafur | 2015 |
[Six-year survival with recurrent intrahepatic cholangiocarcinoma achieved by simple S-1 administration].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Diagnosis, Differential; Drug Combinations; Hepatectomy; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Time Factors | 2015 |
[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[A case of gastric cancer in which grade 2 treatment effects were obtained with preoperative two-week S-1 administration].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2014 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; Body Temperature; Cell-Free System; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Platelet Count; Retrospective Studies; Second-Look Surgery; Serum Albumin; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Combinations; Febrile Neutropenia; Female; Gastrectomy; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Cohort Studies; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2015 |
Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Postoperative Care; Prognosis; Propensity Score; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2015 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
A case report: pancreatic squamous cell carcinoma with effective response by S-1 therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2014 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinations; Female; Humans; Letrozole; Middle Aged; Nitriles; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Triazoles | 2015 |
[Locally Advanced Gastric Cancer Treated with Curative Gastrectomy and Showing Pathological Complete Response after Chemotherapy with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure].
Topics: Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Failure, Chronic; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2015 |
[Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2015 |
Resected tumor seeding in stomach wall due to endoscopic ultrasonography-guided fine needle aspiration of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gastrectomy; Humans; Male; Neoplasm Seeding; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Hypoalbuminemia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Peritoneal Lavage; Peritoneal Neoplasms; Preoperative Period; Prognosis; Proportional Hazards Models; Retrospective Studies; Serum Albumin; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer.
Topics: Chemoradiotherapy; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oxonic Acid; Preoperative Care; Pyridines; Random Allocation; Rectal Neoplasms; Tegafur | 2015 |
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Renal Insufficiency; Stomach Neoplasms; Tegafur; Tissue Distribution | 2016 |
[Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Muscle, Skeletal; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
Successful treatment of bilateral multiple lymph node metastases in extramammary Paget's disease with surgery and sequential chemotherapy of S-1 and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Paget Disease, Extramammary; Taxoids; Tegafur | 2015 |
Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastric Mucosa; Gene Expression; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Disease Progression; Drug Combinations; Epirubicin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2016 |
Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Japan; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tears; Tegafur | 2016 |
Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Digestive System Surgical Procedures; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Preoperative Period; Rectal Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2016 |
Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer.
Topics: Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Tegafur; Thymus Neoplasms; Treatment Outcome | 2014 |
S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2016 |
[Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2015 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Quinazolines; Salvage Therapy; Tegafur | 2015 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Taxoids; Tegafur | 2015 |
[A Case of Adenosquamous Carcinoma of the Ascending Colon].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Colectomy; Colon, Ascending; Colonic Neoplasms; Colonoscopy; Drug Combinations; Female; Humans; Oxonic Acid; Tegafur | 2015 |
[Difficulty in Preoperative Diagnosis of Residual Gastric Cancer after Distal Gastrectomy for Duodenal Ulcer].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations; Duodenal Ulcer; Fatal Outcome; Gastric Bypass; Humans; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2015 |
Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Collagen Type I; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Immunohistochemistry; Mice, Nude; Orotate Phosphoribosyltransferase; Oxonic Acid; Paclitaxel; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Receptor, ErbB-2; Tegafur; Thymidylate Synthase; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Oxonic Acid; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Stomach Neoplasms; Surveys and Questionnaires; Tegafur; Vomiting | 2016 |
Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2016 |
S-1 versus taxanes for HER2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Liver Neoplasms; Oxonic Acid; Paclitaxel; Taxoids; Tegafur | 2016 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Risk; Tegafur; Time Factors; Treatment Outcome | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2A6; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Genotype; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Polymorphism, Genetic; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Acinar Cell; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2016 |
CT images of enterohaemorrhagic Escherichia coli colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colitis; Drug Combinations; Escherichia coli Infections; Escherichia coli O157; Female; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Retrospective Studies; Salvage Therapy; Tegafur | 2016 |
[A Study of Preoperative Chemotherapy with S-1 plus Cisplatin for Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2015 |
[S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur | 2015 |
[Long Term Survival in a Case of Hilar Cholangiocarcinoma Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Male; Oxonic Acid; Pancreatectomy; Tegafur; Time Factors; Treatment Outcome | 2015 |
[A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Recurrence; Tegafur | 2015 |
[A Case of Local Recurrence of Bile Duct Cancer Completely Responding to Chemoradiotherapy with S-1].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Drug Combinations; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Recurrence; Tegafur | 2015 |
[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Recurrence; Tegafur | 2015 |
[A Case of Bone Metastasis from Early Gastric Cancer after a Five-Year Disease-Free Interval Following Gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case of Surgical Resection of Isolated Pulmonary Metastasis from Gastric Cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Lung Neoplasms; Male; Oxonic Acid; Pneumonectomy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2015 |
[A Successful Case of Treatment of Colonic Metastasis and Peritoneal Recurrence of Type 4 Gastric Cancer by Using Colectomy and Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Docetaxel; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
[Liver Metastasis in a Gastric Cancer Patient--A Case of Successful Radiofrequency Ablation Combined with Degradable Starch Microspheres Transcatheter Arterial Chemoembolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Male; Oxonic Acid; Starch; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Pancreatic Cancer with Multiple Liver Metastases That Developed Postoperatively and Showed a Complete Response with S-1 Monotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Remission Induction; Tegafur | 2015 |
[Hepatic Resection of Multiple Liver Metastases from Gastric Cancer after Molecular Targeted Chemotherapy(S-1 plus Cisplatin plus Trastuzumab)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2015 |
[R0 Resection of Locally Advanced Pancreatic Cancer after Combination Chemotherapy with Gemcitabine and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[A Case of Rectal Stenosis For Gastric Cancer Recurrence Effectively Treated with a Colonic Stent].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Intestinal Obstruction; Male; Oxonic Acid; Recurrence; Stents; Stomach Neoplasms; Tegafur | 2015 |
[Four Cases of Primary Small Intestinal Cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Duodenal Neoplasms; Female; Humans; Jejunal Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
[A Three-Year Survival Case of Extrahepatic Cholangiocarcinoma Treated with Palliative Bile Duct Resection and S-1 Monotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinoma; Drug Combinations; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Prognosis; Tegafur | 2015 |
[A Case of Resected Gastric Cancer Occurring Simultaneously with Intrahepatic Cholangiocarcinoma after S-1 plus Cisplatin Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Drug Combinations; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[Surgical Resection after Chemotherapy for Ampullary Carcinoma with Synchronous Liver Metastasis--Report of a Case].
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2015 |
[Signet-Ring Cell Carcinoma of the Ampulla of Vater--Report of a Case].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Combinations; Duodenal Neoplasms; Humans; Intestinal Obstruction; Jaundice, Obstructive; Male; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2015 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasm Staging; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
[A Case of Intraductal Growth Pattern Gastrointestinal Stromal Tumor of the Stomach That Was Difficult to Diagnose by Biopsy].
Topics: Aged; Antineoplastic Agents; Biopsy; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A Case of a Submucosal Tumor-Like Gastric Cancer That Needed to Be Distinguished from Gastric Metastasis of Rectal Cancer].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Mucosa; Humans; Male; Middle Aged; Neoplasms, Second Primary; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur | 2015 |
[A Case Report--A Synchronous Liver Metastasis from Gastric Cancer Treated with Chemotherapy, Surgical Resection of the Gastric Cancer, and RFA of the Liver Metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Catheter Ablation; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Successful Treatment of Metachronous Liver Metastasis from Gastric Cancer with Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A Long Surviving Case of Resected Advanced Gastric Cancer with a Synchronous Adrenal Metastasis].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Combinations; Endometrial Neoplasms; Female; Gastrectomy; Humans; Hysterectomy; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Long-Term Survival after Surgeries for Gastric Cancer and Metachronous Ovarian Metastasis].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[Multidisciplinary Therapy for Advanced Gastric Cancer with Liver and Brain Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Prognosis; Radiosurgery; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Long-Term Survival after Pancreatoduodenectomy for Gastric Cancer with Pancreatic Invasion].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Resected Advanced Gastric Cancer Exhibiting Pathological Complete Response after Neoadjuvant Che-motherapy(DTX/CDDP/S-1:DCS)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
[A Case of Advanced Gastric Cancer Responding to Neoadjuvant Docetaxel/CDDP/S-1 Therapy with Metallic Stent Placement, Leading to Curative Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Metals; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stents; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination Effectively Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2015 |
[Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Ileus; Jaundice, Obstructive; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Advanced Gastric Cancer with Long-Term Survival after Chemotherapy with Combined S-1 and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Prognosis; Splenectomy; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case Report of Advanced Gastric Cancer Demonstrating CR after Treatment with S-1 and Paclitaxel].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Prognosis; Remission Induction; Stomach Neoplasms; Tegafur | 2015 |
[The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Leukocyte Count; Lymphocytes; Neutrophils; Oxonic Acid; Polysaccharides; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A Case of Unresectable Local Recurrence of Gastric Cancer Successfully Resected after Pre-Operative Chemotherapy with Trastuzumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Trastuzumab | 2015 |
[A Case of Sigmoid Colon Cancer with Synchronous Liver Metastasis, Treated with Laparoscopic Liver Resection after SOX plus BV Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Female; Hepatectomy; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Middle Aged; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2015 |
[A Case of Repeat Liver Resection after Laparoscopic Resection of a Synchronous Liver Metastasis of Colon Cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Middle Aged; Oxonic Acid; Recurrence; Sigmoid Neoplasms; Tegafur | 2015 |
[A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Tegafur; Treatment Outcome | 2015 |
[A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2015 |
[A Case of Radical Resection for Locally Advanced Pancreatic Cancer with Positive Peritoneal Cytology Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
[HER2-Positive Advanced Gastric Cancer with Disseminated Intravascular Coagulation and Diffuse Bone Marrow Carcinomatosis Successfully Treated with S-1/Trastuzumab Chemotherapy--A Case Report].
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Neoplasms; Bone Neoplasms; Carcinoma, Signet Ring Cell; Disseminated Intravascular Coagulation; Drug Combinations; Fatal Outcome; Female; Humans; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2015 |
[Evaluation of Drug Interaction between S-1 and Warfarin].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Drug Combinations; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Prothrombin Time; Retrospective Studies; Tegafur; Warfarin | 2016 |
[The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Community Pharmacy Services; Drug Combinations; Female; Health Records, Personal; Humans; Male; Middle Aged; Neoplasms; Oxonic Acid; Pharmacy Service, Hospital; Professional Role; Retrospective Studies; Tegafur | 2016 |
[A Case of Recurrent Gallbladder Cancer with a Complete Response to S-1 Alternate-Day Administration].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gallbladder Neoplasms; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome | 2016 |
Predictive factors for ocular complications caused by anticancer drug S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Female; Health Knowledge, Attitudes, Practice; Humans; Japan; Lacrimal Duct Obstruction; Male; Middle Aged; Neoplasms; Oxonic Acid; Risk Factors; Surveys and Questionnaires; Tegafur | 2016 |
S-1 with leucovorin and oxaliplatin for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2016 |
Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, IGF Type 1; Receptors, Somatomedin; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2016 |
Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Oxonic Acid; Pneumonectomy; Tegafur | 2016 |
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Recurrence; Retrospective Studies; RNA, Messenger; Tegafur; Thymus Neoplasms; Treatment Outcome; Young Adult | 2016 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur | 2016 |
Complete Response Obtained with S-1 Plus CDDP Therapy in a Patient with Multiple Liver Metastases from Gastric Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Gastrectomy; Gastroscopy; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Hypopharyngeal Neoplasms; Infusions, Intra-Arterial; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome | 2016 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |
The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Floxuridine; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Uracil | 2016 |
Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Combinations; Female; Humans; Logistic Models; Lung Diseases, Interstitial; Lung Injury; Lung Neoplasms; Male; Medical Records; Middle Aged; Oxonic Acid; Predictive Value of Tests; Retrospective Studies; Risk; Taxoids; Tegafur; Tomography, X-Ray Computed | 2016 |
[A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fatal Outcome; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2016 |
[Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Recurrence; Retrospective Studies; Tegafur | 2016 |
[A Case of Alternate-Day Treatment with S-1 in a Patient with Multiple Lung Metastases of Colon Cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Combinations; Female; Humans; Lung Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[A Case Report of a Pathological Complete Response of Rectal Cancer to Preoperative Chemoradiotherapy with Tegafur].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Chemoradiotherapy; Drug Combinations; Humans; Male; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2016 |
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Chemoradiotherapy; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Tomography, X-Ray Computed | 2016 |
Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy.
Topics: Adrenal Glands; Adrenal Insufficiency; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Health Status; Humans; Hydrocortisone; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pilot Projects; Prospective Studies; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Random Allocation; Stromal Cells; Tegafur; Xenograft Model Antitumor Assays | 2016 |
Surgical Resection for Solitary Myocardial Metastasis of Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Oxonic Acid; Positron Emission Tomography Computed Tomography; Pyridines; Radiopharmaceuticals; Remission Induction; Stomach Neoplasms; Tegafur | 2016 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Epistaxis; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Maxillary Sinus Neoplasms; Middle Aged; Nasal Cavity; Nasal Obstruction; Neoplasm Staging; Neoplasms, Multiple Primary; Nose Neoplasms; Otorhinolaryngologic Surgical Procedures; Oxonic Acid; Papilloma, Inverted; Paranasal Sinus Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Tomography, X-Ray Computed | 2017 |
Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug Combinations; Female; Gene Expression Profiling; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur | 2016 |
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Drug Combinations; Female; Gemcitabine; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome; Zoledronic Acid | 2016 |
Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer.
Topics: Adult; Aged; Chemoradiotherapy; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Tegafur; Thymidine Phosphorylase; Uracil | 2016 |
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pilot Projects; Prospective Studies; Tegafur | 2016 |
[A Case of Subacute Thyroiditis during Chemotherapy after Distal Pancreatectomy].
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites; Drug Combinations; Fatal Outcome; Female; Fever; Humans; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prednisolone; Tegafur; Thyroiditis, Subacute | 2016 |
[A Case of Recurred Gastric Cancer of the Anastomosis Completely Responding to Docetaxel, Cisplatin, and S-1 Triplet Therapy].
Topics: Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2016 |
[A Case of Virchow's Lymph Node Recurrence of Gastric Cancer Who Had Underwent Gastrectomy, and Treated with S-1 Monotherapy Leading to Complete Response (CR)].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Tegafur; Treatment Outcome | 2017 |
Raising the bar for the adjuvant treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Ductal; Deoxycytidine; Female; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
Prognostic Factors and Multidisciplinary Postoperative Chemoradiotherapy for Clinical T4a Tongue Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Oxonic Acid; Patient Care Team; Postoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Tegafur; Tongue Neoplasms | 2016 |
Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Biliary Tract Surgical Procedures; Biomarkers, Tumor; Biopsy, Needle; Chemotherapy, Adjuvant; Cohort Studies; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Genes, bcl-2; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Rare Diseases; Retrospective Studies; Risk Assessment; Survival Analysis; Tegafur; Thymidylate Synthase | 2016 |
[A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophagogastric Junction; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Receptor, ErbB-2; Stomach Diseases; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2016 |
[A Case of Gastric Cancer with Diffuse Intra-Tumoral Calcifications Showing Pathological Complete Response to Chemotherapy with S-1 plus Docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
[Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Constipation; Drug Combinations; Humans; Ileus; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Sigmoid Neoplasms; Tegafur | 2016 |
[Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Drug Combinations; Follow-Up Studies; Gastrectomy; Humans; Male; Neoplastic Cells, Circulating; Oxonic Acid; Portal Vein; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Survivors; Tegafur; Thrombosis | 2016 |
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Drug Combinations; Drug Interactions; Female; Gastrointestinal Neoplasms; Humans; International Normalized Ratio; Male; Middle Aged; Oxonic Acid; Prothrombin Time; Retrospective Studies; Tegafur; Warfarin | 2016 |
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Reoperation; Survival; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Palliative Care; Pregnancy; Survival Rate; Tegafur; Tumor Suppressor Protein p53 | 2016 |
[Pathological Complete Response of Advanced Gastric Cancer after Docetaxel and S-1 Combination Neoadjuvant Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Docetaxel; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
[A Patient with Stage IV Advanced Gastric Cancer with Multiple Liver Metastases Living for More Than 6 Years after Treatment with TS-1 Alone].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2016 |
Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Fungal Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Polysaccharides; Postoperative Period; Stomach Neoplasms; Tegafur | 2016 |
[Administration of S-1 Monotherapy as Adjuvant Chemotherapy in a Patient with Advanced Gastric Cancer with HIV Infection].
Topics: Anti-Retroviral Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; HIV Infections; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasms, Second Primary; Otorhinolaryngologic Surgical Procedures; Oxonic Acid; Radiotherapy; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tegafur | 2017 |
Evaluation of the anticoagulant effect and timing of the concomitant use of S-1 and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Drug Combinations; Drug Interactions; Female; Humans; International Normalized Ratio; Male; Middle Aged; Oxonic Acid; Prothrombin Time; Retrospective Studies; Stomach Neoplasms; Tegafur; Warfarin | 2016 |
Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Vinblastine; Vinorelbine | 2016 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
[Outcomes of Staging Laparoscopy in Eight Patients with Positive Peritoneal Washing Cytology after S-1 Administration].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
Usefulness of chemoradiotherapy for inoperable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Japan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Radiotherapy, Conformal; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
S-1 combined with cisplatin chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur | 2016 |
[Comparison of the Cost-Effectiveness of the SOX and COX Regimens in Patients with Unresectable Advanced and Recurrent Colorectal Cancer Using a Clinical Decision Analysis Approach].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Recurrence; Tegafur | 2016 |
[A Case of Long-Term Survival after Combination Therapy for Gastric Cancer with Synchronous Multiple Liver Metastasis].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrectomy; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
[A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Autoimmune Diseases; CA-19-9 Antigen; Chemotherapy, Adjuvant; Drug Combinations; Humans; Immunoglobulin G; Male; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pancreatitis; Tegafur; Treatment Outcome | 2016 |
High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer.
Topics: Acid Anhydride Hydrolases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cisplatin; DNA Repair Enzymes; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Humans; MRE11 Homologue Protein; Nuclear Proteins; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Tegafur | 2016 |
Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; RNA Interference; RNAi Therapeutics; Tegafur; Thymidylate Synthase; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Platinum Compounds; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2017 |
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2017 |
Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Paget Disease, Extramammary; Prognosis; Spinal Neoplasms; Tegafur | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Tegafur; Time Factors; Treatment Outcome | 2017 |
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2017 |
Squamous cell carcinoma of the extrahepatic bile duct with metachronous para-aortic lymph node metastasis successfully treated with S-1 plus cisplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2016 |
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Hong Kong; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
Topics: Capecitabine; Drug Combinations; Fluorouracil; Humans; Network Meta-Analysis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Denmark; Drug Combinations; Drug Substitution; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Netherlands; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome; Western World | 2017 |
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Tegafur; Tomography, X-Ray Computed | 2017 |
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Young Adult | 2017 |
[Treatment Outcomes of Advanced Gastric Cancer after Neoadjuvant Chemotherapy with S-1 and Cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Port Site Recurrence after Laparoscopic Distal Gastrectomy for Advanced Gastric Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Laparoscopy; Male; Oxonic Acid; Recurrence; Skin Neoplasms; Stomach Neoplasms; Tegafur | 2016 |
[Curative Resection for Chemorefractory Advanced Gastric Cancer with Pancreatic Invasion by Pancreatoduodenectomy - A Case Report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[A Case of Pathological Complete Response after Neoadjuvant Chemotherapy(S-1 plus Oxaliplatin)and Laparoscopic Low Anterior Resection for Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Intestinal Obstruction; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Stage IV Gastric Cancer Successfully Treated Using Salvage Surgery after S-1/CDDP Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Tegafur | 2016 |
[Remission of Advanced Gastric Cancer with Concurrent Portal Vein Tumor Thrombosis via Chemotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Venous Thrombosis | 2016 |
[A Case of Pulmonary Embolism Developed during Combination Chemotherapy with S-1 and Cisplatin in a Young Female Patient with Type 4Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Pulmonary Embolism; Stomach Neoplasms; Tegafur; Young Adult | 2016 |
[A Case of Advanced Gastric Cancer with Portosystemic Shunt Successfully Treated with Percutaneous Transvenous Coil Embolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Embolization, Therapeutic; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2016 |
[Combination Chemotherapy Using Oxaliplatin plus S-1 for Well-Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Highly Advanced Gastric Cancer Leading to Immediate Perforation on Day Three of Chemotherapy with S-1 plus Oxaliplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritonitis; Stomach Diseases; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2016 |
[Surgical Resection for Advanced Gastric Cancer with Portal Vein Tumor Embolus - Two Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Thrombectomy; Thromboembolism | 2016 |
[Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2016 |
[A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer with Hepatic Arterial Variation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
[A Case of Locally Advanced Gallbladder Cancer That Developed Early Multiple Liver Metastasis after Curative Resection, and Achieved Long-TermPartial Remission Using S-1 and Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Dissection after Neoadjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Combinations; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2016 |
[A Case of Advanced Gastric Cancer Successfully Treated with Curative Conversion Surgery after Chemotherapy with S-1 plus Oxaliplatin].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Thrombosis | 2016 |
[A Case of Advanced Gastric Cancer with a Pathological Complete Response after Neoadjuvant Chemotherapy(S-1/Oxaliplatin)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Long-Term Complete Response by S-1 Chemotherapy for Gastric Cancer with Para-Aortic Lymph Node Metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Aorta; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2016 |
[A Case of Pathological Complete Response after SOX Chemotherapy in Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[Effectiveness of Irinotecan, S-1, and Bevacizumab for Rectal Cancer with Lung and Skin Metastases after Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Oxonic Acid; Rectal Neoplasms; Skin Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Laparoscopic Surgery for Rectal Cancer with Synchronous Lung Metastases after Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colostomy; Drug Combinations; Female; Humans; Laparoscopy; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Rectal Neoplasms; Tegafur | 2016 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2016 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
[A Case of an Elderly Patient with Advanced Gastric Cancer Successfully Treated with Combination S-1 and Oxaliplatin Therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Rectal Metastasis of Gastric Cancer Associated with Dermatomyositis].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dermatomyositis; Drug Combinations; Fatal Outcome; Humans; Male; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur | 2016 |
[A Case of Lymph Node Metastasis of Intrahepatic Bile Duct Cancer Successfully Treated Using Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome | 2016 |
Analysis of the Risk Factors for Severe Oral Mucositis in Head and Neck Cancer after Chemoradiotherapy with S-1.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Logistic Models; Male; Middle Aged; Oropharyngeal Neoplasms; Oxonic Acid; Radiotherapy; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Stomatitis; Tegafur | 2017 |
[A Case of Synchronous Double Cancer of the Lung and Stomach That Responded to Cisplatin and S-1 Combination Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
[A Case of an Elderly Patient Who Experienced Long-Term Survival after Receiving S-1 for Synchronous Advanced Gallbladder and Stomach Cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Female; Gallbladder Neoplasms; Humans; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2017 |
Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Postoperative Period; Risk Factors; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome; Weight Loss | 2017 |
Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Topics: Abdominal Abscess; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Laparotomy; Lymph Node Excision; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pancreatic Fistula; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Time-to-Treatment | 2017 |
Clinical impact of circulating tumor cells and therapy response in pancreatic cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Multivariate Analysis; Neoplasm Staging; Neoplastic Cells, Circulating; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2017 |
Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Lentigo; Male; Oxonic Acid; Pyridines; Tegafur | 2017 |
S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Humans; Male; Middle Aged; Nasolacrimal Duct; Oxonic Acid; Plasma; Prospective Studies; Tears; Tegafur; Young Adult | 2018 |
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Etoposide; Feasibility Studies; Female; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Respiratory Insufficiency; Retrospective Studies; Tegafur | 2017 |
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Proportional Hazards Models; Pyridines; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome; Tumor Burden | 2017 |
[A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Recurrence; Tegafur; Thymus Neoplasms; Time Factors | 2017 |
Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Databases, Factual; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Regional Blood Flow; Retrospective Studies; Survival Analysis; Tegafur | 2017 |
Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2017 |
Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Combinations; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Nivolumab; Oxonic Acid; Paclitaxel; Tegafur; Tomography, X-Ray Computed | 2017 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dermatitis, Exfoliative; Drug Combinations; Drug Eruptions; Fluorouracil; Hand-Foot Syndrome; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Pyridines; Tegafur | 2017 |
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Rectal Neoplasms; Reproducibility of Results; Tegafur; Treatment Outcome | 2017 |
Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Oxonic Acid; Platelet Aggregation; Preoperative Care; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemoradiotherapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thymidylate Synthase | 2017 |
Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Combinations; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Pyridines; Ribonucleoside Diphosphate Reductase; Taxoids; Tegafur; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2017 |
Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs.
Topics: Administration, Ophthalmic; Animals; Antimetabolites, Antineoplastic; Corneal Injuries; Dogs; Drug Combinations; Female; Lubricant Eye Drops; Male; Oxonic Acid; Tegafur | 2017 |
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Male; Oxonic Acid; Pyridines; Tegafur | 2017 |
[Clinical Experience of S-1 and Oxaliplatin(SOX)as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Recurrence; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
[A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2017 |
Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Male; Middle Aged; Orotate Phosphoribosyltransferase; Oxonic Acid; Paget Disease, Extramammary; RNA, Messenger; Skin Neoplasms; Tegafur; Thymidylate Synthase | 2017 |
Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Infections; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Complications; Retrospective Studies; Risk Factors; Stomach Neoplasms; Tegafur; Young Adult | 2017 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Coronary Vasospasm; Drug Combinations; Drug Substitution; Female; Humans; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
Lentinan diminishes apoptotic bodies in the ileal crypts associated with S-1 administration.
Topics: Administration, Intravenous; Animals; CD11b Antigen; Cell Line, Tumor; Colonic Neoplasms; Drug Combinations; Extracellular Vesicles; Humans; Ileum; Lentinan; Membrane Proteins; Mice; Mice, Inbred BALB C; Models, Animal; Oxonic Acid; Tegafur | 2017 |
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur | 2017 |
The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Squamous Cell; Case-Control Studies; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Retrospective Studies; Tegafur; Tumor Microenvironment | 2017 |
Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Second Primary; Oxonic Acid; Survival Analysis; Tegafur | 2017 |
Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Oxonic Acid; Retrospective Studies; Tegafur | 2017 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Synchronous Liver Metastasis and Portal Vein Thrombus after Multidisciplinary Treatment].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Time Factors; Trastuzumab; Venous Thrombosis | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Induction Chemotherapy; Injections, Intraperitoneal; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Taxoids; Tegafur | 2017 |
CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
Topics: Adult; Aged; Asian People; China; Cytochrome P-450 CYP2A6; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Linkage Disequilibrium; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Prospective Studies; Severity of Illness Index; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Oxonic Acid; Retrospective Studies; Tegafur; Temozolomide; Treatment Outcome | 2018 |
The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Prognosis; Receptor, ErbB-2; Taxoids; Tegafur; Young Adult | 2017 |
Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Drug Combinations; Drugs, Chinese Herbal; Fluorouracil; Herb-Drug Interactions; Humans; Male; Models, Biological; Oxonic Acid; Pyridines; Rats, Sprague-Dawley; Tegafur | 2017 |
Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
[A Case Report of Long-Term Survival after SOX Chemotherapy for Metastatic Ovarian Tumor of Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Hysterectomy; Krukenberg Tumor; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2017 |
The Capsule Endoscopy Findings in S-1-induced Enteritis with Severe Diarrhea during Adjuvant Chemotherapy for Gastric Cancer (with Video).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Chemotherapy, Adjuvant; Diarrhea; Drug Combinations; Enteritis; Female; Gastrectomy; Humans; Oxonic Acid; Severity of Illness Index; Stomach Neoplasms; Tegafur | 2018 |
A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation?
Topics: Aged; Antineoplastic Agents; Carcinoma, Acinar Cell; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Japan; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2017 |
Complete response of metastatic gastric cancer to chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Remission Induction; Stomach Neoplasms; Tegafur | 2017 |
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
Topics: Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Drug Combinations; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Treatment Outcome | 2018 |
Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Drug Combinations; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Recurrence; Tegafur | 2017 |
The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Osteonectin; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2018 |
Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
[An Elderly Patient with Metastatic Colon Cancer Achieved Long-Term Survival Following Single-Agent Chemotherapy with S-1].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Cecal Neoplasms; Drug Combinations; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
[A Case Report of Sigmoid Colon Cancer with Multiple Lung Metastases Successfully Treated with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Colectomy; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Treatment Outcome | 2018 |
[Chemoradiotherapy with S-1 for Recurrence Cases of Colorectal Cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Drug Combinations; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Risk Assessment; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Combinations; Drug Therapy, Combination; Humans; Leucovorin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Transplantation, Heterologous | 2018 |
[A Case of Conversion Surgery for a Patient with Initially Unresectable Pancreatic Cancer with a Pathological Complete Response to S-1 Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2017 |
[A Difficult Diagnostic Case of Pancreatic Acinar Cell Carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2017 |
[A Case of Advanced Gastric Cancer with Synchronous Liver Metastases Responding to Preoperative Combination Chemotherapy with S-1 plus Oxaliplatin(SOX)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2017 |
[A Case of Advanced Gastric Cancer Responding Effectively to Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur | 2017 |
[Combination Chemotherapy Including Intraperitoneal(IP)Administration of Paclitaxel(PTX)followed by PTX, CDDP and S-1Triplet Chemotherapy for CY1P0 Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2017 |
[Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors | 2017 |
[A Case of Advanced Gastric Cancer with Liver Metastasis Treated by Curative Surgery after Chemotherapy Using S-1 plus Oxaliplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
[The Clinical Outcome of Conversion Surgery for Unresectable Gastric Cancers in Our Institution].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2017 |
[A Case of Duodenal Invasive Advanced Gastric Cancer in Which the Primary Tumor Achieved pCR, but Viable Cancer Cells Remained in Lymph Node No.13 after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Duodenum; Female; Gastrectomy; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; Humans; Lymphatic Metastasis; Nitriles; Oxonic Acid; Tegafur; Triazoles | 2017 |
[A Case of Anaplastic Carcinoma Spindle Cell Type of the Pancreas].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2017 |
[A Case of Unresectable Gastric Cancer with Multiple Metastases Responding to Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2017 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Male; Oxonic Acid; Silicates; Tegafur; Thoracoscopy; Titanium | 2017 |
[Laparoscopic Total Gastrectomy with Pancreatosplenectomy after Neoadjuvant Chemotherapy for Advanced Gastric Cancer with Adjacent Organs Invasion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Laparoscopy; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatectomy; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
[A Successful Treatment for Stage III c Gastric Cancer with Low Cardiac Function Using S-1 plus Oxaliplatin(SOX)as a Neoadjuvant Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2017 |
[A Case in Which S-1/Oxaliplatin(SOX)/Trastuzumab Therapy Was Effective for Unresectable HER2 Positive Advanced Gastric Cancer and Radical Resection Could Be Performed].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2017 |
Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy.
Topics: Adult; Aged; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Predictive Value of Tests; Radiosurgery; Survival Analysis; Tegafur | 2018 |
Correlation of Expression Levels of Copper Transporter 1 and\
Thymidylate Synthase with Treatment Outcomes in Patients\
with Advanced Non-small Cell Lung Cancer Treated with\
S-1/Carboplatin Doublet Chemotherapy
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cation Transport Proteins; Copper Transporter 1; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survival Rate; Tegafur; Thymidylate Synthase; Treatment Outcome | 2018 |
Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chemoradiotherapy; Drug Combinations; Drug Resistance, Neoplasm; Gamma Rays; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Phosphorylation; Radiation-Sensitizing Agents; Tegafur; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
[A Retrospective Investigation of Lacrimation in Patients Treated with S-1].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasms; Oxonic Acid; Retrospective Studies; Tegafur | 2018 |
[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Time Factors | 2018 |
[A Case of Gastric Cancer Underwent Two-Stage Gastrectomy after Chemotherapy-Induced Perforation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Stomach Diseases; Stomach Neoplasms; Tegafur | 2018 |
Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Combinations; Fluorouracil; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Prognosis; Tegafur; Trifluridine; Xenograft Model Antitumor Assays | 2018 |
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cytoplasm; Deoxycytidine; Disease-Free Survival; Drug Combinations; ELAV-Like Protein 1; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2018 |
Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Neutrophils; Oxonic Acid; Risk Factors; Stomach Neoplasms; Tegafur | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxaloacetates; Oxonic Acid; Pyridines; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2018 |
Successful treatment of extramammary Paget's disease with S-1 and docetaxel combination chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Paget Disease, Extramammary; Pneumonectomy; Positron-Emission Tomography; Skin Neoplasms; Tegafur; Treatment Outcome | 2018 |
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Tegafur | 2018 |
Long-Term Outcomes of Gastric Cancer Patients with Preoperative Sarcopenia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cause of Death; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Multiple Organ Failure; Neoplasm Staging; Oxonic Acid; Postoperative Complications; Preoperative Period; Prognosis; Sarcopenia; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2018 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
[A Case in Which S-1 plus CDDP and S-1 Therapy Responded to Liver Metastasis Recurrence after Gastric Cancer Operation].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Stage IV Gastric Cancer Which Showed Pathological Complete Response after Neo-Adjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Long-Term Survival in Gastric Cancer with Multiple Liver Metastases Successfully Treated by Conversion Surgery after S-1 plus Cisplatin Combination Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Tegafur; Treatment Outcome | 2018 |
[A Case Report of SOX Treatment for Primary Duodenal Carcinoma with Liver Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Duodenal Neoplasms; Female; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2018 |
[A Case of Unresectable Advanced Gastric Cancer Treated by Seven Courses of Chemotherapy with Docetaxel, Cisplatin, and S-1Followed by Conversion Surgery Achieved Five Year Relapse Free Survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2018 |
[Advanced Gastric Cancer with Peritoneal Dissemination Treated with Conversion Surgery after S-1 and CDDP Chemotherapy - A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Advanced Gastric Cancer with Multiple Liver Metastases Treated with Curative Conversion Therapy after S-1 plus CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Digestive System Surgical Procedures; Drug Combinations; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
Gallbladder cancer with tumor thrombus in the portal vein: A case report.
Topics: Administration, Intravenous; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Drug Combinations; Female; Gallbladder Neoplasms; Hepatectomy; Hepatic Artery; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Portal Vein; Tegafur; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Vascular Access Devices; Vascular Neoplasms | 2018 |
Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Patient Compliance; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Postoperative Period; Prognosis; Survival Rate; Tegafur; Young Adult | 2018 |
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Proportional Hazards Models; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Oxonic Acid; Practice Patterns, Physicians'; Stomach Neoplasms; Surveys and Questionnaires; Tegafur | 2019 |
Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Female; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Outpatients; Oxonic Acid; Prognosis; Prospective Studies; Research Design; Survival Rate; Tegafur; Young Adult | 2018 |
Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Nutrition Assessment; Oxonic Acid; Postoperative Period; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; China; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Oxonic Acid; Tears; Tegafur | 2018 |
[Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated
with More Than Two Lines of Chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Safety; Survival Analysis; Tegafur; Treatment Outcome | 2018 |
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2019 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Advanced Gastric Cancer Treated with Curative Resection after Preoperative Secondary Chemotherapy with Irinotecan after Primary Chemotherapy with Docetaxel, Cisplatin, and S-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2018 |
[Severe Liver Injury Due to Sinusoidal Obstruction Syndrome Induced by Oxaliplatin in a Patient with Resectable Colorectal Liver Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2018 |
[Two Case Reports of Chemotherapy-Induced Radiation Myositis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Myositis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2018 |
[A Case of Synchronous Liver Metastasis of Ascending Colon Cancer with Pathological Complete Response to S-1/Oxaliplatin (SOX) and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colon, Ascending; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2018 |
[Pulmonary Metastasis of Gastric Cancer as Carcinomatous Lymphangiosis at Five and Half Years after Surgery;Report of a Case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Oxaliplatin; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2018 |
Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Tegafur | 2019 |
[A Case of Triple Negative Breast Cancer Successfully Treated with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Oxonic Acid; Tegafur; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
[A Case of Intussusception in the Jejunum Due to Small Intestinal Adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Intussusception; Jejunal Neoplasms; Oxonic Acid; Tegafur | 2018 |
Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cohort Studies; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Humans; Immunohistochemistry; Male; Orotate Phosphoribosyltransferase; Oxonic Acid; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2019 |
Erythematous lesion with peripheral purpura on the face.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cheek; Drug Combinations; Erythema; Eyelid Neoplasms; Facial Neoplasms; Humans; Lymphadenopathy; Male; Neck; Oxaliplatin; Oxonic Acid; Purpura; Skin Neoplasms; Tegafur | 2019 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
[Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclobutanes; Disease Progression; Disease-Free Survival; Drug Combinations; Humans; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxonic Acid; Prognosis; Remission Induction; Retrospective Studies; Stomach Neoplasms; Tegafur | 2018 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2018 |
[A Case of Sister Mary Joseph's Nodule from Transverse Colon Cancer Effectively Treated with SOX plus Bevacizumab Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colon, Transverse; Colonic Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxaliplatin; Oxonic Acid; Sister Mary Joseph's Nodule; Tegafur | 2018 |
[A Case of Long-Term Survival in a Patient with Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Who Responded to Combined Modality Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors | 2018 |
[CapeOX Therapy as a Salvage Treatment for Advanced Gastric Cancer Refractory to S-1, Cisplatin, Irinotecan, and Taxanes].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2018 |
[The Case of a Patient with Gastric Cancer Who Showed No Neutropenia Only When Using the Generic S-1 Adjuvant Chemotherapy Formulation].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Drugs, Generic; Female; Gastrectomy; Humans; Neutropenia; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Quality of Life; Tegafur; Treatment Outcome | 2018 |
Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Drug Combinations; Female; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prospective Studies; Retreatment; Stomach Neoplasms; Tegafur; Treatment Outcome | 2019 |
An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2018 |
Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Skin Appendage; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Lip; Lip Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Radiotherapy, Adjuvant; Sweat Gland Neoplasms; Tegafur; Treatment Outcome | 2019 |
Stage II gastric cancer: 1 year of S-1 remains standard of care.
Topics: Humans; Oxonic Acid; Standard of Care; Stomach Neoplasms; Tegafur | 2019 |
[Three Cases of Resectable Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2018 |
[A Case of P0CY1 Gastric Cancer without Recurrence for 13 Years Postoperatively].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Pancreatic Acinar Cell Carcinoma in a Young Woman without Recurrence after Systemic Chemotherapy Using S-1].
Topics: Adult; Carcinoma, Acinar Cell; Drug Combinations; Female; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Tegafur | 2018 |
[A Case of Type 4 Gastric Cancer with Esophageal Invasion That Responded to Neoadjuvant Chemotherapy Containing S-1 and Oxaliplatin followed by Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophagus; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[A Case of cStage Ⅲ Esophagogastric Junction Adenocarcinoma That Showed pCR to Preoperative Chemotherapy Containing SOX].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2018 |
[A Case of Peritoneal Dissemination of Metastatic Gastric Cancer with Successful Docetaxel and S-1 Combination Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2018 |
[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tegafur | 2018 |
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Epithelial Cells; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Tegafur | 2019 |
Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Bilirubin; Blood Urea Nitrogen; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Random Allocation; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin; Stomach Neoplasms; Tegafur | 2019 |
[Gastric Neuroendocrine Carcinoma(NEC)Treated with CDDP plus CPT-11 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Robotic Surgical Procedures; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Gastric Small Cell Carcinoma with Rapid Regrowth after Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2019 |
[A Comparative Study on Feasibility of SOX Therapy and SP Therapy with Short Hydration for Gastric Cancer in the Outpatient Setting].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluid Therapy; Humans; Organoplatinum Compounds; Outpatients; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2019 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2019 |
Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Japan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors | 2019 |
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxonic Acid; Ramucirumab; Retreatment; Tegafur; Treatment Outcome | 2019 |
[A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[Analysis of Five Days of Administration of S-1 Followed by a Two-Day Rest in Patients with Metastatic Breast Cancer].
Topics: Adult; Aged; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Prospective Studies; Retrospective Studies; Tegafur | 2019 |
[Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Dexamethasone; Drug Combinations; Hiccup; Humans; Male; Oxonic Acid; Prednisolone; Receptors, Glucocorticoid; Stomach Neoplasms; Tegafur | 2019 |
Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Humans; Lung Neoplasms; Meta-Analysis as Topic; Oxonic Acid; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Tegafur | 2019 |
Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Clinical Decision-Making; Computational Biology; Databases, Genetic; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Oxonic Acid; Precision Medicine; Protein Interaction Maps; Stomach Neoplasms; Tegafur; Transcriptome; Treatment Outcome | 2019 |
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Plastic Surgery Procedures; Pyridines; Recurrence; Tegafur | 2019 |
Five-year Recurrence-free Survival After Surgery Followed by Oral Chemotherapy for Gastric Cancer With Portal Vein Tumor Thrombosis.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxonic Acid; Portal Vein; Stomach Neoplasms; Tegafur; Venous Thrombosis | 2019 |
Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Postoperative Period; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors | 2019 |
Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Drug Combinations; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Fluorouracil; Genotype; Humans; Neoplasms; Oxonic Acid; Pharmacogenomic Testing; Phenotype; Point-of-Care Testing; Pyrrolidines; Tegafur; Thymine; Trifluridine; Uracil | 2019 |
Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Taiwan; Tegafur; Treatment Outcome; Young Adult | 2019 |
Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Topics: Adult; Aged; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Plasma; Prospective Studies; Pyridines; Stomach Neoplasms; Tears; Tegafur; Tissue Distribution | 2019 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss | 2019 |
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Combined Modality Therapy; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment, Health Care; Oxonic Acid; Patient Participation; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nivolumab; Oxonic Acid; Paclitaxel; Palliative Care; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Failure | 2020 |
Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2019 |
Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Oxonic Acid; Pharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Outcome | 2019 |
[A Case of Advanced Gastric Cancer with Pathological Complete Response after Chemotherapy(S-1/Cisplatin)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Advanced Gastric Cancer with Bone Marrow Metastasis Treated with Low-Dose Combination Chemotherapy Containing S-1 and Docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Neoplasms; Docetaxel; Drug Combinations; Female; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Salvage Therapy; Tegafur; Treatment Failure | 2019 |
Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Collagen; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gels; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Malnutrition; Methotrexate; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Peritoneal Neoplasms; Progression-Free Survival; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome; Withholding Treatment; Young Adult | 2019 |
[Clinicopathological Evaluation of Preoperative Chemotherapy Containing S-1 as a Treatment for Patients with Oral Squamous Cell Carcinoma during Waiting Time for Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Combinations; Humans; Mouth Neoplasms; Oxonic Acid; Retrospective Studies; Tegafur; Waiting Lists | 2019 |
[Long-Term Survival of a Patient with Inoperable Gastric Cancer with Distant Lymph Node Metastasis-A Case Report].
Topics: Aged; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Epirubicin; Factor Xa Inhibitors; Fatal Outcome; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Male; Oxonic Acid; Pyridines; Radiotherapy, Intensity-Modulated; Skin Neoplasms; Syndrome; Tegafur; Thiazoles; Thrombophilia | 2019 |
Histopathological changes in tumor budding between biopsy and resected specimens from patients treated with preoperative S-1 chemotherapy for oral cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Drug Combinations; Humans; Mouth Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2019 |
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Diseases; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Tegafur; Tomography, X-Ray Computed | 2019 |
Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Theoretical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2019 |
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Outcome and Process Assessment, Health Care; Oxaloacetates; Oxonic Acid; Paraneoplastic Polyneuropathy; Stomach Neoplasms; Tegafur | 2019 |
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Humans; Lung Neoplasms; Oxonic Acid; Tegafur | 2019 |
CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Sialic Acid Binding Ig-like Lectin 3; Stomach; Stomach Neoplasms; Tegafur | 2020 |
[Seven-Year Follow-Up of Advanced Gastric Carcinoma Treated Only with Chemotherapy Considering the Macroscopic Findings].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; Gastrectomy; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[Serious S-1-Induced Lung Injury Diagnosed by Early Lung Biopsy-A Case Report].
Topics: Aged; Biopsy; Drug Combinations; Humans; Lung; Lung Injury; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Cavity; Peritoneal Lavage; Peritoneal Neoplasms; Postoperative Period; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2020 |
Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Topics: Aged; Aged, 80 and over; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2020 |
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Tegafur | 2019 |
Case of metastatic extramammary Paget's disease treated with trastuzumab-biosimilar monotherapy after S-1 and docetaxel combination chemotherapy.
Topics: Aged; Antineoplastic Agents; Biosimilar Pharmaceuticals; Delayed Diagnosis; Docetaxel; Drug Combinations; Drug Therapy, Combination; Humans; Male; Oxonic Acid; Paget Disease, Extramammary; Prognosis; Skin Neoplasms; Tegafur; Trastuzumab | 2020 |
Tegafur and 5-fluorouracil levels in tears and changes in tear volume in long-term users of the oral anticancer drug S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Chromatography, Liquid; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Quality of Life; Tandem Mass Spectrometry; Tears; Tegafur | 2019 |
S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Drug Combinations; Female; Humans; Hypertriglyceridemia; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2020 |
[Long-Term Complete Response in an Unresectable Advanced Gastric Cancer Patient Treated with Low-Dose S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Large-Cell Neuroendocrine Carcinoma of the Stomach with Multiple Liver Metastases That Show Complete Response to Multidisciplinary Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Drug Combinations; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxonic Acid; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Young Adult | 2019 |
S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer.
Topics: Docetaxel; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
Addition of S-1 to radiotherapy for treatment of T2N0 glottic cancer: Results of the multiple-center retrospective cohort study in Japan with a propensity score analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Glottis; Humans; Japan; Laryngeal Neoplasms; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Propensity Score; Retrospective Studies; Tegafur | 2019 |
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carrier Proteins; Cell Proliferation; Cisplatin; Docetaxel; Drug Combinations; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured | 2020 |
The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Postoperative Period; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur | 2019 |
Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Renal Insufficiency; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line; Cisplatin; Cytoskeletal Proteins; DNA Methylation; DNA, Neoplasm; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Frizzled Receptors; Gene Silencing; Herpesvirus 4, Human; Humans; Male; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oxonic Acid; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tegafur; Tumor Protein p73 | 2020 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Mediastinum; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2019 |
High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Combinations; Female; gamma-Glutamyl Hydrolase; Gastric Mucosa; Gene Expression; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Peptide Synthases; RNA, Messenger; Stomach Neoplasms; Tegafur | 2020 |
S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Analysis; Taiwan; Tegafur | 2020 |
Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur | 2020 |
Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.
Topics: Aged; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Tegafur; Up-Regulation | 2019 |
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Hepatectomy; Humans; Liver Neoplasms; Oxonic Acid; Tegafur | 2019 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Streptozocin; Tegafur | 2020 |
Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2019 |
[Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Chemotherapy, Adjuvant; Drug Combinations; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Stomach Neoplasms; Tegafur | 2020 |
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Propensity Score; Ramucirumab; Retrospective Studies; Tegafur | 2020 |
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2020 |
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrectomy; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organic Anion Transporters, Sodium-Independent; Oxonic Acid; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Tegafur | 2020 |
Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Topics: Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Postoperative Complications; Prognosis; Stomach Neoplasms; Tegafur | 2020 |
[Results of Neoadjuvant Chemotherapy with S-1 plus CDDP for Gastric Cancer-The Number of Therapeutic Coursers and Therapeutic Effects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Metaplastic Squamous Cell Carcinoma of the Breast Successfully Treated with S-1].
Topics: Antimetabolites, Antineoplastic; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Carcinoma, Squamous Cell; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Receptors, Estrogen; Tegafur | 2019 |
[A Case of Successful Surgical Treatment for Paraaortic Lymph Nodes Recurrence of Gallbladder Cancer].
Topics: Aged; Drug Combinations; Gallbladder Neoplasms; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2019 |
[A Case Report of Advanced Gastric Cancer with Synchronous Liver Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case with Three Resections of the Pulmonary Metastases of a Distal Bile Duct Carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Drug Combinations; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pancreaticoduodenectomy; Pneumonectomy; Tegafur | 2019 |
[Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Kidney Diseases; Outpatients; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Curative Resection of Locally Advanced Gastric Cancer after Nutrition Therapy and Chemotherapy with S-1 and Oxaliplatin Using Elemental Diet Tube].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Food, Formulated; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nutrition Therapy; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2019 |
[A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2019 |
[A Case of Advanced Gastric Cancer with Liver Metastases Treated with Curative Conversion Therapy after S-1 plus Oxaliplatin].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Gastric Endocrine Carcinoma with a Huge Liver Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case in Which pCR Was Obtained by S-1 plus Oxaliplatin Therapy Administered as Neoadjuvant Chemotherapy for Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
[A Case of Advanced Gastric Cancer with Right Gastroepiploic Vein Tumor Thrombus Treated by Preoperative S-1 plus CDDP That Resulted in Pathological Complete Response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Thrombosis | 2019 |
Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2020 |
A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Signet Ring Cell; Drug Combinations; Female; Humans; Immunohistochemistry; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2020 |
ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
Topics: Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinations; Humans; Oxonic Acid; Tegafur | 2020 |
Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2020 |
Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Oncologists; Oxonic Acid; Patient Compliance; Retrospective Studies; Stomach Neoplasms; Surgeons; Tegafur; Time Factors; Withholding Treatment | 2020 |
Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxonic Acid; Pyridines; Survival Rate; Tegafur; Young Adult | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Propensity Score; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tegafur; Time Factors | 2020 |
A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pilot Projects; Prospective Studies; Survival Rate; Tegafur | 2020 |
Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Colorectal Surgery; Dose Fractionation, Radiation; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Prospective Studies; Rectal Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2020 |
Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report.
Topics: Aged; Asian People; Biopsy; Colorectal Neoplasms; Creatinine; Diabetic Nephropathies; Disease Progression; Drug Combinations; Glomerulonephritis; Humans; Kidney; Male; Neoplasm Staging; Oxonic Acid; Proteinuria; Pyridines; Renal Dialysis; Risk Assessment; Serum Albumin; Tegafur; Withholding Treatment | 2020 |
[Pulmonary Adenocarcinoma Responding to Fourth-Line S-1 Monotherapy-A Case Report].
Topics: Adenocarcinoma of Lung; Adult; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Lung Neoplasms; Male; Oxonic Acid; Quality of Life; Tegafur | 2020 |
[A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[Case of Gastric Cancer with Para-Aortic Lymph Node Metastases Successfully Treated with S-1/Docetaxel Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tegafur | 2020 |
[Effective S-1 plus Oxaliplatin(SOX)Therapy in Two Cases of Advanced Gastric Cancer That Was Difficult to Resect and R0 Surgery Could Be Performed].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[Long-Term Survival for a Patient with StageⅣ Gastric Cancer with Multiple Liver Metastases for Ten Years Who Was Treated with Only S-1Chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
Topics: Aged; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
S-1 in combination with docetaxel as salvage therapy for patients with metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paget Disease, Extramammary; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate; Tegafur | 2020 |
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2020 |
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Treatment Outcome | 2020 |
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pilot Projects; Progression-Free Survival; Tegafur | 2020 |
Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Palliative Care; Pyridines; Retrospective Studies; Tegafur; Uterine Cervical Neoplasms | 2020 |
Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Cysteine Dioxygenase; DNA Methylation; Drug Combinations; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Risk Factors; Stomach; Stomach Neoplasms; Tegafur | 2020 |
[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2020 |
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Oxonic Acid; Retrospective Studies; Tegafur | 2020 |
A Study on the Effect and Mechanism of Xiaoaiping (XAP) Injection and S-1 Combination Therapy in Inhibiting the Invasion and Metastasis of Human GC Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Humans; Matrix Metalloproteinase 9; Medicine, Chinese Traditional; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Tegafur; Vascular Endothelial Growth Factor A; Vimentin | 2021 |
Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Drug Combinations; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Zinc Finger Protein GLI1 | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Adjuvant Chemotherapy vs. Surgery Alone for pT3N0M0 Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2021 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Reproducibility of Results; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Axilla; Biopsy; Breast Neoplasms; Carcinoma, Ductal; Drug Combinations; Female; Follow-Up Studies; Humans; Lymph Nodes; Mammaplasty; Mastectomy; Oxonic Acid; Skin Transplantation; Surgical Flaps; Tegafur; Thoracic Wall; Trastuzumab; Treatment Outcome | 2021 |
[Salvage Surgery for Unresectable Advanced Esophagogastric Junction Carcinoma with Multiple Liver Metastases after Successful Second-Line Treatment with Nab-Paclitaxel and Ramucirumab Following a Refractory Response to S-1 plus CDDP Therapy-A Case Report]
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab; Stomach Neoplasms; Tegafur | 2020 |
Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Rectal Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2021 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microwaves; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2021 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Taiwan; Tegafur; Treatment Failure | 2020 |
Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Disease Management; Drug Combinations; Female; Hepatic Veno-Occlusive Disease; Humans; Incidence; Liver Function Tests; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Retrospective Studies; Spleen; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2021 |
[A Case of Type 4 Gastric Cancer with Peritoneal Dissemination Successfully Treated with Conversion Surgery after Intensive S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
[A Case of Histological Response of Grade 3 Achieved by Preoperative Chemotherapy with S-1/Oxaliplatin(SOX)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxaliplatin; Oxonic Acid; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tegafur | 2021 |
[A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastasis That Showed pCR to Preoperative Chemotherapy Containing SP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[A Case of Gastric Cancer That Pathological Completely Responded to Neoadjuvant S-1 plus Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[A Long-Survived Case of Gastric Cancer with Multiple Liver Metastases Who Underwent Gastrectomy and Received Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[A Case of Gastric Neuroendocrine Carcinoma with Rapidly Increasing Liver Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Gastrectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[Pathological Complete Response in a Case of Advanced Gastric Cancer with Para-Aortic Lymph Nodes Metastasis Treated by Preoperative Chemotherapy with S-1 and Oxaliplatin(SOX Therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lymph Nodes; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2020 |
[A Case of Advanced Gastric Cancer with Peritoneal Metastasis Achieved Pathological Complete Response by Chemotherapy(SOX Regimen)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoadjuvant Therapy; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2020 |
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Sarcopenia; Tegafur; Treatment Outcome | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
Topics: Aged; Antineoplastic Agents, Immunological; Drug Combinations; Female; Humans; Nivolumab; Oxonic Acid; Pyridines; Recurrence; Stevens-Johnson Syndrome; Tegafur; Withholding Treatment | 2021 |
Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Drug Combinations; Female; Humans; Lung Neoplasms; Middle Aged; Oxonic Acid; Pyridines; Tegafur | 2021 |
Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nutrition Assessment; Oxonic Acid; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2021 |
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Health Status; Humans; Oxonic Acid; Receptor, ErbB-2; Receptors, Estrogen; Tegafur | 2021 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Tegafur | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur | 2021 |
Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome; Uracil | 2021 |
Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Contrast Media; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Postoperative Care; Precision Medicine; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome | 2021 |
Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Progression-Free Survival; Pyridines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2021 |
[A Case of Gastric Cancer with Extensive Lymph Node Metastasis Causing Stenosis Symptoms in the Primary pCR after Preoperative Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Constriction, Pathologic; Drug Combinations; Gastrectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
A Rare Case of Reversible Cardiac Dysfunction Associated with Tegafur/Gimeracil/Oteracil (S-1) Therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Combinations; Humans; Male; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2021 |
[A Long‒Term Survival Case of Gastric Cancer with Disseminated Intravascular Coagulation due to Myelocarcinomatosis Treated with S‒1 plus Oxaliplatin Therapy].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Combinations; Humans; Male; Neoplasm Recurrence, Local; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur; Thrombomodulin | 2021 |
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur; Time Factors; Young Adult | 2021 |
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nutrition Assessment; Nutrition Therapy; Nutritional Status; Oxonic Acid; Pancreatic Neoplasms; Phytotherapy; Polysaccharides; Shiitake Mushrooms; Tegafur; Treatment Outcome | 2021 |
[Choroidal metastasis from gastric cancer 8 years after surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choroid; Drug Combinations; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
Safety of alternate-day treatment with TS-1
Topics: Animals; Dog Diseases; Dogs; Drug Combinations; Oxonic Acid; Pilot Projects; Pyridines; Silicates; Stomach Neoplasms; Tegafur; Titanium | 2021 |
Clinical Significance of
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Gastric Mucosa; Group II Phospholipases A2; Humans; Male; Neoplasm Staging; Oxonic Acid; Prognosis; RNA, Messenger; Stomach; Stomach Neoplasms; Tegafur | 2021 |
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
Topics: Aged; Chemotherapy, Adjuvant; Drug Combinations; Humans; Middle Aged; Oxonic Acid; Propensity Score; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2021 |
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Retrospective Studies; Tegafur | 2021 |
Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Biomarkers; Capecitabine; Cisplatin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur; Trastuzumab | 2022 |
Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
Topics: Chemoradiotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Pyridines; Quality of Life; Rectal Neoplasms; Tegafur | 2021 |
The Combined Use of 5 or More Drugs Is a Factor Related to Lower Adherence to S-1 in S-1 and Oxaliplatin Treatment for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Female; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Motivation; Nausea; Odds Ratio; Oxaliplatin; Oxonic Acid; Polypharmacy; Prescription Drugs; Stomach Neoplasms; Tegafur; Young Adult | 2021 |
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Fusion Regulatory Protein-1; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Phosphorylation; Prognosis; Prospective Studies; Stomach Neoplasms; Tegafur; TOR Serine-Threonine Kinases | 2021 |
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Survival Rate; Tegafur | 2021 |
Efficacy and Safety of Additional S-1 Chemotherapy to S-1 Plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms; Tegafur | 2022 |
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Kidney; Kidney Function Tests; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Tegafur; Vomiting | 2021 |
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nomograms; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Probability; Proportional Hazards Models; ROC Curve; Sex Factors; Survival Rate; Tegafur | 2021 |
Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study.
Topics: Acetamides; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Head and Neck Neoplasms; Histamine H2 Antagonists; Humans; Male; Middle Aged; Oxonic Acid; Piperidines; Pyridines; Retrospective Studies; Tegafur | 2021 |
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; DNA Mutational Analysis; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Programmed Cell Death 1 Receptor; Response Evaluation Criteria in Solid Tumors; Smad4 Protein; Tegafur; Tuberous Sclerosis Complex 2 Protein | 2021 |
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouracil; Humans; Mice; Neoplasm Recurrence, Local; Oncolytic Viruses; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2021 |
Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.
Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Evidence-Based Nursing; Humans; Lung; Oxonic Acid; Potassium; Pyridines; Quality of Life; Retrospective Studies; Tegafur | 2021 |
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Oxonic Acid; Quinolines; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
[A Case of Gastric Cancer Treated with Resection and Adjuvant Chemotherapy in Japan after FOLFOX Neoadjuvant Chemotherapy in USA].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Japan; Male; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
[A Case of Advanced Gastric Cancer with Distant Lymph Nodes Metastasis Showing a Complete Response to Six-Courses Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Oxonic Acid; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tegafur | 2021 |
[Two Cases of Resectable Gastric Cancer with Extensive Nodal Metastasis That Received Preoperative DOS Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Tegafur | 2021 |
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2022 |
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2022 |
Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Tegafur; Treatment Outcome | 2021 |
[Pathological Complete Response and Long-Term Survival of a Gastric Neuroendocrine Carcinoma Patient Treated by Neoadjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2022 |
[A Case of Complete Response to Chemotherapy and Radical Resection of Unresectable Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrectomy; Humans; Oxonic Acid; Stomach Neoplasms; Tegafur | 2022 |
Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Kidney; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Stomach Neoplasms; Tegafur | 2022 |
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2022 |
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recurrence; Retrospective Studies; Tegafur | 2022 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2023 |
[A Case of Gastric Cancer Invading the Pancreas with Pathological Complete Response Treated by Preoperative S-1 plus Oxaliplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Neoadjuvant Therapy; Oxaliplatin; Oxonic Acid; Pancreas; Stomach Neoplasms; Tegafur | 2022 |
Doxifluridine versus Tegafur/Gimeracil/Oteracil (S-1) as adjuvant chemotherapy for patients with gastric cancer after gastrectomy: A propensity score-matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplasm Staging; Oxonic Acid; Propensity Score; Retrospective Studies; Stomach Neoplasms; Tegafur | 2023 |